uniprot	swissprot	name	act_value	act_type	action_type	source_name	reference	smiles	ChEMBL_Id
P19838	NFKB1_HUMAN	cepharanthine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/31132753	[H][C@]12CC3=CC(OC4=CC=C(C[C@@H]5N(C)CCC6=CC7=C(OCO7)C(OC7=C(OC)C=C(CCN1C)C2=C7)=C56)C=C4)=C(OC)C=C3	CHEMBL449782
Q13131	AAPK1_HUMAN	cepharanthine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/31132753	[H][C@]12CC3=CC(OC4=CC=C(C[C@@H]5N(C)CCC6=CC7=C(OCO7)C(OC7=C(OC)C=C(CCN1C)C2=C7)=C56)C=C4)=C(OC)C=C3	CHEMBL449782
P07711	CATL1_HUMAN	teicoplanin aglycone	5.78	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://dx.doi.org/10.1101/2020.02.05.935387	[H][C@@]12CC3=CC=C(OC4=C(O)C5=CC(=C4)[C@@]([H])(NC(=O)[C@@]([H])(NC1=O)C1=CC(O)=CC(OC4=C(O)C=CC(=C4)[C@@H](N)C(=O)N2)=C1)C(=O)N[C@]1([H])C2=CC(=C(O)C=C2)C2=C(O)C=C(O)C=C2[C@]([H])(NC(=O)[C@@]([H])(NC1=O)[C@H](O)C1=CC(Cl)=C(O5)C=C1)C(O)=O)C(Cl)=C3	CHEMBL2348244
P16234	PGFRA_HUMAN	avapritinib	9.62	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf	CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1	CHEMBL4204794
P10721	KIT_HUMAN	avapritinib	9.57	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf	CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1	CHEMBL4204794
Q15910	EZH2_HUMAN	tazemetostat	7.96	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211723s000lbl.pdf	CCN(C1CCOCC1)C1=CC(=CC(C(=O)NCC2=C(C)C=C(C)NC2=O)=C1C)C1=CC=C(CN2CCOCC2)C=C1	CHEMBL3414621
Q12908	NTCP2_HUMAN	elobixibat	9.275724	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://dx.doi.org/10.1016/S0016-5085(10)61017-7	CCCCC1(CCCC)CN(C2=CC=CC=C2)C2=C(C=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C3=CC=CC=C3)C(SC)=C2)S(=O)(=O)C1	CHEMBL3039515
P13569	CFTR_HUMAN	tezacaftor			PHARMACOLOGICAL CHAPERONE	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf	CC(C)(CO)C1=CC2=C(C=C(F)C(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C2)N1C[C@@H](O)CO	CHEMBL3544914
P30874	SSR2_HUMAN	lutetium (177Lu) oxodotreotide			AGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208700s000lbl.pdf	[177Lu].C[C@@H](O)[C@H](NC(=O)C1CSSC[C@H](NC(=O)C(CC2=CC=CC=C2)NC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O	CHEMBL3989924
Q92847	GHSR_HUMAN	macimorelin	7.81	IC50	AGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205598s000lbl.pdf	[H]C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@@H](CC1=CC2=C(N1)C=CC=C2)NC(=O)C(C)(C)N	CHEMBL278623
P42336	PK3CA_HUMAN	copanlisib	9.301030158996582	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf	COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21	CHEMBL3218576
O00329	PK3CD_HUMAN	copanlisib	9.154901504516602	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf	COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21	CHEMBL3218576
P11802	CDK4_HUMAN	abemaciclib	9.22184875	Ki	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf	CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1	CHEMBL3301610
Q00534	CDK6_HUMAN	abemaciclib	8.619788758	Ki	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf	CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1	CHEMBL3301610
P43088	PF2R_HUMAN	latanoprostene bunod	8.6	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21396362	[H][C@]1(CC[C@@H](O)CCC2=CC=CC=C2)[C@H](O)C[C@H](O)[C@]1([H])C\C=C/CCCC(=O)OCCCCO[N+]([O-])=O	CHEMBL1050
Q01344	IL5RA_HUMAN	benralizumab	10.95860731	Kd	ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf		CHEMBL1742991
P43220	GLP1R_HUMAN	semaglutide	9.420216403	IC50	AGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf	[H]N[C@@H](CC1=CNC=N1)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]([C@@H](C)O)C(=O)N[C@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CO)C(=O)NC(CO)C(=O)NC(CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)NC(CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)[C@H](CCC(O)=O)NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NC(CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O	CHEMBL2108724
O75116	ROCK2_HUMAN	netarsudil	8.376751	Ki	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdf	CC1=CC=C(C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC2=CC3=C(C=C2)C=NC=C3)C(C)=C1	CHEMBL3545126
P09874	PARP1_HUMAN	rucaparib	8.5	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf	CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23	CHEMBL1173055
Q9UGN5	PARP2_HUMAN	rucaparib	7.550000190734863	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf	CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23	CHEMBL1173055
Q9Y6F1	PARP3_HUMAN	rucaparib	6.389999866485596	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf	CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23	CHEMBL1173055
P27815	PDE4A_HUMAN	crisaborole	6.3098039627075195	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207695s000lbl.pdf	OB1OCC2=CC(OC3=CC=C(C=C3)C#N)=CC=C12	CHEMBL484785
Q07343	PDE4B_HUMAN	crisaborole	6.3098039627075195	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207695s000lbl.pdf	OB1OCC2=CC(OC3=CC=C(C=C3)C#N)=CC=C12	CHEMBL484785
Q08493	PDE4C_HUMAN	crisaborole	6.3098039627075195	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207695s000lbl.pdf	OB1OCC2=CC(OC3=CC=C(C=C3)C#N)=CC=C12	CHEMBL484785
Q08499	PDE4D_HUMAN	crisaborole	6.3098039627075195	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207695s000lbl.pdf	OB1OCC2=CC(OC3=CC=C(C=C3)C#N)=CC=C12	CHEMBL484785
P23458	JAK1_HUMAN	baricitinib	8.229147911071777	IC50	INHIBITOR	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004085/WC500223723.pdf	CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2	CHEMBL2105759
O60674	JAK2_HUMAN	baricitinib	8.244125366210938	IC50	INHIBITOR	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004085/WC500223723.pdf	CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2	CHEMBL2105759
P00533	EGFR_HUMAN	icotinib	8.698969841003418	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22088449	C#CC1=CC=CC(NC2=NC=NC3=C2C=C2OCCOCCOCCOC2=C3)=C1	CHEMBL2087361
P00533	EGFR_HUMAN	olmutinib	8.036211967468262	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/27357069	CN1CCN(CC1)C1=CC=C(NC2=NC3=C(SC=C3)C(OC3=CC=CC(NC(=O)C=C)=C3)=N2)C=C1	CHEMBL3786343
P25092	GUC2C_HUMAN	plecanatide	6.721246242523193	EC50	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208745lbl.pdf	[H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC1=O)C(C)C)C(C)C	CHEMBL255489
P08684	CP3A4_HUMAN	cobicistat	6.027334213256836	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203094s005lbl.pdf	CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1	CHEMBL2095208
P20815	CP3A5_HUMAN	cobicistat	6.027334213256836	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203094s005lbl.pdf	CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1	CHEMBL2095208
P24462	CP3A7_HUMAN	cobicistat	6.027334213256836	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203094s005lbl.pdf	CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1	CHEMBL2095208
Q9HB55	CP343_HUMAN	cobicistat	6.027334213256836	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203094s005lbl.pdf	CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1	CHEMBL2095208
P00519	ABL1_HUMAN	radotinib	7.514278411865234	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/25676420	CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=N3)=C2)=CC(=C1)C(F)(F)F	CHEMBL4297524
P35968	VGFR2_HUMAN	apatinib	9.0	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21443688	O=C(NC1=CC=C(C=C1)C1(CCCC1)C#N)C1=CC=CN=C1NCC1=CC=NC=C1	CHEMBL3186534
P08172	ACM2_HUMAN	methanthelinium			ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D00721	CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=C1C=CC=C2	CHEMBL1200988
P08173	ACM4_HUMAN	methanthelinium			ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D00721	CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=C1C=CC=C2	CHEMBL1200988
P08912	ACM5_HUMAN	methanthelinium			ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D00721	CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=C1C=CC=C2	CHEMBL1200988
P11229	ACM1_HUMAN	methanthelinium			ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D00721	CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=C1C=CC=C2	CHEMBL1200988
P20309	ACM3_HUMAN	methanthelinium			ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D00721	CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=C1C=CC=C2	CHEMBL1200988
Q13698	CAC1S_HUMAN	verapamil			BLOCKER	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406	COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1	CHEMBL6966
P08588	ADRB1_HUMAN	landiolol			ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01847	CC1(C)OC[C@@H](COC(=O)CCC2=CC=C(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)C=C2)O1	CHEMBL1742466
P23219	PGH1_HUMAN	piketoprofen			INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D08374	CC(C(=O)NC1=CC(C)=CC=N1)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1	CHEMBL2106966
P35354	PGH2_HUMAN	piketoprofen			INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D08374	CC(C(=O)NC1=CC(C)=CC=N1)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1	CHEMBL2106966
P16234	PGFRA_HUMAN	olaratumab	10.4	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761038lbl.pdf		CHEMBL1743049
Q8NAC3	I17RC_HUMAN	brodalumab	9.199999809265137	Kd	ANTIBODY BINDING	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22455412		CHEMBL1742996
Q96F46	I17RA_HUMAN	brodalumab	9.199999809265137	Kd	ANTIBODY BINDING	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22455412		CHEMBL1742996
P05107	ITB2_HUMAN	lifitegrast	8.045757293701172	IC50	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208073s000lbl.pdf	[H][C@@](CC1=CC(=CC=C1)S(C)(=O)=O)(NC(=O)C1=C(Cl)C=C2CN(CCC2=C1Cl)C(=O)C1=CC=C2C=COC2=C1)C(O)=O	CHEMBL2048028
P20701	ITAL_HUMAN	lifitegrast	8.045757293701172	IC50	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208073s000lbl.pdf	[H][C@@](CC1=CC(=CC=C1)S(C)(=O)=O)(NC(=O)C1=C(Cl)C=C2CN(CCC2=C1Cl)C(=O)C1=CC=C2C=COC2=C1)C(O)=O	CHEMBL2048028
P28335	5HT2C_HUMAN	lorcaserin	7.886056423187256	Ki	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208524s000lbl.pdf	C[C@H]1CNCCC2=CC=C(Cl)C=C12	CHEMBL360328
P04234	CD3D_HUMAN	muromonab-CD3			ANTIBODY BINDING	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6889		CHEMBL1201608
P07766	CD3E_HUMAN	muromonab-CD3			ANTIBODY BINDING	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6889		CHEMBL1201608
P09693	CD3G_HUMAN	muromonab-CD3			ANTIBODY BINDING	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6889		CHEMBL1201608
P35367	HRH1_HUMAN	bilastine	7.193819999694824	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/16274260	CCOCCN1C(=NC2=C1C=CC=C2)C1CCN(CCC2=CC=C(C=C2)C(C)(C)C(O)=O)CC1	CHEMBL1742423
P12821	ACE_HUMAN	enalapril	4.3	IC50	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6322	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O	CHEMBL578
P12821	ACE_HUMAN	enalaprilat	7.5	IC50	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6332	C[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	CHEMBL577
P40238	TPOR_HUMAN	eltrombopag	7.42	EC50	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6961	CC1=NN(C(=O)\C1=N/NC1=CC=CC(C2=CC(=CC=C2)C(O)=O)=C1O)C1=CC(C)=C(C)C=C1	CHEMBL461101
P17181	INAR1_HUMAN	peginterferon beta-1a			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125499s009lbl.pdf		CHEMBL2108677
P48551	INAR2_HUMAN	peginterferon beta-1a			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125499s009lbl.pdf		CHEMBL2108677
P17181	INAR1_HUMAN	interferon beta-1a			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103628s5258lbl.pdf		CHEMBL1201562
P48551	INAR2_HUMAN	interferon beta-1a			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103628s5258lbl.pdf		CHEMBL1201562
P17181	INAR1_HUMAN	interferon beta-1b			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103471s5188lbl.pdf		CHEMBL1201563
P48551	INAR2_HUMAN	interferon beta-1b			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103471s5188lbl.pdf		CHEMBL1201563
P00747	PLMN_HUMAN	alteplase			ACTIVATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103172s5203lbl.pdf		CHEMBL1201593
P28223	5HT2A_HUMAN	pimavanserin	9.300000190734863	Ki	INVERSE AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf	CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C2CCN(C)CC2)C=C1	CHEMBL2111101
P21964	COMT_HUMAN	opicapone	9.0	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/24847974	CC1=C(C2=NOC(=N2)C2=CC(O)=C(O)C(=C2)[N+]([O-])=O)C(Cl)=[N+]([O-])C(C)=C1Cl	CHEMBL1089318
P22888	LSHR_HUMAN	choriogonadotropin alfa			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201464		CHEMBL1201464
P06280	AGAL_HUMAN	migalastat	7.150000095367432	IC50	PHARMACOLOGICAL CHAPERONE	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004059/WC500208434.pdf	OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O	CHEMBL110458
P10415	BCL2_HUMAN	venetoclax	11.0	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf	CC1(C)CCC(CN2CCN(CC2)C2=CC(OC3=CC4=C(NC=C4)N=C3)=C(C=C2)C(=O)NS(=O)(=O)C2=CC(=C(NCC3CCOCC3)C=C2)[N+]([O-])=O)=C(C1)C1=CC=C(Cl)C=C1	CHEMBL3137309
P14416	DRD2_HUMAN	rotigotine	10.22	Ki	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=941	CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1	CHEMBL1303
P06401	PRGR_HUMAN	quingestanol acetate			AGONIST	KEGG DRUG	http://www.kegg.jp/entry/D05679	[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(OC4CCCC4)=CC3=CC[C@@]21[H]	CHEMBL2105291
P20648	ATP4A_HUMAN	dexrabeprazole			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2154989	COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=C(N2)C=CC=C3)=C1C	CHEMBL1219
P51164	ATP4B_HUMAN	dexrabeprazole			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2154989	COCCCOC1=CC=NC(C[S@@](=O)C2=NC3=C(N2)C=CC=C3)=C1C	CHEMBL1219
P20648	ATP4A_HUMAN	ilaprazole			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11304936	COC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC(=C3)N2C=CC=C2)=C1C	CHEMBL2106370
P51164	ATP4B_HUMAN	ilaprazole			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11304936	COC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC(=C3)N2C=CC=C2)=C1C	CHEMBL2106370
Q01668	CAC1D_HUMAN	cilnidipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/9298526	COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1	CHEMBL452076
Q13936	CAC1C_HUMAN	cilnidipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/9298526	COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1	CHEMBL452076
Q01668	CAC1D_HUMAN	dexniguldipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2547493	COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL405355
Q13936	CAC1C_HUMAN	dexniguldipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2547493	COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL405355
P22303	ACES_HUMAN	distigmine			INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D01228	CN(CCCCCCN(C)C(=O)OC1=C[N+](C)=CC=C1)C(=O)OC1=C[N+](C)=CC=C1	CHEMBL1098285
Q01668	CAC1D_HUMAN	manidipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8287905	COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1085699
Q13936	CAC1C_HUMAN	manidipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8287905	COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1085699
Q01668	CAC1D_HUMAN	nilvadipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/7898101	COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N	CHEMBL517427
Q13936	CAC1C_HUMAN	nilvadipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/7898101	COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N	CHEMBL517427
Q9HC29	NOD2_HUMAN	mifamurtide			ACTIVATOR	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000802/WC500026565.pdf	CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC	CHEMBL2107354
Q01668	CAC1D_HUMAN	levamlodipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17213004	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=C(Cl)C=CC=C1)C(=O)OC	CHEMBL2107350
Q13936	CAC1C_HUMAN	levamlodipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17213004	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=C(Cl)C=CC=C1)C(=O)OC	CHEMBL2107350
P00747	PLMN_HUMAN	tenecteplase			ACTIVATOR	DRUG LABEL	http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/UCM200875.pdf		CHEMBL1201593
P28074	PSB5_HUMAN	ixazomib	8.468521118164062	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf	[H][C@@](CC(C)C)(NC(=O)CNC(=O)C1=C(Cl)C=CC(Cl)=C1)B(O)O	CHEMBL2141296
Q7L0J3	SV2A_HUMAN	brivaracetam	7.099999904632568	Ki	MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/18500360	[H][C@@](CC)(N1C[C@]([H])(CCC)CC1=O)C(N)=O	CHEMBL607400
P28907	CD38_HUMAN	daratumumab	8.22	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761036Orig1s000lbledt.pdf		CHEMBL1743007
P00533	EGFR_HUMAN	necitumumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf		CHEMBL1743047
P35367	HRH1_HUMAN	setastine			ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1982751	CC(OCCN1CCCCCC1)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1	CHEMBL1742452
P35367	HRH1_HUMAN	talastine			ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/13499132	CN(C)CCN1N=C(CC2=CC=CC=C2)C2=C(C=CC=C2)C1=O	CHEMBL1742439
P35367	HRH1_HUMAN	moxastine			ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/13757612	CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1742465
P21397	AOFA_HUMAN	pheniprazine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17404836	CC(CC1=CC=CC=C1)NN	CHEMBL22498
P27338	AOFB_HUMAN	pheniprazine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17404836	CC(CC1=CC=CC=C1)NN	CHEMBL22498
P21397	AOFA_HUMAN	mebanazine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/5889715	CC(NN)C1=CC=CC=C1	CHEMBL1909283
P27338	AOFB_HUMAN	mebanazine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/5889715	CC(NN)C1=CC=CC=C1	CHEMBL1909283
P35498	SCN1A_HUMAN	phenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL16	O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL16
Q9NY46	SCN3A_HUMAN	phenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL16	O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL16
Q9UQD0	SCN8A_HUMAN	phenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL16	O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL16
Q15858	SCN9A_HUMAN	phenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL16	O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL16
Q9NQ25	SLAF7_HUMAN	elotuzumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf		CHEMBL1743010
Q7Z2W7	TRPM8_HUMAN	levomenthol	4.6	EC50	ACTIVATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/15306801	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CHEMBL256087
P07949	RET_HUMAN	alectinib	8.318758964538574	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf	CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O	CHEMBL1738797
P43119	PI2R_HUMAN	selexipag	7.698969841003418	Ki	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207947s000lbl.pdf	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=CN=C(C2=CC=CC=C2)C(=N1)C1=CC=CC=C1	CHEMBL238804
P21397	AOFA_HUMAN	pirlindole	7.408935546875	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/9368911	CC1=CC2=C(C=C1)N1CCNC3CCCC2=C13	CHEMBL32350
Q02750	MP2K1_HUMAN	cobimetinib	9.045757293701172	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22084396	[H][C@]1(CCCCN1)C1(O)CN(C1)C(=O)C1=C(NC2=CC=C(I)C=C2F)C(F)=C(F)C=C1	CHEMBL2146883
Q07869	PPARA_HUMAN	saroglitazar	9.187087059020996	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/26171220	CCO[C@@H](CC1=CC=C(OCCN2C(C)=CC=C2C2=CC=C(SC)C=C2)C=C1)C(O)=O	CHEMBL4297530
P37231	PPARG_HUMAN	saroglitazar	8.522878646850586	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/26171220	CCO[C@@H](CC1=CC=C(OCCN2C(C)=CC=C2C2=CC=C(SC)C=C2)C=C1)C(O)=O	CHEMBL4297530
Q9Y5N1	HRH3_HUMAN	pitolisant	9.795880317687988	Ki	INVERSE AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21615387	ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1	CHEMBL462605
P14416	DRD2_HUMAN	aripiprazole lauroxil	9.468521118164062	Ki	PARTIAL AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207533s000lbl.pdf	CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12	CHEMBL2219425
P08908	5HT1A_HUMAN	aripiprazole lauroxil	8.769551277160645	Ki	PARTIAL AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207533s000lbl.pdf	CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12	CHEMBL2219425
P28223	5HT2A_HUMAN	aripiprazole lauroxil	8.468521118164062	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207533s000lbl.pdf	CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=CC=C(OCCCCN3CCN(CC3)C3=C(Cl)C(Cl)=CC=C3)C=C12	CHEMBL2219425
P35367	HRH1_HUMAN	emedastine	8.886056900024414	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20706slr011_emadine_lbl.pdf	CCOCCN1C(=NC2=C1C=CC=C2)N1CCCN(C)CC1	CHEMBL594
P27487	DPP4_HUMAN	omarigliptin	9.09691047668457	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/24660890	CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]1CO[C@@H]([C@@H](N)C1)C1=C(F)C=CC(F)=C1	CHEMBL2105762
P06213	INSR_HUMAN	insulin glulisine			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021629s030lbl.pdf	[H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N[H])CC3=CC=CC=C3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CNC=N3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC	CHEMBL1201613
P08908	5HT1A_HUMAN	flibanserin	9.0	Ki	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	FC(F)(F)C1=CC=CC(=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1	CHEMBL231068
P28223	5HT2A_HUMAN	flibanserin	7.3098039627075195	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	FC(F)(F)C1=CC=CC(=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1	CHEMBL231068
P14416	DRD2_HUMAN	haloperidol decanoate	9.34	Ki	INVERSE AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200986	CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1	CHEMBL1200986
Q12791	KCMA1_HUMAN	chlorzoxazone	4.522878646850586	EC50	OPENER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12480161	ClC1=CC2=C(OC(=O)N2)C=C1	CHEMBL1371
P40189	IL6RB_HUMAN	oprelvekin			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103694s1008lbl.pdf		CHEMBL1201573
Q14626	I11RA_HUMAN	oprelvekin			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103694s1008lbl.pdf		CHEMBL1201573
P25103	NK1R_HUMAN	rolapitant	9.180456161499023	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206500s000lbl.pdf	[H][C@](C)(OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F	CHEMBL3707330
P15509	CSF2R_HUMAN	sargramostim	8.301030158996582	Kd	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2001448		CHEMBL1201670
P32927	IL3RB_HUMAN	sargramostim	8.301030158996582	Kd	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2001448		CHEMBL1201670
P51679	CCR4_HUMAN	mogamulizumab			ANTIBODY BINDING	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22686619		CHEMBL1743041
Q8NBP7	PCSK9_HUMAN	alirocumab	9.42	Kd	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125559Orig1s000lbl.pdf		CHEMBL2109540
P14778	IL1R1_HUMAN	anakinra	7.820000171661377	Kd	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103950s5150lbl.pdf	[H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CHEMBL1201570
Q9NPH3	IL1AP_HUMAN	anakinra	7.820000171661377	Kd	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103950s5150lbl.pdf	[H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CHEMBL1201570
P25021	HRH2_HUMAN	niperotidine			ANTAGONIST	SCIENTIFIC LITERATURE	CAROPPO, R, EFFECT OF NIPEROTIDINE ON HYDROGEN-ION SECRETION AND ELECTRICAL PARAMETERS OF ISOLATED ASTRIC-MUCOSA, Curr. Ther. Res.-Clin. Exp., 1990, 48, 1, 20-29	CN(C)CC1=CC=C(CSCCNC(NCC2=CC3=C(OCO3)C=C2)=C[N+]([O-])=O)O1	CHEMBL1909284
Q96RJ0	TAAR1_HUMAN	hydroxyamfetamine	5.528708457946777	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22037049	CC(N)CC1=CC=C(O)C=C1	CHEMBL1546
P21728	DRD1_HUMAN	pergolide	6.46999979019165	Ki	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf	[H][C@]1(CSC)CN(CCC)[C@]2([H])CC3=CNC4=C3C(=CC=C4)[C@@]2([H])C1	CHEMBL531
P08473	NEP_HUMAN	sacubitril			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207620Orig1s000lbl.pdf	CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C1=CC=CC=C1)NC(=O)CCC(O)=O	CHEMBL3137301
P27487	DPP4_HUMAN	trelagliptin	8.397939682006836	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/26115728	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=CC(F)=CC=C2C#N)C1=O	CHEMBL1650443
P21964	COMT_HUMAN	tolcapone	9.568635940551758	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1324	CC1=CC=C(C=C1)C(=O)C1=CC(=C(O)C(O)=C1)[N+]([O-])=O	CHEMBL1324
P21964	COMT_HUMAN	entacapone	9.522878646850586	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL953	CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N	CHEMBL953
P14324	FPPS_HUMAN	incadronic acid	7.522878646850586	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11160603	OP(O)(=O)C(NC1CCCCCC1)P(O)(O)=O	CHEMBL53950
P14416	DRD2_HUMAN	brexpiprazole	9.522878646850586	Ki	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205422s000lbl.pdf	O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2	CHEMBL2105760
P08908	5HT1A_HUMAN	brexpiprazole	9.920818328857422	Ki	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205422s000lbl.pdf	O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2	CHEMBL2105760
P28223	5HT2A_HUMAN	brexpiprazole	9.327901840209961	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205422s000lbl.pdf	O=C1NC2=C(C=C1)C=CC(OCCCCN1CCN(CC1)C1=C3C=CSC3=CC=C1)=C2	CHEMBL2105760
P10912	GHR_HUMAN	pegvisomant			ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021106s036lbl.pdf		CHEMBL1201515
Q12882	DPYD_HUMAN	gimeracil	6.638272285461426	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21668582	OC1=CC(=O)NC=C1Cl	CHEMBL1730601
P11172	UMPS_HUMAN	oteracil			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8862723	OC(=O)C1=NC(=O)NC(=O)N1	CHEMBL181932
P08588	ADRB1_HUMAN	arbutamine			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8723169	O[C@@H](CNCCCCC1=CC=C(O)C=C1)C1=CC(O)=C(O)C=C1	CHEMBL1200385
P04350	TBB4A_HUMAN	trastuzumab emtansine			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf		CHEMBL1201585
P07437	TBB5_HUMAN	trastuzumab emtansine			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf		CHEMBL1201585
P68371	TBB4B_HUMAN	trastuzumab emtansine			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf		CHEMBL1201585
Q13509	TBB3_HUMAN	trastuzumab emtansine			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf		CHEMBL1201585
Q13885	TBB2A_HUMAN	trastuzumab emtansine			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf		CHEMBL1201585
Q3ZCM7	TBB8_HUMAN	trastuzumab emtansine			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf		CHEMBL1201585
Q9BUF5	TBB6_HUMAN	trastuzumab emtansine			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf		CHEMBL1201585
Q9BVA1	TBB2B_HUMAN	trastuzumab emtansine			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf		CHEMBL1201585
Q9H4B7	TBB1_HUMAN	trastuzumab emtansine			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf		CHEMBL1201585
P04626	ERBB2_HUMAN	trastuzumab emtansine			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125427s033lbl.pdf		CHEMBL1201585
Q99062	CSF3R_HUMAN	lipegfilgrastim			ACTIVATOR	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002556/WC500148380.pdf		CHEMBL2105765
P20648	ATP4A_HUMAN	vonoprazan	8.0	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21828261	CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1	CHEMBL2064032
P51164	ATP4B_HUMAN	vonoprazan	8.0	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21828261	CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1	CHEMBL2064032
P08172	ACM2_HUMAN	aclatonium			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1696381	CC(OC(C)=O)C(=O)OCC[N+](C)(C)C	CHEMBL2106580
P08173	ACM4_HUMAN	aclatonium			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1696381	CC(OC(C)=O)C(=O)OCC[N+](C)(C)C	CHEMBL2106580
P08912	ACM5_HUMAN	aclatonium			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1696381	CC(OC(C)=O)C(=O)OCC[N+](C)(C)C	CHEMBL2106580
P11229	ACM1_HUMAN	aclatonium			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1696381	CC(OC(C)=O)C(=O)OCC[N+](C)(C)C	CHEMBL2106580
P20309	ACM3_HUMAN	aclatonium			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1696381	CC(OC(C)=O)C(=O)OCC[N+](C)(C)C	CHEMBL2106580
P19235	EPOR_HUMAN	epoetin alfa	11.15	IC50	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103234s5323lbl.pdf		CHEMBL1201565
P11388	TOP2A_HUMAN	etoposide	7.3	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL44657	[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=C(C=C3OCOC3=C1)[C@H]2O[C@]1([H])O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O	CHEMBL44657
P40238	TPOR_HUMAN	romiplostim			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125268s141lbl.pdf		CHEMBL1201832
P35372	OPRM_HUMAN	eluxadoline	8.769551277160645	Ki	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206940s000lbl.pdf	COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O	CHEMBL2159122
P41143	OPRD_HUMAN	eluxadoline	8.886056900024414	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206940s000lbl.pdf	COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O	CHEMBL2159122
P06213	INSR_HUMAN	insulin lispro			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020563s124lbl.pdf	[H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N[H])CC3=CC=CC=C3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CNC=N3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC	CHEMBL1201538
P06213	INSR_HUMAN	insulin human			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018780s150lbl.pdf	[H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N[H])CC3=CC=CC=C3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CNC=N3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC	CHEMBL1201641
P35354	PGH2_HUMAN	parecoxib	8.301030158996582	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10794682	CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1	CHEMBL296913
P06401	PRGR_HUMAN	hydroxyprogesterone caproate	7.663540363311768	IC50	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021945s005lbl.pdf	[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1062
Q99062	CSF3R_HUMAN	pegfilgrastim			ACTIVATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125031s082lbl.pdf		CHEMBL1201568
Q99062	CSF3R_HUMAN	filgrastim			ACTIVATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103353s5184lbl.pdf		CHEMBL1201567
P04150	GCR_HUMAN	triamcinolone hexacetonide			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/016466s046lbl.pdf	[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1200878
O75343	GCYB2_HUMAN	nitric oxide			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200689		CHEMBL1200689
P33402	GCYA2_HUMAN	nitric oxide			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200689		CHEMBL1200689
Q02108	GCYA3_HUMAN	nitric oxide			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200689		CHEMBL1200689
Q02153	GCYB1_HUMAN	nitric oxide			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200689		CHEMBL1200689
O43525	KCNQ3_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
O43526	KCNQ2_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
O95259	KCNH1_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
P16389	KCNA2_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
P17658	KCNA6_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
P22001	KCNA3_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
P22459	KCNA4_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
P22460	KCNA5_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
P48547	KCNC1_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
P51787	KCNQ1_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
P56696	KCNQ4_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q03721	KCNC4_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q09470	KCNA1_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q12809	KCNH2_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q14003	KCNC3_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q14721	KCNB1_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q16322	KCA10_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q6PIU1	KCNV1_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q8NCM2	KCNH5_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q8TAE7	KCNG3_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q8TDN1	KCNG4_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q8TDN2	KCNV2_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q92953	KCNB2_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q96KK3	KCNS1_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q96L42	KCNH8_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q96PR1	KCNC2_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q96RP8	KCNA7_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q9BQ31	KCNS3_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q9H252	KCNH6_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q9H3M0	KCNF1_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q9NR82	KCNQ5_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q9NS40	KCNH7_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q9NSA2	KCND1_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q9NZV8	KCND2_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q9UIX4	KCNG1_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q9UJ96	KCNG2_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q9UK17	KCND3_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q9ULD8	KCNH3_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q9ULS6	KCNS2_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
Q9UQ05	KCNH4_HUMAN	guanidine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL821	NC(N)=N	CHEMBL821
P00325	ADH1B_HUMAN	fomepizole			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1308	CC1=CNN=C1	CHEMBL1308
P00326	ADH1G_HUMAN	fomepizole			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1308	CC1=CNN=C1	CHEMBL1308
P07327	ADH1A_HUMAN	fomepizole			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1308	CC1=CNN=C1	CHEMBL1308
Q13936	CAC1C_HUMAN	bepridil			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1281221	CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1	CHEMBL1008
Q01668	CAC1D_HUMAN	bepridil			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1281221	CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1	CHEMBL1008
P54289	CA2D1_HUMAN	gabapentin enacarbil			MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21651903	[H]C(C)(OC(=O)NCC1(CC(O)=O)CCCCC1)OC(=O)C(C)C	CHEMBL1628502
Q9NY47	CA2D2_HUMAN	gabapentin enacarbil			MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21651903	[H]C(C)(OC(=O)NCC1(CC(O)=O)CCCCC1)OC(=O)C(C)C	CHEMBL1628502
P28074	PSB5_HUMAN	carfilzomib	8.221848487854004	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17616698	CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1	CHEMBL451887
Q13547	HDAC1_HUMAN	chidamide	7.022276401519775	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22080169	NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CC=CN=C2)C=C1	CHEMBL3621988
Q92769	HDAC2_HUMAN	chidamide	6.79587984085083	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22080169	NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CC=CN=C2)C=C1	CHEMBL3621988
O15379	HDAC3_HUMAN	chidamide	7.173925399780273	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22080169	NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CC=CN=C2)C=C1	CHEMBL3621988
Q969S8	HDA10_HUMAN	chidamide	7.107905387878418	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22080169	NC1=CC(F)=CC=C1NC(=O)C1=CC=C(CNC(=O)\C=C\C2=CC=CN=C2)C=C1	CHEMBL3621988
P04350	TBB4A_HUMAN	docetaxel	6.698999881744385	ID50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL92	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL92
P07437	TBB5_HUMAN	docetaxel	6.698999881744385	ID50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL92	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL92
P68371	TBB4B_HUMAN	docetaxel	6.698999881744385	ID50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL92	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL92
Q13509	TBB3_HUMAN	docetaxel	6.698999881744385	ID50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL92	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL92
Q13885	TBB2A_HUMAN	docetaxel	6.698999881744385	ID50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL92	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL92
Q3ZCM7	TBB8_HUMAN	docetaxel	6.698999881744385	ID50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL92	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL92
Q9BUF5	TBB6_HUMAN	docetaxel	6.698999881744385	ID50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL92	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL92
Q9BVA1	TBB2B_HUMAN	docetaxel	6.698999881744385	ID50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL92	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL92
Q9H4B7	TBB1_HUMAN	docetaxel	6.698999881744385	ID50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL92	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL92
P04350	TBB4A_HUMAN	paclitaxel	8.05	EC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11309480	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL428647
P07437	TBB5_HUMAN	paclitaxel	8.05	EC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11309480	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL428647
P68371	TBB4B_HUMAN	paclitaxel	8.05	EC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11309480	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL428647
Q13509	TBB3_HUMAN	paclitaxel	8.05	EC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11309480	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL428647
Q13885	TBB2A_HUMAN	paclitaxel	8.05	EC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11309480	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL428647
Q3ZCM7	TBB8_HUMAN	paclitaxel	8.05	EC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11309480	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL428647
Q9BUF5	TBB6_HUMAN	paclitaxel	8.05	EC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11309480	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL428647
Q9BVA1	TBB2B_HUMAN	paclitaxel	8.05	EC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11309480	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL428647
Q9H4B7	TBB1_HUMAN	paclitaxel	8.05	EC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11309480	[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL428647
P04350	TBB4A_HUMAN	brentuximab vedotin			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf		CHEMBL1742994
P07437	TBB5_HUMAN	brentuximab vedotin			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf		CHEMBL1742994
P68371	TBB4B_HUMAN	brentuximab vedotin			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf		CHEMBL1742994
Q13509	TBB3_HUMAN	brentuximab vedotin			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf		CHEMBL1742994
Q13885	TBB2A_HUMAN	brentuximab vedotin			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf		CHEMBL1742994
Q3ZCM7	TBB8_HUMAN	brentuximab vedotin			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf		CHEMBL1742994
Q9BUF5	TBB6_HUMAN	brentuximab vedotin			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf		CHEMBL1742994
Q9BVA1	TBB2B_HUMAN	brentuximab vedotin			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf		CHEMBL1742994
Q9H4B7	TBB1_HUMAN	brentuximab vedotin			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf		CHEMBL1742994
P04350	TBB4A_HUMAN	eribulin	8.229999542236328	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2	CHEMBL1683544
P07437	TBB5_HUMAN	eribulin	8.229999542236328	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2	CHEMBL1683544
P68371	TBB4B_HUMAN	eribulin	8.229999542236328	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2	CHEMBL1683544
Q13509	TBB3_HUMAN	eribulin	8.229999542236328	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2	CHEMBL1683544
Q13885	TBB2A_HUMAN	eribulin	8.229999542236328	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2	CHEMBL1683544
Q3ZCM7	TBB8_HUMAN	eribulin	8.229999542236328	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2	CHEMBL1683544
Q9BUF5	TBB6_HUMAN	eribulin	8.229999542236328	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2	CHEMBL1683544
Q9BVA1	TBB2B_HUMAN	eribulin	8.229999542236328	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2	CHEMBL1683544
Q9H4B7	TBB1_HUMAN	eribulin	8.229999542236328	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2	CHEMBL1683544
P04350	TBB4A_HUMAN	vinblastine	9.0	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL159
P07437	TBB5_HUMAN	vinblastine	9.0	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL159
P68371	TBB4B_HUMAN	vinblastine	9.0	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL159
Q13509	TBB3_HUMAN	vinblastine	9.0	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL159
Q13885	TBB2A_HUMAN	vinblastine	9.0	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL159
Q3ZCM7	TBB8_HUMAN	vinblastine	9.0	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL159
Q9BUF5	TBB6_HUMAN	vinblastine	9.0	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL159
Q9BVA1	TBB2B_HUMAN	vinblastine	9.0	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL159
Q9H4B7	TBB1_HUMAN	vinblastine	9.0	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL159
P04350	TBB4A_HUMAN	vinorelbine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=C(C=C(C(OC)=C3)[C@]3(C[C@@]4([H])C[N@](CC(CC)=C4)CC4=C3NC3=C4C=CC=C3)C(=O)OC)[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H]	CHEMBL553025
P07437	TBB5_HUMAN	vinorelbine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=C(C=C(C(OC)=C3)[C@]3(C[C@@]4([H])C[N@](CC(CC)=C4)CC4=C3NC3=C4C=CC=C3)C(=O)OC)[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H]	CHEMBL553025
P68371	TBB4B_HUMAN	vinorelbine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=C(C=C(C(OC)=C3)[C@]3(C[C@@]4([H])C[N@](CC(CC)=C4)CC4=C3NC3=C4C=CC=C3)C(=O)OC)[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H]	CHEMBL553025
Q13509	TBB3_HUMAN	vinorelbine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=C(C=C(C(OC)=C3)[C@]3(C[C@@]4([H])C[N@](CC(CC)=C4)CC4=C3NC3=C4C=CC=C3)C(=O)OC)[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H]	CHEMBL553025
Q13885	TBB2A_HUMAN	vinorelbine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=C(C=C(C(OC)=C3)[C@]3(C[C@@]4([H])C[N@](CC(CC)=C4)CC4=C3NC3=C4C=CC=C3)C(=O)OC)[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H]	CHEMBL553025
Q3ZCM7	TBB8_HUMAN	vinorelbine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=C(C=C(C(OC)=C3)[C@]3(C[C@@]4([H])C[N@](CC(CC)=C4)CC4=C3NC3=C4C=CC=C3)C(=O)OC)[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H]	CHEMBL553025
Q9BUF5	TBB6_HUMAN	vinorelbine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=C(C=C(C(OC)=C3)[C@]3(C[C@@]4([H])C[N@](CC(CC)=C4)CC4=C3NC3=C4C=CC=C3)C(=O)OC)[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H]	CHEMBL553025
Q9BVA1	TBB2B_HUMAN	vinorelbine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=C(C=C(C(OC)=C3)[C@]3(C[C@@]4([H])C[N@](CC(CC)=C4)CC4=C3NC3=C4C=CC=C3)C(=O)OC)[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H]	CHEMBL553025
Q9H4B7	TBB1_HUMAN	vinorelbine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N(C)C3=C(C=C(C(OC)=C3)[C@]3(C[C@@]4([H])C[N@](CC(CC)=C4)CC4=C3NC3=C4C=CC=C3)C(=O)OC)[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H]	CHEMBL553025
P04350	TBB4A_HUMAN	vincristine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL90555
P07437	TBB5_HUMAN	vincristine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL90555
P68371	TBB4B_HUMAN	vincristine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL90555
Q13509	TBB3_HUMAN	vincristine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL90555
Q13885	TBB2A_HUMAN	vincristine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL90555
Q3ZCM7	TBB8_HUMAN	vincristine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL90555
Q9BUF5	TBB6_HUMAN	vincristine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL90555
Q9BVA1	TBB2B_HUMAN	vincristine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL90555
Q9H4B7	TBB1_HUMAN	vincristine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC	CHEMBL90555
P04350	TBB4A_HUMAN	ixabepilone			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1	CHEMBL1201752
P07437	TBB5_HUMAN	ixabepilone			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1	CHEMBL1201752
P68371	TBB4B_HUMAN	ixabepilone			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1	CHEMBL1201752
Q13509	TBB3_HUMAN	ixabepilone			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1	CHEMBL1201752
Q13885	TBB2A_HUMAN	ixabepilone			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1	CHEMBL1201752
Q3ZCM7	TBB8_HUMAN	ixabepilone			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1	CHEMBL1201752
Q9BUF5	TBB6_HUMAN	ixabepilone			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1	CHEMBL1201752
Q9BVA1	TBB2B_HUMAN	ixabepilone			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1	CHEMBL1201752
Q9H4B7	TBB1_HUMAN	ixabepilone			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1	CHEMBL1201752
P04350	TBB4A_HUMAN	vinflunine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@]5([H])C[C@H](C[N@@](C5)CC5=C4NC4=C5C=CC=C4)C(C)(F)F)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC	CHEMBL2105629
P07437	TBB5_HUMAN	vinflunine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@]5([H])C[C@H](C[N@@](C5)CC5=C4NC4=C5C=CC=C4)C(C)(F)F)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC	CHEMBL2105629
P68371	TBB4B_HUMAN	vinflunine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@]5([H])C[C@H](C[N@@](C5)CC5=C4NC4=C5C=CC=C4)C(C)(F)F)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC	CHEMBL2105629
Q13509	TBB3_HUMAN	vinflunine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@]5([H])C[C@H](C[N@@](C5)CC5=C4NC4=C5C=CC=C4)C(C)(F)F)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC	CHEMBL2105629
Q13885	TBB2A_HUMAN	vinflunine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@]5([H])C[C@H](C[N@@](C5)CC5=C4NC4=C5C=CC=C4)C(C)(F)F)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC	CHEMBL2105629
Q3ZCM7	TBB8_HUMAN	vinflunine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@]5([H])C[C@H](C[N@@](C5)CC5=C4NC4=C5C=CC=C4)C(C)(F)F)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC	CHEMBL2105629
Q9BUF5	TBB6_HUMAN	vinflunine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@]5([H])C[C@H](C[N@@](C5)CC5=C4NC4=C5C=CC=C4)C(C)(F)F)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC	CHEMBL2105629
Q9BVA1	TBB2B_HUMAN	vinflunine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@]5([H])C[C@H](C[N@@](C5)CC5=C4NC4=C5C=CC=C4)C(C)(F)F)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC	CHEMBL2105629
Q9H4B7	TBB1_HUMAN	vinflunine			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19010832	[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@]5([H])C[C@H](C[N@@](C5)CC5=C4NC4=C5C=CC=C4)C(C)(F)F)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC	CHEMBL2105629
P11802	CDK4_HUMAN	palbociclib	7.958607196807861	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf	CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O	CHEMBL189963
Q00534	CDK6_HUMAN	palbociclib	7.823908805847168	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf	CC(=O)C1=C(C)C2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N(C2CCCC2)C1=O	CHEMBL189963
P17948	VGFR1_HUMAN	lenvatinib	7.6575775146484375	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf	COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2	CHEMBL1289601
P35968	VGFR2_HUMAN	lenvatinib	8.397939682006836	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf	COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2	CHEMBL1289601
P35916	VGFR3_HUMAN	lenvatinib	8.28399658203125	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf	COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2	CHEMBL1289601
P11362	FGFR1_HUMAN	lenvatinib	7.337242126464844	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf	COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2	CHEMBL1289601
P16234	PGFRA_HUMAN	lenvatinib	7.2924299240112305	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf	COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2	CHEMBL1289601
P10721	KIT_HUMAN	lenvatinib	7.0	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf	COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2	CHEMBL1289601
P07949	RET_HUMAN	lenvatinib	8.82	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf	COC1=CC2=C(C=C1C(N)=O)C(OC1=CC=C(NC(=O)NC3CC3)C(Cl)=C1)=CC=N2	CHEMBL1289601
P20309	ACM3_HUMAN	pilocarpine	6.96999979019165	EC50	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=305	CC[C@H]1[C@@H](CC2=CN=CN2C)COC1=O	CHEMBL550
P12268	IMDH2_HUMAN	mycophenolate mofetil	8.154901504516602	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10878285	COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1	CHEMBL1456
P20839	IMDH1_HUMAN	mycophenolate mofetil	7.481485843658447	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10878285	COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1	CHEMBL1456
P27338	AOFB_HUMAN	safinamide	6.346787452697754	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17030736	C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O	CHEMBL48582
Q15116	PDCD1_HUMAN	nivolumab	9.14	Kd	ANTIBODY BINDING	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/24872026		CHEMBL2108738
P11229	ACM1_HUMAN	glycopyrronium bromide	9.6899995803833	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201027	C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1	CHEMBL1201027
P08172	ACM2_HUMAN	glycopyrronium bromide	9.25	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7459	C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1	CHEMBL1201027
P20309	ACM3_HUMAN	glycopyrronium bromide	9.640000343322754	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201027	C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1	CHEMBL1201027
P08173	ACM4_HUMAN	glycopyrronium bromide	9.0600004196167	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7459	C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1	CHEMBL1201027
P08912	ACM5_HUMAN	glycopyrronium bromide	8.90999984741211	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7459	C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1	CHEMBL1201027
Q8NER1	TRPV1_HUMAN	zucapsaicin	7.710000038146973	EC50	OPENER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/25171227	COC1=CC(CNC(=O)CCCC\C=C/C(C)C)=CC=C1O	CHEMBL313971
P15391	CD19_HUMAN	blinatumomab	9.0	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125557lbl.pdf		CHEMBL1742992
P04234	CD3D_HUMAN	blinatumomab	7.0	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125557lbl.pdf		CHEMBL1742992
P07766	CD3E_HUMAN	blinatumomab	7.0	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125557lbl.pdf		CHEMBL1742992
P09693	CD3G_HUMAN	blinatumomab	7.0	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125557lbl.pdf		CHEMBL1742992
P07550	ADRB2_HUMAN	reproterol			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10364735	CN1C2=C(N(CCCNCC(O)C3=CC(O)=CC(O)=C3)C=N2)C(=O)N(C)C1=O	CHEMBL1095607
P08588	ADRB1_HUMAN	etilefrine			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/4396765	CCNCC(O)C1=CC(O)=CC=C1	CHEMBL86882
P08588	ADRB1_HUMAN	etilefrine pivalate			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/4396765	CCNCC(O)C1=CC(OC(=O)C(C)(C)C)=CC=C1	CHEMBL2105571
Q9Y271	CLTR1_HUMAN	cinalukast			ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23859232	CCC(CC)(CC(=O)NC1=CC=CC(\C=C\C2=NC(=CS2)C2CCC2)=C1)C(O)=O	CHEMBL283754
Q9Y271	CLTR1_HUMAN	pranlukast	10.0	IC50	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23859232	O=C(NC1=CC=CC2=C1OC(=CC2=O)C1=NN=NN1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1	CHEMBL21333
Q01718	ACTHR_HUMAN	tetracosactide	8.267605781555176	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103784	[H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(O)=O	CHEMBL2103784
Q01718	ACTHR_HUMAN	seractide	8.008773803710938	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17877367	[H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O	CHEMBL1201489
Q92736	RYR2_HUMAN	hydralazine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23319593	NNC1=NN=CC2=CC=CC=C12	CHEMBL276832
Q14524	SCN5A_HUMAN	benzocaine	3.494849920272827	ED50	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12173241	CCOC(=O)C1=CC=C(N)C=C1	CHEMBL278172
P35498	SCN1A_HUMAN	benzocaine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12173241	CCOC(=O)C1=CC=C(N)C=C1	CHEMBL278172
Q99250	SCN2A_HUMAN	benzocaine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12173241	CCOC(=O)C1=CC=C(N)C=C1	CHEMBL278172
Q9NY46	SCN3A_HUMAN	benzocaine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12173241	CCOC(=O)C1=CC=C(N)C=C1	CHEMBL278172
P35499	SCN4A_HUMAN	benzocaine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12173241	CCOC(=O)C1=CC=C(N)C=C1	CHEMBL278172
Q01118	SCN7A_HUMAN	benzocaine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12173241	CCOC(=O)C1=CC=C(N)C=C1	CHEMBL278172
Q9UQD0	SCN8A_HUMAN	benzocaine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12173241	CCOC(=O)C1=CC=C(N)C=C1	CHEMBL278172
Q15858	SCN9A_HUMAN	benzocaine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12173241	CCOC(=O)C1=CC=C(N)C=C1	CHEMBL278172
Q9Y5Y9	SCNAA_HUMAN	benzocaine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12173241	CCOC(=O)C1=CC=C(N)C=C1	CHEMBL278172
Q9UI33	SCNBA_HUMAN	benzocaine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12173241	CCOC(=O)C1=CC=C(N)C=C1	CHEMBL278172
P14416	DRD2_HUMAN	lurasidone	9.00261402130127	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603s015lbl.pdf	[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@@]1([H])CN1CCN(CC1)C1=NSC3=C1C=CC=C3)C2=O	CHEMBL1237021
P28223	5HT2A_HUMAN	lurasidone	9.327901840209961	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603s015lbl.pdf	[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@@]1([H])CN1CCN(CC1)C1=NSC3=C1C=CC=C3)C2=O	CHEMBL1237021
P43220	GLP1R_HUMAN	dulaglutide			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000Lbl.pdf		CHEMBL2108027
P04150	GCR_HUMAN	methylprednisolone acetate			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011757s103lbl.pdf	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	CHEMBL1200844
P35354	PGH2_HUMAN	aceclofenac			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11556519	OC(=O)COC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1	CHEMBL93645
P00374	DYR_HUMAN	methotrexate	8.92	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205776s000lbl.pdf	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CHEMBL426
P07550	ADRB2_HUMAN	tulobuterol			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/15212190	CC(C)(C)NCC(O)C1=C(Cl)C=CC=C1	CHEMBL1159717
Q13370	PDE3B_HUMAN	olprinone			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/9726653	CC1=C(C=C(C#N)C(=O)N1)C1=CN2C=CN=C2C=C1	CHEMBL1474900
Q14432	PDE3A_HUMAN	olprinone			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/9726653	CC1=C(C=C(C#N)C(=O)N1)C1=CN2C=CN=C2C=C1	CHEMBL1474900
P16233	LIPP_HUMAN	cetilistat	8.225482940673828	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/18500680	CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C)C=C2)C(=O)O1	CHEMBL2103825
P47989	XDH_HUMAN	topiroxostat	8.275724411010742	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19783139	N#CC1=NC=CC(=C1)C1=NNC(=N1)C1=CC=NC=C1	CHEMBL1078685
P31639	SC5A2_HUMAN	ipragliflozin	8.131943702697754	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22139434	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC3=C(S2)C=CC=C3)=C(F)C=C1	CHEMBL2018096
P31639	SC5A2_HUMAN	luseogliflozin	8.645891189575195	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20302302	CCOC1=CC=C(CC2=C(C)C=C(OC)C(=C2)[C@@H]2S[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1	
P31639	SC5A2_HUMAN	tofogliflozin	8.537602424621582	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22889351	CCC1=CC=C(CC2=CC3=C(CO[C@]33O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C2)C=C1	CHEMBL2105711
P19971	TYPH_HUMAN	tipiracil	7.698969841003418	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf	ClC1=C(CN2CCCC2=N)NC(=O)NC1=O	CHEMBL65375
P27487	DPP4_HUMAN	teneligliptin	9.431797981262207	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22959556	[H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCSC1)N1CCN(CC1)C1=CC(C)=NN1C1=CC=CC=C1	CHEMBL2147777
P27487	DPP4_HUMAN	anagliptin	8.42021656036377	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22019046	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N	CHEMBL1929387
P25092	GUC2C_HUMAN	linaclotide	8.906578063964844	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20863829	[H]N[C@H]1CSSC[C@@H]2NC(=O)[C@@H]3CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N3)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O	CHEMBL3301675
O43613	OX1R_HUMAN	suvorexant	9.259636878967285	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20565075	C[C@@H]1CCN(CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2	CHEMBL1083659
O43614	OX2R_HUMAN	suvorexant	9.455931663513184	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20565075	C[C@@H]1CCN(CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2	CHEMBL1083659
Q96SW2	CRBN_HUMAN	thalidomide	6.392973899841309	EC50	MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/26131937	O=C1N(C2CCC(=O)NC2=O)C(=O)C2=C1C=CC=C2	CHEMBL468
Q96SW2	CRBN_HUMAN	lenalidomide	6.527390003204346	EC50	MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/26131937	NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1	CHEMBL848
Q96SW2	CRBN_HUMAN	pomalidomide	6.57708215713501	EC50	MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/26131937	NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O	CHEMBL43452
P13945	ADRB3_HUMAN	mirabegron	7.649752140045166	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17293563	NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1	CHEMBL2095212
Q9UM73	ALK_HUMAN	ceritinib	9.698969841003418	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23742252	CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1	CHEMBL2403108
P25116	PAR1_HUMAN	vorapaxar	8.091514587402344	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/18447380	[H][C@@]12C[C@]3([H])C[C@@H](CC[C@@]3([H])[C@H](\C=C\C3=CC=C(C=N3)C3=CC(F)=CC=C3)[C@]1([H])[C@@H](C)OC2=O)NC(=O)OCC	CHEMBL493982
P27487	DPP4_HUMAN	gemigliptin	7.79587984085083	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://professional.diabetes.org/Content/Posters/2008/p502-P.pdf	N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCC2=C(N=C(N=C2C1)C(F)(F)F)C(F)(F)F	CHEMBL3707235
Q16739	CEGT_HUMAN	eliglustat	6.826813697814941	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22058426	CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1	CHEMBL2110588
P31645	SC6A4_HUMAN	levomilnacipran	7.95078182220459	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23499664	CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1	CHEMBL99946
P23975	SC6A2_HUMAN	levomilnacipran	7.035269260406494	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23499664	CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1	CHEMBL99946
Q08499	PDE4D_HUMAN	apremilast	7.130768299102783	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19256507	CCOC1=C(OC)C=CC(=C1)[C@@H](CS(C)(=O)=O)N1C(=O)C2=CC=CC(NC(C)=O)=C2C1=O	CHEMBL514800
P31639	SC5A2_HUMAN	empagliflozin	7.2441253662109375	Kd	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21985634	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1	CHEMBL2107830
P43088	PF2R_HUMAN	travoprost	7.28399658203125	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10454045	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC(=CC=C1)C(F)(F)F	CHEMBL1200799
P48039	MTR1A_HUMAN	tasimelteon	9.449999809265137	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22640220	[H][C@@]1(CNC(=O)CC)C[C@@]1([H])C1=C2CCOC2=CC=C1	CHEMBL2103822
P49286	MTR1B_HUMAN	tasimelteon	9.800000190734863	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22640220	[H][C@@]1(CNC(=O)CC)C[C@@]1([H])C1=C2CCOC2=CC=C1	CHEMBL2103822
P07550	ADRB2_HUMAN	olodaterol	9.140000343322754	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20371707	COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1	CHEMBL605846
P43220	GLP1R_HUMAN	lixisenatide	8.844663619995117	IC50	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7387	[H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O	CHEMBL2108336
P20309	ACM3_HUMAN	umeclidinium	10.221848487854004	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19317446	OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2	CHEMBL523299
P46098	5HT3A_HUMAN	vortioxetine	8.431797981262207	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21486038	CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1	CHEMBL2104993
P34969	5HT7R_HUMAN	vortioxetine	7.721246242523193	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21486038	CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1	CHEMBL2104993
P28222	5HT1B_HUMAN	vortioxetine	7.481485843658447	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21486038	CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1	CHEMBL2104993
P08908	5HT1A_HUMAN	vortioxetine	7.823908805847168	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21486038	CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1	CHEMBL2104993
P31645	SC6A4_HUMAN	vortioxetine	8.795880317687988	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21486038	CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1	CHEMBL2104993
Q02153	GCYB1_HUMAN	riociguat	7.522878646850586	MEC	POSITIVE ALLOSTERIC MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19263460	COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=NC=CC=C12	CHEMBL2107834
P25101	EDNRA_HUMAN	macitentan	9.301030158996582	IC50	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22862294	CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1	CHEMBL2103873
P24530	EDNRB_HUMAN	macitentan	6.407823085784912	IC50	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22862294	CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1	CHEMBL2103873
O76074	PDE5A_HUMAN	avanafil	8.28399658203125	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1963681	COC1=C(Cl)C=C(CNC2=NC(=NC=C2C(=O)NCC2=NC=CC=N2)N2CCC[C@H]2CO)C=C1	CHEMBL1963681
P35372	OPRM_HUMAN	tapentadol	7.017728805541992	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201776	CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1	CHEMBL1201776
P23975	SC6A2_HUMAN	tapentadol	6.318758964538574	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201776	CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1	CHEMBL1201776
P04150	GCR_HUMAN	fluorometholone acetate	8.346799850463867	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201064	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	CHEMBL1201064
P35968	VGFR2_HUMAN	cabozantinib	10.455931663513184	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf	COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC	CHEMBL2103868
P08581	MET_HUMAN	cabozantinib	8.886056900024414	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf	COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC	CHEMBL2103868
P07949	RET_HUMAN	cabozantinib	8.28399658203125	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf	COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC	CHEMBL2103868
Q02763	TIE2_HUMAN	cabozantinib	7.844664096832275	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf	COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC	CHEMBL2103868
P36888	FLT3_HUMAN	cabozantinib	7.946921348571777	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf	COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC	CHEMBL2103868
P10721	KIT_HUMAN	cabozantinib	8.337242126464844	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf	COC1=CC2=NC=CC(OC3=CC=C(NC(=O)C4(CC4)C(=O)NC4=CC=C(F)C=C4)C=C3)=C2C=C1OC	CHEMBL2103868
P00519	ABL1_HUMAN	ponatinib	9.431797981262207	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1171837	CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1	CHEMBL1171837
P13569	CFTR_HUMAN	crofelemer	5.15490198135376	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202292s000lbl.pdf		CHEMBL2108184
Q5XXA6	ANO1_HUMAN	crofelemer	5.187086582183838	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202292s000lbl.pdf		CHEMBL2108184
Q99720	SGMR1_HUMAN	pentazocine	8.76	EC50	MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL560	[H]C12CC3=CC=C(O)C=C3C(C)(CCN1CC=C(C)C)C2C	CHEMBL560
P16444	DPEP1_HUMAN	cilastatin	6.9586	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL766	[H][C@@]1(CC1(C)C)C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O	CHEMBL766
P13631	RARG_HUMAN	alitretinoin	7.13	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL705	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	CHEMBL705
P13631	RARG_HUMAN	tretinoin	6.7	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL38	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O	CHEMBL38
P17787	ACHB2_HUMAN	varenicline	9.3979	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1396	[H][C@]12C[C@]([H])(CNC1)C1=C2C=C2N=CC=NC2=C1	CHEMBL1396
P43681	ACHA4_HUMAN	varenicline	9.3979	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1396	[H][C@]12C[C@]([H])(CNC1)C1=C2C=C2N=CC=NC2=C1	CHEMBL1396
P30926	ACHB4_HUMAN	trimetaphan			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1245	O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1	CHEMBL1245
P32297	ACHA3_HUMAN	trimetaphan			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1245	O=C1N(CC2=CC=CC=C2)C2C[S+]3CCCC3C2N1CC1=CC=CC=C1	CHEMBL1245
P17787	ACHB2_HUMAN	nicotine	8.56	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3	CN1CCC[C@H]1C1=CC=CN=C1	CHEMBL3
P43681	ACHA4_HUMAN	nicotine	8.56	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3	CN1CCC[C@H]1C1=CC=CN=C1	CHEMBL3
P30926	ACHB4_HUMAN	mecamylamine	6.2218	Ki	NEGATIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL267936	[H]C12CCC([H])(C1)C(C)(NC)C2(C)C	CHEMBL267936
P32297	ACHA3_HUMAN	mecamylamine	6.2218	Ki	NEGATIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL267936	[H]C12CCC([H])(C1)C(C)(NC)C2(C)C	CHEMBL267936
P36507	MP2K2_HUMAN	trametinib	9.036212	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103875	CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=C(F)C=C(I)C=C1)C1=CC(NC(C)=O)=CC=C1	CHEMBL2103875
Q02750	MP2K1_HUMAN	trametinib	8.744727	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103875	CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=C(F)C=C(I)C=C1)C1=CC(NC(C)=O)=CC=C1	CHEMBL2103875
P31639	SC5A2_HUMAN	canagliflozin	8.6575775	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2048484	CC1=C(CC2=CC=C(S2)C2=CC=C(F)C=C2)C=C(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	CHEMBL2048484
P55157	MTP_HUMAN	lomitapide	8.09691	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL354541	FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=C1C=CC=C2	CHEMBL354541
P43220	GLP1R_HUMAN	liraglutide	10.2	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201866	[H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O	CHEMBL1201866
P32754	HPPD_HUMAN	nitisinone	7.398	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1337	[O-][N+](=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C1C(=O)CCCC1=O	CHEMBL1337
P21817	RYR1_HUMAN	dantrolene	6.757	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL928	[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O	CHEMBL928
P27487	DPP4_HUMAN	sitagliptin	7.774	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1422	N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1	CHEMBL1422
P07949	RET_HUMAN	sunitinib	8.8	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021938s027lbl.pdf	CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C	CHEMBL535
P15056	BRAF_HUMAN	dabrafenib	9.1549015	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2028663	CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1	CHEMBL2028663
P43088	PF2R_HUMAN	bimatoprost	5.3	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200963	CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1	CHEMBL1200963
Q8TCC7	S22A8_HUMAN	probenecid			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL897	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CHEMBL897
P12268	IMDH2_HUMAN	thioguanine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL727	NC1=NC2=C(NC=N2)C(=S)N1	CHEMBL727
Q16739	CEGT_HUMAN	miglustat	5.13	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1029	CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	CHEMBL1029
P00797	RENI_HUMAN	aliskiren	9.22	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1639	[H][C@@](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)(CC1=CC(OCCCOC)=C(OC)C=C1)C(C)C	CHEMBL1639
P25786	PSA1_HUMAN	bortezomib	9.2076	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL325041	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O	CHEMBL325041
O43451	MGA_HUMAN	acarbose	5.6968	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL404271	[H][C@]1(N[C@@H]2[C@@H](C)O[C@H](O[C@]3([H])[C@@H](CO)O[C@H](O[C@]4([H])[C@@H](CO)OC(O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)C=C(CO)[C@@H](O)[C@H](O)[C@H]1O	CHEMBL404271
P43116	PE2R2_HUMAN	alprostadil	8.0	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL495	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	CHEMBL495
P16233	LIPP_HUMAN	orlistat	8.9	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020766s035lbl.pdf	CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	CHEMBL175247
P27815	PDE4A_HUMAN	theophylline	4.11	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL190	CN1C2=C(N=CN2)C(=O)N(C)C1=O	CHEMBL190
Q9Y5Y9	SCNAA_HUMAN	ropivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1077896	CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C	CHEMBL1077896
Q9Y5Y9	SCNAA_HUMAN	orphenadrine	5.2007	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL900	CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1	CHEMBL900
P25101	EDNRA_HUMAN	ambrisentan	9.65	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022081s033lbl.pdf	COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1111
P15538	C11B1_HUMAN	mitotane			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1670	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1	CHEMBL1670
P11473	VDR_HUMAN	colecalciferol	9.68	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1042	[H][C@@]12CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C	CHEMBL1042
P11473	VDR_HUMAN	ergocalciferol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1536	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	CHEMBL1536
P11473	VDR_HUMAN	paricalcitol	8.7	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200622	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1	CHEMBL1200622
P11473	VDR_HUMAN	calcitriol	8.4	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL846	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)CCCC(C)(C)O	CHEMBL846
P10826	RARB_HUMAN	alitretinoin	7.3	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL705	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	CHEMBL705
P10826	RARB_HUMAN	tretinoin	6.7	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL38	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O	CHEMBL38
P48443	RXRG_HUMAN	alitretinoin	6.66	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL705	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	CHEMBL705
P28702	RXRB_HUMAN	alitretinoin	6.7	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL705	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	CHEMBL705
P19793	RXRA_HUMAN	alitretinoin	6.5	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL705	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	CHEMBL705
O76074	PDE5A_HUMAN	vardenafil	9.1549	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1339	CCCC1=NC(C)=C2N1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(CC)CC1	CHEMBL1339
O76074	PDE5A_HUMAN	sildenafil	9.0	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL192	CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1	CHEMBL192
P37231	PPARG_HUMAN	troglitazone	6.27	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408	[H]C1(CC2=CC=C(OCC3(C)CCC4=C(C)C(O)=C(C)C(C)=C4O3)C=C2)SC(=O)NC1=O	CHEMBL408
P37231	PPARG_HUMAN	rosiglitazone	7.04	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL121	CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1	CHEMBL121
P37231	PPARG_HUMAN	pioglitazone	6.23	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL595	CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1	CHEMBL595
P30518	V2R_HUMAN	tolvaptan	9.0	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022275s014lbl.pdf	CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=CC(Cl)=CC=C12	CHEMBL344159
Q969P6	TOP1M_HUMAN	topotecan			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL84	CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(CN(C)C)C(O)=CC=C4N=C13)C2=O	CHEMBL84
P00533	EGFR_HUMAN	erlotinib	9.22	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL553	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC=CC(=C1)C#C)=NC=N2	CHEMBL553
P30556	AGTR1_HUMAN	candesartan cilexetil			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1014	CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1	CHEMBL1014
P08473	NEP_HUMAN	racecadotril	9.0	IC50	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D08464	CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC1=CC=CC=C1	CHEMBL10247
P00519	ABL1_HUMAN	dasatinib	9.6	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1421	CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1	CHEMBL1421
P49286	MTR1B_HUMAN	ramelteon	10.39	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1218	CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2	CHEMBL1218
P48039	MTR1A_HUMAN	ramelteon	10.9	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1218	CCC(=O)NCC[C@@H]1CCC2=C1C1=C(OCC1)C=C2	CHEMBL1218
P00734	THRB_HUMAN	ximelagatran	6.4318	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10102460	CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(=N)NO	CHEMBL266349
P00734	THRB_HUMAN	argatroban	7.39794	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1166	C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2	CHEMBL1166
P07202	PERT_HUMAN	propylthiouracil	5.06	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1518	CCCC1=CC(=O)NC(=S)N1	CHEMBL1518
P07202	PERT_HUMAN	thiamazole	5.57	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1515	CN1C=CNC1=S	CHEMBL1515
P09917	LOX5_HUMAN	sulfasalazine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL421	OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1	CHEMBL421
P09917	LOX5_HUMAN	meclofenamic acid	4.33	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL509	CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl	CHEMBL509
P30968	GNRHR_HUMAN	triptorelin	9.025	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200554	CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	CHEMBL1200554
P30968	GNRHR_HUMAN	nafarelin	9.699	Kd	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200671	CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	CHEMBL1200671
P30968	GNRHR_HUMAN	leuprorelin	9.5229	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200775	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1	CHEMBL1200775
P43119	PI2R_HUMAN	iloprost	7.75	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL494	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O	CHEMBL494
P43119	PI2R_HUMAN	epoprostenol	7.8	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL962	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	CHEMBL962
P05091	ALDH2_HUMAN	disulfiram			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL964	CCN(CC)C(=S)SSC(=S)N(CC)CC	CHEMBL964
O43570	CAH12_HUMAN	dichlorphenamide	7.301	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL17	NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O	CHEMBL17
Q9H244	P2Y12_HUMAN	ticlopidine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL833	ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1	CHEMBL833
Q9H244	P2Y12_HUMAN	clopidogrel	6.9	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1771	COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C1=C(Cl)C=CC=C1	CHEMBL1771
P00813	ADA_HUMAN	pentostatin	10.8	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1580	OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1NC=NC[C@H]2O	CHEMBL1580
P11511	CP19A_HUMAN	testolactone	4.46	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1571	[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)OC(=O)CC[C@@]21[H]	CHEMBL1571
P11511	CP19A_HUMAN	letrozole	8.22	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1444	N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N	CHEMBL1444
P11511	CP19A_HUMAN	exemestane	5.6925	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200374	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=C)C2=CC(=O)C=C[C@]12C	CHEMBL1200374
P11511	CP19A_HUMAN	anastrozole	6.2218	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1399	CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N	CHEMBL1399
P11511	CP19A_HUMAN	aminoglutethimide	5.11	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL488	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	CHEMBL488
P09884	DPOLA_HUMAN	fludarabine phosphate			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020038s033lbl.pdf	NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]3O)C2=NC(F)=N1	CHEMBL1568
P09884	DPOLA_HUMAN	clofarabine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1750	NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F)C2=NC(Cl)=N1	CHEMBL1750
Q05940	VMAT2_HUMAN	tetrabenazine	7.0	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL117785	[H][C@@]12CC(=O)[C@@H](CC(C)C)CN1CCC1=C2C=C(OC)C(OC)=C1	CHEMBL117785
Q05940	VMAT2_HUMAN	reserpine	7.9	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL772	[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2	CHEMBL772
Q13224	NMDE2_HUMAN	felbamate	4.284	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1094	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CHEMBL1094
P15121	ALDR_HUMAN	tolrestat	8.5086	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/6422042	COC1=CC=C2C(=CC=CC2=C1C(F)(F)F)C(=S)N(C)CC(O)=O	CHEMBL436
P15121	ALDR_HUMAN	epalrestat	7.6778	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/3025043	C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/C1=CC=CC=C1	CHEMBL56337
P47989	XDH_HUMAN	febuxostat	9.22	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1164729	CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N	CHEMBL1164729
Q9BQB6	VKOR1_HUMAN	warfarin	7.0	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1464	CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CHEMBL1464
Q9BQB6	VKOR1_HUMAN	phenindione			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL711	O=C1C(C(=O)C2=C1C=CC=C2)C1=CC=CC=C1	CHEMBL711
Q92731	ESR2_HUMAN	raloxifene	8.0	EC50	MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL81	OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2	CHEMBL81
Q92731	ESR2_HUMAN	fulvestrant	8.74	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1358	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]	CHEMBL1358
P20839	IMDH1_HUMAN	thioguanine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL727	NC1=NC2=C(NC=N2)C(=S)N1	CHEMBL727
P20839	IMDH1_HUMAN	ribavirin	6.0	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1643	NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	CHEMBL1643
P26358	DNMT1_HUMAN	decitabine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201129	NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1	CHEMBL1201129
O95180	CAC1H_HUMAN	mibefradil	6.6021	IC50	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/18974361	COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=CC(F)=CC=C2[C@@H]1C(C)C	CHEMBL45816
O95180	CAC1H_HUMAN	bepridil	5.1487	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1008	CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1	CHEMBL1008
P35346	SSR5_HUMAN	octreotide	8.5229	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408687	[H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC1=O)[C@@H](C)O)C(=O)N[C@]([H])(CO)[C@@]([H])(C)O	CHEMBL408687
P32745	SSR3_HUMAN	octreotide	8.3	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408687	[H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC1=O)[C@@H](C)O)C(=O)N[C@]([H])(CO)[C@@]([H])(C)O	CHEMBL408687
P30874	SSR2_HUMAN	octreotide	10.699	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408687	[H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC1=O)[C@@H](C)O)C(=O)N[C@]([H])(CO)[C@@]([H])(C)O	CHEMBL408687
P22303	ACES_HUMAN	tacrine	7.14	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL95	NC1=C2CCCCC2=NC2=CC=CC=C12	CHEMBL95
P22303	ACES_HUMAN	neostigmine	7.59	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL278020	CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C	CHEMBL278020
P22303	ACES_HUMAN	donepezil	7.8	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL502	COC1=CC2=C(C=C1OC)C(=O)C(CC1CCN(CC3=CC=CC=C3)CC1)C2	CHEMBL502
P41143	OPRD_HUMAN	nalbuphine	6.0	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL895	[H][C@@]12OC3=C4C(C[C@@]5([H])N(CC6CCC6)CC[C@@]14[C@@]5(O)CC[C@@H]2O)=CC=C3O	CHEMBL895
P41143	OPRD_HUMAN	naltrexone	7.99	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL19019	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O	CHEMBL19019
Q13639	5HT4R_HUMAN	metoclopramide	6.0	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL86	CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1	CHEMBL86
P00374	DYR_HUMAN	pemetrexed	5.1805	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL225072	NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1	CHEMBL225072
P04035	HMDH_HUMAN	simvastatin	7.77	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1064	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC	CHEMBL1064
P04035	HMDH_HUMAN	pitavastatin	8.1675	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201753	O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C2=C(C=CC=C2)N=C1C1CC1)CC(O)=O	CHEMBL1201753
P04035	HMDH_HUMAN	lovastatin	7.67	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL503	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CHEMBL503
P04035	HMDH_HUMAN	cerivastatin	8.0	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1477	COCC1=C(C2=CC=C(F)C=C2)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(N=C1C(C)C)C(C)C	CHEMBL1477
P04035	HMDH_HUMAN	atorvastatin	8.0	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL393220	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1	CHEMBL393220
P06401	PRGR_HUMAN	progesterone	9.8761	ED50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL103	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL103
P06401	PRGR_HUMAN	norgestimate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200934	[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O	CHEMBL1200934
P06401	PRGR_HUMAN	norethindrone acetate	11.2596	ED50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1162	[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	CHEMBL1162
P06401	PRGR_HUMAN	norethisterone	11.2596	ED50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1162	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	CHEMBL1162
P06401	PRGR_HUMAN	norelgestromin			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200807	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(C=C3CC[C@@]21[H])=NO	CHEMBL1200807
P06401	PRGR_HUMAN	mifepristone	8.74	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1276308	[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]	CHEMBL1276308
P06401	PRGR_HUMAN	medroxyprogesterone	9.59	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL717	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C	CHEMBL717
P06401	PRGR_HUMAN	levonorgestrel	12.7959	ED50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1389	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	CHEMBL1389
P06401	PRGR_HUMAN	etonogestrel			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1531	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	CHEMBL1531
P06401	PRGR_HUMAN	etynodiol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200624	[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CC[C@H](OC(C)=O)C=C3CC[C@@]21[H]	CHEMBL1200624
P06401	PRGR_HUMAN	drospirenone	10.5	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1509	[H][C@@]12[C@@H]3C[C@@H]3[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@H]2C[C@H]2C2=CC(=O)CC[C@]12C	CHEMBL1509
P06401	PRGR_HUMAN	desogestrel			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1533	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	CHEMBL1533
P06401	PRGR_HUMAN	danazol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1479	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	CHEMBL1479
Q01668	CAC1D_HUMAN	nifedipine	7.7	IC50	GATING INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL193	COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC	CHEMBL193
Q01668	CAC1D_HUMAN	isradipine	9.3	IC50	GATING INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1648	COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C	CHEMBL1648
Q01668	CAC1D_HUMAN	felodipine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1480	CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC	CHEMBL1480
Q01668	CAC1D_HUMAN	clevidipine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1237132	CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC	CHEMBL1237132
Q01668	CAC1D_HUMAN	amlodipine	7.0	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1491	[H]C1(C2=C(Cl)C=CC=C2)C(C(=O)OC)=C(C)NC(COCCN)=C1C(=O)OCC	CHEMBL1491
P10276	RARA_HUMAN	alitretinoin	6.52	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL705	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	CHEMBL705
P10276	RARA_HUMAN	tretinoin	6.7	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL38	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O	CHEMBL38
P54289	CA2D1_HUMAN	pregabalin	7.0969	IC50	MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1059	CC(C)C[C@H](CN)CC(O)=O	CHEMBL1059
P54289	CA2D1_HUMAN	gabapentin	7.26	IC50	MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL940	NCC1(CC(O)=O)CCCCC1	CHEMBL940
P00915	CAH1_HUMAN	dichlorphenamide	8.301	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL17	NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O	CHEMBL17
P04818	TYSY_HUMAN	pemetrexed	6.4685	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL225072	NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1	CHEMBL225072
P04818	TYSY_HUMAN	capecitabine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1773	CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O	CHEMBL1773
P04818	TYSY_HUMAN	fluorouracil			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL185	FC1=CNC(=O)NC1=O	CHEMBL185
P18405	S5A1_HUMAN	dutasteride	8.49	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200969	[H][C@@]12CC[C@H](C(=O)NC3=C(C=CC(=C3)C(F)(F)F)C(F)(F)F)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C	CHEMBL1200969
P31213	S5A2_HUMAN	finasteride	8.26	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020788s024lbl.pdf	[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C	CHEMBL710
P31213	S5A2_HUMAN	dutasteride	9.2	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200969	[H][C@@]12CC[C@H](C(=O)NC3=C(C=CC(=C3)C(F)(F)F)C(F)(F)F)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C	CHEMBL1200969
O43497	CAC1G_HUMAN	trimethadione			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL695	CN1C(=O)OC(C)(C)C1=O	CHEMBL695
O43497	CAC1G_HUMAN	ethosuximide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL696	CCC1(C)CC(=O)NC1=O	CHEMBL696
P10275	ANDR_HUMAN	testosterone	9.2	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL386630	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL386630
P10275	ANDR_HUMAN	oxymetholone			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200585	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)\C(C[C@]12C)=C/O	CHEMBL1200585
P10275	ANDR_HUMAN	nandrolone phenpropionate	9.5	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200412	[H][C@@]12CC[C@H](OC(=O)CCC3=CC=CC=C3)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	CHEMBL1200412
P03372	ESR1_HUMAN	ospemifene	6.0824943	IC50	MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2105395	OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1	CHEMBL2105395
P03372	ESR1_HUMAN	toremifene			MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1655	CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1	CHEMBL1655
P03372	ESR1_HUMAN	fulvestrant	9.62	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1358	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]	CHEMBL1358
P03372	ESR1_HUMAN	ethinylestradiol	9.83	Kd	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL691	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CHEMBL691
P03372	ESR1_HUMAN	estradiol	10.3	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL135	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CHEMBL135
Q8TCU5	NMD3A_HUMAN	memantine			NEGATIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL807	CC12CC3CC(C)(C1)CC(N)(C3)C2	CHEMBL807
P11388	TOP2A_HUMAN	valrubicin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1096885	[H][C@@]1(C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=C(OC)C=CC=C3C(=O)C1=C2O)C(=O)COC(=O)CCCC	CHEMBL1096885
P11388	TOP2A_HUMAN	teniposide			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL452231	[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@]1([H])O[C@]2([H])CO[C@H](O[C@@]2([H])[C@H](O)[C@H]1O)C1=CC=CS1	CHEMBL452231
P11388	TOP2A_HUMAN	mitoxantrone	5.9586	IC90	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL58	OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(O)C=CC(O)=C1C2=O	CHEMBL58
P11388	TOP2A_HUMAN	idarubicin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1117	[H][C@@]1(C[C@H](N)[C@H](O)[C@H](C)O1)O[C@H]1C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=CC=CC=C1C3=O)C(C)=O	CHEMBL1117
P11388	TOP2A_HUMAN	daunorubicin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL178	[H][C@@]1(C[C@H](N)[C@H](O)[C@H](C)O1)O[C@H]1C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=C(OC)C=CC=C1C3=O)C(C)=O	CHEMBL178
Q13936	CAC1C_HUMAN	verapamil	6.0	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL6966	COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1	CHEMBL6966
Q13936	CAC1C_HUMAN	isradipine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1648	COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C	CHEMBL1648
Q13936	CAC1C_HUMAN	felodipine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1480	CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC	CHEMBL1480
Q13936	CAC1C_HUMAN	diltiazem	7.3188	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL23	COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O	CHEMBL23
Q13936	CAC1C_HUMAN	clevidipine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1237132	CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC	CHEMBL1237132
Q13936	CAC1C_HUMAN	amlodipine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1491	[H]C1(C2=C(Cl)C=CC=C2)C(C(=O)OC)=C(C)NC(COCCN)=C1C(=O)OCC	CHEMBL1491
P55017	S12A3_HUMAN	trichlormethiazide	7.0	A2	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1054	NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C(Cl)Cl)C=C1Cl	CHEMBL1054
P55017	S12A3_HUMAN	polythiazide	9.09	A2	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1587	CN1C(CSCC(F)(F)F)NC2=C(C=C(C(Cl)=C2)S(N)(=O)=O)S1(=O)=O	CHEMBL1587
P55017	S12A3_HUMAN	indapamide	7.54	A2	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL406	[H]C1(C)CC2=C(C=CC=C2)N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O	CHEMBL406
P55017	S12A3_HUMAN	hydroflumethiazide	7.37	A2	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1763	NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F	CHEMBL1763
P55017	S12A3_HUMAN	hydrochlorothiazide	7.01	A2	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL435	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	CHEMBL435
P55017	S12A3_HUMAN	chlorothiazide	5.43	A2	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL842	NS(=O)(=O)C1=C(Cl)C=C2N=CNS(=O)(=O)C2=C1	CHEMBL842
P55017	S12A3_HUMAN	benzthiazide	8.17	A2	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201039	NS(=O)(=O)C1=CC2=C(C=C1Cl)N=C(CSCC1=CC=CC=C1)NS2(=O)=O	CHEMBL1201039
P55017	S12A3_HUMAN	bendroflumethiazide	8.3	A2	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1684	NS(=O)(=O)C1=CC2=C(NC(CC3=CC=CC=C3)NS2(=O)=O)C=C1C(F)(F)F	CHEMBL1684
P08235	MCR_HUMAN	spironolactone	9.8844	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1393	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)SC(C)=O	CHEMBL1393
P08235	MCR_HUMAN	eplerenone	7.0	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1095097	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC	CHEMBL1095097
P08235	MCR_HUMAN	drospirenone	10.5	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1509	[H][C@@]12[C@@H]3C[C@@H]3[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@H]2C[C@H]2C2=CC(=O)CC[C@]12C	CHEMBL1509
P08235	MCR_HUMAN	desoxycorticosterone pivalate	11.0	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200592	[H][C@@]12CC[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1200592
P62937	PPIA_HUMAN	ciclosporin	8.0458	IC50	MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL160	[H][C@]1(NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	CHEMBL160
P62942	FKB1A_HUMAN	tacrolimus	9.398	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL269732	[H][C@]12O[C@](O)([C@H](C)C[C@@H]1OC)C(=O)C(=O)N1CCCC[C@@]1([H])C(=O)O[C@@H]([C@@H](C)[C@@H](O)CC(=O)[C@H](CC=C)\C=C(C)\C[C@H](C)C[C@@H]2OC)C(\C)=C\[C@@H]1CC[C@@H](O)[C@@H](C1)OC	CHEMBL269732
P62942	FKB1A_HUMAN	sirolimus	8.96	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL413	[H][C@@](C)(C[C@]1([H])CC[C@@]([H])(O)[C@@]([H])(C1)OC)[C@]1([H])CC(=O)[C@]([H])(C)\C=C(C)\[C@@]([H])(O)[C@@]([H])(OC)C(=O)[C@]([H])(C)C[C@]([H])(C)\C=C\C=C\C=C(C)\[C@]([H])(C[C@]2([H])CC[C@@]([H])(C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@@]2([H])C(=O)O1)OC	CHEMBL413
P62942	FKB1A_HUMAN	pimecrolimus	9.0	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200686	[H][C@]12O[C@](O)([C@H](C)C[C@@H]1OC)C(=O)C(=O)N1CCCC[C@@]1([H])C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC)\C=C(C)\C[C@H](C)C[C@@H]2OC)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC	CHEMBL1200686
P62942	FKB1A_HUMAN	everolimus	8.25964	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1908360	[H][C@@](C)(C[C@]1([H])CC[C@@]([H])(OCCO)[C@@H](C1)OC)[C@]1([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]2([H])CC[C@@]([H])(C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@@]2([H])C(=O)O1)OC	CHEMBL1908360
P41145	OPRK_HUMAN	oxymorphone	6.8297	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL963	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@H](C4)[C@]1(O)CCC2=O	CHEMBL963
P41145	OPRK_HUMAN	nalbuphine	8.0	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL895	[H][C@@]12OC3=C4C(C[C@@]5([H])N(CC6CCC6)CC[C@@]14[C@@]5(O)CC[C@@H]2O)=CC=C3O	CHEMBL895
P41145	OPRK_HUMAN	naltrexone	8.93	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL19019	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O	CHEMBL19019
P41145	OPRK_HUMAN	dezocine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1685	[H][C@@]12CC3=CC=C(O)C=C3[C@@](C)(CCCCC1)[C@H]2N	CHEMBL1685
P41145	OPRK_HUMAN	buprenorphine	9.01	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL511142	[H][C@@]12OC3=C4C(C[C@@]5([H])N(CC6CC6)CC[C@@]14[C@@]51CC[C@@]2(OC)[C@]([H])(C1)[C@](C)(O)C(C)(C)C)=CC=C3O	CHEMBL511142
P35368	ADA1B_HUMAN	terazosin	9.08	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL611	COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1	CHEMBL611
P35368	ADA1B_HUMAN	phenylephrine	6.9	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1215	CNC[C@H](O)C1=CC(O)=CC=C1	CHEMBL1215
P35368	ADA1B_HUMAN	doxazosin	9.1	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL707	[H]C1(COC2=C(O1)C=CC=C2)C(=O)N1CCN(CC1)C1=NC2=CC(OC)=C(OC)C=C2C(N)=N1	CHEMBL707
P35368	ADA1B_HUMAN	bunazosin			ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01887	CCCC(=O)N1CCCN(CC1)C1=NC2=CC(OC)=C(OC)C=C2C(N)=N1	CHEMBL188185
P46098	5HT3A_HUMAN	ondansetron	7.8	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL46	CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2	CHEMBL46
P46098	5HT3A_HUMAN	metoclopramide	6.699	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL86	CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1	CHEMBL86
P46098	5HT3A_HUMAN	granisetron	8.7	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL289469	[H][C@]1(C[C@]2([H])CCC[C@]([H])(C1)N2C)NC(=O)C1=NN(C)C2=C1C=CC=C2	CHEMBL289469
P25100	ADA1D_HUMAN	terazosin	9.2	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL611	COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1	CHEMBL611
P25100	ADA1D_HUMAN	phenylephrine	5.9	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1215	CNC[C@H](O)C1=CC(O)=CC=C1	CHEMBL1215
P25100	ADA1D_HUMAN	methoxamine	4.9	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL524	COC1=CC(C(O)C(C)N)=C(OC)C=C1	CHEMBL524
P25100	ADA1D_HUMAN	doxazosin	8.85	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL707	[H]C1(COC2=C(O1)C=CC=C2)C(=O)N1CCN(CC1)C1=NC2=CC(OC)=C(OC)C=C2C(N)=N1	CHEMBL707
P00918	CAH2_HUMAN	dichlorphenamide	7.4202	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL17	NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O	CHEMBL17
Q07343	PDE4B_HUMAN	pentoxifylline			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL628	CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C	CHEMBL628
Q07343	PDE4B_HUMAN	diprophylline			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL221190	CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O	CHEMBL221190
P29275	AA2BR_HUMAN	caffeine	4.77	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL113	CN1C=NC2=C1C(=O)N(C)C(=O)N2C	CHEMBL113
P29275	AA2BR_HUMAN	adenosine	4.6198	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL477	NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1	CHEMBL477
P30542	AA1R_HUMAN	adenosine	6.5086	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL477	NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1	CHEMBL477
Q01959	SC6A3_HUMAN	armodafinil	5.4975	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201192	NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1201192
Q01959	SC6A3_HUMAN	sibutramine	6.0255	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1419	CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1	CHEMBL1419
Q01959	SC6A3_HUMAN	phenmetrazine	6.8827	EC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200483	CC1NCCOC1C1=CC=CC=C1	CHEMBL1200483
Q01959	SC6A3_HUMAN	dexamfetamine	6.68	Ki	RELEASING AGENT	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL612	C[C@H](N)CC1=CC=CC=C1	CHEMBL612
Q01959	SC6A3_HUMAN	bupropion	6.28	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL894	CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1	CHEMBL894
P01008	ANT3_HUMAN	heparin	7.85	Kd	ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL526514		CHEMBL526514
P34995	PE2R1_HUMAN	alprostadil	6.8	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL495	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	CHEMBL495
Q15858	SCN9A_HUMAN	ropivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1077896	CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C	CHEMBL1077896
Q15858	SCN9A_HUMAN	orphenadrine	4.7645	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL900	CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1	CHEMBL900
Q15858	SCN9A_HUMAN	mepivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1087	[H]C1(CCCCN1C)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1087
Q9UQD0	SCN8A_HUMAN	ropivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1077896	CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C	CHEMBL1077896
Q9UQD0	SCN8A_HUMAN	mepivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1087	[H]C1(CCCCN1C)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1087
P35499	SCN4A_HUMAN	ropivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1077896	CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C	CHEMBL1077896
P35499	SCN4A_HUMAN	orphenadrine	5.6576	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL900	CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1	CHEMBL900
P35499	SCN4A_HUMAN	mexiletine	4.38	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL558	CC(N)COC1=C(C)C=CC=C1C	CHEMBL558
P35499	SCN4A_HUMAN	mepivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1087	[H]C1(CCCCN1C)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1087
P35499	SCN4A_HUMAN	etidocaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL492	CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C	CHEMBL492
P35499	SCN4A_HUMAN	bupivacaine	6.0	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1098	CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C	CHEMBL1098
P35499	SCN4A_HUMAN	levobupivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200749	CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C	CHEMBL1200749
Q9NY46	SCN3A_HUMAN	ropivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1077896	CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C	CHEMBL1077896
Q9NY46	SCN3A_HUMAN	mepivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1087	[H]C1(CCCCN1C)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1087
Q99250	SCN2A_HUMAN	ropivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1077896	CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C	CHEMBL1077896
Q99250	SCN2A_HUMAN	mepivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1087	[H]C1(CCCCN1C)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1087
P35498	SCN1A_HUMAN	zonisamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL750	NS(=O)(=O)CC1=NOC2=CC=CC=C12	CHEMBL750
P35498	SCN1A_HUMAN	ropivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1077896	CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C	CHEMBL1077896
P35498	SCN1A_HUMAN	orphenadrine	4.8894	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL900	CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1	CHEMBL900
P35498	SCN1A_HUMAN	mepivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1087	[H]C1(CCCCN1C)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1087
Q13621	S12A1_HUMAN	torsemide	6.4	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1148	CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC(C)=CC=C1	CHEMBL1148
Q13621	S12A1_HUMAN	furosemide	6.2	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL35	NS(=O)(=O)C1=CC(C(O)=O)=C(NCC2=CC=CO2)C=C1Cl	CHEMBL35
Q13621	S12A1_HUMAN	ethacrynic acid			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL456	CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1	CHEMBL456
Q13621	S12A1_HUMAN	bumetanide	7.6	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1072	CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O	CHEMBL1072
P18825	ADA2C_HUMAN	tolazoline	5.43	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL770	C(C1=NCCN1)C1=CC=CC=C1	CHEMBL770
P18825	ADA2C_HUMAN	tizanidine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1079	ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1	CHEMBL1079
P18825	ADA2C_HUMAN	dipivefrine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200833	CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1	CHEMBL1200833
P18825	ADA2C_HUMAN	clonidine	6.7	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL134	ClC1=CC=CC(Cl)=C1NC1=NCCN1	CHEMBL134
P18825	ADA2C_HUMAN	brimonidine	8.4685	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL844	BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12	CHEMBL844
P28221	5HT1D_HUMAN	zolmitriptan	8.9	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1185	CN(C)CCC1=CNC2=C1C=C(C[C@H]1COC(=O)N1)C=C2	CHEMBL1185
P28221	5HT1D_HUMAN	rizatriptan	7.9	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL905	CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2	CHEMBL905
P28221	5HT1D_HUMAN	naratriptan	8.7959	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1278	CNS(=O)(=O)CCC1=CC=C2NC=C(C3CCN(C)CC3)C2=C1	CHEMBL1278
P28221	5HT1D_HUMAN	almotriptan	7.5	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1505	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2	CHEMBL1505
P28222	5HT1B_HUMAN	zolmitriptan	7.7	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1185	CN(C)CCC1=CNC2=C1C=C(C[C@H]1COC(=O)N1)C=C2	CHEMBL1185
P28222	5HT1B_HUMAN	rizatriptan	6.9	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL905	CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2	CHEMBL905
P28222	5HT1B_HUMAN	almotriptan	8.0	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1505	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2	CHEMBL1505
P04150	GCR_HUMAN	triamcinolone acetonide	9.3	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1504	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO	CHEMBL1504
P04150	GCR_HUMAN	prednisone	8.0	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL635	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL635
P04150	GCR_HUMAN	prednisolone	7.8	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL131	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL131
P04150	GCR_HUMAN	mifepristone	9.0	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1276308	[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]	CHEMBL1276308
P04150	GCR_HUMAN	methylprednisolone	8.5	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL650	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	CHEMBL650
P04150	GCR_HUMAN	hydrocortisone	8.5	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL389621	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL389621
P04150	GCR_HUMAN	fluticasone propionate	10.74	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1473	[H][C@@]1(C)C[C@@]2([H])[C@]3([H])C[C@]([H])(F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@]([H])(O)C[C@]2(C)[C@@]1(OC(=O)CC)C(=O)SCF	CHEMBL1473
P04150	GCR_HUMAN	flunisolide	9.1	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1512	[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO	CHEMBL1512
P04150	GCR_HUMAN	dexamethasone	8.88	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL384467	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL384467
P04150	GCR_HUMAN	cortisone acetate	6.02	Kd	AGONIST	KEGG DRUG	http://www.kegg.jp/entry/D00973	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL111861
P04150	GCR_HUMAN	ciclesonide	7.43	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2040682	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C	CHEMBL2040682
P04150	GCR_HUMAN	budesonide	10.3	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1370	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(CCC)O2)C(=O)CO	CHEMBL1370
P04150	GCR_HUMAN	betamethasone	8.07	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL632	[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL632
P12821	ACE_HUMAN	trandolapril	8.12	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1519	[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O	CHEMBL1519
P12821	ACE_HUMAN	ramipril	8.3418	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1168	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC	CHEMBL1168
P12821	ACE_HUMAN	lisinopril	8.92	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL419213	NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	CHEMBL419213
P12821	ACE_HUMAN	cilazapril	8.7	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2419701	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O	CHEMBL515606
P12821	ACE_HUMAN	captopril	8.7	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1560	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	CHEMBL1560
P12821	ACE_HUMAN	benazepril	6.51	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL838	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O	CHEMBL838
Q14432	PDE3A_HUMAN	theophylline	3.85	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL190	CN1C2=C(N=CN2)C(=O)N(C)C1=O	CHEMBL190
Q14432	PDE3A_HUMAN	cilostazol	6.7	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL799	O=C1CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C2N1	CHEMBL799
Q14432	PDE3A_HUMAN	amrinone	4.78	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12856	NC1=CC(=CNC1=O)C1=CC=NC=C1	CHEMBL12856
P20309	ACM3_HUMAN	fesoterodine	6.2706	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201764	CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C	CHEMBL1201764
P20309	ACM3_HUMAN	trospium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1888176	[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)[N+]21CCCC1	CHEMBL1888176
P20309	ACM3_HUMAN	tiotropium bromide	11.1	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1182657	[H][C@]1(C[C@H]2[C@@H]3O[C@@H]3[C@@H](C1)[N+]2(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1	CHEMBL1182657
P20309	ACM3_HUMAN	ipratropium	9.2924	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1464005	[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C	CHEMBL1464005
P20309	ACM3_HUMAN	hyoscyamine	9.8	Ki	ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D00147	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1	CHEMBL1257084
P20309	ACM3_HUMAN	cevimeline	7.3188	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL168815	CC1OC2(CS1)CN1CCC2CC1	CHEMBL168815
P20309	ACM3_HUMAN	carbachol	8.699	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL14	C[N+](C)(C)CCOC(N)=O	CHEMBL14
P20309	ACM3_HUMAN	atropine	9.5	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL517712	[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(=O)C(CO)C1=CC=CC=C1)N2C	CHEMBL517712
P08172	ACM2_HUMAN	fesoterodine	6.401	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201764	CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(OC(=O)C(C)C)C=CC(CO)=C1)C(C)C	CHEMBL1201764
P08172	ACM2_HUMAN	hyoscyamine	9.3	Ki	ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D00147	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1	CHEMBL1257084
P08172	ACM2_HUMAN	atropine	8.97	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL517712	[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(=O)C(CO)C1=CC=CC=C1)N2C	CHEMBL517712
P11229	ACM1_HUMAN	scopolamine	9.0	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL569713	CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1	CHEMBL569713
P11229	ACM1_HUMAN	oxyphenonium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200906	CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1	CHEMBL1200906
P11229	ACM1_HUMAN	hyoscyamine	9.0	Ki	ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D00147	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1	CHEMBL1257084
P11229	ACM1_HUMAN	profenamine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1206	CCN(CC)C(C)CN1C2=CC=CC=C2SC2=C1C=CC=C2	CHEMBL1206
P11229	ACM1_HUMAN	cycrimine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200828	OC(CCN1CCCCC1)(C1CCCC1)C1=CC=CC=C1	CHEMBL1200828
P11229	ACM1_HUMAN	cevimeline	7.6383	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL168815	CC1OC2(CS1)CN1CCC2CC1	CHEMBL168815
P11229	ACM1_HUMAN	benzatropine	9.6364	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200383	[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(C1=CC=CC=C1)C1=CC=CC=C1)N2C	CHEMBL1200383
P11229	ACM1_HUMAN	atropine	9.31	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL517712	[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(=O)C(CO)C1=CC=CC=C1)N2C	CHEMBL517712
P25021	HRH2_HUMAN	ranitidine	6.86	Kd	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1790041	CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O	CHEMBL1790041
P25021	HRH2_HUMAN	nizatidine	6.92	Kd	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3183075	CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O	CHEMBL3183075
P25021	HRH2_HUMAN	famotidine	7.93	Kd	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL902	NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1	CHEMBL902
P25021	HRH2_HUMAN	cimetidine	6.14	Kd	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL30	CNC(NCCSCC1=C(C)NC=N1)=NC#N	CHEMBL30
P25021	HRH2_HUMAN	betazole			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200949	NCCC1=NNC=C1	CHEMBL1200949
P35367	HRH1_HUMAN	propiomazine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL252103	CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CC(C)N(C)C)C2=C1	CHEMBL252103
P35367	HRH1_HUMAN	promethazine	9.6198	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL643	CC(CN1C2=CC=CC=C2SC2=C1C=CC=C2)N(C)C	CHEMBL643
P35367	HRH1_HUMAN	orphenadrine	7.9586	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL900	CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1	CHEMBL900
P35367	HRH1_HUMAN	olopatadine	8.284	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1719	CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2	CHEMBL1719
P35367	HRH1_HUMAN	loratadine	6.97	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL998	CCOC(=O)N1CCC(CC1)=C1C2=CC=C(Cl)C=C2CCC2=C1N=CC=C2	CHEMBL998
P35367	HRH1_HUMAN	levocetirizine	7.95	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201190	OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1	CHEMBL1201190
P35367	HRH1_HUMAN	levocabastine	7.279	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1237102	[H][C@@]1(C)CN(CC[C@]1(C(O)=O)C1=CC=CC=C1)[C@@]1([H])CC[C@](CC1)(C#N)C1=CC=C(F)C=C1	CHEMBL1237102
P35367	HRH1_HUMAN	ketotifen	9.5086	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL534	CN1CCC(CC1)=C1C2=C(SC=C2)C(=O)CC2=C1C=CC=C2	CHEMBL534
P35367	HRH1_HUMAN	hydroxyzine	8.699	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL896	OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1	CHEMBL896
P35367	HRH1_HUMAN	fexofenadine	8.0	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL914	CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL914
P35367	HRH1_HUMAN	epinastine	8.9	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1106	[H]C12CN=C(N)N1C1=C(CC3=C2C=CC=C3)C=CC=C1	CHEMBL1106
P35367	HRH1_HUMAN	doxepin	9.75	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022036lbl.pdf	CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2	CHEMBL1628227
P35367	HRH1_HUMAN	diphenylpyraline	8.0757	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1492	CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1492
P35367	HRH1_HUMAN	diphenhydramine	7.81	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL657	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL657
P35367	HRH1_HUMAN	desloratadine	9.4	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1172	ClC1=CC=C2C(CCC3=C(N=CC=C3)C2=C2CCNCC2)=C1	CHEMBL1172
P35367	HRH1_HUMAN	cyproheptadine	10.2218	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL516	CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=C1C=CC=C2	CHEMBL516
P35367	HRH1_HUMAN	clemastine	8.585	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1626	CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1	CHEMBL1626
P35367	HRH1_HUMAN	chlorphenamine	8.15	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL505	CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1	CHEMBL505
P35367	HRH1_HUMAN	cetirizine	7.91	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1000	OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1	CHEMBL1000
P35367	HRH1_HUMAN	bromazine	8.8861	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200967	CN(C)CCOC(C1=CC=CC=C1)C1=CC=C(Br)C=C1	CHEMBL1200967
P35367	HRH1_HUMAN	azelastine	8.1675	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL639	[H]C1(CCCN(C)CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=C(C=CC=C2)C1=O	CHEMBL639
P35367	HRH1_HUMAN	acrivastine	7.16	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1224	CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC(\C=C\C(O)=O)=N1	CHEMBL1224
P35367	HRH1_HUMAN	histamine	4.1	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL90	NCCC1=CN=CN1	CHEMBL90
Q8TDS4	HCAR2_HUMAN	nicotinic acid	7.3	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17705685	OC(=O)C1=CN=CC=C1	CHEMBL573
P28223	5HT2A_HUMAN	paliperidone	8.95860767364502	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021999s029lbl.pdf	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1	CHEMBL1621
P14416	DRD2_HUMAN	paliperidone	8.4700288772583	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021999s029lbl.pdf	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1	CHEMBL1621
P18089	ADA2B_HUMAN	xylometazoline	5.980000019073486	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20030735	CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C	CHEMBL312448
P18825	ADA2C_HUMAN	naphazoline	6.389999866485596	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL761	C(C1=NCCN1)C1=CC=CC2=CC=CC=C12	CHEMBL761
P18089	ADA2B_HUMAN	naphazoline	6.389999866485596	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL761	C(C1=NCCN1)C1=CC=CC2=CC=CC=C12	CHEMBL761
P08913	ADA2A_HUMAN	naphazoline	7.679999828338623	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL761	C(C1=NCCN1)C1=CC=CC2=CC=CC=C12	CHEMBL761
P80404	GABT_HUMAN	vigabatrin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL89598	NC(CCC(O)=O)C=C	CHEMBL89598
O00217	NDUS8_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O00483	NDUA4_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O14561	ACPM_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O15239	NDUA1_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O43181	NDUS4_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O43674	NDUB5_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O43676	NDUB3_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O43677	NDUC1_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O43678	NDUA2_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O43920	NDUS5_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O75251	NDUS7_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O75306	NDUS2_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O75380	NDUS6_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O75438	NDUB1_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O75489	NDUS3_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O95139	NDUB6_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O95167	NDUA3_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O95168	NDUB4_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O95169	NDUB8_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O95178	NDUB2_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O95182	NDUA7_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O95298	NDUC2_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O95299	NDUAA_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
O96000	NDUBA_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P03886	NU1M_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P03891	NU2M_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P03897	NU3M_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P03901	NU4LM_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P03905	NU4M_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P03915	NU5M_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P03923	NU6M_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P17568	NDUB7_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P19404	NDUV2_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P28331	NDUS1_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P49821	NDUV1_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P51970	NDUA8_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P56181	NDUV3_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P56556	NDUA6_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
Q16718	NDUA5_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
Q16795	NDUA9_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
Q86Y39	NDUAB_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
Q8N183	MIMIT_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
Q9BU61	NDUF3_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
Q9NRX3	NUA4L_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
Q9NX14	NDUBB_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
Q9P032	NDUF4_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
Q9P0J0	NDUAD_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
Q9UI09	NDUAC_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
Q9Y375	CIA30_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
Q9Y6M9	NDUB9_HUMAN	metformin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1431	CN(C)C(=N)NC(N)=N	CHEMBL1431
P00747	PLMN_HUMAN	aminocaproic acid	4.4	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1046	NCCCCCC(O)=O	CHEMBL1046
P27338	AOFB_HUMAN	tranylcypromine	7.48	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL313833	N[C@@H]1C[C@H]1C1=CC=CC=C1	CHEMBL313833
Q05940	VMAT2_HUMAN	dexamfetamine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL612	C[C@H](N)CC1=CC=CC=C1	CHEMBL612
P23975	SC6A2_HUMAN	amfetamine			RELEASING AGENT	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL405	CC(N)CC1=CC=CC=C1	CHEMBL405
P47989	XDH_HUMAN	allopurinol	5.15	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1467	OC1=NC=NC2=C1C=NN2	CHEMBL1467
P22303	ACES_HUMAN	pralidoxime	4.59	Kd	ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL14577	C[N+]1=CC=CC=C1C=NO	CHEMBL14577
P51649	SSDH_HUMAN	valproic acid			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL433	CCCC(CCC)C(O)=O	CHEMBL433
P20309	ACM3_HUMAN	acetylcholine	6.66	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL667	CC(=O)OCC[N+](C)(C)C	CHEMBL667
Q01959	SC6A3_HUMAN	trimipramine	5.422508239746094	Ki	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7317	CC(CN(C)C)CN1C2=CC=CC=C2CCC2=C1C=CC=C2	CHEMBL644
P31645	SC6A4_HUMAN	trimipramine	6.826813697814941	Ki	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7317	CC(CN(C)C)CN1C2=CC=CC=C2CCC2=C1C=CC=C2	CHEMBL644
P14416	DRD2_HUMAN	triflupromazine	8.552842140197754	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL570	CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(F)(F)F	CHEMBL570
P14416	DRD2_HUMAN	trifluoperazine	8.840968132019043	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL422	CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1	CHEMBL422
P14416	DRD2_HUMAN	thiothixene	9.346787452697754	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201	CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\C2=C\CCN2CCN(C)CC2)C=C1	CHEMBL1201
P35348	ADA1A_HUMAN	phenylpropanolamine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL61006	CC(N)C(O)C1=CC=CC=C1	CHEMBL61006
P23219	PGH1_HUMAN	aminosalicylic acid			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1169	NC1=CC(O)=C(C=C1)C(O)=O	CHEMBL1169
P35354	PGH2_HUMAN	aminosalicylic acid			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1169	NC1=CC(O)=C(C=C1)C(O)=O	CHEMBL1169
P09917	LOX5_HUMAN	mesalazine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL704	NC1=CC(C(O)=O)=C(O)C=C1	CHEMBL704
O43497	CAC1G_HUMAN	paramethadione			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1100	CCC1(C)OC(=O)N(C)C1=O	CHEMBL1100
O95180	CAC1H_HUMAN	paramethadione			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1100	CCC1(C)OC(=O)N(C)C1=O	CHEMBL1100
Q9P0X4	CAC1I_HUMAN	paramethadione			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1100	CCC1(C)OC(=O)N(C)C1=O	CHEMBL1100
P00747	PLMN_HUMAN	tranexamic acid	5.96	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL877	NC[C@H]1CC[C@@H](CC1)C(O)=O	CHEMBL877
P27338	AOFB_HUMAN	pargyline	5.74	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL673	CN(CC#C)CC1=CC=CC=C1	CHEMBL673
P21397	AOFA_HUMAN	pargyline	5.47	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL673	CN(CC#C)CC1=CC=CC=C1	CHEMBL673
P20309	ACM3_HUMAN	methacholine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL978	CC(C[N+](C)(C)C)OC(C)=O	CHEMBL978
O00591	GBRP_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
O14764	GBRD_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
P14867	GBRA1_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
P18505	GBRB1_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
P18507	GBRG2_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
P28472	GBRB3_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
P31644	GBRA5_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
P34903	GBRA3_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
P47869	GBRA2_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
P47870	GBRB2_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
P48169	GBRA4_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
P78334	GBRE_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
Q16445	GBRA6_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
Q8N1C3	GBRG1_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
Q99928	GBRG3_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
Q9UN88	GBRT_HUMAN	methoxyflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
P23975	SC6A2_HUMAN	pseudoephedrine			RELEASING AGENT	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1590	CN[C@@H](C)[C@@H](O)C1=CC=CC=C1	CHEMBL1590
P22303	ACES_HUMAN	edrophonium	8.79	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL60745	CC[N+](C)(C)C1=CC=CC(O)=C1	CHEMBL60745
P23415	GLRA1_HUMAN	desflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
P48167	GLRB_HUMAN	desflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
O00591	GBRP_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
O14764	GBRD_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
P14867	GBRA1_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
P18505	GBRB1_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
P18507	GBRG2_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
P28472	GBRB3_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
P31644	GBRA5_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
P34903	GBRA3_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
P47869	GBRA2_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
P47870	GBRB2_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
P48169	GBRA4_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
P78334	GBRE_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
Q16445	GBRA6_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
Q8N1C3	GBRG1_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
Q99928	GBRG3_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
Q9UN88	GBRT_HUMAN	desflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
P57789	KCNKA_HUMAN	desflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
Q7Z418	KCNKI_HUMAN	desflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
O14649	KCNK3_HUMAN	desflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
Q9NPC2	KCNK9_HUMAN	desflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
O95069	KCNK2_HUMAN	desflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200733	FC(F)OC(F)C(F)(F)F	CHEMBL1200733
P35368	ADA1B_HUMAN	norepinephrine	4.69	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1437	NC[C@H](O)C1=CC(O)=C(O)C=C1	CHEMBL1437
P18825	ADA2C_HUMAN	norepinephrine	7.2	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1437	NC[C@H](O)C1=CC(O)=C(O)C=C1	CHEMBL1437
P07550	ADRB2_HUMAN	norepinephrine	5.4	Kd	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1437	NC[C@H](O)C1=CC(O)=C(O)C=C1	CHEMBL1437
P11229	ACM1_HUMAN	procyclidine	8.337242126464844	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL86715	OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1	CHEMBL86715
P14416	DRD2_HUMAN	pipotiazine palmitate	9.698969841003418	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7557	CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)S(=O)(=O)N(C)C)CC1	CHEMBL398880
P18089	ADA2B_HUMAN	phenoxybenzamine	8.455931663513184	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL753	CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1	CHEMBL753
Q01959	SC6A3_HUMAN	methamphetamine	7.610834121704102	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200952	CN[C@@H](C)CC1=CC=CC=C1	CHEMBL1200952
P28223	5HT2A_HUMAN	mesoridazine	8.12491512298584	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1088	[H]C1(CCN2C3=CC=CC=C3SC3=C2C=C(C=C3)S(C)=O)CCCCN1C	CHEMBL1088
P14416	DRD2_HUMAN	mesoridazine	7.72445821762085	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1088	[H]C1(CCN2C3=CC=CC=C3SC3=C2C=C(C=C3)S(C)=O)CCCCN1C	CHEMBL1088
P14416	DRD2_HUMAN	fluphenazine enanthate	9.267605781555176	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200951	CCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1	CHEMBL1200951
P14416	DRD2_HUMAN	droperidol	9.602060317993164	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1108	FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2	CHEMBL1108
P31645	SC6A4_HUMAN	clomipramine	9.703356742858887	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL415	CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2	CHEMBL415
P35367	HRH1_HUMAN	brompheniramine	8.217527389526367	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL811	CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1	CHEMBL811
P18089	ADA2B_HUMAN	apraclonidine	7.938393592834473	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL647	NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1	CHEMBL647
Q01959	SC6A3_HUMAN	amfetamine	6.935542106628418	Ki	RELEASING AGENT	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL405	CC(N)CC1=CC=CC=C1	CHEMBL405
Q01959	SC6A3_HUMAN	lisdexamfetamine			RELEASING AGENT	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201178	C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN	CHEMBL1201178
P51788	CLCN2_HUMAN	lubiprostone			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201134	[H][C@@]12CC(=O)[C@]([H])(CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC	CHEMBL1201134
Q9Y5Y9	SCNAA_HUMAN	oxybuprocaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200	CCCCOC1=C(N)C=CC(=C1)C(=O)OCCN(CC)CC	CHEMBL1200
P26439	3BHS2_HUMAN	trilostane			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200907	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	CHEMBL1200907
P35498	SCN1A_HUMAN	topiramate			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
P00439	PH4H_HUMAN	sapropterin	5.4	Ki	ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201774	C[C@H](O)[C@H](O)[C@H]1CNC2=C(N1)C(=O)NC(N)=N2	CHEMBL1201774
P12821	ACE_HUMAN	spirapril	9.1	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL431	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(O)=O)SCCS2	CHEMBL431
P23415	GLRA1_HUMAN	sevoflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
P03372	ESR1_HUMAN	quinestrol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201165	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC1CCCC1)C=C3	CHEMBL1201165
Q9Y5Y9	SCNAA_HUMAN	proparacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1196	CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC	CHEMBL1196
Q9Y5Y9	SCNAA_HUMAN	procaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL569	CCN(CC)CCOC(=O)C1=CC=C(N)C=C1	CHEMBL569
Q9NSA0	S22AB_HUMAN	probenecid			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL897	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CHEMBL897
P27338	AOFB_HUMAN	phenelzine	7.82	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1089	NNCCC1=CC=CC=C1	CHEMBL1089
O76074	PDE5A_HUMAN	pentoxifylline			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL628	CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C	CHEMBL628
P10275	ANDR_HUMAN	oxandrolone			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200436	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)OC[C@]12C	CHEMBL1200436
P25100	ADA1D_HUMAN	norepinephrine	7.4	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1437	NC[C@H](O)C1=CC(O)=C(O)C=C1	CHEMBL1437
P04150	GCR_HUMAN	mometasone furoate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1161	[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1161
P07101	TY3H_HUMAN	metirosine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200862	C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O	CHEMBL1200862
P23415	GLRA1_HUMAN	methoxyflurane			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1341	COC(F)(F)C(Cl)Cl	CHEMBL1341
P35354	PGH2_HUMAN	mesalazine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL704	NC1=CC(C(O)=O)=C(O)C=C1	CHEMBL704
Q06203	PUR1_HUMAN	mercaptopurine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1425	S=C1N=CNC2=C1NC=N2	CHEMBL1425
P35348	ADA1A_HUMAN	mephentermine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200996	CNC(C)(C)CC1=CC=CC=C1	CHEMBL1200996
P06401	PRGR_HUMAN	megestrol acetate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201139	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C	CHEMBL1201139
P04150	GCR_HUMAN	loteprednol etabonate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200865	[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1200865
Q15858	SCN9A_HUMAN	lamotrigine	4.77	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL741	NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1	CHEMBL741
Q9UQD0	SCN8A_HUMAN	lamotrigine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL741	NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1	CHEMBL741
Q9NY46	SCN3A_HUMAN	lamotrigine	4.77	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL741	NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1	CHEMBL741
P35498	SCN1A_HUMAN	lamotrigine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL741	NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1	CHEMBL741
P21397	AOFA_HUMAN	isocarboxazid			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201168	CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1	CHEMBL1201168
P27338	AOFB_HUMAN	isocarboxazid			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201168	CC1=CC(=NO1)C(=O)NNCC1=CC=CC=C1	CHEMBL1201168
P11387	TOP1_HUMAN	irinotecan			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL481	CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12	CHEMBL481
Q14524	SCN5A_HUMAN	indecainide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200341	CC(C)NCCCC1(C(N)=O)C2=CC=CC=C2C2=C1C=CC=C2	CHEMBL1200341
P23975	SC6A2_HUMAN	guanadrel			SUBSTRATE	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1037	NC(=N)NCC1COC2(CCCCC2)O1	CHEMBL1037
Q14524	SCN5A_HUMAN	fosphenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL919	OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL919
P04150	GCR_HUMAN	flumetasone pivalate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200877	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)C(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	CHEMBL1200877
P08235	MCR_HUMAN	fludrocortisone acetate	9.92	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201010	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1201010
P04818	TYSY_HUMAN	floxuridine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL917	OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(F)C(=O)NC1=O	CHEMBL917
Q12879	NMDE1_HUMAN	felbamate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1094	NC(=O)OCC(COC(N)=O)C1=CC=CC=C1	CHEMBL1094
P48443	RXRG_HUMAN	etretinate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL464	CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(C)=C(OC)C=C1C	CHEMBL464
P06401	PRGR_HUMAN	dydrogesterone	6.9	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200853	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C	CHEMBL1200853
Q9Y5Y9	SCNAA_HUMAN	dyclonine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200478	CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1	CHEMBL1200478
P10275	ANDR_HUMAN	drostanolone propionate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201048	[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)[C@H](C)C[C@]12C	CHEMBL1201048
P20309	ACM3_HUMAN	diphemanil			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200880	C[N+]1(C)CCC(CC1)=C(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1200880
P03372	ESR1_HUMAN	dienestrol	4.88	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1018	C\C=C(\C(=C\C)\C1=CC=C(O)C=C1)/C1=CC=C(O)C=C1	CHEMBL1018
Q9Y5Y9	SCNAA_HUMAN	cinchocaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1086	CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC	CHEMBL1086
Q14524	SCN5A_HUMAN	cinchocaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1086	CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC	CHEMBL1086
P35367	HRH1_HUMAN	dexbrompheniramine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200638	CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1	CHEMBL1200638
P22303	ACES_HUMAN	demecarium			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200514	CN(CCCCCCCCCCN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C	CHEMBL1200514
Q9Y5Y9	SCNAA_HUMAN	chloroprocaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL944	CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1	CHEMBL944
P32238	CCKAR_HUMAN	ceruletide			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200755	CSCC[C@H](NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)[C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O	CHEMBL1200755
P14416	DRD2_HUMAN	carfenazine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201328	CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(CCO)CC3)C2=C1	CHEMBL1201328
P00734	THRB_HUMAN	bivalirudin	8.6	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103749	[H]N[C@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O	CHEMBL2103749
P23975	SC6A2_HUMAN	betanidine			SUBSTRATE	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201260	CNC(NC)=NCC1=CC=CC=C1	CHEMBL1201260
P35367	HRH1_HUMAN	bepotastine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201758	OC(=O)CCCN1CCC(CC1)O[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1	CHEMBL1201758
P35367	HRH1_HUMAN	azatadine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL946	CN1CCC(CC1)=C1C2=CC=CC=C2CCC2=C1N=CC=C2	CHEMBL946
P20309	ACM3_HUMAN	octatropine methylbromide			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1578	CCCC(CCC)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C	CHEMBL1578
P11229	ACM1_HUMAN	octatropine methylbromide			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1578	CCCC(CCC)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C	CHEMBL1578
P38435	VKGC_HUMAN	anisindione			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL712	COC1=CC=C(C=C1)C1C(=O)C2=C(C=CC=C2)C1=O	CHEMBL712
Q14432	PDE3A_HUMAN	anagrelide	7.27	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL760	ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl	CHEMBL760
P00750	TPA_HUMAN	aminocaproic acid			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1046	NCCCCCC(O)=O	CHEMBL1046
P14416	DRD2_HUMAN	acetophenazine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1085	CC(=O)C1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(CCO)CC3)C2=C1	CHEMBL1085
P26358	DNMT1_HUMAN	azacitidine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1489	NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	CHEMBL1489
P08588	ADRB1_HUMAN	levdobutamine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1367478	C[C@@H](CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1	CHEMBL1367478
P07550	ADRB2_HUMAN	carvedilol	9.9	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL723	COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1	CHEMBL723
P30968	GNRHR_HUMAN	abarelix	9.49	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1252	CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	CHEMBL1252
P14416	DRD2_HUMAN	cabergoline	9.2	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201087	[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC	CHEMBL1201087
P07550	ADRB2_HUMAN	bupranolol	9.1	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=550	CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1	CHEMBL305380
P35348	ADA1A_HUMAN	oxymetazoline	8.2	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20030735	CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C	CHEMBL762
P14416	DRD2_HUMAN	domperidone	8.4	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=965	ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=C3C=CC=C4)CC1)C(=O)N2	CHEMBL219916
P14416	DRD2_HUMAN	flupentixol	8.82	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=948	OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1	CHEMBL42055
P08588	ADRB1_HUMAN	bupranolol	9.0	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=550	CC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1	CHEMBL305380
P07550	ADRB2_HUMAN	nadolol	8.6	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL649	CC(C)(C)NCC(O)COC1=CC=CC2=C1CC(O)C(O)C2	CHEMBL649
Q13936	CAC1C_HUMAN	nisoldipine	7.1	IC50	GATING INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1726	COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)C	CHEMBL1726
P21728	DRD1_HUMAN	flupentixol	8.4	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=948	OCCN1CCN(CCC=C2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1	CHEMBL42055
P14416	DRD2_HUMAN	piribedil	6.9	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20600305	C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1	CHEMBL1256997
Q01668	CAC1D_HUMAN	nisoldipine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1726	COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)C	CHEMBL1726
Q13639	5HT4R_HUMAN	mosapride	6.9	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8950316	CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1	CHEMBL60889
P08588	ADRB1_HUMAN	practolol	6.8	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=555	CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1	CHEMBL6995
Q01668	CAC1D_HUMAN	nimodipine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1428	COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C	CHEMBL1428
P18089	ADA2B_HUMAN	oxymetazoline	6.2	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20030735	CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C	CHEMBL762
P30542	AA1R_HUMAN	caffeine	4.97	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL113	CN1C=NC2=C1C(=O)N(C)C(=O)N2C	CHEMBL113
P20309	ACM3_HUMAN	propantheline	10.0	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1240	CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=C1C=CC=C2)C(C)C	CHEMBL1240
P11229	ACM1_HUMAN	propantheline	9.7	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1240	CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=C1C=CC=C2)C(C)C	CHEMBL1240
P20309	ACM3_HUMAN	clidinium	9.6	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL620	C[N+]12CCC(CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL620
P08172	ACM2_HUMAN	propantheline	9.5	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1240	CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=C1C=CC=C2)C(C)C	CHEMBL1240
P08588	ADRB1_HUMAN	carvedilol	9.5	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL723	COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=CC=CC=C2N3)C=CC=C1	CHEMBL723
Q13936	CAC1C_HUMAN	nitrendipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17276408	CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC	CHEMBL475534
Q00975	CAC1B_HUMAN	ziconotide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1795072	[H]N[C@H]1CSSC[C@@H]2NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC1=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N3)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(N)=O	CHEMBL1795072
P20309	ACM3_HUMAN	hexocyclium	8.9	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201325	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	CHEMBL1201325
P11229	ACM1_HUMAN	hexocyclium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201325	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	CHEMBL1201325
P10828	THB_HUMAN	levothyroxine	8.52	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL559	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	CHEMBL559
P25100	ADA1D_HUMAN	epinephrine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL679	CNC[C@H](O)C1=CC=C(O)C(O)=C1	CHEMBL679
P08588	ADRB1_HUMAN	nadolol	6.9	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL649	CC(C)(C)NCC(O)COC1=CC=CC2=C1CC(O)C(O)C2	CHEMBL649
Q13936	CAC1C_HUMAN	nimodipine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1428	COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C	CHEMBL1428
P35368	ADA1B_HUMAN	epinephrine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL679	CNC[C@H](O)C1=CC=C(O)C(O)=C1	CHEMBL679
P43115	PE2R3_HUMAN	misoprostol	8.1	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL606	[H][C@@]1(O)CC(=O)[C@]([H])(CCCCCCC(=O)OC)[C@@]1([H])\C=C\CC(C)(O)CCCC	CHEMBL606
P28223	5HT2A_HUMAN	molindone	6.5	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=207	CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2	CHEMBL460
P43088	PF2R_HUMAN	latanoprost	6.3	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1050	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1	CHEMBL1050
P28335	5HT2C_HUMAN	agomelatine	6.2	Ki	ANTAGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000916/WC500038317.pdf	COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1	CHEMBL10878
Q99250	SCN2A_HUMAN	etidocaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL492	CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C	CHEMBL492
O60741	HCN1_HUMAN	ivabradine	5.7	IC50	BLOCKER	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206143Orig1s000lbl.pdf	COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1	CHEMBL471737
P07550	ADRB2_HUMAN	ephedrine	5.6	Ki	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=556	CN[C@@H](C)[C@H](O)C1=CC=CC=C1	CHEMBL211456
Q9UL51	HCN2_HUMAN	ivabradine			BLOCKER	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206143Orig1s000lbl.pdf	COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1	CHEMBL471737
Q9P1Z3	HCN3_HUMAN	ivabradine	5.7	IC50	BLOCKER	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206143Orig1s000lbl.pdf	COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1	CHEMBL471737
P08172	ACM2_HUMAN	dexetimide	8.9	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=354	O=C1CC[C@@](C2CCN(CC3=CC=CC=C3)CC2)(C(=O)N1)C1=CC=CC=C1	CHEMBL1908364
Q99250	SCN2A_HUMAN	lidocaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL79	CCN(CC)CC(=O)NC1=C(C)C=CC=C1C	CHEMBL79
Q14524	SCN5A_HUMAN	lidocaine	4.8	Kd	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL79	CCN(CC)CC(=O)NC1=C(C)C=CC=C1C	CHEMBL79
Q99250	SCN2A_HUMAN	phenytoin	4.9	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL16	O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL16
Q07869	PPARA_HUMAN	bezafibrate	4.3	EC50	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2668	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	CHEMBL264374
P20309	ACM3_HUMAN	bethanechol	4.2	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1482	CC(C[N+](C)(C)C)OC(N)=O	CHEMBL1482
P08172	ACM2_HUMAN	bethanechol	4.0	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1482	CC(C[N+](C)(C)C)OC(N)=O	CHEMBL1482
P35368	ADA1B_HUMAN	methoxamine	4.0	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL524	COC1=CC(C(O)C(C)N)=C(OC)C=C1	CHEMBL524
Q9Y5Y9	SCNAA_HUMAN	lidocaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL79	CCN(CC)CC(=O)NC1=C(C)C=CC=C1C	CHEMBL79
P11473	VDR_HUMAN	doxercalciferol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200810	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\[C@H](C)C(C)C	CHEMBL1200810
P28221	5HT1D_HUMAN	dihydroergotamine	9.9	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1732	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O	CHEMBL1732
P18089	ADA2B_HUMAN	dexmedetomidine	9.7	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL778	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1	CHEMBL778
P18825	ADA2C_HUMAN	dexmedetomidine	9.3	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL778	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1	CHEMBL778
Q8TDS4	HCAR2_HUMAN	acipimox	5.6	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17705685	CC1=CN=C(C=[N+]1[O-])C(O)=O	CHEMBL345714
P47871	GLR_HUMAN	glucagon	9.0	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL266481	[H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O	CHEMBL266481
P28223	5HT2A_HUMAN	terguride	8.3	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21762037	[H][C@@]12CC3=CNC4=C3C(=CC=C4)[C@@]1([H])C[C@@H](CN2C)NC(=O)N(CC)CC	CHEMBL73151
P41595	5HT2B_HUMAN	terguride	8.2	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21762037	[H][C@@]12CC3=CNC4=C3C(=CC=C4)[C@@]1([H])C[C@@H](CN2C)NC(=O)N(CC)CC	CHEMBL73151
P34981	TRFR_HUMAN	taltirelin	6.5	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/15931571	CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCCC1C(N)=O	CHEMBL2107016
P08588	ADRB1_HUMAN	denopamine	5.8	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12487507	COC1=CC=C(CCNC[C@H](O)C2=CC=C(O)C=C2)C=C1OC	CHEMBL493682
Q07869	PPARA_HUMAN	clofibrate	4.25	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL565	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	CHEMBL565
P31645	SC6A4_HUMAN	amoxapine	7.468521083	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1113	ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1	CHEMBL1113
P23975	SC6A2_HUMAN	amoxapine	7.886056648	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1113	ClC1=CC=C2OC3=C(C=CC=C3)N=C(N3CCNCC3)C2=C1	CHEMBL1113
P04150	GCR_HUMAN	beclometasone dipropionate	8.427128398	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1370	[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1370
P11229	ACM1_HUMAN	diphenidol	7.107905397	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL936	OC(CCCN1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL936
P08588	ADRB1_HUMAN	levobunolol	8.399027104	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201177	CC(C)(C)NC[C@H](O)COC1=C2CCCC(=O)C2=CC=C1	CHEMBL1201177
P07550	ADRB2_HUMAN	levobunolol	9.262807357	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201177	CC(C)(C)NC[C@H](O)COC1=C2CCCC(=O)C2=CC=C1	CHEMBL1201177
P03372	ESR1_HUMAN	clomifene	8.886056648	Ki	MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2355051	CCN(CC)CCOC1=CC=C(C=C1)C(=C(Cl)C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL2355051
P35367	HRH1_HUMAN	cyclizine	8.35261703	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL648	CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL648
P25100	ADA1D_HUMAN	dapiprazole	8.388276692	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7155	CC1=C(C=CC=C1)N1CCN(CCC2=NN=C3CCCCN23)CC1	CHEMBL1201044
P04150	GCR_HUMAN	desoximetasone	8.931814138	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL16829	[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL16829
P11229	ACM1_HUMAN	dicycloverine	9.078833949	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1123	CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1	CHEMBL1123
P20309	ACM3_HUMAN	dicycloverine	9.032920266	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1123	CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1	CHEMBL1123
P35367	HRH1_HUMAN	dimenhydrinate	7.431798276	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200406	CN1C2=C(N=C(Cl)N2)C(=O)N(C)C1=O.CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1200406
P27815	PDE4A_HUMAN	dipyridamole	5.80161787	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
P28223	5HT2A_HUMAN	droperidol	9.131943638	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1108	FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=C1C=CC=C2	CHEMBL1108
P08913	ADA2A_HUMAN	epinephrine	6.559090918	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL679	CNC[C@H](O)C1=CC=C(O)C(O)=C1	CHEMBL679
P18089	ADA2B_HUMAN	epinephrine	6.401209493	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL679	CNC[C@H](O)C1=CC=C(O)C(O)=C1	CHEMBL679
P18825	ADA2C_HUMAN	epinephrine	6.448550002	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL679	CNC[C@H](O)C1=CC=C(O)C(O)=C1	CHEMBL679
P23219	PGH1_HUMAN	felbinac	6.048662481	IC50	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D01675	OC(=O)CC1=CC=C(C=C1)C1=CC=CC=C1	CHEMBL413965
P04150	GCR_HUMAN	fluocinolone acetonide	8.847711656	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL989	[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@]([H])(O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO	CHEMBL989
P04150	GCR_HUMAN	fluocinonide	8.621602099	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL989	[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@]([H])(O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O	CHEMBL989
P04150	GCR_HUMAN	fluorometholone	8.801342913	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200600	[H][C@@]12CC[C@](O)(C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	CHEMBL1200600
P04150	GCR_HUMAN	fludroxycortide	8.694648631	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201012	[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO	CHEMBL1201012
P08172	ACM2_HUMAN	gallamine	6.148130399	Ki	NEGATIVE ALLOSTERIC MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/18305010	CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC	CHEMBL360055
P08588	ADRB1_HUMAN	labetalol	8.233587153	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL429	CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1	CHEMBL429
P07550	ADRB2_HUMAN	labetalol	7.958607315	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL429	CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1	CHEMBL429
P41595	5HT2B_HUMAN	lisuride	8.48945499	Ki	ANTAGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2011/05/WC500106736.pdf	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC	CHEMBL157138
P03372	ESR1_HUMAN	mestranol	8.282329497	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201151	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC)C=C3	CHEMBL1201151
P21728	DRD1_HUMAN	methylergometrine	6.268411235	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200843	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO	CHEMBL1200843
Q01959	SC6A3_HUMAN	modafinil	5.836838625	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1373	NC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1373
P23219	PGH1_HUMAN	oxaprozin	6.067526235	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1071	OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1071
P21397	AOFA_HUMAN	phenelzine	6.835647144	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1089	NNCCC1=CC=CC=C1	CHEMBL1089
P08588	ADRB1_HUMAN	propafenone	6.688246139	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL631	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1	CHEMBL631
P04150	GCR_HUMAN	triamcinolone	7.585026652	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1451	[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1451
P20309	ACM3_HUMAN	tropicamide	7.522878745	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200604	CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1	CHEMBL1200604
P08913	ADA2A_HUMAN	guanabenz	7.823908741	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL420	NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl	CHEMBL420
P18089	ADA2B_HUMAN	guanabenz	7.167491087	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL420	NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl	CHEMBL420
P18825	ADA2C_HUMAN	guanabenz	6.793174124	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL420	NC(=N)N\N=C\C1=C(Cl)C=CC=C1Cl	CHEMBL420
P04150	GCR_HUMAN	clobetasol propionate	9.179142011	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1159650	[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1159650
P04150	GCR_HUMAN	diflorasone diacetate	8.536107011	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200545	[H][C@@]12C[C@H](C)[C@](OC(C)=O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	CHEMBL1200545
P04150	GCR_HUMAN	halcinonide	9.135488919	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200845	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CCl	CHEMBL1200845
P04150	GCR_HUMAN	betamethasone phosphate	8.428291168	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200762	[H][C@@]12C[C@H](C)[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1200762
P08913	ADA2A_HUMAN	norepinephrine	7.18	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1437	NC[C@H](O)C1=CC(O)=C(O)C=C1	CHEMBL1437
P35348	ADA1A_HUMAN	norepinephrine	5.82	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1437	NC[C@H](O)C1=CC(O)=C(O)C=C1	CHEMBL1437
Q7L0J3	SV2A_HUMAN	levetiracetam	6.099999904632568	Ki	MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1286	CC[C@H](N1CCCC1=O)C(N)=O	CHEMBL1286
P49895	IOD1_HUMAN	propylthiouracil			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1518	CCCC1=CC(=O)NC(=S)N1	CHEMBL1518
P27338	AOFB_HUMAN	rasagiline	6.15	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL887	C#CCN[C@@H]1CCC2=C1C=CC=C2	CHEMBL887
P14867	GBRA1_HUMAN	propofol	5.7	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL526	CC(C)C1=CC=CC(C(C)C)=C1O	CHEMBL526
P18507	GBRG2_HUMAN	propofol	5.7	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL526	CC(C)C1=CC=CC(C(C)C)=C1O	CHEMBL526
P47870	GBRB2_HUMAN	propofol	5.7	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL526	CC(C)C1=CC=CC(C(C)C)=C1O	CHEMBL526
P14867	GBRA1_HUMAN	propofol	5.39	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL526	CC(C)C1=CC=CC(C(C)C)=C1O	CHEMBL526
P18507	GBRG2_HUMAN	propofol	5.39	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL526	CC(C)C1=CC=CC(C(C)C)=C1O	CHEMBL526
P28472	GBRB3_HUMAN	propofol	5.39	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL526	CC(C)C1=CC=CC(C(C)C)=C1O	CHEMBL526
P18507	GBRG2_HUMAN	propofol	4.95	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL526	CC(C)C1=CC=CC(C(C)C)=C1O	CHEMBL526
P47869	GBRA2_HUMAN	propofol	4.95	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL526	CC(C)C1=CC=CC(C(C)C)=C1O	CHEMBL526
P47870	GBRB2_HUMAN	propofol	4.95	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL526	CC(C)C1=CC=CC(C(C)C)=C1O	CHEMBL526
P21397	AOFA_HUMAN	iproniazid	5.18	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1101049	CC(C)NNC(=O)C1=CC=NC=C1	CHEMBL92401
P27338	AOFB_HUMAN	iproniazid	5.12	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1101049	CC(C)NNC(=O)C1=CC=NC=C1	CHEMBL92401
Q9Y5Y9	SCNAA_HUMAN	mexiletine	4.25	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL558	CC(N)COC1=C(C)C=CC=C1C	CHEMBL558
Q15858	SCN9A_HUMAN	mexiletine	4.89	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL558	CC(N)COC1=C(C)C=CC=C1C	CHEMBL558
Q99250	SCN2A_HUMAN	mexiletine	5.54	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL558	CC(N)COC1=C(C)C=CC=C1C	CHEMBL558
Q05586	NMDZ1_HUMAN	memantine	5.26	IC50	NEGATIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL807	CC12CC3CC(C)(C1)CC(N)(C3)C2	CHEMBL807
Q13224	NMDE2_HUMAN	memantine	5.26	IC50	NEGATIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL807	CC12CC3CC(C)(C1)CC(N)(C3)C2	CHEMBL807
Q05586	NMDZ1_HUMAN	memantine	9.02	IC50	NEGATIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL807	CC12CC3CC(C)(C1)CC(N)(C3)C2	CHEMBL807
Q12879	NMDE1_HUMAN	memantine	9.02	IC50	NEGATIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL807	CC12CC3CC(C)(C1)CC(N)(C3)C2	CHEMBL807
Q05586	NMDZ1_HUMAN	memantine	5.02	IC50	NEGATIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL807	CC12CC3CC(C)(C1)CC(N)(C3)C2	CHEMBL807
P29275	AA2BR_HUMAN	theophylline	5.57	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL190	CN1C2=C(N=CN2)C(=O)N(C)C1=O	CHEMBL190
P29274	AA2AR_HUMAN	theophylline	9.22	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL190	CN1C2=C(N=CN2)C(=O)N(C)C1=O	CHEMBL190
P30542	AA1R_HUMAN	theophylline	9.22	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL190	CN1C2=C(N=CN2)C(=O)N(C)C1=O	CHEMBL190
O15399	NMDE4_HUMAN	acamprosate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201293	CC(=O)NCCCS(O)(=O)=O	CHEMBL1201293
O60391	NMD3B_HUMAN	acamprosate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201293	CC(=O)NCCCS(O)(=O)=O	CHEMBL1201293
Q05586	NMDZ1_HUMAN	acamprosate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201293	CC(=O)NCCCS(O)(=O)=O	CHEMBL1201293
Q12879	NMDE1_HUMAN	acamprosate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201293	CC(=O)NCCCS(O)(=O)=O	CHEMBL1201293
Q13224	NMDE2_HUMAN	acamprosate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201293	CC(=O)NCCCS(O)(=O)=O	CHEMBL1201293
Q14957	NMDE3_HUMAN	acamprosate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201293	CC(=O)NCCCS(O)(=O)=O	CHEMBL1201293
Q8TCU5	NMD3A_HUMAN	acamprosate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201293	CC(=O)NCCCS(O)(=O)=O	CHEMBL1201293
P22303	ACES_HUMAN	pyridostigmine	6.44	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL812	CN(C)C(=O)OC1=C[N+](C)=CC=C1	CHEMBL812
P07550	ADRB2_HUMAN	epinephrine	6.2	Kd	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL679	CNC[C@H](O)C1=CC=C(O)C(O)=C1	CHEMBL679
P35348	ADA1A_HUMAN	epinephrine	5.7	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL679	CNC[C@H](O)C1=CC=C(O)C(O)=C1	CHEMBL679
P22303	ACES_HUMAN	fluostigmine	5.22	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1025	CC(C)OP(F)(=O)OC(C)C	CHEMBL1025
P23415	GLRA1_HUMAN	isoflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
P48167	GLRB_HUMAN	isoflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
O00591	GBRP_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
O14764	GBRD_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
P14867	GBRA1_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
P18505	GBRB1_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
P18507	GBRG2_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
P28472	GBRB3_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
P31644	GBRA5_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
P34903	GBRA3_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
P47869	GBRA2_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
P47870	GBRB2_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
P48169	GBRA4_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
P78334	GBRE_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
Q16445	GBRA6_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
Q8N1C3	GBRG1_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
Q99928	GBRG3_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
Q9UN88	GBRT_HUMAN	isoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
P57789	KCNKA_HUMAN	isoflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
Q7Z418	KCNKI_HUMAN	isoflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
O14649	KCNK3_HUMAN	isoflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
Q9NPC2	KCNK9_HUMAN	isoflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
O95069	KCNK2_HUMAN	isoflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256	FC(F)OC(Cl)C(F)(F)F	CHEMBL1256
P57789	KCNKA_HUMAN	enflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1257	FC(F)OC(F)(F)C(F)Cl	CHEMBL1257
Q7Z418	KCNKI_HUMAN	enflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1257	FC(F)OC(F)(F)C(F)Cl	CHEMBL1257
O14649	KCNK3_HUMAN	enflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1257	FC(F)OC(F)(F)C(F)Cl	CHEMBL1257
Q9NPC2	KCNK9_HUMAN	enflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1257	FC(F)OC(F)(F)C(F)Cl	CHEMBL1257
O95069	KCNK2_HUMAN	enflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1257	FC(F)OC(F)(F)C(F)Cl	CHEMBL1257
P27338	AOFB_HUMAN	selegiline	7.26	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL972	C[C@H](CC1=CC=CC=C1)N(C)CC#C	CHEMBL972
O43497	CAC1G_HUMAN	phensuximide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL797	CN1C(=O)CC(C1=O)C1=CC=CC=C1	CHEMBL797
O95180	CAC1H_HUMAN	phensuximide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL797	CN1C(=O)CC(C1=O)C1=CC=CC=C1	CHEMBL797
Q9P0X4	CAC1I_HUMAN	phensuximide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL797	CN1C(=O)CC(C1=O)C1=CC=CC=C1	CHEMBL797
P31327	CPSM_HUMAN	carglumic acid			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201780	NC(=O)N[C@@H](CCC(O)=O)C(O)=O	CHEMBL1201780
O75343	GCYB2_HUMAN	isosorbide mononitrate			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1311	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O	CHEMBL1311
P33402	GCYA2_HUMAN	isosorbide mononitrate			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1311	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O	CHEMBL1311
Q02108	GCYA3_HUMAN	isosorbide mononitrate			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1311	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O	CHEMBL1311
Q02153	GCYB1_HUMAN	isosorbide mononitrate			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1311	[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O	CHEMBL1311
Q01959	SC6A3_HUMAN	phendimetrazine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1744	[H][C@@]1(C)N(C)CCO[C@@]1([H])C1=CC=CC=C1	CHEMBL1744
P23975	SC6A2_HUMAN	phendimetrazine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1744	[H][C@@]1(C)N(C)CCO[C@@]1([H])C1=CC=CC=C1	CHEMBL1744
P29274	AA2AR_HUMAN	caffeine	5.61	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL113	CN1C=NC2=C1C(=O)N(C)C(=O)N2C	CHEMBL113
P23415	GLRA1_HUMAN	halothane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
P48167	GLRB_HUMAN	halothane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
O00591	GBRP_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
O14764	GBRD_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
P14867	GBRA1_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
P18505	GBRB1_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
P18507	GBRG2_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
P28472	GBRB3_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
P31644	GBRA5_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
P34903	GBRA3_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
P47869	GBRA2_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
P47870	GBRB2_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
P48169	GBRA4_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
P78334	GBRE_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
Q16445	GBRA6_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
Q8N1C3	GBRG1_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
Q99928	GBRG3_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
Q9UN88	GBRT_HUMAN	halothane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
P57789	KCNKA_HUMAN	halothane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
Q7Z418	KCNKI_HUMAN	halothane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
O14649	KCNK3_HUMAN	halothane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
Q9NPC2	KCNK9_HUMAN	halothane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
O95069	KCNK2_HUMAN	halothane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL931	FC(F)(F)C(Cl)Br	CHEMBL931
Q16881	TRXR1_HUMAN	arsenic trioxide			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200978		CHEMBL1200978
O00591	GBRP_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
O14764	GBRD_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
P14867	GBRA1_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
P18505	GBRB1_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
P18507	GBRG2_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
P28472	GBRB3_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
P31644	GBRA5_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
P34903	GBRA3_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
P47869	GBRA2_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
P47870	GBRB2_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
P48169	GBRA4_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
P78334	GBRE_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
Q16445	GBRA6_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
Q8N1C3	GBRG1_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
Q99928	GBRG3_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
Q9UN88	GBRT_HUMAN	metharbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL450	CCC1(CC)C(=O)NC(=O)N(C)C1=O	CHEMBL450
O00591	GBRP_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
O14764	GBRD_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
P14867	GBRA1_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
P18505	GBRB1_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
P18507	GBRG2_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
P28472	GBRB3_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
P31644	GBRA5_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
P34903	GBRA3_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
P47869	GBRA2_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
P47870	GBRB2_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
P48169	GBRA4_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
P78334	GBRE_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
Q16445	GBRA6_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
Q8N1C3	GBRG1_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
Q99928	GBRG3_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
Q9UN88	GBRT_HUMAN	sevoflurane			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
P57789	KCNKA_HUMAN	sevoflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
Q7Z418	KCNKI_HUMAN	sevoflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
O14649	KCNK3_HUMAN	sevoflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
Q9NPC2	KCNK9_HUMAN	sevoflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
O95069	KCNK2_HUMAN	sevoflurane			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200694	FCOC(C(F)(F)F)C(F)(F)F	CHEMBL1200694
P14679	TYRO_HUMAN	monobenzone			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1388	OC1=CC=C(OCC2=CC=CC=C2)C=C1	CHEMBL1388
P08913	ADA2A_HUMAN	tetryzoline			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1266	[H]C1(CCCC2=CC=CC=C12)C1=NCCN1	CHEMBL1266
P18089	ADA2B_HUMAN	tetryzoline			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1266	[H]C1(CCCC2=CC=CC=C12)C1=NCCN1	CHEMBL1266
P18825	ADA2C_HUMAN	tetryzoline			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1266	[H]C1(CCCC2=CC=CC=C12)C1=NCCN1	CHEMBL1266
P25100	ADA1D_HUMAN	tetryzoline			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1266	[H]C1(CCCC2=CC=CC=C12)C1=NCCN1	CHEMBL1266
P35348	ADA1A_HUMAN	tetryzoline			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1266	[H]C1(CCCC2=CC=CC=C12)C1=NCCN1	CHEMBL1266
P35368	ADA1B_HUMAN	tetryzoline			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1266	[H]C1(CCCC2=CC=CC=C12)C1=NCCN1	CHEMBL1266
P08913	ADA2A_HUMAN	dexmedetomidine	8.82	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL778	C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1	CHEMBL778
O43497	CAC1G_HUMAN	methsuximide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL697	CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1	CHEMBL697
O95180	CAC1H_HUMAN	methsuximide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL697	CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1	CHEMBL697
Q9P0X4	CAC1I_HUMAN	methsuximide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL697	CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1	CHEMBL697
P35498	SCN1A_HUMAN	ethotoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1095	CCN1C(=O)NC(C1=O)C1=CC=CC=C1	CHEMBL1095
P35499	SCN4A_HUMAN	ethotoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1095	CCN1C(=O)NC(C1=O)C1=CC=CC=C1	CHEMBL1095
Q01118	SCN7A_HUMAN	ethotoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1095	CCN1C(=O)NC(C1=O)C1=CC=CC=C1	CHEMBL1095
Q14524	SCN5A_HUMAN	ethotoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1095	CCN1C(=O)NC(C1=O)C1=CC=CC=C1	CHEMBL1095
Q15858	SCN9A_HUMAN	ethotoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1095	CCN1C(=O)NC(C1=O)C1=CC=CC=C1	CHEMBL1095
Q99250	SCN2A_HUMAN	ethotoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1095	CCN1C(=O)NC(C1=O)C1=CC=CC=C1	CHEMBL1095
Q9NY46	SCN3A_HUMAN	ethotoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1095	CCN1C(=O)NC(C1=O)C1=CC=CC=C1	CHEMBL1095
Q9UI33	SCNBA_HUMAN	ethotoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1095	CCN1C(=O)NC(C1=O)C1=CC=CC=C1	CHEMBL1095
Q9UQD0	SCN8A_HUMAN	ethotoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1095	CCN1C(=O)NC(C1=O)C1=CC=CC=C1	CHEMBL1095
Q9Y5Y9	SCNAA_HUMAN	ethotoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1095	CCN1C(=O)NC(C1=O)C1=CC=CC=C1	CHEMBL1095
Q01959	SC6A3_HUMAN	diethylpropion			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1693	CCN(CC)C(C)C(=O)C1=CC=CC=C1	CHEMBL1693
P23975	SC6A2_HUMAN	diethylpropion			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1693	CCN(CC)C(C)C(=O)C1=CC=CC=C1	CHEMBL1693
O43451	MGA_HUMAN	miglitol	6.0	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1561	OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	CHEMBL1561
P10253	LYAG_HUMAN	miglitol	6.46	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1561	OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	CHEMBL1561
P21397	AOFA_HUMAN	toloxatone	5.82	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1546145	CC1=CC=CC(=C1)N1CC(CO)OC1=O	CHEMBL18116
O60706	ABCC9_HUMAN	minoxidil			OPENER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/18258787	NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1	CHEMBL802
Q14654	KCJ11_HUMAN	minoxidil			OPENER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/18258787	NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1	CHEMBL802
Q14432	PDE3A_HUMAN	milrinone	6.36	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL189	CC1=C(C=C(C#N)C(=O)N1)C1=CC=NC=C1	CHEMBL189
P07550	ADRB2_HUMAN	orciprenaline	6.3	Kd	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL776	CC(C)NCC(O)C1=CC(O)=CC(O)=C1	CHEMBL776
P07550	ADRB2_HUMAN	droxidopa			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103827	N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O	CHEMBL2103827
P08588	ADRB1_HUMAN	droxidopa			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103827	N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O	CHEMBL2103827
P08913	ADA2A_HUMAN	droxidopa			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103827	N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O	CHEMBL2103827
P13945	ADRB3_HUMAN	droxidopa			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103827	N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O	CHEMBL2103827
P18089	ADA2B_HUMAN	droxidopa			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103827	N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O	CHEMBL2103827
P18825	ADA2C_HUMAN	droxidopa			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103827	N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O	CHEMBL2103827
P25100	ADA1D_HUMAN	droxidopa			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103827	N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O	CHEMBL2103827
P35348	ADA1A_HUMAN	droxidopa			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103827	N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O	CHEMBL2103827
P35368	ADA1B_HUMAN	droxidopa			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103827	N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O	CHEMBL2103827
P35498	SCN1A_HUMAN	phenazopyridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1242	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CHEMBL1242
P35499	SCN4A_HUMAN	phenazopyridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1242	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CHEMBL1242
Q01118	SCN7A_HUMAN	phenazopyridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1242	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CHEMBL1242
Q14524	SCN5A_HUMAN	phenazopyridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1242	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CHEMBL1242
Q15858	SCN9A_HUMAN	phenazopyridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1242	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CHEMBL1242
Q99250	SCN2A_HUMAN	phenazopyridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1242	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CHEMBL1242
Q9NY46	SCN3A_HUMAN	phenazopyridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1242	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CHEMBL1242
Q9UI33	SCNBA_HUMAN	phenazopyridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1242	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CHEMBL1242
Q9UQD0	SCN8A_HUMAN	phenazopyridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1242	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CHEMBL1242
Q9Y5Y9	SCNAA_HUMAN	phenazopyridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1242	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CHEMBL1242
O75899	GABR2_HUMAN	baclofen	7.46	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL701	NCC(CC(O)=O)C1=CC=C(Cl)C=C1	CHEMBL701
Q9UBS5	GABR1_HUMAN	baclofen	7.46	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL701	NCC(CC(O)=O)C1=CC=C(Cl)C=C1	CHEMBL701
P00390	GSHR_HUMAN	carmustine	5.09	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL513	ClCCNC(=O)N(CCCl)N=O	CHEMBL513
P35498	SCN1A_HUMAN	mephenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL861	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CHEMBL861
P35499	SCN4A_HUMAN	mephenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL861	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CHEMBL861
Q01118	SCN7A_HUMAN	mephenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL861	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CHEMBL861
Q14524	SCN5A_HUMAN	mephenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL861	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CHEMBL861
Q15858	SCN9A_HUMAN	mephenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL861	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CHEMBL861
Q99250	SCN2A_HUMAN	mephenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL861	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CHEMBL861
Q9NY46	SCN3A_HUMAN	mephenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL861	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CHEMBL861
Q9UI33	SCNBA_HUMAN	mephenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL861	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CHEMBL861
Q9UQD0	SCN8A_HUMAN	mephenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL861	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CHEMBL861
Q9Y5Y9	SCNAA_HUMAN	mephenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL861	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CHEMBL861
P00918	CAH2_HUMAN	acetazolamide	8.48	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL20	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CHEMBL20
O43570	CAH12_HUMAN	acetazolamide	8.6	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL20	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CHEMBL20
P22748	CAH4_HUMAN	acetazolamide	7.96	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL20	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CHEMBL20
P00915	CAH1_HUMAN	acetazolamide	7.92	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL20	CC(=O)NC1=NN=C(S1)S(N)(=O)=O	CHEMBL20
P11511	CP19A_HUMAN	fadrozole	10.3	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2521224	N#CC1=CC=C(C=C1)C1CCCC2=CN=CN12	CHEMBL9298
O00591	GBRP_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
O14764	GBRD_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
P14867	GBRA1_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
P18505	GBRB1_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
P18507	GBRG2_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
P28472	GBRB3_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
P31644	GBRA5_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
P34903	GBRA3_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
P47869	GBRA2_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
P47870	GBRB2_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
P48169	GBRA4_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
P78334	GBRE_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
Q16445	GBRA6_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
Q8N1C3	GBRG1_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
Q99928	GBRG3_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
Q9UN88	GBRT_HUMAN	talbutal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200802	CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL1200802
P20711	DDC_HUMAN	carbidopa			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200748	C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O	CHEMBL1200748
P28472	GBRB3_HUMAN	pentobarbital	4.06	IC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL448	CCCC(C)C1(CC)C(=O)NC(=O)NC1=O	CHEMBL448
P15538	C11B1_HUMAN	metyrapone	7.84	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012911Orig1s033lbl.pdf	CC(C)(C(=O)C1=CN=CC=C1)C1=CN=CC=C1	CHEMBL934
O75343	GCYB2_HUMAN	glyceryl trinitrate			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL730	[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O	CHEMBL730
P33402	GCYA2_HUMAN	glyceryl trinitrate			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL730	[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O	CHEMBL730
Q02108	GCYA3_HUMAN	glyceryl trinitrate			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL730	[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O	CHEMBL730
Q02153	GCYB1_HUMAN	glyceryl trinitrate			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL730	[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O	CHEMBL730
Q9Y6K1	DNM3A_HUMAN	decitabine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201129	NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1	CHEMBL1201129
P35354	PGH2_HUMAN	nabumetone			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1070	COC1=CC=C2C=C(CCC(C)=O)C=CC2=C1	CHEMBL1070
O00591	GBRP_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
O14764	GBRD_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
P14867	GBRA1_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
P18505	GBRB1_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
P18507	GBRG2_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
P28472	GBRB3_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
P31644	GBRA5_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
P34903	GBRA3_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
P47869	GBRA2_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
P47870	GBRB2_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
P48169	GBRA4_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
P78334	GBRE_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
Q16445	GBRA6_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
Q8N1C3	GBRG1_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
Q99928	GBRG3_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
Q9UN88	GBRT_HUMAN	triclofos			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200789	OP(O)(=O)OCC(Cl)(Cl)Cl	CHEMBL1200789
P37088	SCNNA_HUMAN	amiloride	6.7	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL945	NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1	CHEMBL945
P51168	SCNNB_HUMAN	amiloride	6.7	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL945	NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1	CHEMBL945
P51170	SCNNG_HUMAN	amiloride	6.7	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL945	NC(=N)NC(=O)C1=C(N)N=C(N)C(Cl)=N1	CHEMBL945
P18089	ADA2B_HUMAN	clonidine	7.5	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL134	ClC1=CC=CC(Cl)=C1NC1=NCCN1	CHEMBL134
P08913	ADA2A_HUMAN	clonidine	8.42	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL134	ClC1=CC=CC(Cl)=C1NC1=NCCN1	CHEMBL134
P35354	PGH2_HUMAN	naproxen	5.6	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL154	COC1=CC=C2C=C(C=CC2=C1)[C@H](C)C(O)=O	CHEMBL154
P05108	CP11A_HUMAN	aminoglutethimide			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL488	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	CHEMBL488
Q01959	SC6A3_HUMAN	methylphenidate	6.96	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL796	[H]C1(CCCCN1)C(C(=O)OC)C1=CC=CC=C1	CHEMBL796
P23975	SC6A2_HUMAN	methylphenidate	6.18	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL796	[H]C1(CCCCN1)C(C(=O)OC)C1=CC=CC=C1	CHEMBL796
Q01959	SC6A3_HUMAN	dexmethylphenidate	7.8	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL827	[H][C@@]1(CCCCN1)[C@H](C(=O)OC)C1=CC=CC=C1	CHEMBL827
P35499	SCN4A_HUMAN	lidocaine	5.7	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL79	CCN(CC)CC(=O)NC1=C(C)C=CC=C1C	CHEMBL79
Q15858	SCN9A_HUMAN	lidocaine	4.54	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL79	CCN(CC)CC(=O)NC1=C(C)C=CC=C1C	CHEMBL79
Q9NY46	SCN3A_HUMAN	lidocaine	4.98	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL79	CCN(CC)CC(=O)NC1=C(C)C=CC=C1C	CHEMBL79
P14324	FPPS_HUMAN	pamidronic acid	7.25	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL676	NCCC(O)(P(O)(O)=O)P(O)(O)=O	CHEMBL676
O75343	GCYB2_HUMAN	isosorbide dinitrate			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL6622	[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O	CHEMBL6622
P33402	GCYA2_HUMAN	isosorbide dinitrate			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL6622	[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O	CHEMBL6622
Q02108	GCYA3_HUMAN	isosorbide dinitrate			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL6622	[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O	CHEMBL6622
Q02153	GCYB1_HUMAN	isosorbide dinitrate			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL6622	[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O	CHEMBL6622
P35499	SCN4A_HUMAN	carbamazepine	4.28	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL108	NC(=O)N1C2=CC=CC=C2C=CC2=C1C=CC=C2	CHEMBL108
Q15858	SCN9A_HUMAN	carbamazepine	4.66	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL108	NC(=O)N1C2=CC=CC=C2C=CC2=C1C=CC=C2	CHEMBL108
P00918	CAH2_HUMAN	methazolamide	8.05	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL19	CN1N=C(SC1=NC(C)=O)S(N)(=O)=O	CHEMBL19
P43166	CAH7_HUMAN	methazolamide	8.68	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL19	CN1N=C(SC1=NC(C)=O)S(N)(=O)=O	CHEMBL19
P22748	CAH4_HUMAN	methazolamide	6.62	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL19	CN1N=C(SC1=NC(C)=O)S(N)(=O)=O	CHEMBL19
P00915	CAH1_HUMAN	methazolamide	7.85	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL19	CN1N=C(SC1=NC(C)=O)S(N)(=O)=O	CHEMBL19
P09917	LOX5_HUMAN	zileuton	6.52	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL93	CC(N(O)C(N)=O)C1=CC2=C(S1)C=CC=C2	CHEMBL93
P23975	SC6A2_HUMAN	viloxazine	6.81	Kd	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D02572	CCOC1=CC=CC=C1OCC1CNCCO1	CHEMBL306700
P35498	SCN1A_HUMAN	rufinamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201754	NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1	CHEMBL1201754
P35499	SCN4A_HUMAN	rufinamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201754	NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1	CHEMBL1201754
Q01118	SCN7A_HUMAN	rufinamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201754	NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1	CHEMBL1201754
Q14524	SCN5A_HUMAN	rufinamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201754	NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1	CHEMBL1201754
Q15858	SCN9A_HUMAN	rufinamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201754	NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1	CHEMBL1201754
Q99250	SCN2A_HUMAN	rufinamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201754	NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1	CHEMBL1201754
Q9NY46	SCN3A_HUMAN	rufinamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201754	NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1	CHEMBL1201754
Q9UI33	SCNBA_HUMAN	rufinamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201754	NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1	CHEMBL1201754
Q9UQD0	SCN8A_HUMAN	rufinamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201754	NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1	CHEMBL1201754
Q9Y5Y9	SCNAA_HUMAN	rufinamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201754	NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1	CHEMBL1201754
P07550	ADRB2_HUMAN	levosalbutamol	5.42	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1002	CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1	CHEMBL1002
P07550	ADRB2_HUMAN	isoetarine	6.0	Kd	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200920	CCC(NC(C)C)C(O)C1=CC(O)=C(O)C=C1	CHEMBL1200920
P23975	SC6A2_HUMAN	benzphetamine			RELEASING AGENT	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3544906	C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1	CHEMBL3544906
Q05940	VMAT2_HUMAN	benzphetamine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3544906	C[C@@H](CC1=CC=CC=C1)N(C)CC1=CC=CC=C1	CHEMBL3544906
P23975	SC6A2_HUMAN	bupropion	5.16	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL894	CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1	CHEMBL894
Q9NYK1	TLR7_HUMAN	imiquimod	4.97	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1282	CC(C)CN1C=NC2=C(N)N=C3C=CC=CC3=C12	CHEMBL1282
P35367	HRH1_HUMAN	pheniramine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1193	[H]C(CCN(C)C)(C1=CC=CC=C1)C1=NC=CC=C1	CHEMBL1193
P30926	ACHB4_HUMAN	pentolonium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1271	C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1	CHEMBL1271
P32297	ACHA3_HUMAN	pentolonium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1271	C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1	CHEMBL1271
Q9Y2I1	NISCH_HUMAN	moxonidine	8.38	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8872297	COC1=NC(C)=NC(Cl)=C1NC1=NCCN1	CHEMBL19236
P23975	SC6A2_HUMAN	bretylium			SUBSTRATE	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1095292	CC[N+](C)(C)CC1=C(Br)C=CC=C1	CHEMBL1095292
P09884	DPOLA_HUMAN	cytarabine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL803	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	CHEMBL803
P28340	DPOD1_HUMAN	cytarabine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL803	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	CHEMBL803
Q07864	DPOE1_HUMAN	cytarabine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL803	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	CHEMBL803
P48039	MTR1A_HUMAN	agomelatine	10.22	Ki	AGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000916/WC500038317.pdf	COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1	CHEMBL10878
P49286	MTR1B_HUMAN	agomelatine	10.0	Ki	AGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000916/WC500038317.pdf	COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1	CHEMBL10878
P28222	5HT1B_HUMAN	frovatriptan	7.99	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1279	CN[C@@H]1CCC2=C(C1)C1=CC(=CC=C1N2)C(N)=O	CHEMBL1279
P28221	5HT1D_HUMAN	frovatriptan	8.36	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1279	CN[C@@H]1CCC2=C(C1)C1=CC(=CC=C1N2)C(N)=O	CHEMBL1279
Q9Y6K1	DNM3A_HUMAN	azacitidine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1489	NC1=NC(=O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	CHEMBL1489
P18825	ADA2C_HUMAN	apraclonidine	7.52	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL647	NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1	CHEMBL647
P08913	ADA2A_HUMAN	apraclonidine	8.54	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL647	NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1	CHEMBL647
O60706	ABCC9_HUMAN	pinacidil	6.49	Ki	OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1159	CC(NC(NC1=CC=NC=C1)=NC#N)C(C)(C)C	CHEMBL1159
Q14654	KCJ11_HUMAN	pinacidil	6.49	Ki	OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1159	CC(NC(NC1=CC=NC=C1)=NC#N)C(C)(C)C	CHEMBL1159
P35372	OPRM_HUMAN	dezocine	7.42	EC50	PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1685	[H][C@@]12CC3=CC=C(O)C=C3[C@@](C)(CCCCC1)[C@H]2N	CHEMBL1685
P23219	PGH1_HUMAN	loxoprofen	5.19	IC50	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D08149	CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1	CHEMBL19299
P35354	PGH2_HUMAN	loxoprofen	5.0	IC50	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D08149	CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1	CHEMBL19299
P35372	OPRM_HUMAN	pethidine	6.04	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL607	CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1	CHEMBL607
P14324	FPPS_HUMAN	alendronic acid	7.35	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL675	NCCCC(O)(P(O)(O)=O)P(O)(O)=O	CHEMBL675
P22303	ACES_HUMAN	rivastigmine	7.43	IC50	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6602	CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C	CHEMBL636
P06276	CHLE_HUMAN	rivastigmine	7.52	IC50	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6602	CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C	CHEMBL636
P35499	SCN4A_HUMAN	phenytoin	4.62	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL16	O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL16
Q14432	PDE3A_HUMAN	diprophylline			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL221190	CN1C2=C(N(CC(O)CO)C=N2)C(=O)N(C)C1=O	CHEMBL221190
P23219	PGH1_HUMAN	dexketoprofen	8.72	IC50	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D07269	C[C@H](C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1	CHEMBL75435
P35354	PGH2_HUMAN	dexketoprofen	7.57	IC50	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D07269	C[C@H](C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1	CHEMBL75435
O00591	GBRP_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
O14764	GBRD_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
P14867	GBRA1_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
P18505	GBRB1_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
P18507	GBRG2_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
P28472	GBRB3_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
P31644	GBRA5_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
P34903	GBRA3_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
P47869	GBRA2_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
P47870	GBRB2_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
P48169	GBRA4_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
P78334	GBRE_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
Q16445	GBRA6_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
Q8N1C3	GBRG1_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
Q99928	GBRG3_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
Q9UN88	GBRT_HUMAN	thiamylal			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL440	CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O	CHEMBL440
P23975	SC6A2_HUMAN	atomoxetine	8.69	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL641	CNCC[C@@H](OC1=C(C)C=CC=C1)C1=CC=CC=C1	CHEMBL641
P35367	HRH1_HUMAN	tripelennamine	7.4	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1241	CN(C)CCN(CC1=CC=CC=C1)C1=CC=CC=N1	CHEMBL1241
Q9Y5Y9	SCNAA_HUMAN	lamotrigine	4.02	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL741	NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1	CHEMBL741
Q14524	SCN5A_HUMAN	lamotrigine	4.21	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL741	NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1	CHEMBL741
P35499	SCN4A_HUMAN	lamotrigine	4.77	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL741	NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1	CHEMBL741
Q99250	SCN2A_HUMAN	lamotrigine	5.0	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL741	NC1=NN=C(C(N)=N1)C1=C(Cl)C(Cl)=CC=C1	CHEMBL741
P22303	ACES_HUMAN	echothiophate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200367	CCOP(=O)(OCC)SCC[N+](C)(C)C	CHEMBL1200367
P35372	OPRM_HUMAN	levorphanol	9.68	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL592	[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13[H])CCN2C	CHEMBL592
P35218	CAH5A_HUMAN	ethoxzolamide	7.6	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	CHEMBL18
P00918	CAH2_HUMAN	ethoxzolamide	9.31	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	CHEMBL18
Q9ULX7	CAH14_HUMAN	ethoxzolamide	8.6	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	CHEMBL18
P43166	CAH7_HUMAN	ethoxzolamide	9.15	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	CHEMBL18
O43570	CAH12_HUMAN	ethoxzolamide	7.66	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	CHEMBL18
Q16790	CAH9_HUMAN	ethoxzolamide	7.47	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	CHEMBL18
P35218	CAH5A_HUMAN	ethoxzolamide	8.7	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	CHEMBL18
Q9Y2D0	CAH5B_HUMAN	ethoxzolamide	8.7	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	CHEMBL18
P22748	CAH4_HUMAN	ethoxzolamide	7.03	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	CHEMBL18
P00915	CAH1_HUMAN	ethoxzolamide	7.85	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	CHEMBL18
Q9Y2D0	CAH5B_HUMAN	ethoxzolamide	7.72	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	CHEMBL18
P07451	CAH3_HUMAN	ethoxzolamide	5.3	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	CHEMBL18
Q8N1Q1	CAH13_HUMAN	ethoxzolamide	7.89	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	CHEMBL18
P23280	CAH6_HUMAN	ethoxzolamide	7.48	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18	CCOC1=CC2=C(C=C1)N=C(S2)S(N)(=O)=O	CHEMBL18
P02708	ACHA_HUMAN	decamethonium			PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1134	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	CHEMBL1134
P07510	ACHG_HUMAN	decamethonium			PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1134	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	CHEMBL1134
P11230	ACHB_HUMAN	decamethonium			PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1134	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	CHEMBL1134
Q04844	ACHE_HUMAN	decamethonium			PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1134	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	CHEMBL1134
Q07001	ACHD_HUMAN	decamethonium			PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1134	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	CHEMBL1134
P08913	ADA2A_HUMAN	lofexidine	8.36	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20040696	CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1	CHEMBL17860
P35498	SCN1A_HUMAN	hexylcaine	5.15	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1197	CC(CNC1CCCCC1)OC(=O)C1=CC=CC=C1	CHEMBL1197
Q99250	SCN2A_HUMAN	hexylcaine	5.15	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1197	CC(CNC1CCCCC1)OC(=O)C1=CC=CC=C1	CHEMBL1197
Q9NY46	SCN3A_HUMAN	hexylcaine	5.15	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1197	CC(CNC1CCCCC1)OC(=O)C1=CC=CC=C1	CHEMBL1197
P09884	DPOLA_HUMAN	gemcitabine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL888	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F	CHEMBL888
P28340	DPOD1_HUMAN	gemcitabine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL888	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F	CHEMBL888
Q07864	DPOE1_HUMAN	gemcitabine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL888	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F	CHEMBL888
P35372	OPRM_HUMAN	tramadol	5.8	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1237044	COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C	CHEMBL1237044
Q14524	SCN5A_HUMAN	tetracaine	6.28	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL698	CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C	CHEMBL698
Q15858	SCN9A_HUMAN	tetracaine	6.3	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL698	CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C	CHEMBL698
P35498	SCN1A_HUMAN	tetracaine	5.47	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL698	CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C	CHEMBL698
Q99250	SCN2A_HUMAN	tetracaine	5.47	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL698	CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C	CHEMBL698
Q9NY46	SCN3A_HUMAN	tetracaine	5.47	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL698	CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C	CHEMBL698
Q99250	SCN2A_HUMAN	tetracaine	5.96	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL698	CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C	CHEMBL698
P28335	5HT2C_HUMAN	mirtazapine	7.41	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL654	[H]C12CN(C)CCN1C1=C(CC3=C2C=CC=C3)C=CC=N1	CHEMBL654
P28223	5HT2A_HUMAN	mirtazapine	7.16	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL654	[H]C12CN(C)CCN1C1=C(CC3=C2C=CC=C3)C=CC=N1	CHEMBL654
P35367	HRH1_HUMAN	antazoline			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1305	C(N(CC1=CC=CC=C1)C1=CC=CC=C1)C1=NCCN1	CHEMBL1305
P10253	LYAG_HUMAN	voglibose	7.15	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8536820	OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O	CHEMBL476960
P14416	DRD2_HUMAN	apomorphine	9.21	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL53	[H][C@]12CC3=CC=C(O)C(O)=C3C3=CC=CC(CCN1C)=C23	CHEMBL53
P03372	ESR1_HUMAN	diethylstilbestrol	9.66	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL411	CC\C(=C(\CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1	CHEMBL411
P21397	AOFA_HUMAN	moclobemide	8.3	Ki	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7428	ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1	CHEMBL86304
Q02127	PYRD_HUMAN	leflunomide	5.0	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL960	CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F	CHEMBL960
P03372	ESR1_HUMAN	estrone	9.15	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1405	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CHEMBL1405
P35367	HRH1_HUMAN	doxylamine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1004	CN(C)CCOC(C)(C1=CC=CC=C1)C1=NC=CC=C1	CHEMBL1004
P14324	FPPS_HUMAN	zoledronic acid	10.15	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL924	OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O	CHEMBL924
P35354	PGH2_HUMAN	carprofen	7.0	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1316	CC(C(O)=O)C1=CC2=C(C=C1)C1=CC(Cl)=CC=C1N2	CHEMBL1316
P22303	ACES_HUMAN	physostigmine	9.37	IC50	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6598	[H][C@]12N(C)CC[C@@]1(C)C1=CC(OC(=O)NC)=CC=C1N2C	CHEMBL94
P10275	ANDR_HUMAN	flutamide	5.89	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL806	CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F	CHEMBL806
P29275	AA2BR_HUMAN	pentoxifylline	5.29	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL628	CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C	CHEMBL628
P35367	HRH1_HUMAN	triprolidine	9.9	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL855	CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1	CHEMBL855
P11229	ACM1_HUMAN	diphemanil			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200880	C[N+]1(C)CCC(CC1)=C(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1200880
P46098	5HT3A_HUMAN	ramosetron	10.22	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17652911	CN1C=C(C(=O)[C@@H]2CCC3=C(C2)NC=N3)C2=CC=CC=C12	CHEMBL1643895
P35368	ADA1B_HUMAN	phentolamine	7.32	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL597	CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1	CHEMBL597
P18089	ADA2B_HUMAN	phentolamine	8.12	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL597	CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1	CHEMBL597
P18825	ADA2C_HUMAN	phentolamine	8.08	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL597	CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1	CHEMBL597
P25100	ADA1D_HUMAN	phentolamine	7.71	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL597	CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1	CHEMBL597
P08913	ADA2A_HUMAN	phentolamine	8.77	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL597	CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1	CHEMBL597
P35348	ADA1A_HUMAN	phentolamine	8.39	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL597	CC1=CC=C(C=C1)N(CC1=NCCN1)C1=CC(O)=CC=C1	CHEMBL597
P14324	FPPS_HUMAN	risedronic acid	9.44	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL923	OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O	CHEMBL923
P35372	OPRM_HUMAN	levallorphan	9.32	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1254682	[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13[H])CCN2CC=C	CHEMBL1254682
P35498	SCN1A_HUMAN	articaine	4.29	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1093	CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC	CHEMBL1093
Q99250	SCN2A_HUMAN	articaine	4.29	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1093	CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC	CHEMBL1093
Q9NY46	SCN3A_HUMAN	articaine	4.29	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1093	CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC	CHEMBL1093
Q01959	SC6A3_HUMAN	mazindol	8.0	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL781	OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1	CHEMBL781
P23975	SC6A2_HUMAN	mazindol	9.3	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL781	OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1	CHEMBL781
P31645	SC6A4_HUMAN	mazindol	7.3	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL781	OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1	CHEMBL781
P35372	OPRM_HUMAN	hydromorphone	9.55	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL398707	[H][C@@]12OC3=C4C(C[C@@]5([H])N(C)CC[C@@]14[C@@]5([H])CCC2=O)=CC=C3O	CHEMBL398707
P35367	HRH1_HUMAN	mepyramine	9.1	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL511	COC1=CC=C(CN(CCN(C)C)C2=CC=CC=N2)C=C1	CHEMBL511
P22303	ACES_HUMAN	galantamine	7.21	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL659	[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=CC=C(OC)C(O2)=C13	CHEMBL659
P35354	PGH2_HUMAN	etodolac	5.7	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL622	CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O	CHEMBL622
P10275	ANDR_HUMAN	ethylestrenol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200623	[H][C@@]12CC[C@@](O)(CC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H]	CHEMBL1200623
Q07869	PPARA_HUMAN	ciprofibrate	6.05	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/15123680	CC(C)(OC1=CC=C(C=C1)C1CC1(Cl)Cl)C(O)=O	CHEMBL557555
P55017	S12A3_HUMAN	quinethazone			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1532	CCC1NC(=O)C2=CC(=C(Cl)C=C2N1)S(N)(=O)=O	CHEMBL1532
P02708	ACHA_HUMAN	suxamethonium			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL703	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	CHEMBL703
P07510	ACHG_HUMAN	suxamethonium			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL703	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	CHEMBL703
P11230	ACHB_HUMAN	suxamethonium			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL703	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	CHEMBL703
Q04844	ACHE_HUMAN	suxamethonium			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL703	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	CHEMBL703
Q07001	ACHD_HUMAN	suxamethonium			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL703	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	CHEMBL703
P35367	HRH1_HUMAN	carbinoxamine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL864	[H]C(OCCN(C)C)(C1=CC=C(Cl)C=C1)C1=CC=CC=N1	CHEMBL864
Q13464	ROCK1_HUMAN	fasudil	7.0	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10644512	O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2	CHEMBL38380
O75116	ROCK2_HUMAN	fasudil	7.11	Kd	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10644512	O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2	CHEMBL38380
P20309	ACM3_HUMAN	cyclopentolate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200473	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	CHEMBL1200473
P35354	PGH2_HUMAN	lumiracoxib	6.49	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/15017615	CC1=CC(CC(O)=O)=C(NC2=C(Cl)C=CC=C2F)C=C1	CHEMBL404108
P46098	5HT3A_HUMAN	alosetron	9.3	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1110	CN1C2=C(C3=C1C=CC=C3)C(=O)N(CC1=C(C)N=CN1)CC2	CHEMBL1110
P35498	SCN1A_HUMAN	propoxycaine	4.62	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1195	CCCOC1=C(C=CC(N)=C1)C(=O)OCCN(CC)CC	CHEMBL1195
Q99250	SCN2A_HUMAN	propoxycaine	4.62	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1195	CCCOC1=C(C=CC(N)=C1)C(=O)OCCN(CC)CC	CHEMBL1195
Q9NY46	SCN3A_HUMAN	propoxycaine	4.62	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1195	CCCOC1=C(C=CC(N)=C1)C(=O)OCCN(CC)CC	CHEMBL1195
P35498	SCN1A_HUMAN	proparacaine	5.72	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1196	CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC	CHEMBL1196
Q99250	SCN2A_HUMAN	proparacaine	5.72	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1196	CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC	CHEMBL1196
Q9NY46	SCN3A_HUMAN	proparacaine	5.72	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1196	CCCOC1=C(N)C=C(C=C1)C(=O)OCCN(CC)CC	CHEMBL1196
P28222	5HT1B_HUMAN	sumatriptan	8.26	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL128	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	CHEMBL128
P28221	5HT1D_HUMAN	sumatriptan	8.92	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL128	CNS(=O)(=O)CC1=CC2=C(NC=C2CCN(C)C)C=C1	CHEMBL128
P46098	5HT3A_HUMAN	palonosetron	10.5	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1720	[H][C@@]12CCCC3=CC=CC(C(=O)N(C1)[C@]1([H])CN4CCC1CC4)=C23	CHEMBL1720
P35367	HRH1_HUMAN	methdilazine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200532	CN1CCC(CN2C3=CC=CC=C3SC3=C2C=CC=C3)C1	CHEMBL1200532
P23975	SC6A2_HUMAN	duloxetine	8.22	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1175	CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1	CHEMBL1175
P31645	SC6A4_HUMAN	duloxetine	9.62	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1175	CNCC[C@H](OC1=CC=CC2=C1C=CC=C2)C1=CC=CS1	CHEMBL1175
P27815	PDE4A_HUMAN	amlexanox			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1096	CC(C)C1=CC=C2OC3=C(C=C(C(O)=O)C(N)=N3)C(=O)C2=C1	CHEMBL1096
Q07343	PDE4B_HUMAN	amlexanox			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1096	CC(C)C1=CC=C2OC3=C(C=C(C(O)=O)C(N)=N3)C(=O)C2=C1	CHEMBL1096
Q08493	PDE4C_HUMAN	amlexanox			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1096	CC(C)C1=CC=C2OC3=C(C=C(C(O)=O)C(N)=N3)C(=O)C2=C1	CHEMBL1096
Q08499	PDE4D_HUMAN	amlexanox			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1096	CC(C)C1=CC=C2OC3=C(C=C(C(O)=O)C(N)=N3)C(=O)C2=C1	CHEMBL1096
P06401	PRGR_HUMAN	norethynodrel			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1387	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])CC(=O)CC3	CHEMBL1387
P35367	HRH1_HUMAN	alimemazine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL829	CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=CC=C2	CHEMBL829
P35372	OPRM_HUMAN	hydrocodone	8.02	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1457	[H][C@@]12OC3=C4C(C[C@@]5([H])N(C)CC[C@@]14[C@@]5([H])CCC2=O)=CC=C3OC	CHEMBL1457
P35372	OPRM_HUMAN	codeine	6.14	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL485	[H][C@@]12OC3=C4C(C[C@@]5([H])N(C)CC[C@@]14[C@@]5([H])C=C[C@@H]2O)=CC=C3OC	CHEMBL485
P10826	RARB_HUMAN	isotretinoin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL547	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O	CHEMBL547
P41143	OPRD_HUMAN	oxymorphone	7.3	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL963	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@H](C4)[C@]1(O)CCC2=O	CHEMBL963
P35372	OPRM_HUMAN	dihydrocodeine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1595	[H][C@@]12OC3=C4C(C[C@@]5([H])N(C)CC[C@@]14[C@@]5([H])CC[C@@H]2O)=CC=C3OC	CHEMBL1595
Q13639	5HT4R_HUMAN	tegaserod	8.4	Ki	PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL76370	CCCCCNC(=N)NN=CC1=CNC2=C1C=C(OC)C=C2	CHEMBL76370
P11229	ACM1_HUMAN	trihexyphenidyl	8.89	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1092	OC(CCN1CCCCC1)(C1CCCCC1)C1=CC=CC=C1	CHEMBL1092
P09917	LOX5_HUMAN	olsalazine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL425	OC(=O)C1=CC(=CC=C1O)N=NC1=CC(C(O)=O)=C(O)C=C1	CHEMBL425
P37231	PPARG_HUMAN	olsalazine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL425	OC(=O)C1=CC(=CC=C1O)N=NC1=CC(C(O)=O)=C(O)C=C1	CHEMBL425
P23219	PGH1_HUMAN	olsalazine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL425	OC(=O)C1=CC(=CC=C1O)N=NC1=CC(C(O)=O)=C(O)C=C1	CHEMBL425
P35354	PGH2_HUMAN	olsalazine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL425	OC(=O)C1=CC(=CC=C1O)N=NC1=CC(C(O)=O)=C(O)C=C1	CHEMBL425
P48169	GBRA4_HUMAN	flumazenil	8.7	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P27487	DPP4_HUMAN	vildagliptin	8.52	Ki	INHIBITOR	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf	OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N	CHEMBL142703
P22748	CAH4_HUMAN	dichlorphenamide	7.02	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL17	NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O	CHEMBL17
Q8NER1	TRPV1_HUMAN	capsaicin	8.22	Ki	OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL294199	COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1	CHEMBL294199
P21728	DRD1_HUMAN	fenoldopam	7.55	Kd	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL588	OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12	CHEMBL588
P31645	SC6A4_HUMAN	sertraline	9.54	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL809	CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12	CHEMBL809
P23219	PGH1_HUMAN	phenylbutazone	5.52	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL101	CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL101
P35498	SCN1A_HUMAN	oxybuprocaine	5.54	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200	CCCCOC1=C(N)C=CC(=C1)C(=O)OCCN(CC)CC	CHEMBL1200
Q99250	SCN2A_HUMAN	oxybuprocaine	5.54	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200	CCCCOC1=C(N)C=CC(=C1)C(=O)OCCN(CC)CC	CHEMBL1200
Q9NY46	SCN3A_HUMAN	oxybuprocaine	5.54	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200	CCCCOC1=C(N)C=CC(=C1)C(=O)OCCN(CC)CC	CHEMBL1200
P08588	ADRB1_HUMAN	metipranolol			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1291	CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1	CHEMBL1291
P07550	ADRB2_HUMAN	metipranolol			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1291	CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1	CHEMBL1291
P11229	ACM1_HUMAN	metixene			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200426	CN1CCCC(CC2C3=CC=CC=C3SC3=C2C=CC=C3)C1	CHEMBL1200426
P28335	5HT2C_HUMAN	metixene			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200426	CN1CCCC(CC2C3=CC=CC=C3SC3=C2C=CC=C3)C1	CHEMBL1200426
Q09428	ABCC8_HUMAN	tolazamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL817	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1	CHEMBL817
Q14654	KCJ11_HUMAN	tolazamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL817	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1	CHEMBL817
Q15413	RYR3_HUMAN	dantrolene			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL928	[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O	CHEMBL928
P21554	CNR1_HUMAN	dronabinol	8.54	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL465	[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=CC(CCCCC)=CC(O)=C21	CHEMBL465
P27487	DPP4_HUMAN	saxagliptin	9.22	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL385517	[H][C@@](N)(C(=O)N1[C@@]2([H])C[C@@]2([H])C[C@@]1([H])C#N)C12CC3CC(CC(O)(C3)C1)C2	CHEMBL385517
P14416	DRD2_HUMAN	chlorprothixene	8.53	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL908	CN(C)CC\C=C1\C2=CC=CC=C2SC2=C1C=C(Cl)C=C2	CHEMBL908
P10275	ANDR_HUMAN	nilutamide	8.05	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1274	CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F	CHEMBL1274
P11229	ACM1_HUMAN	methscopolamine	9.9	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL376897	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1	CHEMBL376897
P20309	ACM3_HUMAN	tridihexethyl			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200771	CC[N+](CC)(CC)CCC(O)(C1CCCCC1)C1=CC=CC=C1	CHEMBL1200771
P11229	ACM1_HUMAN	tridihexethyl			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200771	CC[N+](CC)(CC)CCC(O)(C1CCCCC1)C1=CC=CC=C1	CHEMBL1200771
P14324	FPPS_HUMAN	ibandronic acid	8.44	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL997	CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O	CHEMBL997
P05108	CP11A_HUMAN	mitotane			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1670	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1	CHEMBL1670
P12268	IMDH2_HUMAN	mycophenolic acid	4.7	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL866	COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C	CHEMBL866
P20839	IMDH1_HUMAN	mycophenolic acid	4.7	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL866	COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C	CHEMBL866
P23219	PGH1_HUMAN	oxyphenbutazone			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1228	CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1	CHEMBL1228
P35354	PGH2_HUMAN	oxyphenbutazone			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1228	CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1	CHEMBL1228
P18089	ADA2B_HUMAN	tolazoline	5.5	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL770	C(C1=NCCN1)C1=CC=CC=C1	CHEMBL770
P18089	ADA2B_HUMAN	tizanidine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1079	ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1	CHEMBL1079
P18089	ADA2B_HUMAN	dipivefrine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200833	CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1	CHEMBL1200833
P18089	ADA2B_HUMAN	brimonidine	7.2596	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL844	BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12	CHEMBL844
P35348	ADA1A_HUMAN	terazosin	8.95	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL611	COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N1CCN(CC1)C(=O)C1CCCO1	CHEMBL611
P35348	ADA1A_HUMAN	tolazoline	5.5	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL770	C(C1=NCCN1)C1=CC=CC=C1	CHEMBL770
P35348	ADA1A_HUMAN	phenylephrine	5.3	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1215	CNC[C@H](O)C1=CC(O)=CC=C1	CHEMBL1215
P35348	ADA1A_HUMAN	phenoxybenzamine	7.27	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL753	CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1	CHEMBL753
P35348	ADA1A_HUMAN	midodrine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL255027	COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1	CHEMBL255027
P35348	ADA1A_HUMAN	methoxamine	5.1	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL524	COC1=CC(C(O)C(C)N)=C(OC)C=C1	CHEMBL524
P35348	ADA1A_HUMAN	metaraminol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201319	C[C@H](N)[C@H](O)C1=CC(O)=CC=C1	CHEMBL1201319
P35348	ADA1A_HUMAN	doxazosin	8.8	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL707	[H]C1(COC2=C(O1)C=CC=C2)C(=O)N1CCN(CC1)C1=NC2=CC(OC)=C(OC)C=C2C(N)=N1	CHEMBL707
P35348	ADA1A_HUMAN	dapiprazole			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201044	CC1=C(C=CC=C1)N1CCN(CCC2=NN=C3CCCCN23)CC1	CHEMBL1201044
P35348	ADA1A_HUMAN	bunazosin			ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01887	CCCC(=O)N1CCCN(CC1)C1=NC2=CC(OC)=C(OC)C=C2C(N)=N1	CHEMBL188185
P28335	5HT2C_HUMAN	trazodone	6.65	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL621	ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1	CHEMBL621
P28223	5HT2A_HUMAN	asenapine	9.61	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201756	[H]C12CN(C)CC1([H])C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1	CHEMBL1201756
P28223	5HT2A_HUMAN	iloperidone	9.8594	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL14376	COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O	CHEMBL14376
P28223	5HT2A_HUMAN	ziprasidone	9.4	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL708	ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2	CHEMBL708
P28223	5HT2A_HUMAN	trazodone	7.35	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL621	ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1	CHEMBL621
P28223	5HT2A_HUMAN	risperidone	9.3643	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL85	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1	CHEMBL85
P28223	5HT2A_HUMAN	quetiapine	7.1311	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL716	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12	CHEMBL716
P28223	5HT2A_HUMAN	promazine	7.7959	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL564	CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2	CHEMBL564
P28223	5HT2A_HUMAN	olanzapine	8.3188	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL715	CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2	CHEMBL715
P28223	5HT2A_HUMAN	nefazodone	8.0	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL623	CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1	CHEMBL623
P28223	5HT2A_HUMAN	cyclobenzaprine	7.5409	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL669	CN(C)CCC=C1C2=CC=CC=C2C=CC2=C1C=CC=C2	CHEMBL669
P28223	5HT2A_HUMAN	clozapine	8.3	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL42	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2	CHEMBL42
P28223	5HT2A_HUMAN	aripiprazole	7.9	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1112	ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl	CHEMBL1112
P08908	5HT1A_HUMAN	buspirone	7.25	EC50	PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL49	O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1	CHEMBL49
P08908	5HT1A_HUMAN	aripiprazole	8.15	Ki	PARTIAL AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207533s000lbl.pdf	ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl	CHEMBL1112
P23975	SC6A2_HUMAN	desvenlafaxine	6.2747	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1118	CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1	CHEMBL1118
P23975	SC6A2_HUMAN	venlafaxine	5.9747	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL637	COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1	CHEMBL637
P23975	SC6A2_HUMAN	trimipramine	5.61	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL644	CC(CN(C)C)CN1C2=CC=CC=C2CCC2=C1C=CC=C2	CHEMBL644
P23975	SC6A2_HUMAN	sibutramine	5.2635	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1419	CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1	CHEMBL1419
P23975	SC6A2_HUMAN	protriptyline	8.39	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL668	CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2	CHEMBL668
P23975	SC6A2_HUMAN	phentermine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1574	CC(C)(N)CC1=CC=CC=C1	CHEMBL1574
P23975	SC6A2_HUMAN	phenmetrazine	7.2976	EC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200483	CC1NCCOC1C1=CC=CC=C1	CHEMBL1200483
P23975	SC6A2_HUMAN	nortriptyline	8.3595	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL445	CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2	CHEMBL445
P23975	SC6A2_HUMAN	nefazodone	6.4437	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL623	CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1	CHEMBL623
P23975	SC6A2_HUMAN	milnacipran	7.6	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL259209	CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1	CHEMBL259209
P23975	SC6A2_HUMAN	maprotiline	8.27	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL21731	CNCCCC12CCC(C3=CC=CC=C13)C1=C2C=CC=C1	CHEMBL21731
P23975	SC6A2_HUMAN	imipramine	7.4318	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL11	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2	CHEMBL11
P23975	SC6A2_HUMAN	guanethidine			SUBSTRATE	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL765	NC(=N)NCCN1CCCCCCC1	CHEMBL765
P23975	SC6A2_HUMAN	doxepin	7.53	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1628227	CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=CC=C2	CHEMBL1628227
P23975	SC6A2_HUMAN	dexmethylphenidate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL827	[H][C@@]1(CCCCN1)[C@H](C(=O)OC)C1=CC=CC=C1	CHEMBL827
P23975	SC6A2_HUMAN	desipramine	9.0809	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL72	CNCCCN1C2=CC=CC=C2CCC2=C1C=CC=C2	CHEMBL72
P23975	SC6A2_HUMAN	amitriptyline	7.4559	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL629	CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2	CHEMBL629
P31645	SC6A4_HUMAN	desvenlafaxine	7.3251	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1118	CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1	CHEMBL1118
P31645	SC6A4_HUMAN	venlafaxine	8.0506	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL637	COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1	CHEMBL637
P31645	SC6A4_HUMAN	trazodone	6.8	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL621	ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1	CHEMBL621
P31645	SC6A4_HUMAN	sibutramine	6.5257	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1419	CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1	CHEMBL1419
P31645	SC6A4_HUMAN	protriptyline	7.34	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL668	CNCCCC1C2=CC=CC=C2C=CC2=C1C=CC=C2	CHEMBL668
P31645	SC6A4_HUMAN	nortriptyline	7.34	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL445	CNCCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2	CHEMBL445
P31645	SC6A4_HUMAN	nefazodone	6.699	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL623	CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1	CHEMBL623
P31645	SC6A4_HUMAN	milnacipran	7.29	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL259209	CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1	CHEMBL259209
P31645	SC6A4_HUMAN	imipramine	8.8539	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL11	CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2	CHEMBL11
P31645	SC6A4_HUMAN	fluvoxamine	8.51	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL814	COCCCC\C(=N/OCCN)C1=CC=C(C=C1)C(F)(F)F	CHEMBL814
P31645	SC6A4_HUMAN	fluoxetine	9.0915	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL41	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	CHEMBL41
P31645	SC6A4_HUMAN	escitalopram	8.9586	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1508	CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1	CHEMBL1508
P31645	SC6A4_HUMAN	citalopram	8.9355	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL549	CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1	CHEMBL549
P31645	SC6A4_HUMAN	chlorphentermine	6.4711	Ki	SUBSTRATE	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200595	CC(C)(N)CC1=CC=C(Cl)C=C1	CHEMBL1200595
P31645	SC6A4_HUMAN	amitriptyline	8.3665	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL629	CN(C)CCC=C1C2=CC=CC=C2CCC2=C1C=CC=C2	CHEMBL629
Q12809	KCNH2_HUMAN	sotalol	4.0	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL471	CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1	CHEMBL471
Q12809	KCNH2_HUMAN	amiodarone	5.0	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL633	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CHEMBL633
P08913	ADA2A_HUMAN	tolazoline	6.64	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL770	C(C1=NCCN1)C1=CC=CC=C1	CHEMBL770
P08913	ADA2A_HUMAN	tizanidine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1079	ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1	CHEMBL1079
P08913	ADA2A_HUMAN	phenoxybenzamine	6.28	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL753	CC(COC1=CC=CC=C1)N(CCCl)CC1=CC=CC=C1	CHEMBL753
P08913	ADA2A_HUMAN	methyldopa			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL459	C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O	CHEMBL459
P08913	ADA2A_HUMAN	guanfacine	7.1642	EC50	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022037s011lbl.pdf	NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl	CHEMBL862
P08913	ADA2A_HUMAN	dipivefrine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200833	CNCC(O)C1=CC(OC(=O)C(C)(C)C)=C(OC(=O)C(C)(C)C)C=C1	CHEMBL1200833
P08913	ADA2A_HUMAN	brimonidine	8.3872	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL844	BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12	CHEMBL844
P29274	AA2AR_HUMAN	regadenoson	5.8861	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL317052	CNC(=O)C1=CN(N=C1)C1=NC(N)=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=N1	CHEMBL317052
P29274	AA2AR_HUMAN	adenosine	6.1549	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL477	NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1	CHEMBL477
P14416	DRD2_HUMAN	asenapine	8.75	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201756	[H]C12CN(C)CC1([H])C1=C(OC3=C2C=CC=C3)C=CC(Cl)=C1	CHEMBL1201756
P14416	DRD2_HUMAN	iloperidone	8.9687	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL14376	COC1=C(OCCCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C=CC(=C1)C(C)=O	CHEMBL14376
P14416	DRD2_HUMAN	ziprasidone	8.32	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL708	ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=C1C=CC=C2	CHEMBL708
P14416	DRD2_HUMAN	thioridazine	7.4	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL479	[H]C1(CCN2C3=CC=CC=C3SC3=CC=C(SC)C=C23)CCCCN1C	CHEMBL479
P14416	DRD2_HUMAN	thiethylperazine	8.699	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1378	CCSC1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(C)CC3)C2=C1	CHEMBL1378
P14416	DRD2_HUMAN	risperidone	8.49	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL85	CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1	CHEMBL85
P14416	DRD2_HUMAN	quetiapine	6.4828	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL716	OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12	CHEMBL716
P14416	DRD2_HUMAN	promazine	6.7037	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL564	CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2	CHEMBL564
P14416	DRD2_HUMAN	prochlorperazine	8.7642	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL728	CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1	CHEMBL728
P14416	DRD2_HUMAN	pramipexole	6.6	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL301265	CCCN[C@H]1CCC2=C(C1)SC(N)=N2	CHEMBL301265
P14416	DRD2_HUMAN	pimozide	8.8623	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1423	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=C1C=CC=C2)C1=CC=C(F)C=C1	CHEMBL1423
P14416	DRD2_HUMAN	perphenazine	9.32	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL567	OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1	CHEMBL567
P14416	DRD2_HUMAN	pergolide	8.3	EC50	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf	[H][C@]1(CSC)CN(CCC)[C@]2([H])CC3=CNC4=C3C(=CC=C4)[C@@]2([H])C1	CHEMBL531
P14416	DRD2_HUMAN	olanzapine	8.5229	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL715	CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2	CHEMBL715
P14416	DRD2_HUMAN	molindone	6.1568	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL460	CCC1=C(C)NC2=C1C(=O)C(CN1CCOCC1)CC2	CHEMBL460
P14416	DRD2_HUMAN	metoclopramide	7.1938	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL86	CCN(CC)CCNC(=O)C1=C(OC)C=C(N)C(Cl)=C1	CHEMBL86
P14416	DRD2_HUMAN	haloperidol	9.15	Ki	INVERSE AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL54	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1	CHEMBL54
P14416	DRD2_HUMAN	fluphenazine	9.269	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL726	OCCN1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(C=C23)C(F)(F)F)CC1	CHEMBL726
P14416	DRD2_HUMAN	clozapine	6.86	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL42	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=C1C=CC=C2	CHEMBL42
P14416	DRD2_HUMAN	chlorpromazine	8.15	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL71	CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2	CHEMBL71
P14416	DRD2_HUMAN	bromocriptine	9.7	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL493	[H][C@@]12CCCN1C(=O)[C@]([H])(CC(C)C)N1C(=O)[C@](NC(=O)[C@@]3([H])CN(C)[C@]4([H])CC5=C(Br)NC6=C5C(=CC=C6)C4=C3)(O[C@@]21O)C(C)C	CHEMBL493
P14416	DRD2_HUMAN	aripiprazole	8.71	Ki	PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1112	ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl	CHEMBL1112
P35372	OPRM_HUMAN	methylnaltrexone	7.55	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1186579	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CC[N+](C)(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O	CHEMBL1186579
P35372	OPRM_HUMAN	sufentanil	8.13	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL658	CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1	CHEMBL658
P35372	OPRM_HUMAN	remifentanil			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1005	CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC	CHEMBL1005
P35372	OPRM_HUMAN	oxymorphone	9.4437	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL963	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@H](C4)[C@]1(O)CCC2=O	CHEMBL963
P35372	OPRM_HUMAN	oxycodone	7.7959	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL656	[H][C@@]12OC3=C4C(C[C@@]5([H])N(C)CC[C@@]14[C@@]5(O)CCC2=O)=CC=C3OC	CHEMBL656
P35372	OPRM_HUMAN	naloxone	8.81	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL80	[H][C@@]12OC3=C4C(C[C@@]5([H])N(CC=C)CC[C@@]14[C@@]5(O)CCC2=O)=CC=C3O	CHEMBL80
P35372	OPRM_HUMAN	nalbuphine	8.8	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL895	[H][C@@]12OC3=C4C(C[C@@]5([H])N(CC6CCC6)CC[C@@]14[C@@]5(O)CC[C@@H]2O)=CC=C3O	CHEMBL895
P35372	OPRM_HUMAN	morphine	7.86	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL70	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O	CHEMBL70
P35372	OPRM_HUMAN	naltrexone	9.38	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL19019	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O	CHEMBL19019
P35372	OPRM_HUMAN	methadone	8.78	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL651	CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL651
P35372	OPRM_HUMAN	loperamide	8.8239	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL841	CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL841
P35372	OPRM_HUMAN	levomethadyl acetate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1514	CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1514
P35372	OPRM_HUMAN	fentanyl	9.0014	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL596	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1	CHEMBL596
P35372	OPRM_HUMAN	diphenoxylate	7.1674	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200665	CCOC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1	CHEMBL1200665
P35372	OPRM_HUMAN	dextropropoxyphene			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213351	[H][C@@](C)(CN(C)C)[C@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1	CHEMBL1213351
P35372	OPRM_HUMAN	buprenorphine	8.29	Ki	PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL511142	[H][C@@]12OC3=C4C(C[C@@]5([H])N(CC6CC6)CC[C@@]14[C@@]51CC[C@@]2(OC)[C@]([H])(C1)[C@](C)(O)C(C)(C)C)=CC=C3O	CHEMBL511142
Q06187	BTK_HUMAN	ibrutinib	9.142667770385742	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17154430	NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C	CHEMBL1873475
P35372	OPRM_HUMAN	anileridine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200543	CCOC(=O)C1(CCN(CCC2=CC=C(N)C=C2)CC1)C1=CC=CC=C1	CHEMBL1200543
P35372	OPRM_HUMAN	alvimopan	9.3979	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL270190	C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1	CHEMBL270190
P35372	OPRM_HUMAN	alfentanil	8.5	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL634	CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O	CHEMBL634
P23219	PGH1_HUMAN	tolmetin	6.27	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1020	CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1	CHEMBL1020
P23219	PGH1_HUMAN	suprofen	5.96	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL956	CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1	CHEMBL956
P23219	PGH1_HUMAN	piroxicam	5.18	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL527	CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=CC=CC=C2S1(=O)=O	CHEMBL527
P23219	PGH1_HUMAN	naproxen	5.16	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL154	COC1=CC=C2C=C(C=CC2=C1)[C@H](C)C(O)=O	CHEMBL154
P23219	PGH1_HUMAN	mesalazine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL704	NC1=CC(C(O)=O)=C(O)C=C1	CHEMBL704
P23219	PGH1_HUMAN	mefenamic acid	4.78	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL686	CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C	CHEMBL686
P23219	PGH1_HUMAN	meclofenamic acid	6.66	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL509	CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl	CHEMBL509
P23219	PGH1_HUMAN	ketorolac	9.72	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL469	OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1	CHEMBL469
P23219	PGH1_HUMAN	ketoprofen	7.33	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL571	CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1	CHEMBL571
P23219	PGH1_HUMAN	indomethacin	7.21	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL6	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CHEMBL6
P23219	PGH1_HUMAN	ibuprofen	5.12	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL521	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O	CHEMBL521
P23219	PGH1_HUMAN	flurbiprofen	8.74	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL563	CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1	CHEMBL563
P23219	PGH1_HUMAN	fenoprofen	5.36	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1297	CC(C(O)=O)C1=CC=CC(OC2=CC=CC=C2)=C1	CHEMBL1297
P23219	PGH1_HUMAN	diflunisal	4.4	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL898	OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1	CHEMBL898
P23219	PGH1_HUMAN	diclofenac	7.52	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL139	OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1	CHEMBL139
P23219	PGH1_HUMAN	bromfenac	8.29	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL751	NC1=C(C=CC=C1CC(O)=O)C(=O)C1=CC=C(Br)C=C1	CHEMBL751
P23219	PGH1_HUMAN	balsalazide			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200760	OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O	CHEMBL1200760
P23219	PGH1_HUMAN	nepafenac	6.6	IC50	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D05143	NC(=O)CC1=C(N)C(=CC=C1)C(=O)C1=CC=CC=C1	CHEMBL25146
P23219	PGH1_HUMAN	acetylsalicylic acid	5.77	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL25	CC(=O)OC1=CC=CC=C1C(O)=O	CHEMBL25
Q14524	SCN5A_HUMAN	topiramate			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
Q14524	SCN5A_HUMAN	ropivacaine	4.56	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1077896	CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C	CHEMBL1077896
Q14524	SCN5A_HUMAN	riluzole			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL744	NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2	CHEMBL744
Q14524	SCN5A_HUMAN	phenytoin			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL16	O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL16
Q14524	SCN5A_HUMAN	oxcarbazepine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1068	NC(=O)N1C2=CC=CC=C2C(=O)CC2=C1C=CC=C2	CHEMBL1068
Q14524	SCN5A_HUMAN	orphenadrine	4.8861	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL900	CN(C)CCOC(C1=CC=CC=C1)C1=C(C)C=CC=C1	CHEMBL900
Q14524	SCN5A_HUMAN	moracizine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1075	CCOC(=O)NC1=CC=C2SC3=CC=CC=C3N(C(=O)CCN3CCOCC3)C2=C1	CHEMBL1075
Q14524	SCN5A_HUMAN	mexiletine	4.53	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL558	CC(N)COC1=C(C)C=CC=C1C	CHEMBL558
Q14524	SCN5A_HUMAN	mepivacaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1087	[H]C1(CCCCN1C)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1087
Q14524	SCN5A_HUMAN	etidocaine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL492	CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C	CHEMBL492
Q14524	SCN5A_HUMAN	disopyramide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL517	CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=N1)C(C)C	CHEMBL517
Q14524	SCN5A_HUMAN	carbamazepine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL108	NC(=O)N1C2=CC=CC=C2C=CC2=C1C=CC=C2	CHEMBL108
P21554	CNR1_HUMAN	paracetamol			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23940628	CC(=O)NC1=CC=C(O)C=C1	CHEMBL112
Q8NER1	TRPV1_HUMAN	paracetamol			OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL112	CC(=O)NC1=CC=C(O)C=C1	CHEMBL112
P35354	PGH2_HUMAN	valdecoxib	8.3	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL865	CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O	CHEMBL865
P35354	PGH2_HUMAN	tolmetin	6.84	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1020	CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1	CHEMBL1020
P35354	PGH2_HUMAN	suprofen	5.06	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL956	CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1	CHEMBL956
P35354	PGH2_HUMAN	sulindac	4.25	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL15770	CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)=O	CHEMBL15770
P35354	PGH2_HUMAN	rofecoxib	6.51	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL122	CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1	CHEMBL122
P35354	PGH2_HUMAN	piroxicam	4.7	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL527	CN1C(C(=O)NC2=CC=CC=N2)=C(O)C2=CC=CC=C2S1(=O)=O	CHEMBL527
P35354	PGH2_HUMAN	oxaprozin	4.44	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1071	OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1071
P35354	PGH2_HUMAN	mefenamic acid	6.83	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL686	CC1=CC=CC(NC2=C(C=CC=C2)C(O)=O)=C1C	CHEMBL686
P35354	PGH2_HUMAN	meclofenamic acid	6.7	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL509	CC1=CC=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C1Cl	CHEMBL509
P35354	PGH2_HUMAN	ketorolac	6.9	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL469	OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1	CHEMBL469
P35354	PGH2_HUMAN	ketoprofen	6.62	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL571	CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1	CHEMBL571
P35354	PGH2_HUMAN	indomethacin	6.33	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL6	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CHEMBL6
P35354	PGH2_HUMAN	ibuprofen	5.14	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL521	CC(C)CC1=CC=C(C=C1)C(C)C(O)=O	CHEMBL521
P35354	PGH2_HUMAN	flurbiprofen	8.39	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL563	CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1	CHEMBL563
P35354	PGH2_HUMAN	fenoprofen	5.23	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1297	CC(C(O)=O)C1=CC=CC(OC2=CC=CC=C2)=C1	CHEMBL1297
P35354	PGH2_HUMAN	etoricoxib	6.1	IC50	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2896	CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O	CHEMBL416146
P35354	PGH2_HUMAN	diflunisal	5.09	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL898	OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1	CHEMBL898
P35354	PGH2_HUMAN	diclofenac	7.7	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL139	OC(=O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1	CHEMBL139
P35354	PGH2_HUMAN	celecoxib	7.24	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL118	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F	CHEMBL118
P35354	PGH2_HUMAN	bromfenac	8.4	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL751	NC1=C(C=CC=C1CC(O)=O)C(=O)C1=CC=C(Br)C=C1	CHEMBL751
P35354	PGH2_HUMAN	balsalazide			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200760	OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O	CHEMBL1200760
P35354	PGH2_HUMAN	nepafenac	6.82	IC50	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D05143	NC(=O)CC1=C(N)C(=CC=C1)C(=O)C1=CC=CC=C1	CHEMBL25146
P35354	PGH2_HUMAN	acetylsalicylic acid	5.12	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL25	CC(=O)OC1=CC=CC=C1C(O)=O	CHEMBL25
P35354	PGH2_HUMAN	paracetamol	4.31	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL112	CC(=O)NC1=CC=C(O)C=C1	CHEMBL112
P07550	ADRB2_HUMAN	vilanterol	9.4	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1084647	OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl	CHEMBL1084647
P07550	ADRB2_HUMAN	timolol	9.7	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL499	CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1	CHEMBL499
P07550	ADRB2_HUMAN	terbutaline	5.6	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1760	CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1	CHEMBL1760
P07550	ADRB2_HUMAN	sotalol	6.9	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL471	CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1	CHEMBL471
P07550	ADRB2_HUMAN	ritodrine	7.62	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL785	C[C@@H](NCCC1=CC=C(O)C=C1)[C@@H](O)C1=CC=C(O)C=C1	CHEMBL785
P07550	ADRB2_HUMAN	propranolol	8.25	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/016419s029lbl.pdf	[H]C(O)(CNC(C)C)COC1=C2C=CC=CC2=CC=C1	CHEMBL27
P07550	ADRB2_HUMAN	pirbuterol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1094966	CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1	CHEMBL1094966
P07550	ADRB2_HUMAN	pindolol	9.0	Ki	PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL500	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	CHEMBL500
P07550	ADRB2_HUMAN	penbutolol	9.0	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1290	CC(C)(C)NC[C@H](O)COC1=C(C=CC=C1)C1CCCC1	CHEMBL1290
P07550	ADRB2_HUMAN	oxprenolol	8.0	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL546	CC(C)NCC(O)COC1=C(OCC=C)C=CC=C1	CHEMBL546
P07550	ADRB2_HUMAN	nebivolol	7.5	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL434394	[H]C1(CCC2=CC(F)=CC=C2O1)C(O)CNCC(O)C1([H])CCC2=CC(F)=CC=C2O1	CHEMBL434394
P07550	ADRB2_HUMAN	isoprenaline	9.8	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL434	CC(C)NCC(O)C1=CC=C(O)C(O)=C1	CHEMBL434
P07550	ADRB2_HUMAN	dobutamine	6.2	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL926	CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1	CHEMBL926
P07550	ADRB2_HUMAN	carteolol	9.2	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL839	CC(C)(C)NCC(O)COC1=C2CCC(=O)NC2=CC=C1	CHEMBL839
P07550	ADRB2_HUMAN	salbutamol	5.95	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL714	CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1	CHEMBL714
P08588	ADRB1_HUMAN	timolol	9.0	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL499	CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1	CHEMBL499
P08588	ADRB1_HUMAN	sotalol	6.1	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL471	CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1	CHEMBL471
P08588	ADRB1_HUMAN	propranolol	8.71	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/016419s029lbl.pdf	[H]C(O)(CNC(C)C)COC1=C2C=CC=CC2=CC=C1	CHEMBL27
P08588	ADRB1_HUMAN	pindolol	9.4	Ki	PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL500	CC(C)NCC(O)COC1=CC=CC2=C1C=CN2	CHEMBL500
P08588	ADRB1_HUMAN	penbutolol	8.8	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1290	CC(C)(C)NC[C@H](O)COC1=C(C=CC=C1)C1CCCC1	CHEMBL1290
P08588	ADRB1_HUMAN	oxprenolol	8.11	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL546	CC(C)NCC(O)COC1=C(OCC=C)C=CC=C1	CHEMBL546
P08588	ADRB1_HUMAN	nebivolol	8.5	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL434394	[H]C1(CCC2=CC(F)=CC=C2O1)C(O)CNCC(O)C1([H])CCC2=CC(F)=CC=C2O1	CHEMBL434394
P08588	ADRB1_HUMAN	metoprolol	7.6	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL13	COCCC1=CC=C(OCC(O)CNC(C)C)C=C1	CHEMBL13
P08588	ADRB1_HUMAN	isoprenaline	9.0	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL434	CC(C)NCC(O)C1=CC=C(O)C(O)=C1	CHEMBL434
P08588	ADRB1_HUMAN	dopamine	5.0	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL59	NCCC1=CC(O)=C(O)C=C1	CHEMBL59
P08588	ADRB1_HUMAN	dobutamine	5.5	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL926	CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1	CHEMBL926
P08588	ADRB1_HUMAN	carteolol	9.3	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL839	CC(C)(C)NCC(O)COC1=C2CCC(=O)NC2=CC=C1	CHEMBL839
P08588	ADRB1_HUMAN	bisoprolol	7.65	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL645	CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1	CHEMBL645
P08588	ADRB1_HUMAN	betaxolol	8.8	Kd	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL423	CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1	CHEMBL423
P08588	ADRB1_HUMAN	atenolol	7.3	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL24	CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1	CHEMBL24
P08588	ADRB1_HUMAN	acebutolol	7.3	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL642	CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1	CHEMBL642
P34903	GBRA3_HUMAN	diazepam	6.6655	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P47870	GBRB2_HUMAN	diazepam	6.6655	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
Q99928	GBRG3_HUMAN	diazepam	6.6655	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P14867	GBRA1_HUMAN	diazepam	6.7055	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P47870	GBRB2_HUMAN	diazepam	6.7055	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
Q99928	GBRG3_HUMAN	diazepam	6.7055	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P23975	SC6A2_HUMAN	clomipramine	7.4202	Kd	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2398	CN(C)CCCN1C2=CC(Cl)=CC=C2CCC2=C1C=CC=C2	CHEMBL415
P14867	GBRA1_HUMAN	zopiclone	7.1759	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P18507	GBRG2_HUMAN	zopiclone	7.1759	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P47870	GBRB2_HUMAN	zopiclone	7.1759	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P18507	GBRG2_HUMAN	zopiclone	6.5817	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P34903	GBRA3_HUMAN	zopiclone	6.5817	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P47870	GBRB2_HUMAN	zopiclone	6.5817	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P14867	GBRA1_HUMAN	zolpidem	6.7033	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P18507	GBRG2_HUMAN	zolpidem	6.7033	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P47870	GBRB2_HUMAN	zolpidem	6.7033	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P14867	GBRA1_HUMAN	zolpidem	7.5735	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P18507	GBRG2_HUMAN	zolpidem	7.5735	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P28472	GBRB3_HUMAN	zolpidem	7.5735	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P18507	GBRG2_HUMAN	zolpidem	6.8069	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P28472	GBRB3_HUMAN	zolpidem	6.8069	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P47869	GBRA2_HUMAN	zolpidem	6.8069	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P18507	GBRG2_HUMAN	zolpidem	6.1643	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P34903	GBRA3_HUMAN	zolpidem	6.1643	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P47870	GBRB2_HUMAN	zolpidem	6.1643	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P18507	GBRG2_HUMAN	zolpidem	6.4168	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P28472	GBRB3_HUMAN	zolpidem	6.4168	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P34903	GBRA3_HUMAN	zolpidem	6.4168	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL911	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P14867	GBRA1_HUMAN	zaleplon	6.5302	EC50	POSITIVE ALLOSTERIC MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11755161	CCN(C(C)=O)C1=CC(=CC=C1)C1=CC=NC2=C(C=NN12)C#N	CHEMBL1521
P18507	GBRG2_HUMAN	zaleplon	6.5302	EC50	POSITIVE ALLOSTERIC MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11755161	CCN(C(C)=O)C1=CC(=CC=C1)C1=CC=NC2=C(C=NN12)C#N	CHEMBL1521
P47870	GBRB2_HUMAN	zaleplon	6.5302	EC50	POSITIVE ALLOSTERIC MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11755161	CCN(C(C)=O)C1=CC(=CC=C1)C1=CC=NC2=C(C=NN12)C#N	CHEMBL1521
P18507	GBRG2_HUMAN	zaleplon	5.7889	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1521	CCN(C(C)=O)C1=CC(=CC=C1)C1=CC=NC2=C(C=NN12)C#N	CHEMBL1521
P28472	GBRB3_HUMAN	zaleplon	5.7889	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1521	CCN(C(C)=O)C1=CC(=CC=C1)C1=CC=NC2=C(C=NN12)C#N	CHEMBL1521
P47869	GBRA2_HUMAN	zaleplon	5.7889	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1521	CCN(C(C)=O)C1=CC(=CC=C1)C1=CC=NC2=C(C=NN12)C#N	CHEMBL1521
P18507	GBRG2_HUMAN	triazolam	9.02	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P28472	GBRB3_HUMAN	triazolam	9.02	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P31644	GBRA5_HUMAN	triazolam	9.02	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P14867	GBRA1_HUMAN	triazolam	9.1549	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P18507	GBRG2_HUMAN	triazolam	9.1549	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P47870	GBRB2_HUMAN	triazolam	9.1549	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P14867	GBRA1_HUMAN	triazolam	9.0969	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P18507	GBRG2_HUMAN	triazolam	9.0969	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P28472	GBRB3_HUMAN	triazolam	9.0969	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P18507	GBRG2_HUMAN	triazolam	9.2291	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P28472	GBRB3_HUMAN	triazolam	9.2291	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P47869	GBRA2_HUMAN	triazolam	9.2291	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P18507	GBRG2_HUMAN	triazolam	8.8761	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P34903	GBRA3_HUMAN	triazolam	8.8761	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P47870	GBRB2_HUMAN	triazolam	8.8761	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P18507	GBRG2_HUMAN	triazolam	8.8447	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P28472	GBRB3_HUMAN	triazolam	8.8447	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P34903	GBRA3_HUMAN	triazolam	8.8447	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P14867	GBRA1_HUMAN	topiramate			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
P18507	GBRG2_HUMAN	topiramate			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
P47870	GBRB2_HUMAN	topiramate			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
P14867	GBRA1_HUMAN	thiopental			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL441	CCCC(C)C1(CC)C(=O)NC(=S)NC1=O	CHEMBL441
P18507	GBRG2_HUMAN	thiopental			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL441	CCCC(C)C1(CC)C(=O)NC(=S)NC1=O	CHEMBL441
P47870	GBRB2_HUMAN	thiopental			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL441	CCCC(C)C1(CC)C(=O)NC(=S)NC1=O	CHEMBL441
P14867	GBRA1_HUMAN	temazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL967	CN1C2=CC=C(Cl)C=C2C(=NC(O)C1=O)C1=CC=CC=C1	CHEMBL967
P18507	GBRG2_HUMAN	temazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL967	CN1C2=CC=C(Cl)C=C2C(=NC(O)C1=O)C1=CC=CC=C1	CHEMBL967
P47870	GBRB2_HUMAN	temazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL967	CN1C2=CC=C(Cl)C=C2C(=NC(O)C1=O)C1=CC=CC=C1	CHEMBL967
P14867	GBRA1_HUMAN	secobarbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL447	CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL447
P18507	GBRG2_HUMAN	secobarbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL447	CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL447
P47870	GBRB2_HUMAN	secobarbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL447	CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL447
P18505	GBRB1_HUMAN	quazepam	6.6271	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200472	FC1=C(C=CC=C1)C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12	CHEMBL1200472
P18507	GBRG2_HUMAN	quazepam	6.6271	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200472	FC1=C(C=CC=C1)C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12	CHEMBL1200472
P34903	GBRA3_HUMAN	quazepam	6.6271	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200472	FC1=C(C=CC=C1)C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12	CHEMBL1200472
P18505	GBRB1_HUMAN	quazepam	6.6882	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200472	FC1=C(C=CC=C1)C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12	CHEMBL1200472
P18507	GBRG2_HUMAN	quazepam	6.6882	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200472	FC1=C(C=CC=C1)C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12	CHEMBL1200472
P47869	GBRA2_HUMAN	quazepam	6.6882	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200472	FC1=C(C=CC=C1)C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12	CHEMBL1200472
P14867	GBRA1_HUMAN	primidone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL856	CCC1(C(=O)NCNC1=O)C1=CC=CC=C1	CHEMBL856
P18507	GBRG2_HUMAN	primidone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL856	CCC1(C(=O)NCNC1=O)C1=CC=CC=C1	CHEMBL856
P47870	GBRB2_HUMAN	primidone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL856	CCC1(C(=O)NCNC1=O)C1=CC=CC=C1	CHEMBL856
P14867	GBRA1_HUMAN	prazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL969	ClC1=CC=C2N(CC3CC3)C(=O)CN=C(C3=CC=CC=C3)C2=C1	CHEMBL969
P18507	GBRG2_HUMAN	prazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL969	ClC1=CC=C2N(CC3CC3)C(=O)CN=C(C3=CC=CC=C3)C2=C1	CHEMBL969
P47870	GBRB2_HUMAN	prazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL969	ClC1=CC=C2N(CC3CC3)C(=O)CN=C(C3=CC=CC=C3)C2=C1	CHEMBL969
P14867	GBRA1_HUMAN	pentobarbital	4.301	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL448	CCCC(C)C1(CC)C(=O)NC(=O)NC1=O	CHEMBL448
P18507	GBRG2_HUMAN	pentobarbital	4.301	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL448	CCCC(C)C1(CC)C(=O)NC(=O)NC1=O	CHEMBL448
P47870	GBRB2_HUMAN	pentobarbital	4.301	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL448	CCCC(C)C1(CC)C(=O)NC(=O)NC1=O	CHEMBL448
P14867	GBRA1_HUMAN	oxazepam	7.745	IC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL568	OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL568
P18507	GBRG2_HUMAN	oxazepam	7.745	IC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL568	OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL568
P28472	GBRB3_HUMAN	oxazepam	7.745	IC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL568	OC1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL568
P14867	GBRA1_HUMAN	nitrazepam	8.0	EC50	POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D00531	[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1	CHEMBL13209
P18507	GBRG2_HUMAN	nitrazepam	8.0	EC50	POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D00531	[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1	CHEMBL13209
P47870	GBRB2_HUMAN	nitrazepam	8.0	EC50	POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D00531	[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1	CHEMBL13209
P14867	GBRA1_HUMAN	midazolam	8.7447	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P18507	GBRG2_HUMAN	midazolam	8.7447	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P47870	GBRB2_HUMAN	midazolam	8.7447	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P18507	GBRG2_HUMAN	midazolam	8.4437	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P34903	GBRA3_HUMAN	midazolam	8.4437	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P47870	GBRB2_HUMAN	midazolam	8.4437	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P14867	GBRA1_HUMAN	methyprylon			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200790	[H]C1(C)CNC(=O)C(CC)(CC)C1=O	CHEMBL1200790
P18507	GBRG2_HUMAN	methyprylon			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200790	[H]C1(C)CNC(=O)C(CC)(CC)C1=O	CHEMBL1200790
P28472	GBRB3_HUMAN	methyprylon			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200790	[H]C1(C)CNC(=O)C(CC)(CC)C1=O	CHEMBL1200790
P14867	GBRA1_HUMAN	methohexital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL7413	CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O	CHEMBL7413
P18507	GBRG2_HUMAN	methohexital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL7413	CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O	CHEMBL7413
P28472	GBRB3_HUMAN	methohexital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL7413	CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O	CHEMBL7413
P14867	GBRA1_HUMAN	meprobamate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL979	CCCC(C)(COC(N)=O)COC(N)=O	CHEMBL979
P18507	GBRG2_HUMAN	meprobamate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL979	CCCC(C)(COC(N)=O)COC(N)=O	CHEMBL979
P28472	GBRB3_HUMAN	meprobamate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL979	CCCC(C)(COC(N)=O)COC(N)=O	CHEMBL979
P18507	GBRG2_HUMAN	meprobamate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL979	CCCC(C)(COC(N)=O)COC(N)=O	CHEMBL979
P28472	GBRB3_HUMAN	meprobamate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL979	CCCC(C)(COC(N)=O)COC(N)=O	CHEMBL979
P47869	GBRA2_HUMAN	meprobamate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL979	CCCC(C)(COC(N)=O)COC(N)=O	CHEMBL979
P18507	GBRG2_HUMAN	meprobamate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL979	CCCC(C)(COC(N)=O)COC(N)=O	CHEMBL979
P28472	GBRB3_HUMAN	meprobamate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL979	CCCC(C)(COC(N)=O)COC(N)=O	CHEMBL979
P34903	GBRA3_HUMAN	meprobamate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL979	CCCC(C)(COC(N)=O)COC(N)=O	CHEMBL979
P18507	GBRG2_HUMAN	meprobamate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL979	CCCC(C)(COC(N)=O)COC(N)=O	CHEMBL979
P28472	GBRB3_HUMAN	meprobamate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL979	CCCC(C)(COC(N)=O)COC(N)=O	CHEMBL979
P31644	GBRA5_HUMAN	meprobamate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL979	CCCC(C)(COC(N)=O)COC(N)=O	CHEMBL979
P14867	GBRA1_HUMAN	lorazepam	8.456	IC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL580	OC1N=C(C2=CC(Cl)=CC=C2NC1=O)C1=C(Cl)C=CC=C1	CHEMBL580
P18507	GBRG2_HUMAN	lorazepam	8.456	IC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL580	OC1N=C(C2=CC(Cl)=CC=C2NC1=O)C1=C(Cl)C=CC=C1	CHEMBL580
P28472	GBRB3_HUMAN	lorazepam	8.456	IC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL580	OC1N=C(C2=CC(Cl)=CC=C2NC1=O)C1=C(Cl)C=CC=C1	CHEMBL580
P14867	GBRA1_HUMAN	glutethimide			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1102	CCC1(CCC(=O)NC1=O)C1=CC=CC=C1	CHEMBL1102
P18507	GBRG2_HUMAN	glutethimide			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1102	CCC1(CCC(=O)NC1=O)C1=CC=CC=C1	CHEMBL1102
P28472	GBRB3_HUMAN	glutethimide			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1102	CCC1(CCC(=O)NC1=O)C1=CC=CC=C1	CHEMBL1102
P14867	GBRA1_HUMAN	flurazepam	8.1	IC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL968	CCN(CC)CCN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=C(F)C=CC=C1	CHEMBL968
P18507	GBRG2_HUMAN	flurazepam	8.1	IC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL968	CCN(CC)CCN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=C(F)C=CC=C1	CHEMBL968
P47870	GBRB2_HUMAN	flurazepam	8.1	IC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL968	CCN(CC)CCN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=C(F)C=CC=C1	CHEMBL968
P14867	GBRA1_HUMAN	flumazenil	9.0969	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P18507	GBRG2_HUMAN	flumazenil	9.0969	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P28472	GBRB3_HUMAN	flumazenil	9.0969	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P18507	GBRG2_HUMAN	flumazenil	9.0458	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P28472	GBRB3_HUMAN	flumazenil	9.0458	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P47869	GBRA2_HUMAN	flumazenil	9.0458	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P18507	GBRG2_HUMAN	flumazenil	8.9788	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P28472	GBRB3_HUMAN	flumazenil	8.9788	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P34903	GBRA3_HUMAN	flumazenil	8.9788	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P18507	GBRG2_HUMAN	flumazenil	9.2218	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P28472	GBRB3_HUMAN	flumazenil	9.2218	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P31644	GBRA5_HUMAN	flumazenil	9.2218	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P18507	GBRG2_HUMAN	flumazenil	6.8297	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P28472	GBRB3_HUMAN	flumazenil	6.8297	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
Q16445	GBRA6_HUMAN	flumazenil	6.8297	Ki	ALLOSTERIC ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL407	CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1	CHEMBL407
P14867	GBRA1_HUMAN	etomidate	5.4559	EC50	POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL23731	CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1	CHEMBL23731
P18507	GBRG2_HUMAN	etomidate	5.4559	EC50	POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL23731	CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1	CHEMBL23731
P47870	GBRB2_HUMAN	etomidate	5.4559	EC50	POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL23731	CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1	CHEMBL23731
P14867	GBRA1_HUMAN	ethchlorvynol			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL591	CCC(O)(C=CCl)C#C	CHEMBL591
P18507	GBRG2_HUMAN	ethchlorvynol			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL591	CCC(O)(C=CCl)C#C	CHEMBL591
P28472	GBRB3_HUMAN	ethchlorvynol			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL591	CCC(O)(C=CCl)C#C	CHEMBL591
P14867	GBRA1_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P18507	GBRG2_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P47870	GBRB2_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P18507	GBRG2_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P34903	GBRA3_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P47870	GBRB2_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P18507	GBRG2_HUMAN	estazolam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL285674	ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1	CHEMBL285674
P28472	GBRB3_HUMAN	estazolam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL285674	ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1	CHEMBL285674
P31644	GBRA5_HUMAN	estazolam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL285674	ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1	CHEMBL285674
P18507	GBRG2_HUMAN	estazolam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL285674	ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1	CHEMBL285674
P28472	GBRB3_HUMAN	estazolam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL285674	ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1	CHEMBL285674
P34903	GBRA3_HUMAN	estazolam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL285674	ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1	CHEMBL285674
P14867	GBRA1_HUMAN	estazolam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL285674	ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1	CHEMBL285674
P18507	GBRG2_HUMAN	estazolam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL285674	ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1	CHEMBL285674
P47870	GBRB2_HUMAN	estazolam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL285674	ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1	CHEMBL285674
P18507	GBRG2_HUMAN	estazolam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL285674	ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1	CHEMBL285674
P28472	GBRB3_HUMAN	estazolam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL285674	ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1	CHEMBL285674
P47869	GBRA2_HUMAN	estazolam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL285674	ClC1=CC=C2N3C=NN=C3CN=C(C3=CC=CC=C3)C2=C1	CHEMBL285674
P18507	GBRG2_HUMAN	diazepam	7.65	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P28472	GBRB3_HUMAN	diazepam	7.65	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P34903	GBRA3_HUMAN	diazepam	7.65	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P14867	GBRA1_HUMAN	diazepam	7.1427	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P18507	GBRG2_HUMAN	diazepam	7.1427	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P47870	GBRB2_HUMAN	diazepam	7.1427	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P14867	GBRA1_HUMAN	diazepam	7.8539	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P18507	GBRG2_HUMAN	diazepam	7.8539	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P28472	GBRB3_HUMAN	diazepam	7.8539	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P18507	GBRG2_HUMAN	diazepam	7.699	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P28472	GBRB3_HUMAN	diazepam	7.699	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P47869	GBRA2_HUMAN	diazepam	7.699	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P18507	GBRG2_HUMAN	diazepam	7.9393	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P34903	GBRA3_HUMAN	diazepam	7.9393	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P47870	GBRB2_HUMAN	diazepam	7.9393	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P18507	GBRG2_HUMAN	diazepam	7.9586	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P28472	GBRB3_HUMAN	diazepam	7.9586	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P31644	GBRA5_HUMAN	diazepam	7.9586	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P14867	GBRA1_HUMAN	clorazepate	7.47	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213252	OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL1213252
P18507	GBRG2_HUMAN	clorazepate	7.47	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213252	OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL1213252
P47870	GBRB2_HUMAN	clorazepate	7.47	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213252	OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL1213252
P18507	GBRG2_HUMAN	clorazepate			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213252	OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL1213252
P28472	GBRB3_HUMAN	clorazepate			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213252	OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL1213252
P47869	GBRA2_HUMAN	clorazepate			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213252	OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL1213252
P18507	GBRG2_HUMAN	clorazepate			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213252	OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL1213252
P28472	GBRB3_HUMAN	clorazepate			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213252	OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL1213252
P34903	GBRA3_HUMAN	clorazepate			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213252	OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL1213252
P18507	GBRG2_HUMAN	clorazepate			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213252	OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL1213252
P28472	GBRB3_HUMAN	clorazepate			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213252	OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL1213252
P31644	GBRA5_HUMAN	clorazepate			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1213252	OC(=O)C1N=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C2NC1=O	CHEMBL1213252
P14867	GBRA1_HUMAN	clonazepam	8.0706	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL452	[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C2=C1)C1=C(Cl)C=CC=C1	CHEMBL452
P18507	GBRG2_HUMAN	clonazepam	8.0706	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL452	[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C2=C1)C1=C(Cl)C=CC=C1	CHEMBL452
P47870	GBRB2_HUMAN	clonazepam	8.0706	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL452	[O-][N+](=O)C1=CC=C2NC(=O)CN=C(C2=C1)C1=C(Cl)C=CC=C1	CHEMBL452
P14867	GBRA1_HUMAN	clobazam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL70418	CN1C2=CC=C(Cl)C=C2N(C2=CC=CC=C2)C(=O)CC1=O	CHEMBL70418
P18507	GBRG2_HUMAN	clobazam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL70418	CN1C2=CC=C(Cl)C=C2N(C2=CC=CC=C2)C(=O)CC1=O	CHEMBL70418
P47870	GBRB2_HUMAN	clobazam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL70418	CN1C2=CC=C(Cl)C=C2N(C2=CC=CC=C2)C(=O)CC1=O	CHEMBL70418
P14867	GBRA1_HUMAN	chlordiazepoxide	6.2518	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL451	CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1	CHEMBL451
P18507	GBRG2_HUMAN	chlordiazepoxide	6.2518	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL451	CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1	CHEMBL451
P47870	GBRB2_HUMAN	chlordiazepoxide	6.2518	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL451	CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1	CHEMBL451
P18507	GBRG2_HUMAN	chlordiazepoxide	6.3372	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL451	CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1	CHEMBL451
P28472	GBRB3_HUMAN	chlordiazepoxide	6.3372	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL451	CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1	CHEMBL451
P47869	GBRA2_HUMAN	chlordiazepoxide	6.3372	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL451	CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1	CHEMBL451
P18507	GBRG2_HUMAN	chlordiazepoxide	6.5607	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL451	CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1	CHEMBL451
P28472	GBRB3_HUMAN	chlordiazepoxide	6.5607	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL451	CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1	CHEMBL451
P34903	GBRA3_HUMAN	chlordiazepoxide	6.5607	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL451	CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1	CHEMBL451
P18507	GBRG2_HUMAN	chlordiazepoxide	6.4949	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL451	CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1	CHEMBL451
P28472	GBRB3_HUMAN	chlordiazepoxide	6.4949	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL451	CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1	CHEMBL451
P31644	GBRA5_HUMAN	chlordiazepoxide	6.4949	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL451	CNC1=NC2=CC=C(Cl)C=C2C(C2=CC=CC=C2)=[N+]([O-])C1	CHEMBL451
P14867	GBRA1_HUMAN	butalbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL454	CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL454
P18507	GBRG2_HUMAN	butalbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL454	CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL454
P28472	GBRB3_HUMAN	butalbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL454	CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O	CHEMBL454
P14867	GBRA1_HUMAN	secbutabarbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL449	CCC(C)C1(CC)C(=O)NC(=O)NC1=O	CHEMBL449
P18507	GBRG2_HUMAN	secbutabarbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL449	CCC(C)C1(CC)C(=O)NC(=O)NC1=O	CHEMBL449
P47870	GBRB2_HUMAN	secbutabarbital			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL449	CCC(C)C1(CC)C(=O)NC(=O)NC1=O	CHEMBL449
P14867	GBRA1_HUMAN	alprazolam	7.4318	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL661	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL661
P18507	GBRG2_HUMAN	alprazolam	7.4318	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL661	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL661
P47870	GBRB2_HUMAN	alprazolam	7.4318	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL661	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL661
P18507	GBRG2_HUMAN	alprazolam	7.9208	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL661	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL661
P28472	GBRB3_HUMAN	alprazolam	7.9208	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL661	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL661
P47869	GBRA2_HUMAN	alprazolam	7.9208	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL661	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL661
P18507	GBRG2_HUMAN	alprazolam	7.1612	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL661	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL661
P28472	GBRB3_HUMAN	alprazolam	7.1612	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL661	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL661
P34903	GBRA3_HUMAN	alprazolam	7.1612	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL661	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL661
P18507	GBRG2_HUMAN	alprazolam	8.0	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL661	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL661
P28472	GBRB3_HUMAN	alprazolam	8.0	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL661	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL661
P31644	GBRA5_HUMAN	alprazolam	8.0	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL661	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL661
P14867	GBRA1_HUMAN	acamprosate			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201293	CC(=O)NCCCS(O)(=O)=O	CHEMBL1201293
P18507	GBRG2_HUMAN	acamprosate			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201293	CC(=O)NCCCS(O)(=O)=O	CHEMBL1201293
P28472	GBRB3_HUMAN	acamprosate			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201293	CC(=O)NCCCS(O)(=O)=O	CHEMBL1201293
P14867	GBRA1_HUMAN	quazepam	7.7077	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200472	FC1=C(C=CC=C1)C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12	CHEMBL1200472
P18505	GBRB1_HUMAN	quazepam	7.7077	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200472	FC1=C(C=CC=C1)C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12	CHEMBL1200472
P18507	GBRG2_HUMAN	quazepam	7.7077	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200472	FC1=C(C=CC=C1)C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12	CHEMBL1200472
P02708	ACHA_HUMAN	doxacurium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1237099	[H]C1(CC2=CC(OC)=C(OC)C(OC)=C2)C2=C(OC)C(OC)=C(OC)C=C2CC[N+]1(C)CCCOC(=O)CCC(=O)OCCC[N+]1(C)CCC2=CC(OC)=C(OC)C(OC)=C2C1([H])CC1=CC(OC)=C(OC)C(OC)=C1	CHEMBL1237099
P11230	ACHB_HUMAN	doxacurium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1237099	[H]C1(CC2=CC(OC)=C(OC)C(OC)=C2)C2=C(OC)C(OC)=C(OC)C=C2CC[N+]1(C)CCCOC(=O)CCC(=O)OCCC[N+]1(C)CCC2=CC(OC)=C(OC)C(OC)=C2C1([H])CC1=CC(OC)=C(OC)C(OC)=C1	CHEMBL1237099
Q07001	ACHD_HUMAN	doxacurium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1237099	[H]C1(CC2=CC(OC)=C(OC)C(OC)=C2)C2=C(OC)C(OC)=C(OC)C=C2CC[N+]1(C)CCCOC(=O)CCC(=O)OCCC[N+]1(C)CCC2=CC(OC)=C(OC)C(OC)=C2C1([H])CC1=CC(OC)=C(OC)C(OC)=C1	CHEMBL1237099
P02708	ACHA_HUMAN	vecuronium	7.8239	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200629	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1	CHEMBL1200629
P11230	ACHB_HUMAN	vecuronium	7.8239	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200629	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1	CHEMBL1200629
Q07001	ACHD_HUMAN	vecuronium	7.8239	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200629	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1	CHEMBL1200629
P02708	ACHA_HUMAN	tubocurarine	7.6198	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL339427	[H][C@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC=C(O)C(OC6=CC1=C(CCN2C)C=C6OC)=C5)=CC(OC)=C4O)C=C3	CHEMBL339427
P11230	ACHB_HUMAN	tubocurarine	7.6198	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL339427	[H][C@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC=C(O)C(OC6=CC1=C(CCN2C)C=C6OC)=C5)=CC(OC)=C4O)C=C3	CHEMBL339427
Q07001	ACHD_HUMAN	tubocurarine	7.6198	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL339427	[H][C@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC=C(O)C(OC6=CC1=C(CCN2C)C=C6OC)=C5)=CC(OC)=C4O)C=C3	CHEMBL339427
P02708	ACHA_HUMAN	rocuronium	7.7696	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200648	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1	CHEMBL1200648
P11230	ACHB_HUMAN	rocuronium	7.7696	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200648	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1	CHEMBL1200648
Q07001	ACHD_HUMAN	rocuronium	7.7696	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200648	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1	CHEMBL1200648
P02708	ACHA_HUMAN	pipecuronium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200722	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1	CHEMBL1200722
P11230	ACHB_HUMAN	pipecuronium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200722	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1	CHEMBL1200722
Q07001	ACHD_HUMAN	pipecuronium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200722	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1	CHEMBL1200722
P02708	ACHA_HUMAN	pancuronium	8.2007	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL185073	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1	CHEMBL185073
P11230	ACHB_HUMAN	pancuronium	8.2007	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL185073	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1	CHEMBL185073
Q07001	ACHD_HUMAN	pancuronium	8.2007	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL185073	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1	CHEMBL185073
P02708	ACHA_HUMAN	mivacurium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL984	COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC	CHEMBL984
P11230	ACHB_HUMAN	mivacurium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL984	COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC	CHEMBL984
Q07001	ACHD_HUMAN	mivacurium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL984	COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC	CHEMBL984
P02708	ACHA_HUMAN	dimethyltubocurarinium	7.7447	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1259	[H][C@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC=C(OC)C(OC6=CC1=C(CC[N+]2(C)C)C=C6OC)=C5)=CC(OC)=C4OC)C=C3	CHEMBL1259
P11230	ACHB_HUMAN	dimethyltubocurarinium	7.7447	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1259	[H][C@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC=C(OC)C(OC6=CC1=C(CC[N+]2(C)C)C=C6OC)=C5)=CC(OC)=C4OC)C=C3	CHEMBL1259
Q07001	ACHD_HUMAN	dimethyltubocurarinium	7.7447	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1259	[H][C@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC=C(OC)C(OC6=CC1=C(CC[N+]2(C)C)C=C6OC)=C5)=CC(OC)=C4OC)C=C3	CHEMBL1259
P02708	ACHA_HUMAN	cisatracurium	8.0	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200641	COC1=C(OC)C=C(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C=C2)C=C1	CHEMBL1200641
P11230	ACHB_HUMAN	cisatracurium	8.0	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200641	COC1=C(OC)C=C(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C=C2)C=C1	CHEMBL1200641
Q07001	ACHD_HUMAN	cisatracurium	8.0	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200641	COC1=C(OC)C=C(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@H]2CC2=CC(OC)=C(OC)C=C2)C=C1	CHEMBL1200641
P02708	ACHA_HUMAN	atracurium	7.7696	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1360	COC1=C(OC)C=C(CC2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3C2CC2=CC(OC)=C(OC)C=C2)C=C1	CHEMBL1360
P11230	ACHB_HUMAN	atracurium	7.7696	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1360	COC1=C(OC)C=C(CC2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3C2CC2=CC(OC)=C(OC)C=C2)C=C1	CHEMBL1360
Q07001	ACHD_HUMAN	atracurium	7.7696	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1360	COC1=C(OC)C=C(CC2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3C2CC2=CC(OC)=C(OC)C=C2)C=C1	CHEMBL1360
P34903	GBRA3_HUMAN	zopiclone	6.4881	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P47870	GBRB2_HUMAN	zopiclone	6.4881	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
Q99928	GBRG3_HUMAN	zopiclone	6.4881	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P34903	GBRA3_HUMAN	triazolam	8.1079	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P47870	GBRB2_HUMAN	triazolam	8.1079	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
Q99928	GBRG3_HUMAN	triazolam	8.1079	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P34903	GBRA3_HUMAN	midazolam	7.6126	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P47870	GBRB2_HUMAN	midazolam	7.6126	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
Q99928	GBRG3_HUMAN	midazolam	7.6126	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P34903	GBRA3_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P47870	GBRB2_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
Q99928	GBRG3_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P14867	GBRA1_HUMAN	zopiclone	7.1549	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P47870	GBRB2_HUMAN	zopiclone	7.1549	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
Q99928	GBRG3_HUMAN	zopiclone	7.1549	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P14867	GBRA1_HUMAN	triazolam	8.6383	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P47870	GBRB2_HUMAN	triazolam	8.6383	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
Q99928	GBRG3_HUMAN	triazolam	8.6383	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P14867	GBRA1_HUMAN	midazolam	7.7496	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P47870	GBRB2_HUMAN	midazolam	7.7496	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
Q99928	GBRG3_HUMAN	midazolam	7.7496	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P14867	GBRA1_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P47870	GBRB2_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
Q99928	GBRG3_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P49286	MTR1B_HUMAN	melatonin	9.7	EC50	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224	COC1=CC2=C(NC=C2CCNC(C)=O)C=C1	CHEMBL45
P48039	MTR1A_HUMAN	melatonin	9.4	EC50	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224	COC1=CC2=C(NC=C2CCNC(C)=O)C=C1	CHEMBL45
Q96RJ0	TAAR1_HUMAN	tyramine	7.16	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21073468	NCCC1=CC=C(O)C=C1	CHEMBL11608
P07202	PERT_HUMAN	carbimazole			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1278093	CCOC(=O)N1C=CN(C)C1=S	CHEMBL508102
P43119	PI2R_HUMAN	beraprost	8.37	IC50	AGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500005871.pdf	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C1=C(O2)C(CCCC(O)=O)=CC=C1	CHEMBL435883
P31350	RIR2_HUMAN	hydroxycarbamide			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL467	NC(=O)NO	CHEMBL467
P31350	RIR2_HUMAN	gemcitabine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL888	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F	CHEMBL888
P31350	RIR2_HUMAN	clofarabine	8.3	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1750	NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F)C2=NC(Cl)=N1	CHEMBL1750
P23921	RIR1_HUMAN	hydroxycarbamide			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL467	NC(=O)NO	CHEMBL467
P23921	RIR1_HUMAN	gemcitabine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL888	NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F	CHEMBL888
P23921	RIR1_HUMAN	clofarabine	8.3	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1750	NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3F)C2=NC(Cl)=N1	CHEMBL1750
P00374	DYR_HUMAN	edatrexate	8.36	IC50	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D03942	CCC(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CHEMBL296373
P10276	RARA_HUMAN	etretinate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL464	CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(C)=C(OC)C=C1C	CHEMBL464
P10276	RARA_HUMAN	acitretin			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1131	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	CHEMBL1131
P0DP23	CALM1_HUMAN	aprindine	4.7447	ID50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/6186851	CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C1=CC=CC=C1	CHEMBL1213033
P0DP24	CALM2_HUMAN	aprindine	4.7447	ID50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/6186851	CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C1=CC=CC=C1	CHEMBL1213033
P0DP25	CALM3_HUMAN	aprindine	4.7447	ID50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/6186851	CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C1=CC=CC=C1	CHEMBL1213033
P18405	S5A1_HUMAN	finasteride	7.58	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020788s024lbl.pdf	[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C	CHEMBL710
P10275	ANDR_HUMAN	cyproterone acetate	7.432	IC50	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2865	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]12C	CHEMBL142130
P03372	ESR1_HUMAN	raloxifene	9.4	IC50	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2820	OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2	CHEMBL81
P23415	GLRA1_HUMAN	enflurane			POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1257	FC(F)OC(F)(F)C(F)Cl	CHEMBL1257
P35368	ADA1B_HUMAN	urapidil	7.1	Ki	ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01333	COC1=C(C=CC=C1)N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1	CHEMBL279229
P25100	ADA1D_HUMAN	urapidil	7.9	Ki	ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01333	COC1=C(C=CC=C1)N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1	CHEMBL279229
Q01959	SC6A3_HUMAN	nomifensine	7.31	Ki	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4792	CN1CC(C2=CC=CC=C2)C2=CC=CC(N)=C2C1	CHEMBL273575
Q13621	S12A1_HUMAN	piretanide	8.3	Kd	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D01634	NS(=O)(=O)C1=CC(=CC(N2CCCC2)=C1OC1=CC=CC=C1)C(O)=O	CHEMBL349803
P11229	ACM1_HUMAN	pirenzepine	7.68	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=328	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CHEMBL9967
P25021	HRH2_HUMAN	roxatidine acetate	7.6	Kd	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1717223	CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1	CHEMBL46102
P35367	HRH1_HUMAN	terfenadine	8.699	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2608	[H]C(O)(CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=C(C=C1)C(C)(C)C	CHEMBL17157
P35367	HRH1_HUMAN	oxatomide	7.699	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/6200290	O=C1NC2=C(C=CC=C2)N1CCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL13828
P35367	HRH1_HUMAN	mizolastine	8.84	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1354949	CN(C1CCN(CC1)C1=NC2=C(C=CC=C2)N1CC1=CC=C(F)C=C1)C1=NC=CC(=O)N1	CHEMBL94454
P35367	HRH1_HUMAN	mebhydrolin	7.1192	Ki	ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01786	CN1CCC2=C(C1)C1=C(C=CC=C1)N2CC1=CC=CC=C1	CHEMBL1625607
P35367	HRH1_HUMAN	ebastine	8.0	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2905151	CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL305660
P35367	HRH1_HUMAN	astemizole	8.58	A2	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/6114717	COC1=CC=C(CCN2CCC(CC2)NC2=NC3=C(C=CC=C3)N2CC2=CC=C(F)C=C2)C=C1	CHEMBL296419
P35462	DRD3_HUMAN	prochlorperazine	8.611	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7279	CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1	CHEMBL728
P35462	DRD3_HUMAN	amisulpride	8.4946	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11740949	CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC	CHEMBL243712
P35348	ADA1A_HUMAN	urapidil	8.85	Ki	ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01333	COC1=C(C=CC=C1)N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1	CHEMBL279229
P28335	5HT2C_HUMAN	mianserin	8.5204	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=135	[H]C12CN(C)CCN1C1=C(CC3=C2C=CC=C3)C=CC=C1	CHEMBL6437
P41595	5HT2B_HUMAN	mianserin	8.12	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=135	[H]C12CN(C)CCN1C1=C(CC3=C2C=CC=C3)C=CC=C1	CHEMBL6437
P28223	5HT2A_HUMAN	mianserin	8.17	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=135	[H]C12CN(C)CCN1C1=C(CC3=C2C=CC=C3)C=CC=C1	CHEMBL6437
P23975	SC6A2_HUMAN	nomifensine	7.67	Ki	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4792	CN1CC(C2=CC=CC=C2)C2=CC=CC(N)=C2C1	CHEMBL273575
P23975	SC6A2_HUMAN	lofepramine	8.2676	Ki	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7551	CN(CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2)CC(=O)C1=CC=C(Cl)C=C1	CHEMBL87708
P23975	SC6A2_HUMAN	dosulepin	7.3372	Kd	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7549	CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12	CHEMBL108947
P31645	SC6A4_HUMAN	lofepramine	7.1549	Ki	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7551	CN(CCCN1C2=CC=CC=C2CCC2=C1C=CC=C2)CC(=O)C1=CC=C(Cl)C=C1	CHEMBL87708
P31645	SC6A4_HUMAN	dosulepin	8.0655	Kd	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7549	CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12	CHEMBL108947
P14416	DRD2_HUMAN	zuclopenthixol			ANTAGONIST	DRUG LABEL	http://www.medicines.org.uk/emc/medicine/1073	OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1	CHEMBL53904
P14416	DRD2_HUMAN	levodopa			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/7878037	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	CHEMBL1009
P14416	DRD2_HUMAN	bromperidol	8.43	Ki	ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01101	OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1	CHEMBL28218
P14416	DRD2_HUMAN	amisulpride	8.5528	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11740949	CCN1CCCC1CNC(=O)C1=C(OC)C=C(N)C(=C1)S(=O)(=O)CC	CHEMBL243712
P21728	DRD1_HUMAN	zuclopenthixol			ANTAGONIST	DRUG LABEL	http://www.medicines.org.uk/emc/medicine/1073	OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1	CHEMBL53904
P21728	DRD1_HUMAN	levodopa			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/7878037	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	CHEMBL1009
P35372	OPRM_HUMAN	tilidine	5.1	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/15627429	[H]C1(C=CCCC1(C(=O)OCC)C1=CC=CC=C1)N(C)C	CHEMBL2218854
P35372	OPRM_HUMAN	propiram			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/7693433	CCC(=O)N(C(C)CN1CCCCC1)C1=CC=CC=N1	CHEMBL2106935
P35372	OPRM_HUMAN	meptazinol	8.06	EC50	PARTIAL AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/6141283	CCC1(CCCCN(C)C1)C1=CC(O)=CC=C1	CHEMBL314437
P23219	PGH1_HUMAN	tiaprofenic acid	5.9	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/6782492	CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1	CHEMBL365795
P23219	PGH1_HUMAN	flufenamic acid	5.52	IC50	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D01581	OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1	CHEMBL23588
P23219	PGH1_HUMAN	fenbufen			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/6356910	OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1	CHEMBL277522
P35354	PGH2_HUMAN	tiaprofenic acid	7.1	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/6782492	CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1	CHEMBL365795
P35354	PGH2_HUMAN	flufenamic acid	6.93	IC50	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D01581	OC(=O)C1=C(NC2=CC(=CC=C2)C(F)(F)F)C=CC=C1	CHEMBL23588
P35354	PGH2_HUMAN	fenbufen			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/6356910	OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1	CHEMBL277522
P07550	ADRB2_HUMAN	fenoterol	6.9	EC50	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=557	CC(CC1=CC=C(O)C=C1)NCC(O)C1=CC(O)=CC(O)=C1	CHEMBL32800
P07550	ADRB2_HUMAN	bopindolol	9.65	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11314603	CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1	CHEMBL357995
P08588	ADRB1_HUMAN	celiprolol	8.1	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/9205952	CCN(CC)C(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)(C)C)C=C1	CHEMBL27810
P08588	ADRB1_HUMAN	bopindolol	9.51	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11314603	CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1	CHEMBL357995
P08588	ADRB1_HUMAN	bevantolol			ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2858236	COC1=C(OC)C=C(CCNCC(O)COC2=CC(C)=CC=C2)C=C1	CHEMBL314010
P05093	CP17A_HUMAN	ketoconazole	7.28	IC50	INHIBITOR	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003906/WC500181492.pdf	CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CHEMBL295698
P18507	GBRG2_HUMAN	zopiclone	7.2782	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P31644	GBRA5_HUMAN	zopiclone	7.2782	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P47870	GBRB2_HUMAN	zopiclone	7.2782	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P31644	GBRA5_HUMAN	zopiclone	6.7496	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P47870	GBRB2_HUMAN	zopiclone	6.7496	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
Q99928	GBRG3_HUMAN	zopiclone	6.7496	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P18507	GBRG2_HUMAN	triazolam	9.2218	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P31644	GBRA5_HUMAN	triazolam	9.2218	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P47870	GBRB2_HUMAN	triazolam	9.2218	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P31644	GBRA5_HUMAN	triazolam	8.699	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P47870	GBRB2_HUMAN	triazolam	8.699	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
Q99928	GBRG3_HUMAN	triazolam	8.699	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P18507	GBRG2_HUMAN	midazolam	9.1249	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P31644	GBRA5_HUMAN	midazolam	9.1249	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P47870	GBRB2_HUMAN	midazolam	9.1249	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P31644	GBRA5_HUMAN	midazolam	8.2596	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P47870	GBRB2_HUMAN	midazolam	8.2596	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
Q99928	GBRG3_HUMAN	midazolam	8.2596	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P18507	GBRG2_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P31644	GBRA5_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P47870	GBRB2_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P31644	GBRA5_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P47870	GBRB2_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
Q99928	GBRG3_HUMAN	eszopiclone			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P18507	GBRG2_HUMAN	diazepam	8.0044	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P31644	GBRA5_HUMAN	diazepam	8.0044	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P47870	GBRB2_HUMAN	diazepam	8.0044	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P31644	GBRA5_HUMAN	diazepam	7.2034	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P47870	GBRB2_HUMAN	diazepam	7.2034	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
Q99928	GBRG3_HUMAN	diazepam	7.2034	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P01008	ANT3_HUMAN	enoxaparin sodium			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201476		CHEMBL1201476
P11473	VDR_HUMAN	alfacalcidol			AGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01518	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)CCCC(C)C	CHEMBL1601669
P35498	SCN1A_HUMAN	quinidine	5.49	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL21578	[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12	CHEMBL21578
Q99250	SCN2A_HUMAN	quinidine	5.49	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL21578	[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12	CHEMBL21578
Q9NY46	SCN3A_HUMAN	quinidine	5.49	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL21578	[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12	CHEMBL21578
Q14524	SCN5A_HUMAN	quinidine	5.16	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL21578	[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12	CHEMBL21578
P00918	CAH2_HUMAN	dorzolamide	9.7	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL218490	CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O	CHEMBL218490
P11511	CP19A_HUMAN	vorozole	8.86	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/7726994	CN1N=NC2=C1C=C(C=C2)[C@@H](N1C=NC=N1)C1=CC=C(Cl)C=C1	CHEMBL224060
P08172	ACM2_HUMAN	tolterodine	8.57	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1382	CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C	CHEMBL1382
P20309	ACM3_HUMAN	tolterodine	8.49	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1382	CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C	CHEMBL1382
P41145	OPRK_HUMAN	butorphanol	9.92	Ki	PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL33986	[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1	CHEMBL33986
P35372	OPRM_HUMAN	butorphanol	9.92	Ki	PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL33986	[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1	CHEMBL33986
P14416	DRD2_HUMAN	loxapine	7.68	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL831	CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2	CHEMBL831
P28223	5HT2A_HUMAN	loxapine	8.62	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL831	CN1CCN(CC1)C1=NC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2	CHEMBL831
P10275	ANDR_HUMAN	stanozolol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2079587	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=C(C[C@]12C)C=NN3	CHEMBL2079587
P31645	SC6A4_HUMAN	paroxetine	10.4	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL490	[H][C@@]1(COC2=CC3=C(OCO3)C=C2)CNCC[C@@]1([H])C1=CC=C(F)C=C1	CHEMBL490
P07550	ADRB2_HUMAN	protokylol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200893	CC(CC1=CC=C2OCOC2=C1)NCC(O)C1=CC=C(O)C(O)=C1	CHEMBL1200893
P28222	5HT1B_HUMAN	naratriptan	8.48	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1278	CNS(=O)(=O)CCC1=CC=C2NC=C(C3CCN(C)CC3)C2=C1	CHEMBL1278
P10275	ANDR_HUMAN	fluoxymesterone	8.24	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1445	[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1445
P55017	S12A3_HUMAN	chlortalidone			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1055	NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12	CHEMBL1055
P00918	CAH2_HUMAN	topiramate	8.3	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
P22748	CAH4_HUMAN	topiramate	5.31	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
P42261	GRIA1_HUMAN	topiramate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
P42262	GRIA2_HUMAN	topiramate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
P42263	GRIA3_HUMAN	topiramate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
P48058	GRIA4_HUMAN	topiramate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
P39086	GRIK1_HUMAN	topiramate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
Q13002	GRIK2_HUMAN	topiramate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
Q13003	GRIK3_HUMAN	topiramate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
Q16099	GRIK4_HUMAN	topiramate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
Q16478	GRIK5_HUMAN	topiramate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220492	[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2	CHEMBL220492
P41145	OPRK_HUMAN	nalmefene	9.92	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL982	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C	CHEMBL982
P41143	OPRD_HUMAN	nalmefene	9.04	Kd	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL982	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C	CHEMBL982
P35372	OPRM_HUMAN	nalmefene	9.53	Kd	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL982	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C	CHEMBL982
P20309	ACM3_HUMAN	mepenzolate	8.59	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL524004	C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL524004
P11229	ACM1_HUMAN	mepenzolate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL524004	C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL524004
P14416	DRD2_HUMAN	sulpiride	8.12	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5501	CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O	CHEMBL26
P56524	HDAC4_HUMAN	belinostat	7.568636417388916	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12939461	ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1	CHEMBL408513
Q14524	SCN5A_HUMAN	propafenone	5.48	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL631	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1	CHEMBL631
P07550	ADRB2_HUMAN	formoterol	8.6	Kd	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1256786	COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1	CHEMBL1256786
P20309	ACM3_HUMAN	oxyphencyclimine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1495	CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1	CHEMBL1495
P11229	ACM1_HUMAN	oxyphencyclimine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1495	CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1	CHEMBL1495
P04150	GCR_HUMAN	medrysone			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201173	[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C	CHEMBL1201173
P20648	ATP4A_HUMAN	omeprazole	5.7	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1503	COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C	CHEMBL1503
P51164	ATP4B_HUMAN	omeprazole	5.7	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1503	COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C	CHEMBL1503
P20648	ATP4A_HUMAN	esomeprazole			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200470	COC1=CC=C2N=C(NC2=C1)[S@@](=O)CC1=C(C)C(OC)=C(C)C=N1	CHEMBL1200470
P51164	ATP4B_HUMAN	esomeprazole			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200470	COC1=CC=C2N=C(NC2=C1)[S@@](=O)CC1=C(C)C(OC)=C(C)C=N1	CHEMBL1200470
Q13936	CAC1C_HUMAN	nifedipine	9.4	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17276408	COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OC	CHEMBL193
P07477	TRY1_HUMAN	nafamostat	7.77	IC50	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262	NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N	CHEMBL273264
P00736	C1R_HUMAN	nafamostat	6.0	IC50	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262	NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N	CHEMBL273264
P19793	RXRA_HUMAN	bexarotene	7.85	Kd	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1023	CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O	CHEMBL1023
P28702	RXRB_HUMAN	bexarotene	8.23	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1023	CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O	CHEMBL1023
P48443	RXRG_HUMAN	bexarotene	8.08	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1023	CC1=C(C=C2C(=C1)C(C)(C)CCC2(C)C)C(=C)C1=CC=C(C=C1)C(O)=O	CHEMBL1023
P20309	ACM3_HUMAN	oxyphenonium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200906	CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1	CHEMBL1200906
O00329	PK3CD_HUMAN	idelalisib	8.602060317993164	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20959606	CC[C@H](NC1=NC=NC2=C1NC=N2)C1=NC2=C(C(F)=CC=C2)C(=O)N1C1=CC=CC=C1	CHEMBL2216870
P35354	PGH2_HUMAN	meloxicam	6.8	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL599	CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O	CHEMBL599
P10826	RARB_HUMAN	tazarotene	9.1	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1657	CCOC(=O)C1=CN=C(C=C1)C#CC1=CC=C2SCCC(C)(C)C2=C1	CHEMBL1657
P10276	RARA_HUMAN	tazarotene	7.2	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1657	CCOC(=O)C1=CN=C(C=C1)C#CC1=CC=C2SCCC(C)(C)C2=C1	CHEMBL1657
P13631	RARG_HUMAN	tazarotene	7.4	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1657	CCOC(=O)C1=CN=C(C=C1)C#CC1=CC=C2SCCC(C)(C)C2=C1	CHEMBL1657
P11229	ACM1_HUMAN	clidinium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL620	C[N+]12CCC(CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL620
P35408	PE2R4_HUMAN	dinoprostone	9.77	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL548	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	CHEMBL548
P34995	PE2R1_HUMAN	dinoprostone	8.04	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL548	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	CHEMBL548
P43116	PE2R2_HUMAN	dinoprostone	8.77	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL548	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	CHEMBL548
P43115	PE2R3_HUMAN	dinoprostone	9.48	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL548	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	CHEMBL548
O00591	GBRP_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
O14764	GBRD_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
P14867	GBRA1_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
P18505	GBRB1_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
P18507	GBRG2_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
P28472	GBRB3_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
P31644	GBRA5_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
P34903	GBRA3_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
P47869	GBRA2_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
P47870	GBRB2_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
P48169	GBRA4_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
P78334	GBRE_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
Q16445	GBRA6_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
Q8N1C3	GBRG1_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
Q99928	GBRG3_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
Q9UN88	GBRT_HUMAN	halazepam			POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL970	FC(F)(F)CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL970
P20309	ACM3_HUMAN	isopropamide			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200347	CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C	CHEMBL1200347
P11229	ACM1_HUMAN	isopropamide			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200347	CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C	CHEMBL1200347
P08913	ADA2A_HUMAN	yohimbine	9.38	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102	[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=C3C=CC=C1)C2	CHEMBL15245
P18089	ADA2B_HUMAN	yohimbine	8.7	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102	[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=C3C=CC=C1)C2	CHEMBL15245
P18825	ADA2C_HUMAN	yohimbine	9.3	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102	[H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=C3C=CC=C1)C2	CHEMBL15245
P43088	PF2R_HUMAN	dinoprost	8.4	Kd	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL815	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	CHEMBL815
P03372	ESR1_HUMAN	estradiol valerate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1511	[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CHEMBL1511
P09917	LOX5_HUMAN	balsalazide			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200760	OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O	CHEMBL1200760
P37231	PPARG_HUMAN	balsalazide			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200760	OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O	CHEMBL1200760
P41180	CASR_HUMAN	cinacalcet	7.7	EC50	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200776	C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=C1C=CC=C2	CHEMBL1200776
P11229	ACM1_HUMAN	oxybutynin	9.0	Ki	ANTAGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000532/WC500040171.pdf	CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1	CHEMBL1133
P20309	ACM3_HUMAN	oxybutynin	9.11	Ki	ANTAGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000532/WC500040171.pdf	CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1	CHEMBL1133
P20648	ATP4A_HUMAN	rabeprazole			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1219	COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C	CHEMBL1219
P51164	ATP4B_HUMAN	rabeprazole			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1219	COCCCOC1=CC=NC(CS(=O)C2=NC3=C(N2)C=CC=C3)=C1C	CHEMBL1219
P55017	S12A3_HUMAN	methylclothiazide			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1577	CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O	CHEMBL1577
Q07869	PPARA_HUMAN	fenofibrate	6.0	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL672	CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1	CHEMBL672
P34981	TRFR_HUMAN	protirelin	7.7	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1472	NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1	CHEMBL1472
P08172	ACM2_HUMAN	solifenacin	6.24	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1734	O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1	CHEMBL1734
P20309	ACM3_HUMAN	solifenacin	6.88	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1734	O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1	CHEMBL1734
P55017	S12A3_HUMAN	metolazone			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL878	CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=C(C)C=CC=C1)S(N)(=O)=O	CHEMBL878
Q13639	5HT4R_HUMAN	prucalopride	8.6	Ki	AGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001012/WC500053998.pdf	COCCCN1CCC(CC1)NC(=O)C1=CC(Cl)=C(N)C2=C1OCC2	CHEMBL117287
P12821	ACE_HUMAN	perindopril	8.82	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1581	[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O	CHEMBL1581
P43088	PF2R_HUMAN	carboprost			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1237105	CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	CHEMBL1237105
P20648	ATP4A_HUMAN	lansoprazole			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL480	CC1=C(CS(=O)C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	CHEMBL480
P51164	ATP4B_HUMAN	lansoprazole			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL480	CC1=C(CS(=O)C2=NC3=C(N2)C=CC=C3)N=CC=C1OCC(F)(F)F	CHEMBL480
P04150	GCR_HUMAN	rimexolone			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200617	[H][C@@]12C[C@@H](C)[C@](C)(C(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1200617
P14416	DRD2_HUMAN	remoxipride	6.06	IC50	ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D02682	CCN1CCC[C@H]1CNC(=O)C1=C(OC)C(Br)=CC=C1OC	CHEMBL22242
P03372	ESR1_HUMAN	tamoxifen	7.51	Ki	MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL83	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1	CHEMBL83
P04150	GCR_HUMAN	meprednisone			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201148	[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1201148
P08235	MCR_HUMAN	desoxycorticosterone acetate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200542	[H][C@@]12CC[C@H](C(=O)COC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1200542
P21554	CNR1_HUMAN	nabilone	8.4	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL947	[H]C12CC(=O)CCC1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC	CHEMBL947
P30531	SC6A1_HUMAN	tiagabine	7.77	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1027	CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1	CHEMBL1027
P04062	GLCM_HUMAN	ambroxol	5.39	IC50		IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10692	NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br	CHEMBL153479
P04150	GCR_HUMAN	fluprednisolone			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200774	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	CHEMBL1200774
O14649	KCNK3_HUMAN	doxapram			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1754	CCN1CC(CCN2CCOCC2)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1754
Q9NPC2	KCNK9_HUMAN	doxapram			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1754	CCN1CC(CCN2CCOCC2)C(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1754
Q92731	ESR2_HUMAN	chlorotrianisene			MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200761	COC1=CC=C(C=C1)C(Cl)=C(C1=CC=C(OC)C=C1)C1=CC=C(OC)C=C1	CHEMBL1200761
P28222	5HT1B_HUMAN	eletriptan	8.52	Kd	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1510	CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2	CHEMBL1510
P28221	5HT1D_HUMAN	eletriptan	9.05	Kd	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1510	CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2	CHEMBL1510
P20648	ATP4A_HUMAN	pantoprazole			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1502	COC1=CC=NC(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=C1OC	CHEMBL1502
P51164	ATP4B_HUMAN	pantoprazole			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1502	COC1=CC=NC(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=C1OC	CHEMBL1502
P00918	CAH2_HUMAN	brinzolamide	9.9	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL220491	CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O	CHEMBL220491
P20618	PSB1_HUMAN	bortezomib	7.28	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL325041	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O	CHEMBL325041
P28074	PSB5_HUMAN	bortezomib	9.26	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL325041	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O	CHEMBL325041
P49721	PSB2_HUMAN	bortezomib	6.23	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL325041	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O	CHEMBL325041
P28062	PSB8_HUMAN	bortezomib	8.09	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL325041	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O	CHEMBL325041
P48169	GBRA4_HUMAN	eszopiclone	6.99	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
P47869	GBRA2_HUMAN	eszopiclone	6.94	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1522	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=CC=C(Cl)C=N1	CHEMBL1522
O76074	PDE5A_HUMAN	tadalafil	8.0	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL779	[H][C@]12CC3=C(NC4=C3C=CC=C4)[C@]([H])(N1C(=O)CN(C)C2=O)C1=CC=C2OCOC2=C1	CHEMBL779
P25100	ADA1D_HUMAN	alfuzosin	8.44	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL709	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1	CHEMBL709
P35348	ADA1A_HUMAN	alfuzosin	8.09	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL709	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1	CHEMBL709
P35368	ADA1B_HUMAN	alfuzosin	8.55	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL709	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1	CHEMBL709
P55017	S12A3_HUMAN	cyclothiazide			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL61593	NS(=O)(=O)C1=CC2=C(NC(NS2(=O)=O)C2CC3CC2C=C3)C=C1Cl	CHEMBL61593
P35367	HRH1_HUMAN	meclozine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1623	CC1=CC=CC(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)=C1	CHEMBL1623
P27815	PDE4A_HUMAN	flavoxate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1493	CC1=C(OC2=C(C=CC=C2C1=O)C(=O)OCCN1CCCCC1)C1=CC=CC=C1	CHEMBL1493
Q07343	PDE4B_HUMAN	flavoxate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1493	CC1=C(OC2=C(C=CC=C2C1=O)C(=O)OCCN1CCCCC1)C1=CC=CC=C1	CHEMBL1493
Q08493	PDE4C_HUMAN	flavoxate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1493	CC1=C(OC2=C(C=CC=C2C1=O)C(=O)OCCN1CCCCC1)C1=CC=CC=C1	CHEMBL1493
Q08499	PDE4D_HUMAN	flavoxate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1493	CC1=C(OC2=C(C=CC=C2C1=O)C(=O)OCCN1CCCCC1)C1=CC=CC=C1	CHEMBL1493
Q13946	PDE7A_HUMAN	flavoxate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1493	CC1=C(OC2=C(C=CC=C2C1=O)C(=O)OCCN1CCCCC1)C1=CC=CC=C1	CHEMBL1493
Q9NP56	PDE7B_HUMAN	flavoxate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1493	CC1=C(OC2=C(C=CC=C2C1=O)C(=O)OCCN1CCCCC1)C1=CC=CC=C1	CHEMBL1493
O60658	PDE8A_HUMAN	flavoxate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1493	CC1=C(OC2=C(C=CC=C2C1=O)C(=O)OCCN1CCCCC1)C1=CC=CC=C1	CHEMBL1493
O95263	PDE8B_HUMAN	flavoxate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1493	CC1=C(OC2=C(C=CC=C2C1=O)C(=O)OCCN1CCCCC1)C1=CC=CC=C1	CHEMBL1493
P08172	ACM2_HUMAN	trospium			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1888176	[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)[N+]21CCCC1	CHEMBL1888176
Q96RI1	NR1H4_HUMAN	ursodiol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1551	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O	CHEMBL1551
P14416	DRD2_HUMAN	spiperone	10.22	Ki	ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01051	FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1	CHEMBL267930
P28223	5HT2A_HUMAN	spiperone	8.65	Ki	ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01051	FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1	CHEMBL267930
P03372	ESR1_HUMAN	estradiol cypionate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200973	[H][C@@]12CC[C@H](OC(=O)CCC3CCCC3)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CHEMBL1200973
P23219	PGH1_HUMAN	sulfasalazine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL421	OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1	CHEMBL421
P35354	PGH2_HUMAN	sulfasalazine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL421	OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1	CHEMBL421
P07477	TRY1_HUMAN	camostat	7.3	IC50	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6432	CN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1	CHEMBL590799
P36888	FLT3_HUMAN	sunitinib	9.66	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL535	CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C	CHEMBL535
P35968	VGFR2_HUMAN	sunitinib	9.7	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL535	CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C	CHEMBL535
P09619	PGFRB_HUMAN	sunitinib	10.12	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL535	CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C	CHEMBL535
P10721	KIT_HUMAN	sunitinib	9.68	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL535	CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C	CHEMBL535
P07333	CSF1R_HUMAN	sunitinib	8.7	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL535	CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C	CHEMBL535
P35916	VGFR3_HUMAN	sunitinib	7.77	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL535	CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C	CHEMBL535
P11473	VDR_HUMAN	calcifediol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1040	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C)[C@H](C)CCCC(C)(C)O	CHEMBL1040
P04150	GCR_HUMAN	prednisolone acetate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1152	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1152
P27815	PDE4A_HUMAN	roflumilast	9.1	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL193240	FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl	CHEMBL193240
Q07343	PDE4B_HUMAN	roflumilast	9.1	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL193240	FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl	CHEMBL193240
Q08493	PDE4C_HUMAN	roflumilast	9.1	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL193240	FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl	CHEMBL193240
Q08499	PDE4D_HUMAN	roflumilast	9.1	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL193240	FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl	CHEMBL193240
Q96S37	S22AC_HUMAN	sulfinpyrazone	4.0	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL832	O=C1C(CCS(=O)C2=CC=CC=C2)C(=O)N(N1C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL832
O95180	CAC1H_HUMAN	flunarizine	5.44	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19582593	FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1	CHEMBL30008
Q9P0X4	CAC1I_HUMAN	flunarizine	6.08	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19582593	FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1	CHEMBL30008
O43497	CAC1G_HUMAN	flunarizine	6.28	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19582593	FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1	CHEMBL30008
P12821	ACE_HUMAN	imidapril	5.0	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1666418	[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(=O)OCC)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O	CHEMBL317094
O75907	DGAT1_HUMAN	icosapent ethyl			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202057s009lbl.pdf	CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	CHEMBL2095209
P16066	ANPRA_HUMAN	nesiritide			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/20920s033lbl.pdf	[H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O	CHEMBL1201668
P00734	THRB_HUMAN	lepirudin	13.0	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020807s011lbl.pdf	[H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC2=O)[C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC1=O)C(C)C	CHEMBL1201666
P00734	THRB_HUMAN	desirudin	12.7	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021271s006lbl.pdf	[H]N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC2=O)[C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC1=O)C(C)C	CHEMBL1201662
O14764	GBRD_HUMAN	fospropofol			POSITIVE ALLOSTERIC MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CHEMBL1201766
P14867	GBRA1_HUMAN	fospropofol			POSITIVE ALLOSTERIC MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CHEMBL1201766
P18505	GBRB1_HUMAN	fospropofol			POSITIVE ALLOSTERIC MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CHEMBL1201766
P18507	GBRG2_HUMAN	fospropofol			POSITIVE ALLOSTERIC MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CHEMBL1201766
P28472	GBRB3_HUMAN	fospropofol			POSITIVE ALLOSTERIC MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CHEMBL1201766
P31644	GBRA5_HUMAN	fospropofol			POSITIVE ALLOSTERIC MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CHEMBL1201766
P34903	GBRA3_HUMAN	fospropofol			POSITIVE ALLOSTERIC MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CHEMBL1201766
P47869	GBRA2_HUMAN	fospropofol			POSITIVE ALLOSTERIC MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CHEMBL1201766
P47870	GBRB2_HUMAN	fospropofol			POSITIVE ALLOSTERIC MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CHEMBL1201766
P48169	GBRA4_HUMAN	fospropofol			POSITIVE ALLOSTERIC MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CHEMBL1201766
Q16445	GBRA6_HUMAN	fospropofol			POSITIVE ALLOSTERIC MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CHEMBL1201766
Q8N1C3	GBRG1_HUMAN	fospropofol			POSITIVE ALLOSTERIC MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CHEMBL1201766
Q99928	GBRG3_HUMAN	fospropofol			POSITIVE ALLOSTERIC MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019627s062lbl.pdf	CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O	CHEMBL1201766
P03372	ESR1_HUMAN	conjugated estrogens			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21396_prempro_lbl.pdf		CHEMBL1201649
Q92731	ESR2_HUMAN	conjugated estrogens			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21396_prempro_lbl.pdf		CHEMBL1201649
P04150	GCR_HUMAN	prednisolone sodium phosphate			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf	[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1201014
P14416	DRD2_HUMAN	paliperidone palmitate			ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022264s013s014lbl.pdf	CCCCCCCCCCCCCCCC(=O)OC1CCCN2C(=O)C(CCN3CCC(CC3)C3=NOC4=C3C=CC(F)=C4)=C(C)N=C12	CHEMBL2107360
P28223	5HT2A_HUMAN	paliperidone palmitate			ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022264s013s014lbl.pdf	CCCCCCCCCCCCCCCC(=O)OC1CCCN2C(=O)C(CCN3CCC(CC3)C3=NOC4=C3C=CC(F)=C4)=C(C)N=C12	CHEMBL2107360
P21802	FGFR2_HUMAN	palifermin			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125103s146lbl.pdf	[H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O	CHEMBL1201821
P48357	LEPR_HUMAN	metreleptin			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s004lbl.pdf	[H]N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H](NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC=N2)NC1=O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C(C)C)C(O)=O	CHEMBL2107857
P03952	KLKB1_HUMAN	ecallantide	10.602060317993164	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125277s071lbl.pdf	[H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC4=CNC5=C4C=CC=C5)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC4=CNC=N4)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@@H](NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC3=O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](C)NC1=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O	CHEMBL1201837
P10912	GHR_HUMAN	somatropin			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020280s077lbl.pdf	[H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)NC1=O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)C(C)C)C(C)C)C(C)C)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(C)C)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O	CHEMBL1201621
P03372	ESR1_HUMAN	estrone sulphate			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/083220s041lbl.pdf	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OS(O)(=O)=O)C=C3	CHEMBL494753
Q92731	ESR2_HUMAN	estrone sulphate			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/083220s041lbl.pdf	[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OS(O)(=O)=O)C=C3	CHEMBL494753
P35372	OPRM_HUMAN	naloxegol			ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204760s000lbl.pdf	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC=C)[C@]([H])(C4)[C@]1(O)CC[C@@H]2OCCOCCOCCOCCOCCOCCOCCOC	CHEMBL2219416
P21964	COMT_HUMAN	flopropione			INHIBITOR	DRUG LABEL	http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	CCC(=O)C1=C(O)C=C(O)C=C1O	CHEMBL1605835
P00742	FA10_HUMAN	edoxaban	9.251811981201172	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20503967	CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=CC=C(Cl)C=N2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1	CHEMBL1269025
P14416	DRD2_HUMAN	benzquinamide	5.4	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200707	CCN(CC)C(=O)C1CN2CCC3=C(C=C(OC)C(OC)=C3)C2CC1OC(C)=O	CHEMBL1200707
P11229	ACM1_HUMAN	biperiden	9.32	Kd	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1101	[H]C1(CC2CC1C=C2)C(O)(CCN1CCCCC1)C1=CC=CC=C1	CHEMBL1101
P25103	NK1R_HUMAN	netupitant	9.022275924682617	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/16332435	CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=C(C)C=CC=C1)N1CCN(C)CC1	CHEMBL206253
P41231	P2RY2_HUMAN	diquafosol	7.4685211181640625	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/18232657	O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)NC1=O)N1C=CC(=O)NC1=O	CHEMBL221326
P22460	KCNA5_HUMAN	vernakalant	4.874518871307373	IC50	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17872968	COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1	CHEMBL2107383
P20309	ACM3_HUMAN	imidafenacin	9.498940467834473	Kb	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10428387	CC1=NC=CN1CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL53366
P35968	VGFR2_HUMAN	nintedanib	8.301030158996582	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19522465	COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2	CHEMBL502835
P11362	FGFR1_HUMAN	nintedanib	7.4202165603637695	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19522465	COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2	CHEMBL502835
P16234	PGFRA_HUMAN	nintedanib	7.744727611541748	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19522465	COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2	CHEMBL502835
P17948	VGFR1_HUMAN	nintedanib	6.982966423034668	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19522465	COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2	CHEMBL502835
P35916	VGFR3_HUMAN	nintedanib	8.301030158996582	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19522465	COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2	CHEMBL502835
P01375	TNFA_HUMAN	adalimumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125057s367lbl.pdf		CHEMBL1201580
P63316	TNNC1_HUMAN	levosimendan	3.1549019813537598	Kd	OPENER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/18570382	C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1	CHEMBL2051955
P30556	AGTR1_HUMAN	fimasartan	9.376750946044922	IC50	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22264484	CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1	CHEMBL1951143
P35499	SCN4A_HUMAN	pilsicainide	4.376750946044922	IC50	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20590641	CC1=CC=CC(C)=C1NC(=O)CC12CCCN1CCC2	CHEMBL163238
P09874	PARP1_HUMAN	olaparib	8.301030158996582	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/18800822	FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1	CHEMBL521686
Q9UGN5	PARP2_HUMAN	olaparib	9.0	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/18800822	FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1	CHEMBL521686
Q01726	MSHR_HUMAN	afamelanotide	10.0	IC50	AGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002548/WC500182307.pdf	CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O	CHEMBL441738
P15692	VEGFA_HUMAN	pegaptanib			ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021756s018lbl.pdf		CHEMBL1201421
P02766	TTHY_HUMAN	tafamidis	6.812	Kd	BINDING AGENT	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002294/WC500117862.pdf	OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1	CHEMBL2103837
Q01668	CAC1D_HUMAN	efonidipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17276408	CC1=C(C(C2=CC(=CC=C2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(CC1=CC=CC=C1)C1=CC=CC=C1	CHEMBL2074922
Q13936	CAC1C_HUMAN	efonidipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17276408	CC1=C(C(C2=CC(=CC=C2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(CC1=CC=CC=C1)C1=CC=CC=C1	CHEMBL2074922
Q01668	CAC1D_HUMAN	aranidipine			BLOCKER	KEGG DRUG	http://www.kegg.jp/entry/D01562	COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)=O	CHEMBL2104030
Q13936	CAC1C_HUMAN	aranidipine			BLOCKER	KEGG DRUG	http://www.kegg.jp/entry/D01562	COC(=O)C1=C(C)NC(C)=C(C1C1=C(C=CC=C1)[N+]([O-])=O)C(=O)OCC(C)=O	CHEMBL2104030
Q01668	CAC1D_HUMAN	(S)-nicardipine			BLOCKER	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022276s003lbl.pdf	COC(=O)C1=C(C)NC(C)=C([C@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1	
Q13936	CAC1C_HUMAN	(S)-nicardipine			BLOCKER	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022276s003lbl.pdf	COC(=O)C1=C(C)NC(C)=C([C@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1	
Q01668	CAC1D_HUMAN	barnidipine			BLOCKER	KEGG DRUG	http://www.kegg.jp/entry/D07494	COC(=O)C1=C(C)NC(C)=C([C@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)O[C@H]1CCN(CC2=CC=CC=C2)C1	CHEMBL2103761
Q13936	CAC1C_HUMAN	barnidipine			BLOCKER	KEGG DRUG	http://www.kegg.jp/entry/D07494	COC(=O)C1=C(C)NC(C)=C([C@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)O[C@H]1CCN(CC2=CC=CC=C2)C1	CHEMBL2103761
Q01668	CAC1D_HUMAN	azelnidipine			BLOCKER	KEGG DRUG	http://www.kegg.jp/entry/D01145	CC(C)OC(=O)C1=C(C)NC(N)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC1CN(C1)C(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1275868
Q13936	CAC1C_HUMAN	azelnidipine			BLOCKER	KEGG DRUG	http://www.kegg.jp/entry/D01145	CC(C)OC(=O)C1=C(C)NC(N)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC1CN(C1)C(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1275868
P00797	RENI_HUMAN	remikiren	9.154901504516602	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1830563	[H][C@@](CC1CCCCC1)(NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CC1=CC=CC=C1)CS(=O)(=O)C(C)(C)C)[C@@H](O)[C@@H](O)C1CC1	CHEMBL31601
Q9NY47	CA2D2_HUMAN	pregabalin	7.259637355804443	IC50	MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21651903	CC(C)C[C@H](CN)CC(O)=O	CHEMBL1059
Q9NY47	CA2D2_HUMAN	gabapentin	6.9281182289123535	IC50	MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21651903	NCC1(CC(O)=O)CCCCC1	CHEMBL940
Q02643	GHRHR_HUMAN	tesamorelin			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022505s004lbl.pdf	[H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O	CHEMBL1237026
O15379	HDAC3_HUMAN	romidepsin	5.96	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf	[H][C@]12CC(=O)N[C@]([H])(C(C)C)C(=O)N[C@]([H])(CSSCC\C=C\1)C(=O)N\C(=C/C)C(=O)N[C@@]([H])(C(C)C)C(=O)O2	CHEMBL343448
P56524	HDAC4_HUMAN	romidepsin	5.96	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf	[H][C@]12CC(=O)N[C@]([H])(C(C)C)C(=O)N[C@]([H])(CSSCC\C=C\1)C(=O)N\C(=C/C)C(=O)N[C@@]([H])(C(C)C)C(=O)O2	CHEMBL343448
Q13547	HDAC1_HUMAN	romidepsin	5.96	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf	[H][C@]12CC(=O)N[C@]([H])(C(C)C)C(=O)N[C@]([H])(CSSCC\C=C\1)C(=O)N\C(=C/C)C(=O)N[C@@]([H])(C(C)C)C(=O)O2	CHEMBL343448
Q8WUI4	HDAC7_HUMAN	romidepsin	5.96	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf	[H][C@]12CC(=O)N[C@]([H])(C(C)C)C(=O)N[C@]([H])(CSSCC\C=C\1)C(=O)N\C(=C/C)C(=O)N[C@@]([H])(C(C)C)C(=O)O2	CHEMBL343448
Q92769	HDAC2_HUMAN	romidepsin	5.96	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf	[H][C@]12CC(=O)N[C@]([H])(C(C)C)C(=O)N[C@]([H])(CSSCC\C=C\1)C(=O)N\C(=C/C)C(=O)N[C@@]([H])(C(C)C)C(=O)O2	CHEMBL343448
Q969S8	HDA10_HUMAN	romidepsin	5.96	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf	[H][C@]12CC(=O)N[C@]([H])(C(C)C)C(=O)N[C@]([H])(CSSCC\C=C\1)C(=O)N\C(=C/C)C(=O)N[C@@]([H])(C(C)C)C(=O)O2	CHEMBL343448
Q96DB2	HDA11_HUMAN	romidepsin	5.96	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf	[H][C@]12CC(=O)N[C@]([H])(C(C)C)C(=O)N[C@]([H])(CSSCC\C=C\1)C(=O)N\C(=C/C)C(=O)N[C@@]([H])(C(C)C)C(=O)O2	CHEMBL343448
Q9BY41	HDAC8_HUMAN	romidepsin	5.96	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf	[H][C@]12CC(=O)N[C@]([H])(C(C)C)C(=O)N[C@]([H])(CSSCC\C=C\1)C(=O)N\C(=C/C)C(=O)N[C@@]([H])(C(C)C)C(=O)O2	CHEMBL343448
Q9UBN7	HDAC6_HUMAN	romidepsin	5.96	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf	[H][C@]12CC(=O)N[C@]([H])(C(C)C)C(=O)N[C@]([H])(CSSCC\C=C\1)C(=O)N\C(=C/C)C(=O)N[C@@]([H])(C(C)C)C(=O)O2	CHEMBL343448
Q9UKV0	HDAC9_HUMAN	romidepsin	5.96	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf	[H][C@]12CC(=O)N[C@]([H])(C(C)C)C(=O)N[C@]([H])(CSSCC\C=C\1)C(=O)N\C(=C/C)C(=O)N[C@@]([H])(C(C)C)C(=O)O2	CHEMBL343448
Q9UQL6	HDAC5_HUMAN	romidepsin	5.96	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022393s013lbl.pdf	[H][C@]12CC(=O)N[C@]([H])(C(C)C)C(=O)N[C@]([H])(CSSCC\C=C\1)C(=O)N\C(=C/C)C(=O)N[C@@]([H])(C(C)C)C(=O)O2	CHEMBL343448
P06276	CHLE_HUMAN	tacrine	7.301030158996582	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/24508831	NC1=C2CCCCC2=NC2=CC=CC=C12	CHEMBL95
P22303	ACES_HUMAN	acotiamide	5.522878646850586	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21651906	COC1=CC(O)=C(C=C1OC)C(=O)NC1=NC(=CS1)C(=O)NCCN(C(C)C)C(C)C	CHEMBL2107308
P12821	ACE_HUMAN	temocapril			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8427943	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)C1=CC=CS1	CHEMBL300841
P12821	ACE_HUMAN	delapril	9.970000267028809	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8891872	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=C(C1)C=CC=C2	CHEMBL589583
P12821	ACE_HUMAN	alacepril			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/3000389	C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O	CHEMBL2103775
P06213	INSR_HUMAN	insulin glargine			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021081s062lbl.pdf	[H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N[H])CC3=CC=CC=C3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CNC=N3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)NCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC	CHEMBL1201497
P30556	AGTR1_HUMAN	tasosartan	7.49	IC50	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10487332	CC1=NC(C)=C2CCC(=O)N(CC3=CC=C(C=C3)C3=C(C=CC=C3)C3=NN=NN3)C2=N1	CHEMBL432162
P04035	HMDH_HUMAN	fluvastatin	7.55	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020261s048,021192s021lbl.pdf	CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C(C2=C1C=CC=C2)C1=CC=C(F)C=C1	CHEMBL2218894
P13631	RARG_HUMAN	adapalene	6.89	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1265	COC1=CC=C(C=C1C12CC3CC(CC(C3)C1)C2)C1=CC=C2C=C(C=CC2=C1)C(O)=O	CHEMBL1265
P10826	RARB_HUMAN	adapalene	7.47	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1265	COC1=CC=C(C=C1C12CC3CC(CC(C3)C1)C2)C1=CC=C2C=C(C=CC2=C1)C(O)=O	CHEMBL1265
P11473	VDR_HUMAN	calcipotriene	9.51	Kd	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200666	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\[C@@H](O)C1CC1	CHEMBL1200666
Q14524	SCN5A_HUMAN	flecainide	5.19	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL652	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CHEMBL652
P23975	SC6A2_HUMAN	dexamfetamine	7.0	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL612	C[C@H](N)CC1=CC=CC=C1	CHEMBL612
O95263	PDE8B_HUMAN	dipyridamole	4.3	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
P11926	DCOR_HUMAN	eflornithine	4.89	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL830	NCCCC(N)(C(F)F)C(O)=O	CHEMBL830
Q9UHC9	NPCL1_HUMAN	ezetimibe	6.66	Kd	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1138	O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1	CHEMBL1138
Q07869	PPARA_HUMAN	gemfibrozil	4.23	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL457	CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1	CHEMBL457
P07550	ADRB2_HUMAN	salmeterol	9.41	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1263	OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1	CHEMBL1263
P35367	HRH1_HUMAN	rupatadine	8.41	IC50	ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D07407	CC1=CC(CN2CCC(CC2)=C2C3=CC=C(Cl)C=C3CCC3=C2N=CC=C3)=CN=C1	CHEMBL91397
Q9NYK1	TLR7_HUMAN	hydroxychloroquine	5.56	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1535	CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12	CHEMBL1535
Q9NR96	TLR9_HUMAN	hydroxychloroquine	7.1	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1535	CCN(CCO)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12	CHEMBL1535
P35346	SSR5_HUMAN	lanreotide	9.3	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201184	[H][C@](N)(CC1=CC=C2C=CC=CC2=C1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(N)=O	CHEMBL1201184
P30874	SSR2_HUMAN	lanreotide	9.6	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201184	[H][C@](N)(CC1=CC=C2C=CC=CC2=C1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(N)=O	CHEMBL1201184
P21731	TA2R_HUMAN	ramatroban	9.24	Ki	INVERSE AGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01128	OC(=O)CCN1C2=C(C[C@@H](CC2)NS(=O)(=O)C2=CC=C(F)C=C2)C2=CC=CC=C12	CHEMBL361812
P04150	GCR_HUMAN	desonide			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201109	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO	CHEMBL1201109
P00915	CAH1_HUMAN	methocarbamol	7.6	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201117	COC1=C(OCC(O)COC(N)=O)C=CC=C1	CHEMBL1201117
P08588	ADRB1_HUMAN	norepinephrine	6.0	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1437	NC[C@H](O)C1=CC(O)=C(O)C=C1	CHEMBL1437
P30556	AGTR1_HUMAN	olmesartan medoxomil	8.1	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1516	CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=O)OCC1=C(C)OC(=O)O1)C(C)(C)O	CHEMBL1516
P30518	V2R_HUMAN	conivaptan	9.44	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1755	CC1=NC2=C(N1)C1=C(C=CC=C1)N(CC2)C(=O)C1=CC=C(NC(=O)C2=C(C=CC=C2)C2=CC=CC=C2)C=C1	CHEMBL1755
P37288	V1AR_HUMAN	conivaptan	9.37	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1755	CC1=NC2=C(N1)C1=C(C=CC=C1)N(CC2)C(=O)C1=CC=C(NC(=O)C2=C(C=CC=C2)C2=CC=CC=C2)C=C1	CHEMBL1755
P30556	AGTR1_HUMAN	losartan	9.48	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL995	CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1	CHEMBL995
Q96S37	S22AC_HUMAN	benzbromarone	7.59	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/16135657	CCC1=C(C(=O)C2=CC(Br)=C(O)C(Br)=C2)C2=C(O1)C=CC=C2	CHEMBL388590
P30556	AGTR1_HUMAN	eprosartan	8.7	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL813	CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O	CHEMBL813
P04035	HMDH_HUMAN	pravastatin	7.52	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL690	[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC	CHEMBL690
Q4U2R8	S22A6_HUMAN	probenecid	4.9	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL897	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CHEMBL897
P35372	OPRM_HUMAN	difenoxin			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200599	OC(=O)C1(CCN(CCC(C#N)(C2=CC=CC=C2)C2=CC=CC=C2)CC1)C1=CC=CC=C1	CHEMBL1200599
P28223	5HT2A_HUMAN	carfenazine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201328	CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CCCN3CCN(CCO)CC3)C2=C1	CHEMBL1201328
P20309	ACM3_HUMAN	darifenacin	9.52	Kd	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1346	NC(=O)C([C@@H]1CCN(CCC2=CC=C3OCCC3=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL1346
P47872	SCTR_HUMAN	secretin human	9.7	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201488	[H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O	CHEMBL1201488
P43119	PI2R_HUMAN	treprostinil	8.72	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1237119	[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC1=CC=CC(OCC(O)=O)=C1C2	CHEMBL1237119
P37088	SCNNA_HUMAN	triamterene	5.300000191	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL585	NC1=NC2=NC(N)=C(N=C2C(N)=N1)C1=CC=CC=C1	CHEMBL585
P51168	SCNNB_HUMAN	triamterene	5.300000191	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL585	NC1=NC2=NC(N)=C(N=C2C(N)=N1)C1=CC=CC=C1	CHEMBL585
P51170	SCNNG_HUMAN	triamterene	5.300000191	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL585	NC1=NC2=NC(N)=C(N=C2C(N)=N1)C1=CC=CC=C1	CHEMBL585
O14764	GBRD_HUMAN	triazolam	9.100000381469727	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P14867	GBRA1_HUMAN	triazolam	9.100000381469727	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P18505	GBRB1_HUMAN	triazolam	9.100000381469727	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P18507	GBRG2_HUMAN	triazolam	9.100000381469727	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P28472	GBRB3_HUMAN	triazolam	9.100000381469727	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P31644	GBRA5_HUMAN	triazolam	9.100000381469727	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P34903	GBRA3_HUMAN	triazolam	9.100000381469727	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P47869	GBRA2_HUMAN	triazolam	9.100000381469727	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P47870	GBRB2_HUMAN	triazolam	9.100000381469727	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P48169	GBRA4_HUMAN	triazolam	9.100000381469727	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
Q16445	GBRA6_HUMAN	triazolam	9.100000381469727	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
Q8N1C3	GBRG1_HUMAN	triazolam	9.100000381469727	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
Q99928	GBRG3_HUMAN	triazolam	9.100000381469727	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P10275	ANDR_HUMAN	methyltestosterone	9.66	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1395	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1395
P28472	GBRB3_HUMAN	diazepam	7.2034	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P31644	GBRA5_HUMAN	diazepam	7.2034	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
Q99928	GBRG3_HUMAN	diazepam	7.2034	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL12	CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C1=CC=CC=C1	CHEMBL12
P00374	DYR_HUMAN	pralatrexate	7.35	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201746	NC1=NC2=NC=C(CC(CC#C)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N=C2C(N)=N1	CHEMBL1201746
P06401	PRGR_HUMAN	ulipristal	9.7	IC50	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7460	[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]	CHEMBL260538
O43526	KCNQ2_HUMAN	retigabine	5.6	EC50	ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL41355	CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1	CHEMBL41355
P56696	KCNQ4_HUMAN	retigabine	5.2	EC50	ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL41355	CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1	CHEMBL41355
Q9NR82	KCNQ5_HUMAN	retigabine	5.0	EC50	ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL41355	CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1	CHEMBL41355
O43525	KCNQ3_HUMAN	retigabine	6.2	EC50	ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL41355	CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1	CHEMBL41355
P31645	SC6A4_HUMAN	vilazodone	9.3	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL439849	NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1	CHEMBL439849
P08908	5HT1A_HUMAN	vilazodone	9.7	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL439849	NC(=O)C1=CC2=C(O1)C=CC(=C2)N1CCN(CCCCC2=CNC3=C2C=C(C=C3)C#N)CC1	CHEMBL439849
P30556	AGTR1_HUMAN	azilsartan medoxomil			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL57242	CCOC1=NC2=CC=CC(C(=O)OCC3=C(C)OC(=O)O3)=C2N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NOC(=O)N1	CHEMBL57242
P32745	SSR3_HUMAN	pasireotide	8.8	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3039583	NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)C(NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1	CHEMBL3039583
P30872	SSR1_HUMAN	pasireotide	8.0	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3039583	NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)C(NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1	CHEMBL3039583
P35346	SSR5_HUMAN	pasireotide	9.8	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3039583	NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)C(NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1	CHEMBL3039583
P30874	SSR2_HUMAN	pasireotide	9.0	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3039583	NCCCC[C@@H]1NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)C(NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O)OC(=O)NCCN)C1=CC=CC=C1	CHEMBL3039583
Q01668	CAC1D_HUMAN	nitrendipine	8.4	IC50	GATING INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2334	CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC	CHEMBL475534
P05023	AT1A1_HUMAN	digitoxin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL254219	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])CC[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL254219
P30968	GNRHR_HUMAN	degarelix	8.77	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL415606	[H][C@]1(CC(=O)NC(=O)N1)C(=O)NC1=CC=C(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](CC2=CN=CC=C2)NC(=O)[C@@H](CC2=CC=C(Cl)C=C2)NC(=O)[C@@H](CC2=CC3=C(C=CC=C3)C=C2)NC(C)=O)C(=O)N[C@H](CC2=CC=C(NC(N)=O)C=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](C)C(N)=O)C=C1	CHEMBL415606
P35367	HRH1_HUMAN	dexchlorpheniramine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200927	CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1	CHEMBL1200927
P25103	NK1R_HUMAN	fosaprepitant	8.92	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1199324	C[C@@H](O[C@H]1OCCN(CC2=NN(C(=O)N2)P(O)(O)=O)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F	CHEMBL1199324
Q03431	PTH1R_HUMAN	teriparatide	7.4	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL525610	[H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O	CHEMBL525610
P35968	VGFR2_HUMAN	regorafenib	7.9	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1946170	CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1	CHEMBL1946170
O76074	PDE5A_HUMAN	udenafil	8.083545684814453	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12510841	CCCOC1=CC=C(C=C1C1=NC(=O)C2=C(N1)C(CCC)=NN2C)S(=O)(=O)NCCC1CCCN1C	CHEMBL2103849
P31358	CD52_HUMAN	alemtuzumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf		CHEMBL1201587
P25100	ADA1D_HUMAN	naftopidil	8.920818328857422	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10976457	COC1=C(C=CC=C1)N1CCN(CC(O)COC2=CC=CC3=CC=CC=C23)CC1	CHEMBL142635
P35348	ADA1A_HUMAN	naftopidil	8.431797981262207	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10976457	COC1=C(C=CC=C1)N1CCN(CC(O)COC2=CC=CC3=CC=CC=C23)CC1	CHEMBL142635
P35368	ADA1B_HUMAN	naftopidil	7.698969841003418	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10976457	COC1=C(C=CC=C1)N1CCN(CC(O)COC2=CC=CC3=CC=CC=C23)CC1	CHEMBL142635
P35372	OPRM_HUMAN	ciramadol			MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2572952	[H][C@@]1(CCCC[C@H]1O)[C@@H](N(C)C)C1=CC(O)=CC=C1	CHEMBL2104041
P35372	OPRM_HUMAN	acetylmethadol			AGONIST	KEGG DRUG	http://www.kegg.jp/entry/D04973	CCC(OC(C)=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL170179
P37288	V1AR_HUMAN	felypressin			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/18655903	[H]N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(N)=O	CHEMBL1908309
Q9BQB6	VKOR1_HUMAN	acenocoumarol	6.113509178161621	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/3207986	[H]C(CC(C)=O)(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=C(OC1=O)C=CC=C2	CHEMBL397420
Q9BQB6	VKOR1_HUMAN	phenprocoumon	5.744727611541748	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL16694	CCC(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CHEMBL16694
Q9BQB6	VKOR1_HUMAN	dicoumarol	5.508638381958008	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1466	OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=CC=CC=C12	CHEMBL1466
P35367	HRH1_HUMAN	aceprometazine			ANTAGONIST	DRUG LABEL	http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-09/mepronizine_ct_8952.pdf	CC(CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C(C)=O)N(C)C	CHEMBL2104054
O14764	GBRD_HUMAN	adinazolam			POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D02770	CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL328250
P14867	GBRA1_HUMAN	adinazolam			POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D02770	CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL328250
P18505	GBRB1_HUMAN	adinazolam			POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D02770	CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL328250
P18507	GBRG2_HUMAN	adinazolam			POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D02770	CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL328250
P28472	GBRB3_HUMAN	adinazolam			POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D02770	CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL328250
P31644	GBRA5_HUMAN	adinazolam			POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D02770	CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL328250
P34903	GBRA3_HUMAN	adinazolam			POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D02770	CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL328250
P47869	GBRA2_HUMAN	adinazolam			POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D02770	CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL328250
P47870	GBRB2_HUMAN	adinazolam			POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D02770	CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL328250
P48169	GBRA4_HUMAN	adinazolam			POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D02770	CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL328250
Q16445	GBRA6_HUMAN	adinazolam			POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D02770	CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL328250
Q8N1C3	GBRG1_HUMAN	adinazolam			POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D02770	CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL328250
Q99928	GBRG3_HUMAN	adinazolam			POSITIVE ALLOSTERIC MODULATOR	KEGG DRUG	http://www.kegg.jp/entry/D02770	CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C3=CC(Cl)=CC=C3N12	CHEMBL328250
P06401	PRGR_HUMAN	dienogest			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022252s004lbl.pdf	[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]	CHEMBL1201864
P14416	DRD2_HUMAN	blonanserin	9.853872299194336	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/15686911	CCN1CCN(CC1)C1=NC2=C(CCCCCC2)C(=C1)C1=CC=C(F)C=C1	CHEMBL178803
P28223	5HT2A_HUMAN	blonanserin	9.091514587402344	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/15686911	CCN1CCN(CC1)C1=NC2=C(CCCCCC2)C(=C1)C1=CC=C(F)C=C1	CHEMBL178803
Q05655	KPCD_HUMAN	ingenol mebutate	8.327901840209961	EC50	ACTIVATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/15126366	[H][C@@]12C[C@@]([H])(C)[C@]34C=C(C)[C@]([H])(OC(=O)C(\C)=C/C)[C@@]3(O)[C@]([H])(O)C(CO)=C[C@]([H])(C4=O)[C@]1([H])C2(C)C	CHEMBL1863513
O60741	HCN1_HUMAN	dronedarone			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23647933	CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2	CHEMBL184412
Q9UL51	HCN2_HUMAN	dronedarone			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23647933	CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2	CHEMBL184412
Q9P1Z3	HCN3_HUMAN	dronedarone			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23647933	CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2	CHEMBL184412
Q9Y3Q4	HCN4_HUMAN	dronedarone			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23647933	CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=C1C=C(NS(C)(=O)=O)C=C2	CHEMBL184412
P28472	GBRB3_HUMAN	midazolam	8.2596	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P31644	GBRA5_HUMAN	midazolam	8.2596	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
Q99928	GBRG3_HUMAN	midazolam	8.2596	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P28472	GBRB3_HUMAN	triazolam	8.699	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P31644	GBRA5_HUMAN	triazolam	8.699	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
Q99928	GBRG3_HUMAN	triazolam	8.699	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL646	CC1=NN=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(Cl)C=CC=C1	CHEMBL646
P28472	GBRB3_HUMAN	zopiclone	6.7496	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P31644	GBRA5_HUMAN	zopiclone	6.7496	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
Q99928	GBRG3_HUMAN	zopiclone	6.7496	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P18507	GBRG2_HUMAN	midazolam	9.1249	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P28472	GBRB3_HUMAN	midazolam	9.1249	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P31644	GBRA5_HUMAN	midazolam	9.1249	Ki	POSITIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL655	CC1=NC=C2CN=C(C3=CC(Cl)=CC=C3N12)C1=C(F)C=CC=C1	CHEMBL655
P18507	GBRG2_HUMAN	zopiclone	7.2782	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P28472	GBRB3_HUMAN	zopiclone	7.2782	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P31644	GBRA5_HUMAN	zopiclone	7.2782	Ki	POSITIVE MODULATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1N=CC=N2)C1=CC=C(Cl)C=N1	CHEMBL135400
P10635	CP2D6_HUMAN	quinidine	7.92081880569458	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021879s005lbl.pdf	[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C1=CC=NC2=CC=C(OC)C=C12	CHEMBL21578
P08588	ADRB1_HUMAN	alprenolol	9.677781105041504	Kd	ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01182	CC(C)NCC(O)COC1=C(CC=C)C=CC=C1	CHEMBL266195
P07550	ADRB2_HUMAN	alprenolol	9.657577514648438	Kd	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=563	CC(C)NCC(O)COC1=C(CC=C)C=CC=C1	CHEMBL266195
O75899	GABR2_HUMAN	phenibut			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11830761	NCC(CC(O)=O)C1=CC=CC=C1	CHEMBL315818
Q9UBS5	GABR1_HUMAN	phenibut			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11830761	NCC(CC(O)=O)C1=CC=CC=C1	CHEMBL315818
P35968	VGFR2_HUMAN	ramucirumab	10.3	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125477s007lbl.pdf		CHEMBL1743062
O60894	RAMP1_HUMAN	pramlintide	9.449999809265137	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/24169554	[H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O	CHEMBL2103758
P30988	CALCR_HUMAN	pramlintide	9.449999809265137	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/24169554	[H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O	CHEMBL2103758
O60896	RAMP3_HUMAN	pramlintide	9.050000190734863	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/24169554	[H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O	CHEMBL2103758
P30988	CALCR_HUMAN	pramlintide	9.050000190734863	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/24169554	[H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O	CHEMBL2103758
O60895	RAMP2_HUMAN	pramlintide	8.640000343322754	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/15494035	[H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O	CHEMBL2103758
P30988	CALCR_HUMAN	pramlintide	8.640000343322754	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/15494035	[H]N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(N)=O	CHEMBL2103758
P49765	VEGFB_HUMAN	aflibercept	11.71669864654541	Kd	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125418s020lbl.pdf		CHEMBL1742982
P49763	PLGF_HUMAN	aflibercept	10.408935546875	Kd	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125418s020lbl.pdf		CHEMBL1742982
P15692	VEGFA_HUMAN	aflibercept	12.301030158996582	Kd	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125418s020lbl.pdf		CHEMBL1742982
Q15116	PDCD1_HUMAN	pembrolizumab	10.0	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf		CHEMBL3137343
P55011	S12A2_HUMAN	piretanide	5.62	IC50	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D01634	NS(=O)(=O)C1=CC(=CC(N2CCCC2)=C1OC1=CC=CC=C1)C(O)=O	CHEMBL349803
P00747	PLMN_HUMAN	aprotinin	6.8	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201619	[H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCSC)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@@H](NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC3=O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N2)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CCCN2C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC1=O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O	CHEMBL1201619
P14867	GBRA1_HUMAN	zolpidem	7.68	Ki	ALLOSTERIC MODULATOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4348	CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1	CHEMBL911
P34903	GBRA3_HUMAN	flunitrazepam	7.8	Ki	ALLOSTERIC MODULATOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4193	CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O	CHEMBL13280
P31644	GBRA5_HUMAN	flunitrazepam	8.26	Ki	ALLOSTERIC MODULATOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4193	CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O	CHEMBL13280
P14867	GBRA1_HUMAN	flunitrazepam	8.28	Ki	ALLOSTERIC MODULATOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4193	CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O	CHEMBL13280
P47869	GBRA2_HUMAN	flunitrazepam	8.28	Ki	ALLOSTERIC MODULATOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4193	CN1C2=CC=C(C=C2C(=NCC1=O)C1=C(F)C=CC=C1)[N+]([O-])=O	CHEMBL13280
P07550	ADRB2_HUMAN	procaterol	8.43	EC50	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3464	CC[C@@H](NC(C)C)[C@@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1	CHEMBL160519
P14416	DRD2_HUMAN	perospirone	9.22	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7556	[H][C@@]12CCCC[C@]1([H])C(=O)N(CCCCN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O	CHEMBL1472975
Q15661	TRYB1_HUMAN	nafamostat	10.0	IC50	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262	NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N	CHEMBL273264
P19235	EPOR_HUMAN	peginesatide	10.43	IC50	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202799s001lbl.pdf	[H]C(CCCCNC(=O)OCCOC)(NC(=O)OCCOC)C(=O)NCCC(=O)N(CC(=O)NCCCC[C@H](NC(=O)CN(C)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)CNC(C)=O)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@]([H])(CC2=CC=CC3=C2C=CC=C3)C(=O)N[C@@H](C(C)C)C(=O)N1)C(N)=O)CC(=O)NCCCC[C@H](NC(=O)CN(C)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)CNC(C)=O)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@]([H])(CC2=CC=CC3=C2C=CC=C3)C(=O)N[C@@H](C(C)C)C(=O)N1)C(N)=O	CHEMBL1963684
P08235	MCR_HUMAN	desoxycortone	11.0	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1498	[H][C@@]12CC[C@H](C(=O)CO)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1498
Q09428	ABCC8_HUMAN	gliclazide	6.221848964691162	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1	CHEMBL427216
Q14654	KCJ11_HUMAN	gliclazide	6.221848964691162	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1	CHEMBL427216
Q09428	ABCC8_HUMAN	glibenclamide	9.522878646850586	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	CHEMBL472
Q14654	KCJ11_HUMAN	glibenclamide	9.522878646850586	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	CHEMBL472
Q09428	ABCC8_HUMAN	glipizide	9.09691047668457	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	CC1=CN=C(C=N1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	CHEMBL1073
Q14654	KCJ11_HUMAN	glipizide	9.09691047668457	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	CC1=CN=C(C=N1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	CHEMBL1073
Q09428	ABCC8_HUMAN	gliquidone	9.0	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C	CHEMBL383634
Q14654	KCJ11_HUMAN	gliquidone	9.0	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	COC1=CC=C2C(=C1)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C	CHEMBL383634
Q09428	ABCC8_HUMAN	glisoxepide	7.958607196807861	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	CC1=CC(=NO1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1	CHEMBL2106618
Q14654	KCJ11_HUMAN	glisoxepide	7.958607196807861	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	CC1=CC(=NO1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1	CHEMBL2106618
Q09428	ABCC8_HUMAN	glibornuride	7.045757293701172	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N[C@@H]1[C@H](O)[C@]2(C)CC[C@H]1C2(C)C	CHEMBL529888
Q14654	KCJ11_HUMAN	glibornuride	7.045757293701172	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N[C@@H]1[C@H](O)[C@]2(C)CC[C@H]1C2(C)C	CHEMBL529888
Q09428	ABCC8_HUMAN	chlorpropamide	5.045757293701172	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1	CHEMBL498
Q14654	KCJ11_HUMAN	chlorpropamide	5.045757293701172	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1	CHEMBL498
Q09428	ABCC8_HUMAN	tolbutamide	5.045757293701172	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1	CHEMBL782
Q14654	KCJ11_HUMAN	tolbutamide	5.045757293701172	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1	CHEMBL782
Q09428	ABCC8_HUMAN	carbutamide	4.602059841156006	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1	CHEMBL448570
Q14654	KCJ11_HUMAN	carbutamide	4.602059841156006	Kd	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2445740	CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1	CHEMBL448570
Q09428	ABCC8_HUMAN	glimepiride	9.239999771118164	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1481	CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O	CHEMBL1481
Q14654	KCJ11_HUMAN	glimepiride	9.239999771118164	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1481	CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O	CHEMBL1481
Q09428	ABCC8_HUMAN	nateglinide	6.460000038146973	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL783	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC1=CC=CC=C1)C(O)=O	CHEMBL783
Q14654	KCJ11_HUMAN	nateglinide	6.460000038146973	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL783	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC1=CC=CC=C1)C(O)=O	CHEMBL783
Q09428	ABCC8_HUMAN	repaglinide	9.140000343322754	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1272	CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=C(C=CC=C2)N2CCCCC2)=C1)C(O)=O	CHEMBL1272
Q14654	KCJ11_HUMAN	repaglinide	9.140000343322754	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1272	CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=C(C=CC=C2)N2CCCCC2)=C1)C(O)=O	CHEMBL1272
P28221	5HT1D_HUMAN	vortioxetine	7.267606258392334	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204447s004lbl.pdf	CC1=CC=C(SC2=C(C=CC=C2)N2CCNCC2)C(C)=C1	CHEMBL2104993
P41595	5HT2B_HUMAN	methysergide	9.34000015258789	Ki	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=134	[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO	CHEMBL1065
P28335	5HT2C_HUMAN	methysergide	8.34000015258789	Ki	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=134	[H][C@@]12CC3=CN(C)C4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO	CHEMBL1065
Q09428	ABCC8_HUMAN	mitiglinide	7.0	IC50	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11716850	[H][C@@]12CN(C[C@]1([H])CCCC2)C(=O)C[C@H](CC1=CC=CC=C1)C(O)=O	CHEMBL471498
Q14654	KCJ11_HUMAN	mitiglinide	7.0	IC50	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11716850	[H][C@@]12CN(C[C@]1([H])CCCC2)C(=O)C[C@H](CC1=CC=CC=C1)C(O)=O	CHEMBL471498
Q09428	ABCC8_HUMAN	acetohexamide	4.639406681060791	Ki	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10742287	CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	CHEMBL1589
Q14654	KCJ11_HUMAN	acetohexamide	4.639406681060791	Ki	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10742287	CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1	CHEMBL1589
P09619	PGFRB_HUMAN	becaplermin			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103691s5095lbl.pdf		CHEMBL1201556
P16234	PGFRA_HUMAN	becaplermin			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103691s5095lbl.pdf		CHEMBL1201556
Q92847	GHSR_HUMAN	pralmorelin			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/15646370	C[C@@H](N)C(=O)N[C@H](CC1=CC=C2C=CC=CC2=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(N)=O	CHEMBL106593
Q02643	GHRHR_HUMAN	sermorelin			AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6998	[H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O	CHEMBL1201490
P43220	GLP1R_HUMAN	albiglutide	9.698969841003418	EC50	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125431s000lbl.pdf	[H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O	CHEMBL2107841
P23945	FSHR_HUMAN	follitropin			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021289s019lbl.pdf		CHEMBL1201520
P22888	LSHR_HUMAN	lutropin alfa	10.9	IC50	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21322lbl.pdf		CHEMBL1201419
P16473	TSHR_HUMAN	thyrotropin alfa			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21322lbl.pdf		CHEMBL1201532
P30968	GNRHR_HUMAN	buserelin	10.52	EC50	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3860	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1	CHEMBL2110824
Q01718	ACTHR_HUMAN	corticotropin			AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1331	[H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O	CHEMBL1201609
P46098	5HT3A_HUMAN	tropisetron	8.8	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=260	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C1=CNC2=C1C=CC=C2	CHEMBL56564
P08887	IL6RA_HUMAN	tocilizumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125276s092lbl.pdf		CHEMBL1237022
P40189	IL6RB_HUMAN	tocilizumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125276s092lbl.pdf		CHEMBL1237022
P17948	VGFR1_HUMAN	sunitinib	7.229147911071777	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021938s027lbl.pdf	CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C	CHEMBL535
P16234	PGFRA_HUMAN	sunitinib	6.958607196807861	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021938s027lbl.pdf	CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C	CHEMBL535
Q9UM73	ALK_HUMAN	alectinib	8.721246719360352	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf	CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=O	CHEMBL1738797
P15538	C11B1_HUMAN	ketoconazole	6.896196365356445	IC50	INHIBITOR	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003906/WC500181492.pdf	CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CHEMBL295698
P01589	IL2RA_HUMAN	basiliximab	10.0	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/basnova032301LB.pdf		CHEMBL1201439
O75116	ROCK2_HUMAN	ripasudil	7.721246242523193	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/25414122	[H][C@]1(C)CNCCCN1S(=O)(=O)C1=CC=CC2=C1C(F)=CN=C2	
Q13464	ROCK1_HUMAN	ripasudil	7.2924299240112305	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/25414122	[H][C@]1(C)CNCCCN1S(=O)(=O)C1=CC=CC2=C1C(F)=CN=C2	
Q03431	PTH1R_HUMAN	parathyroid hormone			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125511s000lbl.pdf	[H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O	CHEMBL2108078
Q16552	IL17_HUMAN	secukinumab			ANTIBODY BINDING	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23253932		CHEMBL1743068
P07550	ADRB2_HUMAN	arformoterol	8.537602424621582	Kd	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021912s013lbl.pdf	[H]C(=O)NC1=C(O)C=CC(=C1)[C@@H](O)CN[C@H](C)CC1=CC=C(OC)C=C1	CHEMBL1363
P22102	PUR2_HUMAN	pemetrexed	6.42	Ki	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021462lbl.pdf	NC1=NC(=O)C2=C(NC=C2CCC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N1	CHEMBL225072
Q14524	SCN5A_HUMAN	ranolazine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1404	COC1=C(OCC(O)CN2CCN(CC(=O)NC3=C(C)C=CC=C3C)CC2)C=CC=C1	CHEMBL1404
P30518	V2R_HUMAN	mozavaptan	8.03	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1387020	CN(C)C1CCCN(C(=O)C2=CC=C(NC(=O)C3=C(C)C=CC=C3)C=C2)C2=CC=CC=C12	CHEMBL420762
P03372	ESR1_HUMAN	fosfestrol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200598	CC\C(=C(\CC)C1=CC=C(OP(O)(O)=O)C=C1)C1=CC=C(OP(O)(O)=O)C=C1	CHEMBL1200598
Q92731	ESR2_HUMAN	fosfestrol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200598	CC\C(=C(\CC)C1=CC=C(OP(O)(O)=O)C=C1)C1=CC=C(OP(O)(O)=O)C=C1	CHEMBL1200598
P30556	AGTR1_HUMAN	irbesartan	9.1	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1513	CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1	CHEMBL1513
P10275	ANDR_HUMAN	nandrolone decanoate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL757	[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	CHEMBL757
P12821	ACE_HUMAN	zofenopril	9.4	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2484083	C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1=CC=CC=C1	CHEMBL16332
P10275	ANDR_HUMAN	bicalutamide	7.72	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL409	CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F	CHEMBL409
P04150	GCR_HUMAN	hydrocortisone butyrate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1683	[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1683
P35367	HRH1_HUMAN	buclizine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200403	CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C2=CC=CC=C2)C2=CC=C(Cl)C=C2)C=C1	CHEMBL1200403
P08246	ELNE_HUMAN	sivelestat	6.7	Ki		IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6441	CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC1=C(C=CC=C1)C(=O)NCC(O)=O	CHEMBL76688
P04150	GCR_HUMAN	dexamethasone acetate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1651	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1651
P04150	GCR_HUMAN	betamethasone acetate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200538	[H][C@@]12C[C@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1200538
P30556	AGTR1_HUMAN	valsartan	5.33	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1069	CCCCC(=O)N(CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)[C@@H](C(C)C)C(O)=O	CHEMBL1069
P17948	VGFR1_HUMAN	pazopanib	7.85	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL477772	CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1	CHEMBL477772
P35968	VGFR2_HUMAN	pazopanib	7.85	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL477772	CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1	CHEMBL477772
P22607	FGFR3_HUMAN	pazopanib	6.21	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL477772	CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1	CHEMBL477772
P16234	PGFRA_HUMAN	pazopanib	8.31	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL477772	CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1	CHEMBL477772
P09619	PGFRB_HUMAN	pazopanib	8.7	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL477772	CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1	CHEMBL477772
P11362	FGFR1_HUMAN	pazopanib	6.0	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL477772	CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1	CHEMBL477772
P10721	KIT_HUMAN	pazopanib	8.74	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL477772	CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1	CHEMBL477772
P07333	CSF1R_HUMAN	pazopanib	8.1	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL477772	CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1	CHEMBL477772
P35916	VGFR3_HUMAN	pazopanib	7.57	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL477772	CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1	CHEMBL477772
P06239	LCK_HUMAN	pazopanib	5.92	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL477772	CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1	CHEMBL477772
Q08881	ITK_HUMAN	pazopanib			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL477772	CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1	CHEMBL477772
P12821	ACE_HUMAN	quinapril	8.08	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1592	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O	CHEMBL1592
P14416	DRD2_HUMAN	sertindole	9.35	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/9469684	FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2	CHEMBL12713
P28335	5HT2C_HUMAN	sertindole	9.7	Ki	INVERSE AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10991983	FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2	CHEMBL12713
P28223	5HT2A_HUMAN	sertindole	9.22	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/9469684	FC1=CC=C(C=C1)N1C=C(C2CCN(CCN3CCNC3=O)CC2)C2=C1C=CC(Cl)=C2	CHEMBL12713
Q12809	KCNH2_HUMAN	dofetilide	8.19	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL473	CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1	CHEMBL473
P00533	EGFR_HUMAN	gefitinib	9.4	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL939	COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1	CHEMBL939
P25101	EDNRA_HUMAN	sitaxentan	9.37	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3950	CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC2=CC3=C(OCO3)C=C2C)=C1Cl	CHEMBL282724
P10275	ANDR_HUMAN	testosterone undecanoate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2107067	[H][C@@]12CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL2107067
P04150	GCR_HUMAN	prednisolone tebutate	9.28	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL131	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL131
P07550	ADRB2_HUMAN	bitolterol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200405	CC1=CC=C(C=C1)C(=O)OC1=C(OC(=O)C2=CC=C(C)C=C2)C=C(C=C1)C(O)CNC(C)(C)C	CHEMBL1200405
P36888	FLT3_HUMAN	sorafenib	8.35	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1336	CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1	CHEMBL1336
P17948	VGFR1_HUMAN	sorafenib	7.51	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1336	CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1	CHEMBL1336
P35968	VGFR2_HUMAN	sorafenib	10.68	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1336	CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1	CHEMBL1336
P04049	RAF1_HUMAN	sorafenib	8.22	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1336	CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1	CHEMBL1336
P15056	BRAF_HUMAN	sorafenib	7.66	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1336	CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1	CHEMBL1336
P09619	PGFRB_HUMAN	sorafenib	7.43	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1336	CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1	CHEMBL1336
P10721	KIT_HUMAN	sorafenib	7.8	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1336	CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1	CHEMBL1336
P35916	VGFR3_HUMAN	sorafenib	7.8	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1336	CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1	CHEMBL1336
P07949	RET_HUMAN	sorafenib	8.13	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1336	CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1	CHEMBL1336
Q13639	5HT4R_HUMAN	cisapride	7.54	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1729	[H]C1(CCN(CCCOC2=CC=C(F)C=C2)CC1([H])OC)NC(=O)C1=C(OC)C=C(N)C(Cl)=C1	CHEMBL1729
P04150	GCR_HUMAN	dexamethasone phosphate	9.3	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL384467	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL384467
P04150	GCR_HUMAN	methylprednisolone succinate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201081	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	CHEMBL1201081
P04150	GCR_HUMAN	hydrocortamate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200635	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CN(CC)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1200635
P04150	GCR_HUMAN	betamethasone valerate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1497	[H][C@]1(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@]([H])(O)C[C@]2(C)[C@@]1(OC(=O)CCCC)C(=O)CO	CHEMBL1497
P04150	GCR_HUMAN	triamcinolone diacetate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200449	[H][C@@]12C[C@@H](OC(C)=O)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1200449
P04035	HMDH_HUMAN	rosuvastatin	9.05	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1496	CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1	CHEMBL1496
P04150	GCR_HUMAN	ulobetasol propionate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200908	[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	CHEMBL1200908
P04150	GCR_HUMAN	hydrocortisone cypionate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1549	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC3CCCC3)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1549
P12931	SRC_HUMAN	dasatinib	9.68	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1421	CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1	CHEMBL1421
P29317	EPHA2_HUMAN	dasatinib	9.07	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1421	CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1	CHEMBL1421
P07947	YES_HUMAN	dasatinib	9.52	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1421	CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1	CHEMBL1421
P09619	PGFRB_HUMAN	dasatinib	9.2	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1421	CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1	CHEMBL1421
P10721	KIT_HUMAN	dasatinib	9.24	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1421	CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1	CHEMBL1421
P06241	FYN_HUMAN	dasatinib	9.1	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1421	CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1	CHEMBL1421
P06239	LCK_HUMAN	dasatinib	9.7	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1421	CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1	CHEMBL1421
P04150	GCR_HUMAN	prednicarbate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200386	[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1200386
P00519	ABL1_HUMAN	imatinib	8.96	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL941	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1	CHEMBL941
P09619	PGFRB_HUMAN	imatinib	7.85	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL941	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1	CHEMBL941
P10721	KIT_HUMAN	imatinib	7.89	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL941	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)CC1	CHEMBL941
P07098	LIPG_HUMAN	orlistat			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020766s035lbl.pdf	CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	CHEMBL175247
P04150	GCR_HUMAN	betamethasone benzoate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200376	[H][C@@]12C[C@H](C)[C@](OC(=O)C3=CC=CC=C3)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1200376
P12821	ACE_HUMAN	moexipril	8.59	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1165	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O	CHEMBL1165
P04150	GCR_HUMAN	amcinonide			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200732	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC1(CCCC1)O2)C(=O)COC(C)=O	CHEMBL1200732
P22303	ACES_HUMAN	hexafluronium			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200933	C[N+](C)(CCCCCC[N+](C)(C)C1C2=CC=CC=C2C2=C1C=CC=C2)C1C2=CC=CC=C2C2=C1C=CC=C2	CHEMBL1200933
P04150	GCR_HUMAN	betamethasone dipropionate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200384	[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL1200384
O76074	PDE5A_HUMAN	dipyridamole	6.28	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
Q99808	S29A1_HUMAN	dipyridamole	8.5	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
O43924	PDE6D_HUMAN	dipyridamole	6.9	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
P16499	PDE6A_HUMAN	dipyridamole	6.9	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
P18545	CNRG_HUMAN	dipyridamole	6.9	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
P35913	PDE6B_HUMAN	dipyridamole	6.9	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
P51160	PDE6C_HUMAN	dipyridamole	6.9	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
Q13956	CNCG_HUMAN	dipyridamole	6.9	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
Q9NP56	PDE7B_HUMAN	dipyridamole	6.0	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
Q13946	PDE7A_HUMAN	dipyridamole	6.22	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
Q9NP56	PDE7B_HUMAN	dipyridamole	6.22	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
P54750	PDE1A_HUMAN	dipyridamole	4.35	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
Q01064	PDE1B_HUMAN	dipyridamole	4.35	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
Q14123	PDE1C_HUMAN	dipyridamole	4.35	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
O00408	PDE2A_HUMAN	dipyridamole	5.49	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
Q13370	PDE3B_HUMAN	dipyridamole	4.37	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
Q14432	PDE3A_HUMAN	dipyridamole	4.37	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
Q9Y233	PDE10_HUMAN	dipyridamole	6.0	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
O60658	PDE8A_HUMAN	dipyridamole	5.1	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL932	OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO	CHEMBL932
P04150	GCR_HUMAN	difluprednate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201749	[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	CHEMBL1201749
P51681	CCR5_HUMAN	maraviroc	7.6	Kd	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201187	[H][C@]12CC[C@]([H])(C[C@@H](C1)N1C(C)=NN=C1C(C)C)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1	CHEMBL1201187
P30556	AGTR1_HUMAN	telmisartan	9.31	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1017	CCCC1=NC2=C(C=C(C=C2C)C2=NC3=C(C=CC=C3)N2C)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C(O)=O	CHEMBL1017
O95477	ABCA1_HUMAN	probucol			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL608	CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C	CHEMBL608
Q92731	ESR2_HUMAN	estramustine phosphate			MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1756	[H][C@@]12CC[C@H](OP(O)(O)=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC(=O)N(CCCl)CCCl)C=C3	CHEMBL1756
P00519	ABL1_HUMAN	nilotinib	8.44	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL255863	CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F	CHEMBL255863
P25103	NK1R_HUMAN	aprepitant	10.7	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1471	C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F	CHEMBL1471
P22303	ACES_HUMAN	ambenonium			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1652	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=C(Cl)C=CC=C1)CC1=C(Cl)C=CC=C1	CHEMBL1652
P11388	TOP2A_HUMAN	doxorubicin	6.0	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL53463	[H][C@@]1(C[C@H](N)[C@H](O)[C@H](C)O1)O[C@H]1C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=C(OC)C=CC=C1C3=O)C(=O)CO	CHEMBL53463
P25101	EDNRA_HUMAN	bosentan	8.19	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL957	COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)C2=NC=CC=N2)C=CC=C1	CHEMBL957
P24530	EDNRB_HUMAN	bosentan	7.1	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL957	COC1=C(OC2=C(OCCO)N=C(N=C2NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)C2=NC=CC=N2)C=CC=C1	CHEMBL957
P12821	ACE_HUMAN	fosinopril	9.0	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL581	CCC(=O)O[C@@H](O[P@](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C	CHEMBL581
P28845	DHI1_HUMAN	carbenoxolone	7.08	IC50	INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D01899	[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](OC(=O)CCC(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O	CHEMBL499915
Q9Y271	CLTR1_HUMAN	zafirlukast	9.5	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL603	COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC2CCCC2)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C1=C(C)C=CC=C1	CHEMBL603
Q05940	VMAT2_HUMAN	deserpidine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200515	[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2	CHEMBL1200515
P00533	EGFR_HUMAN	lapatinib	9.04	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL554	CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1	CHEMBL554
P04626	ERBB2_HUMAN	lapatinib	8.15	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL554	CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC=C2N=CN=C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)C2=C1	CHEMBL554
P28221	5HT1D_HUMAN	ergotamine	9.1	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL442	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O	CHEMBL442
Q9Y271	CLTR1_HUMAN	montelukast	9.3	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL787	CC(C)(O)C1=C(CC[C@@H](SCC2(CC(O)=O)CC2)C2=CC(\C=C\C3=NC4=CC(Cl)=CC=C4C=C3)=CC=C2)C=CC=C1	CHEMBL787
P14416	DRD2_HUMAN	fluphenazine decanoate			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200854	CCCCCCCCCC(=O)OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1	CHEMBL1200854
P02708	ACHA_HUMAN	rapacuronium			ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8680742	[H][C@@]12C[C@@H]([C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1	CHEMBL1200549
P07510	ACHG_HUMAN	rapacuronium			ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8680742	[H][C@@]12C[C@@H]([C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1	CHEMBL1200549
P11230	ACHB_HUMAN	rapacuronium			ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8680742	[H][C@@]12C[C@@H]([C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1	CHEMBL1200549
Q04844	ACHE_HUMAN	rapacuronium			ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8680742	[H][C@@]12C[C@@H]([C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1	CHEMBL1200549
Q07001	ACHD_HUMAN	rapacuronium			ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8680742	[H][C@@]12C[C@@H]([C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(CC=C)CCCCC1	CHEMBL1200549
P00734	THRB_HUMAN	dabigatran etexilate	8.35	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL48361	CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=CC(=CC=C3N2C)C(=O)N(CCC(=O)OCC)C2=NC=CC=C2)C=C1	CHEMBL48361
Q05940	VMAT2_HUMAN	rescinnamine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1668	[H][C@]12C[C@@H](OC(=O)\C=C\C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2	CHEMBL1668
P04035	HMDH_HUMAN	bezafibrate			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2907502	CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O	CHEMBL264374
P37231	PPARG_HUMAN	mesalazine			AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2700	NC1=CC(C(O)=O)=C(O)C=C1	CHEMBL704
P10275	ANDR_HUMAN	nandrolone			AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6949	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]	CHEMBL757
P31639	SC5A2_HUMAN	dapagliflozin	9.3	IC50	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4594	[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC(CC2=CC=C(OCC)C=C2)=C(Cl)C=C1	CHEMBL429910
Q9Y275	TN13B_HUMAN	belimumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125370s053lbl.pdf		CHEMBL1789843
P05106	ITB3_HUMAN	abciximab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103575s5126lbl.pdf		CHEMBL1201584
P08514	ITA2B_HUMAN	abciximab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103575s5126lbl.pdf		CHEMBL1201584
P11836	CD20_HUMAN	ofatumumab	9.92	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125326s060lbl.pdf		CHEMBL1201836
P01584	IL1B_HUMAN	canakinumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125319s081lbl.pdf		CHEMBL1201834
P01589	IL2RA_HUMAN	daclizumab	8.0	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/103749s5059lbl.pdf		CHEMBL1201605
P14784	IL2RB_HUMAN	daclizumab	8.0	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/103749s5059lbl.pdf		CHEMBL1201605
P31785	IL2RG_HUMAN	daclizumab	8.0	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/103749s5059lbl.pdf		CHEMBL1201605
P00533	EGFR_HUMAN	cetuximab	9.41	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125084s063lbl.pdf		CHEMBL1201577
P00533	EGFR_HUMAN	panitumumab	10.3	Kd	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125147s200lbl.pdf		CHEMBL1201827
P15692	VEGFA_HUMAN	bevacizumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125085s305lbl.pdf		CHEMBL1201583
P04626	ERBB2_HUMAN	pertuzumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125409s104lbl.pdf		CHEMBL2007641
P16410	CTLA4_HUMAN	ipilimumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125377s055lbl.pdf		CHEMBL1789844
P20701	ITAL_HUMAN	efalizumab	11.4	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125075s130lbl.pdf		CHEMBL1201575
P06213	INSR_HUMAN	insulin degludec			AGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf	[H]NCC(=O)NC([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)NC(CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC1CSSC[C@@H]2NC(=O)[C@H](NC(=O)[C@@H](CO)NC(=O)C(NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)C(CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)C(N[H])CC3=CC=CC=C3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)NC(CC3=CNC=N3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSCC(NC(=O)[C@@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)NC(CC2=CC=CC=C2)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CC2=CC=C(O)C=C2)C(=O)N[C@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC	CHEMBL2107869
Q9Y6F1	PARP3_HUMAN	olaparib	7.34	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf	FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1	CHEMBL521686
P28908	TNR8_HUMAN	brentuximab vedotin			BINDING AGENT	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_S056S078lbl.pdf		CHEMBL1742994
O14788	TNF11_HUMAN	denosumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125320s170lbl.pdf		CHEMBL1237023
P29459	IL12A_HUMAN	ustekinumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125261s114lbl.pdf		CHEMBL1201835
P29460	IL12B_HUMAN	ustekinumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125261s114lbl.pdf		CHEMBL1201835
P29460	IL12B_HUMAN	ustekinumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125261s114lbl.pdf		CHEMBL1201835
Q9NPF7	IL23A_HUMAN	ustekinumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125261s114lbl.pdf		CHEMBL1201835
P01375	TNFA_HUMAN	golimumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125289s094lbl.pdf		CHEMBL1201833
P01375	TNFA_HUMAN	certolizumab pegol	10.045757293701172	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125160s215lbl.pdf		CHEMBL1201831
P01031	CO5_HUMAN	eculizumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125166s368s380lbl.pdf		CHEMBL1201828
P05556	ITB1_HUMAN	natalizumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125104s840s847s889lbl.pdf		CHEMBL1201607
P13612	ITA4_HUMAN	natalizumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125104s840s847s889lbl.pdf		CHEMBL1201607
P13612	ITA4_HUMAN	natalizumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125104s840s847s889lbl.pdf		CHEMBL1201607
P26010	ITB7_HUMAN	natalizumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125104s840s847s889lbl.pdf		CHEMBL1201607
P15692	VEGFA_HUMAN	ranibizumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125156s106lbl.pdf		CHEMBL1201825
P01854	IGHE_HUMAN	omalizumab	8.16	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103976s5161lbl.pdf		CHEMBL1201589
P11836	CD20_HUMAN	rituximab	8.51	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103705s5432lbl.pdf		CHEMBL1201576
P04746	AMYP_HUMAN	acarbose			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL404271	[H][C@]1(N[C@@H]2[C@@H](C)O[C@H](O[C@]3([H])[C@@H](CO)O[C@H](O[C@]4([H])[C@@H](CO)OC(O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)C=C(CO)[C@@H](O)[C@H](O)[C@H]1O	CHEMBL404271
P10827	THA_HUMAN	liothyronine	10.24	Kd	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1544	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O	CHEMBL1544
P10828	THB_HUMAN	liothyronine	10.1	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1544	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O	CHEMBL1544
P11388	TOP2A_HUMAN	etoposide phosphate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200645	[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(OP(O)(O)=O)C(OC)=C1)C1=C(C=C3OCOC3=C1)[C@H]2O[C@]1([H])O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O	CHEMBL1200645
P10827	THA_HUMAN	dextrothyroxine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL559	N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	CHEMBL559
P10828	THB_HUMAN	dextrothyroxine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL559	N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	CHEMBL559
P05023	AT1A1_HUMAN	digoxin	6.4	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1751	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1751
P05026	AT1B1_HUMAN	digoxin	6.4	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1751	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1751
P13637	AT1A3_HUMAN	digoxin	6.4	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1751	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1751
P14415	AT1B2_HUMAN	digoxin	6.4	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1751	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1751
P50993	AT1A2_HUMAN	digoxin	6.4	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1751	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1751
P54709	AT1B3_HUMAN	digoxin	6.4	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1751	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1751
P54710	ATNG_HUMAN	digoxin	6.4	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1751	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1751
Q13733	AT1A4_HUMAN	digoxin	6.4	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1751	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1751
P03372	ESR1_HUMAN	polyestradiol phosphate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201477		CHEMBL1201477
P05023	AT1A1_HUMAN	acetyldigitoxin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3545057	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])CC[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL3545057
P05026	AT1B1_HUMAN	acetyldigitoxin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3545057	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])CC[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL3545057
P13637	AT1A3_HUMAN	acetyldigitoxin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3545057	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])CC[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL3545057
P14415	AT1B2_HUMAN	acetyldigitoxin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3545057	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])CC[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL3545057
P50993	AT1A2_HUMAN	acetyldigitoxin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3545057	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])CC[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL3545057
P54709	AT1B3_HUMAN	acetyldigitoxin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3545057	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])CC[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL3545057
P54710	ATNG_HUMAN	acetyldigitoxin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3545057	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])CC[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL3545057
Q13733	AT1A4_HUMAN	acetyldigitoxin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL3545057	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])CC[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL3545057
P30556	AGTR1_HUMAN	saralasin	9.77	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL938	CNCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O	CHEMBL938
P05023	AT1A1_HUMAN	deslanoside			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1614	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1614
P05026	AT1B1_HUMAN	deslanoside			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1614	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1614
P13637	AT1A3_HUMAN	deslanoside			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1614	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1614
P14415	AT1B2_HUMAN	deslanoside			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1614	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1614
P50993	AT1A2_HUMAN	deslanoside			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1614	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1614
P54709	AT1B3_HUMAN	deslanoside			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1614	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1614
P54710	ATNG_HUMAN	deslanoside			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1614	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1614
Q13733	AT1A4_HUMAN	deslanoside			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1614	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1	CHEMBL1614
P0DJD9	PEPA5_HUMAN	sucralfate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2367706		CHEMBL2367706
P30559	OXYR_HUMAN	atosiban	7.96	Ki	ANTAGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000253/WC500040495.pdf	[H][C@]1(NC(=O)[C@@]([H])(NC(=O)[C@@H](CC2=CC=C(OCC)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)[C@@H](C)CC)[C@@H](C)O	CHEMBL382301
P30559	OXYR_HUMAN	oxytocin	9.1	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL395429	[H]N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)[C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	CHEMBL395429
P30872	SSR1_HUMAN	octreotide	6.65	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408687	[H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC1=O)[C@@H](C)O)C(=O)N[C@]([H])(CO)[C@@]([H])(C)O	CHEMBL408687
P31391	SSR4_HUMAN	octreotide	6.4	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408687	[H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC1=O)[C@@H](C)O)C(=O)N[C@]([H])(CO)[C@@]([H])(C)O	CHEMBL408687
P30518	V2R_HUMAN	desmopressin	8.3	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/9792651	NC(=O)CCC1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)C(CC(N)=O)NC1=O)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O	CHEMBL376685
P30518	V2R_HUMAN	vasopressin	8.92	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL373742	[H]N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O	CHEMBL373742
P37288	V1AR_HUMAN	vasopressin	9.59	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL373742	[H]N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O	CHEMBL373742
P47901	V1BR_HUMAN	vasopressin	9.31	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL373742	[H]N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O	CHEMBL373742
P30518	V2R_HUMAN	lypressin			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200690	[H]N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(N)=O	CHEMBL1200690
P37288	V1AR_HUMAN	lypressin			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200690	[H]N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(N)=O	CHEMBL1200690
P47901	V1BR_HUMAN	lypressin			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200690	[H]N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(N)=O	CHEMBL1200690
P30968	GNRHR_HUMAN	gonadorelin	8.0	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1007	CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	CHEMBL1007
P30968	GNRHR_HUMAN	goserelin			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200501	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O	CHEMBL1200501
P30968	GNRHR_HUMAN	histrelin			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200509	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CN(CC2=CC=CC=C2)C=N1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1	CHEMBL1200509
P30968	GNRHR_HUMAN	cetrorelix	8.8	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200490	CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	CHEMBL1200490
P01008	ANT3_HUMAN	fondaparinux	7.49	Kd	ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200644	[H][C@@]1(O[C@@H]2[C@@H](COS(O)(=O)=O)O[C@H](O[C@@]3([H])[C@H](O)[C@@H](OS(O)(=O)=O)[C@H](O[C@@]4([H])[C@H](O)[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@@H]4COS(O)(=O)=O)O[C@H]3C(O)=O)[C@H](NS(O)(=O)=O)[C@H]2OS(O)(=O)=O)O[C@@H]([C@@H](O[C@@]2([H])O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]2NS(O)(=O)=O)[C@H](O)[C@H]1O)C(O)=O	CHEMBL1200644
P30968	GNRHR_HUMAN	ganirelix			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1251	CCNC(NCC)=NCCCC[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	CHEMBL1251
P30874	SSR2_HUMAN	somatostatin	10.46	Ki	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=61	[H]N[C@@H](C)C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O)[C@@H](C)O)[C@@H](C)O)C(O)=O	CHEMBL1823872
P30872	SSR1_HUMAN	somatostatin	9.54	Ki	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=61	[H]N[C@@H](C)C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O)[C@@H](C)O)[C@@H](C)O)C(O)=O	CHEMBL1823872
P35346	SSR5_HUMAN	somatostatin	9.85	Ki	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=61	[H]N[C@@H](C)C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O)[C@@H](C)O)[C@@H](C)O)C(O)=O	CHEMBL1823872
P32745	SSR3_HUMAN	somatostatin	10.0	Ki	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=61	[H]N[C@@H](C)C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O)[C@@H](C)O)[C@@H](C)O)C(O)=O	CHEMBL1823872
P31391	SSR4_HUMAN	somatostatin	9.23	Ki	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=61	[H]N[C@@H](C)C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O)[C@@H](C)O)[C@@H](C)O)C(O)=O	CHEMBL1823872
P43220	GLP1R_HUMAN	exenatide	9.18	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL414357	[H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O	CHEMBL414357
Q9UBN7	HDAC6_HUMAN	vorinostat	9.0	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL98	ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1	CHEMBL98
Q13547	HDAC1_HUMAN	vorinostat	8.89	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL98	ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1	CHEMBL98
O15379	HDAC3_HUMAN	vorinostat	8.3	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL98	ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1	CHEMBL98
Q92769	HDAC2_HUMAN	vorinostat	8.8	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL98	ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1	CHEMBL98
P23975	SC6A2_HUMAN	lisdexamfetamine			RELEASING AGENT	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201178	C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN	CHEMBL1201178
Q05940	VMAT2_HUMAN	lisdexamfetamine			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201178	C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN	CHEMBL1201178
P10275	ANDR_HUMAN	testosterone propionate	9.6	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1170	[H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1170
P35348	ADA1A_HUMAN	silodosin	10.44	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL24778	C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F	CHEMBL24778
P21554	CNR1_HUMAN	rimonabant	9.72	Ki	ANTAGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000666/WC500021287.pdf	CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=CC=C(Cl)C=C1Cl)C1=CC=C(Cl)C=C1	CHEMBL111
P62942	FKB1A_HUMAN	temsirolimus			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201182	[H][C@@](C)(C[C@]1([H])CC[C@@]([H])(OC(=O)C(C)(CO)CO)[C@@]([H])(C1)OC)[C@]1([H])CC(=O)[C@]([H])(C)\C=C(C)\[C@@]([H])(O)[C@@]([H])(OC)C(=O)[C@]([H])(C)C[C@]([H])(C)\C=C\C=C\C=C(C)\[C@]([H])(C[C@]2([H])CC[C@@]([H])(C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@@]2([H])C(=O)O1)OC	CHEMBL1201182
P20648	ATP4A_HUMAN	dexlansoprazole			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201863	CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=C(N1)C=CC=C2	CHEMBL1201863
P51164	ATP4B_HUMAN	dexlansoprazole			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201863	CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=C(N1)C=CC=C2	CHEMBL1201863
O43525	KCNQ3_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
O43526	KCNQ2_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
O95259	KCNH1_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
P16389	KCNA2_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
P17658	KCNA6_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
P22001	KCNA3_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
P22459	KCNA4_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
P22460	KCNA5_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
P48547	KCNC1_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
P51787	KCNQ1_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
P56696	KCNQ4_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q03721	KCNC4_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q09470	KCNA1_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q12809	KCNH2_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q14003	KCNC3_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q14721	KCNB1_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q16322	KCA10_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q6PIU1	KCNV1_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q8NCM2	KCNH5_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q8TAE7	KCNG3_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q8TDN1	KCNG4_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q8TDN2	KCNV2_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q92953	KCNB2_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q96KK3	KCNS1_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q96L42	KCNH8_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q96PR1	KCNC2_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q96RP8	KCNA7_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q9BQ31	KCNS3_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q9H252	KCNH6_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q9H3M0	KCNF1_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q9NR82	KCNQ5_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q9NS40	KCNH7_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q9NSA2	KCND1_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q9NZV8	KCND2_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q9UIX4	KCNG1_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q9UJ96	KCNG2_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q9UK17	KCND3_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q9ULD8	KCNH3_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q9ULS6	KCNS2_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
Q9UQ05	KCNH4_HUMAN	fampridine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL284348	NC1=CC=NC=C1	CHEMBL284348
P35367	HRH1_HUMAN	alcaftadine			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201747	CN1CCC(CC1)=C1C2=NC=C(C=O)N2CCC2=C1C=CC=C2	CHEMBL1201747
Q99500	S1PR3_HUMAN	fingolimod	8.52	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL314854	CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1	CHEMBL314854
Q9H228	S1PR5_HUMAN	fingolimod	9.52	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL314854	CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1	CHEMBL314854
O95977	S1PR4_HUMAN	fingolimod	9.52	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL314854	CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1	CHEMBL314854
P21453	S1PR1_HUMAN	fingolimod	9.52	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL314854	CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1	CHEMBL314854
P27487	DPP4_HUMAN	linagliptin	10.0	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL237500	CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1	CHEMBL237500
P05093	CP17A_HUMAN	abiraterone acetate	8.54	IC50	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9288	[H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@]([H])(CC[C@]12C)OC(C)=O	CHEMBL254328
P00533	EGFR_HUMAN	vandetanib	8.32	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL24828	COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1	CHEMBL24828
P35968	VGFR2_HUMAN	vandetanib	6.33	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL24828	COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1	CHEMBL24828
P07949	RET_HUMAN	vandetanib	7.85	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL24828	COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1	CHEMBL24828
P00742	FA10_HUMAN	rivaroxaban	9.4	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL198362	ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O	CHEMBL198362
P07550	ADRB2_HUMAN	indacaterol	7.8	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1095777	CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2	CHEMBL1095777
Q9H244	P2Y12_HUMAN	ticagrelor	7.85	Ki	NEGATIVE ALLOSTERIC MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL398435	CCCSC1=NC(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=C2N=NN([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C2=N1	CHEMBL398435
P15056	BRAF_HUMAN	vemurafenib	7.68	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1229517	CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C1F	CHEMBL1229517
P30411	BKRB2_HUMAN	icatibant	10.22	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2028850	[H]N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@]([H])(O)C[C@@]1([H])C(=O)NCC(=O)N[C@@H](CC1=CC=CS1)C(=O)N[C@@H](CO)C(=O)N1CC2=C(C[C@@H]1C(=O)N1[C@@H](C[C@]3([H])CCCC[C@]13[H])C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C=CC=C2	CHEMBL2028850
P08581	MET_HUMAN	crizotinib	9.26	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL601719	[H][C@](C)(OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl	CHEMBL601719
Q9UM73	ALK_HUMAN	crizotinib	9.13	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL601719	[H][C@](C)(OC1=C(N)N=CC(=C1)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl	CHEMBL601719
O60674	JAK2_HUMAN	ruxolitinib	10.44	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1789941	N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1	CHEMBL1789941
P23458	JAK1_HUMAN	ruxolitinib	10.05	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1789941	N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1	CHEMBL1789941
P29218	IMPA1_HUMAN	lithium carbonate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200826		CHEMBL1200826
P49840	GSK3A_HUMAN	lithium carbonate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200826		CHEMBL1200826
P49841	GSK3B_HUMAN	lithium carbonate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200826		CHEMBL1200826
P25100	ADA1D_HUMAN	prazosin	9.7	Ki	INVERSE AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1	CHEMBL2
P35348	ADA1A_HUMAN	prazosin	10.4	Ki	INVERSE AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1	CHEMBL2
P35368	ADA1B_HUMAN	prazosin	9.68	Ki	INVERSE AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503	COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1	CHEMBL2
P04150	GCR_HUMAN	hydrocortisone acetate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1091	[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1091
P08913	ADA2A_HUMAN	methyldopate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200432	CCOC(=O)[C@@](C)(N)CC1=CC(O)=C(O)C=C1	CHEMBL1200432
P18089	ADA2B_HUMAN	methyldopate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200432	CCOC(=O)[C@@](C)(N)CC1=CC(O)=C(O)C=C1	CHEMBL1200432
P18825	ADA2C_HUMAN	methyldopate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200432	CCOC(=O)[C@@](C)(N)CC1=CC(O)=C(O)C=C1	CHEMBL1200432
P14679	TYRO_HUMAN	mequinol			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL544	COC1=CC=C(O)C=C1	CHEMBL544
P17948	VGFR1_HUMAN	axitinib	8.24	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1289926	CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1	CHEMBL1289926
P35968	VGFR2_HUMAN	axitinib	8.23	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1289926	CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1	CHEMBL1289926
P35916	VGFR3_HUMAN	axitinib	6.77	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1289926	CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1	CHEMBL1289926
Q99835	SMO_HUMAN	vismodegib	7.79	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL473417	CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1	CHEMBL473417
P13569	CFTR_HUMAN	ivacaftor	8.52	EC50	POSITIVE MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2010601	CC(C)(C)C1=CC(=C(NC(=O)C2=CNC3=CC=CC=C3C2=O)C=C1O)C(C)(C)C	CHEMBL2010601
P43088	PF2R_HUMAN	tafluprost			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1963683	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1	CHEMBL1963683
P14679	TYRO_HUMAN	avobenzone			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200522	COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C	CHEMBL1200522
P23219	PGH1_HUMAN	bismuth subsalicylate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1120	O[Bi]1OC(=O)C2=CC=CC=C2O1	CHEMBL1120
P35354	PGH2_HUMAN	bismuth subsalicylate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1120	O[Bi]1OC(=O)C2=CC=CC=C2O1	CHEMBL1120
P00742	FA10_HUMAN	apixaban	10.1	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL231779	COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O	CHEMBL231779
P35498	SCN1A_HUMAN	eslicarbazepine acetate			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL315985	CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=CC=CC=C12	CHEMBL315985
P35499	SCN4A_HUMAN	eslicarbazepine acetate			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL315985	CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=CC=CC=C12	CHEMBL315985
Q01118	SCN7A_HUMAN	eslicarbazepine acetate			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL315985	CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=CC=CC=C12	CHEMBL315985
Q14524	SCN5A_HUMAN	eslicarbazepine acetate			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL315985	CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=CC=CC=C12	CHEMBL315985
Q15858	SCN9A_HUMAN	eslicarbazepine acetate			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL315985	CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=CC=CC=C12	CHEMBL315985
Q99250	SCN2A_HUMAN	eslicarbazepine acetate			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL315985	CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=CC=CC=C12	CHEMBL315985
Q9NY46	SCN3A_HUMAN	eslicarbazepine acetate			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL315985	CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=CC=CC=C12	CHEMBL315985
Q9UI33	SCNBA_HUMAN	eslicarbazepine acetate			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL315985	CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=CC=CC=C12	CHEMBL315985
Q9UQD0	SCN8A_HUMAN	eslicarbazepine acetate			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL315985	CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=CC=CC=C12	CHEMBL315985
Q9Y5Y9	SCNAA_HUMAN	eslicarbazepine acetate			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL315985	CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=CC=CC=C12	CHEMBL315985
P03372	ESR1_HUMAN	lasofoxifene	8.89	IC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12825935	[H]C1(CCC2=CC(O)=CC=C2C1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1	CHEMBL328190
Q92731	ESR2_HUMAN	lasofoxifene	8.74	IC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12825935	[H]C1(CCC2=CC(O)=CC=C2C1([H])C1=CC=C(OCCN2CCCC2)C=C1)C1=CC=CC=C1	CHEMBL328190
Q15858	SCN9A_HUMAN	lacosamide	6.74	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL58323	COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1	CHEMBL58323
P00533	EGFR_HUMAN	afatinib	10.0	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1173655	CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1	CHEMBL1173655
P04626	ERBB2_HUMAN	afatinib	8.3	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1173655	CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1	CHEMBL1173655
Q15303	ERBB4_HUMAN	afatinib	8.2	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1173655	CN(C)C\C=C\C(=O)NC1=CC2=C(C=C1O[C@H]1CCOC1)N=CN=C2NC1=CC(Cl)=C(F)C=C1	CHEMBL1173655
Q13258	PD2R_HUMAN	laropiprant	10.52	Kd	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17300164	CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1	CHEMBL426559
P03372	ESR1_HUMAN	bazedoxifene	9.22	IC50	MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL46740	CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1	CHEMBL46740
Q92731	ESR2_HUMAN	bazedoxifene	8.42	IC50	MODULATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL46740	CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1	CHEMBL46740
P27487	DPP4_HUMAN	alogliptin	9.0	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL227529	CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O	CHEMBL227529
P00519	ABL1_HUMAN	bosutinib	10.54	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL288441	COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl	CHEMBL288441
P12931	SRC_HUMAN	bosutinib	9.0	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL288441	COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl	CHEMBL288441
P08631	HCK_HUMAN	bosutinib	8.47	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL288441	COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl	CHEMBL288441
P07948	LYN_HUMAN	bosutinib	8.38	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL288441	COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl	CHEMBL288441
Q96RI1	NR1H4_HUMAN	chenodiol	5.47	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL240597	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O	CHEMBL240597
P27815	PDE4A_HUMAN	choline theophyllinate	4.25	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200434	C[N+](C)(C)CCO.CN1C2=C(N=C[N-]2)C(=O)N(C)C1=O	CHEMBL1200434
Q07343	PDE4B_HUMAN	choline theophyllinate	4.25	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200434	C[N+](C)(C)CCO.CN1C2=C(N=C[N-]2)C(=O)N(C)C1=O	CHEMBL1200434
Q08493	PDE4C_HUMAN	choline theophyllinate	4.25	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200434	C[N+](C)(C)CCO.CN1C2=C(N=C[N-]2)C(=O)N(C)C1=O	CHEMBL1200434
Q08499	PDE4D_HUMAN	choline theophyllinate	4.25	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200434	C[N+](C)(C)CCO.CN1C2=C(N=C[N-]2)C(=O)N(C)C1=O	CHEMBL1200434
P30542	AA1R_HUMAN	choline theophyllinate	9.22	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200434	C[N+](C)(C)CCO.CN1C2=C(N=C[N-]2)C(=O)N(C)C1=O	CHEMBL1200434
P29274	AA2AR_HUMAN	choline theophyllinate	9.22	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200434	C[N+](C)(C)CCO.CN1C2=C(N=C[N-]2)C(=O)N(C)C1=O	CHEMBL1200434
P29275	AA2BR_HUMAN	choline theophyllinate	5.57	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200434	C[N+](C)(C)CCO.CN1C2=C(N=C[N-]2)C(=O)N(C)C1=O	CHEMBL1200434
P29274	AA2AR_HUMAN	choline theophyllinate	4.85	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200434	C[N+](C)(C)CCO.CN1C2=C(N=C[N-]2)C(=O)N(C)C1=O	CHEMBL1200434
P29275	AA2BR_HUMAN	choline theophyllinate	4.85	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200434	C[N+](C)(C)CCO.CN1C2=C(N=C[N-]2)C(=O)N(C)C1=O	CHEMBL1200434
Q13370	PDE3B_HUMAN	choline theophyllinate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200434	C[N+](C)(C)CCO.CN1C2=C(N=C[N-]2)C(=O)N(C)C1=O	CHEMBL1200434
Q14432	PDE3A_HUMAN	choline theophyllinate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200434	C[N+](C)(C)CCO.CN1C2=C(N=C[N-]2)C(=O)N(C)C1=O	CHEMBL1200434
P25103	NK1R_HUMAN	casopitant	9.9	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19536319	C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=C(C)C=C(F)C=C1)N1CCN(CC1)C(C)=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F	CHEMBL1672054
P61073	CXCR4_HUMAN	plerixafor	6.05	Ki	PARTIAL AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL18442	C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1	CHEMBL18442
P27815	PDE4A_HUMAN	bufylline	4.25	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2104089		CHEMBL2104089
Q07343	PDE4B_HUMAN	bufylline	4.25	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2104089		CHEMBL2104089
Q08493	PDE4C_HUMAN	bufylline	4.25	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2104089		CHEMBL2104089
Q08499	PDE4D_HUMAN	bufylline	4.25	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2104089		CHEMBL2104089
P30542	AA1R_HUMAN	bufylline	9.22	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2104089		CHEMBL2104089
P29274	AA2AR_HUMAN	bufylline	9.22	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2104089		CHEMBL2104089
P29275	AA2BR_HUMAN	bufylline	5.57	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2104089		CHEMBL2104089
P29274	AA2AR_HUMAN	bufylline	4.85	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2104089		CHEMBL2104089
P29275	AA2BR_HUMAN	bufylline	4.85	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2104089		CHEMBL2104089
Q13370	PDE3B_HUMAN	bufylline			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2104089		CHEMBL2104089
Q14432	PDE3A_HUMAN	bufylline			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2104089		CHEMBL2104089
P10275	ANDR_HUMAN	testosterone cypionate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201101	[H][C@@]12CC[C@H](OC(=O)CCC3CCCC3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1201101
P04150	GCR_HUMAN	hydrocortisone succinate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL977	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL977
P08913	ADA2A_HUMAN	corbadrine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL677	C[C@H](N)[C@H](O)C1=CC(O)=C(O)C=C1	CHEMBL677
P18089	ADA2B_HUMAN	corbadrine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL677	C[C@H](N)[C@H](O)C1=CC(O)=C(O)C=C1	CHEMBL677
P18825	ADA2C_HUMAN	corbadrine			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL677	C[C@H](N)[C@H](O)C1=CC(O)=C(O)C=C1	CHEMBL677
P20309	ACM3_HUMAN	aclidinium bromide	10.15	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL551466	OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1	CHEMBL551466
P04150	GCR_HUMAN	alclometasone dipropionate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200989	[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])[C@H](Cl)CC2=CC(=O)C=C[C@]12C	CHEMBL1200989
P03372	ESR1_HUMAN	estradiol acetate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200430	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OC(C)=O)C=C3	CHEMBL1200430
P04150	GCR_HUMAN	hydrocortisone valerate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200562	[H][C@@]12CC[C@](OC(=O)CCCC)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1200562
Q07869	PPARA_HUMAN	choline fenofibrate	4.46	Ki	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL981	CC(C)(OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1)C(O)=O	CHEMBL981
P29218	IMPA1_HUMAN	lithium citrate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200826	[Li+].[Li+].[Li+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CHEMBL1200826
P49840	GSK3A_HUMAN	lithium citrate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200826	[Li+].[Li+].[Li+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CHEMBL1200826
P49841	GSK3B_HUMAN	lithium citrate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200826	[Li+].[Li+].[Li+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	CHEMBL1200826
P04150	GCR_HUMAN	fluticasone furoate	10.12	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1473	[H][C@@]1(C)C[C@@]2([H])[C@]3([H])C[C@]([H])(F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@]([H])(O)C[C@]2(C)[C@@]1(OC(=O)C1=CC=CO1)C(=O)SCF	CHEMBL1473
O75899	GABR2_HUMAN	sodium oxybate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1342	[Na+].OCCCC([O-])=O	CHEMBL1342
Q9UBS5	GABR1_HUMAN	sodium oxybate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1342	[Na+].OCCCC([O-])=O	CHEMBL1342
P04150	GCR_HUMAN	hydrocortisone probutate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200953	[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1200953
P04150	GCR_HUMAN	clocortolone pivalate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200975	[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C	CHEMBL1200975
P10275	ANDR_HUMAN	testosterone enantate			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200335	[H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C	CHEMBL1200335
P10275	ANDR_HUMAN	enzalutamide	7.31	EC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1082407	CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC(=C(C=C1)C#N)C(F)(F)F	CHEMBL1082407
O75343	GCYB2_HUMAN	nitroprusside			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL136478		CHEMBL136478
P33402	GCYA2_HUMAN	nitroprusside			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL136478		CHEMBL136478
Q02108	GCYA3_HUMAN	nitroprusside			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL136478		CHEMBL136478
Q02153	GCYB1_HUMAN	nitroprusside			ACTIVATOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL136478		CHEMBL136478
Q02127	PYRD_HUMAN	teriflunomide	7.52	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL973	C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F	CHEMBL973
Q96RJ0	TAAR1_HUMAN	levmetamfetamine	5.48	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22037049	CN[C@H](C)CC1=CC=CC=C1	CHEMBL1927030
P15056	BRAF_HUMAN	regorafenib	7.55	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1946170	CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=CC=N1	CHEMBL1946170
P41145	OPRK_HUMAN	nalfurafine	9.64	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/16251241	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CC[C@H]2N(C)C(=O)\C=C\C1=COC=C1	CHEMBL267495
Q969S8	HDA10_HUMAN	panobinostat	7.51	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf	CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1	CHEMBL483254
Q96DB2	HDA11_HUMAN	panobinostat	8.46	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf	CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1	CHEMBL483254
Q9BY41	HDAC8_HUMAN	panobinostat	7.66	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf	CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1	CHEMBL483254
Q9UKV0	HDAC9_HUMAN	panobinostat	8.92	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf	CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1	CHEMBL483254
Q9UBN7	HDAC6_HUMAN	panobinostat	9.15	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf	CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1	CHEMBL483254
Q13547	HDAC1_HUMAN	panobinostat	9.0	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf	CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1	CHEMBL483254
P56524	HDAC4_HUMAN	panobinostat	9.22	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf	CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1	CHEMBL483254
O15379	HDAC3_HUMAN	panobinostat	8.96	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf	CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1	CHEMBL483254
Q92769	HDAC2_HUMAN	panobinostat	9.19	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf	CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1	CHEMBL483254
Q9UQL6	HDAC5_HUMAN	panobinostat	9.15	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf	CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1	CHEMBL483254
Q8WUI4	HDAC7_HUMAN	panobinostat	8.64	Ki	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf	CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C2=CC=CC=C2N1	CHEMBL483254
P42261	GRIA1_HUMAN	perampanel	6.61	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1214124	O=C1N(C=C(C=C1C1=C(C=CC=C1)C#N)C1=CC=CC=N1)C1=CC=CC=C1	CHEMBL1214124
P42262	GRIA2_HUMAN	perampanel	6.61	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1214124	O=C1N(C=C(C=C1C1=C(C=CC=C1)C#N)C1=CC=CC=N1)C1=CC=CC=C1	CHEMBL1214124
P42263	GRIA3_HUMAN	perampanel	6.61	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1214124	O=C1N(C=C(C=C1C1=C(C=CC=C1)C#N)C1=CC=CC=N1)C1=CC=CC=C1	CHEMBL1214124
P48058	GRIA4_HUMAN	perampanel	6.61	IC50	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1214124	O=C1N(C=C(C=C1C1=C(C=CC=C1)C#N)C1=CC=CC=N1)C1=CC=CC=C1	CHEMBL1214124
O60674	JAK2_HUMAN	tofacitinib	6.64	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL221959	C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N	CHEMBL221959
P29597	TYK2_HUMAN	tofacitinib	6.64	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL221959	C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N	CHEMBL221959
P23458	JAK1_HUMAN	tofacitinib	7.46	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL221959	C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N	CHEMBL221959
P29597	TYK2_HUMAN	tofacitinib	7.46	IC50	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL221959	C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N	CHEMBL221959
P11274	BCR_HUMAN	ponatinib			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1171837	CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC3=CN=C4C=CC=NN34)C=C2C(F)(F)F)CC1	CHEMBL1171837
O95838	GLP2R_HUMAN	teduglutide	10.05	EC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2104987	[H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O	CHEMBL2104987
P08588	ADRB1_HUMAN	levobetaxolol	9.1	Ki	ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200837	CC(C)NC[C@H](O)COC1=CC=C(CCOCC2CC2)C=C1	CHEMBL1200837
Q14145	KEAP1_HUMAN	dimethyl fumarate			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL589586	COC(=O)\C=C\C(=O)OC	CHEMBL589586
P03952	KLKB1_HUMAN	aprotinin			INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201619	[H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCSC)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@@H](NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC3=O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N2)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CCCN2C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC1=O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O	CHEMBL1201619
Q969S8	HDA10_HUMAN	belinostat	7.23	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408513	ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1	CHEMBL408513
Q96DB2	HDA11_HUMAN	belinostat	7.57	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408513	ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1	CHEMBL408513
Q9BY41	HDAC8_HUMAN	belinostat	7.66	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408513	ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1	CHEMBL408513
Q9UKV0	HDAC9_HUMAN	belinostat	7.62	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408513	ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1	CHEMBL408513
Q9UBN7	HDAC6_HUMAN	belinostat	8.8	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408513	ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1	CHEMBL408513
Q13547	HDAC1_HUMAN	belinostat	9.07	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408513	ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1	CHEMBL408513
O15379	HDAC3_HUMAN	belinostat	8.82	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408513	ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1	CHEMBL408513
Q92769	HDAC2_HUMAN	belinostat	9.07	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408513	ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1	CHEMBL408513
Q9UQL6	HDAC5_HUMAN	belinostat	7.6	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408513	ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1	CHEMBL408513
Q8WUI4	HDAC7_HUMAN	belinostat	7.29	Ki	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL408513	ONC(=O)C=CC1=CC(=CC=C1)S(=O)(=O)NC1=CC=CC=C1	CHEMBL408513
P29274	AA2AR_HUMAN	istradefylline	8.66	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/16004599	CCN1C2=C(N(C)C(\C=C\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O	CHEMBL431770
P22607	FGFR3_HUMAN	nintedanib	7.03	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL502835	COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2	CHEMBL502835
P22455	FGFR4_HUMAN	nintedanib	5.74	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL502835	COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2	CHEMBL502835
P09619	PGFRB_HUMAN	nintedanib	7.82	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL502835	COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2	CHEMBL502835
P21802	FGFR2_HUMAN	nintedanib	6.46	Kd	INHIBITOR	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL502835	COC(=O)C1=CC2=C(C=C1)\C(=C(\NC1=CC=C(C=C1)N(C)C(=O)CN1CCN(C)CC1)C1=CC=CC=C1)C(=O)N2	CHEMBL502835
O60674	JAK2_HUMAN	tofacitinib	6.391473770141602	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203214s007lbl.pdf	C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N	CHEMBL221959
P23458	JAK1_HUMAN	tofacitinib	6.391473770141602	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203214s007lbl.pdf	C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N	CHEMBL221959
P23458	JAK1_HUMAN	tofacitinib	7.251811981201172	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203214s007lbl.pdf	C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N	CHEMBL221959
P52333	JAK3_HUMAN	tofacitinib	7.251811981201172	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203214s007lbl.pdf	C[C@@H]1CCN(C[C@@H]1N(C)C1=C2C=CNC2=NC=N1)C(=O)CC#N	CHEMBL221959
P05231	IL6_HUMAN	siltuximab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125496s000lbl.pdf		CHEMBL1743070
P01375	TNFA_HUMAN	etanercept			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103795s5548lbl.pdf		CHEMBL1201572
P04626	ERBB2_HUMAN	trastuzumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103792s5311lbl.pdf		CHEMBL1201585
Q01668	CAC1D_HUMAN	nicardipine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1484	COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1	CHEMBL1484
Q13936	CAC1C_HUMAN	nicardipine			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1484	COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1	CHEMBL1484
P20138	CD33_HUMAN	gemtuzumab ozogamicin			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021174s020lbl.pdf		CHEMBL1201506
P06213	INSR_HUMAN	insulin aspart			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020986s059s081lbl.pdf	[H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N[H])CC3=CC=CC=C3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CNC=N3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC	CHEMBL1201496
P11836	CD20_HUMAN	obinutuzumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125486_s008lbl.pdf		CHEMBL1743048
P11836	CD20_HUMAN	ibritumomab tiuxetan	7.853871822357178	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125019s210s213lbl.pdf		CHEMBL1201606
P06213	INSR_HUMAN	insulin detemir			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021536s031s051lbl.pdf	[H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC3=CNC=N3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N[H])CC3=CC=CC=C3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CNC=N3)C(=O)N[C@@H](CC(C)C)C(=O)NC(C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CC=C(O)C=C3)C(=O)N[C@H](CC(C)C)C(=O)NC(C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(=O)NC(CC2=CC=CC=C2)C(=O)NC(CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CCCCCCCCCCCCC)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC	CHEMBL2104391
Q8NBP7	PCSK9_HUMAN	evolocumab	9.72	Kd	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23083772		CHEMBL2364655
P32239	GASR_HUMAN	proglumide			ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/2863192	CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1	CHEMBL316561
O75762	TRPA1_HUMAN	metamizole	4.040958404541016	IC50	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/25765567	CN(CS(O)(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1	CHEMBL461522
O75762	TRPA1_HUMAN	propyphenazone	4.481485843658447	IC50	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/25765567	CC(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1	CHEMBL28318
O75762	TRPA1_HUMAN	phenazone	3.0809218883514404	IC50	BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/25765567	CN1N(C(=O)C=C1C)C1=CC=CC=C1	CHEMBL277474
P20648	ATP4A_HUMAN	revaprazan			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/14681344	CC1N(CCC2=CC=CC=C12)C1=C(C)C(C)=NC(NC2=CC=C(F)C=C2)=N1	CHEMBL1257753
P51164	ATP4B_HUMAN	revaprazan			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/14681344	CC1N(CCC2=CC=CC=C12)C1=C(C)C(C)=NC(NC2=CC=C(F)C=C2)=N1	CHEMBL1257753
Q9Y5N1	HRH3_HUMAN	betahistine	9.522878646850586	EC50	INVERSE AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20530654	CNCCC1=CC=CC=N1	CHEMBL24441
P34998	CRFR1_HUMAN	corticorelin	8.481486320495605	Kd	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=212	[H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O	CHEMBL2107324
P42345	MTOR_HUMAN	ridaforolimus	9.698969841003418	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21482695	[H][C@@]12CC[C@@H](C)[C@@](O)(O1)C(=O)C(=O)N1CCCC[C@@]1([H])C(=O)O[C@@]([H])(CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C2)OC)[C@H](C)C[C@@H]1CC[C@@H](OP(C)(C)=O)[C@@H](C1)OC	CHEMBL2103839
O43525	KCNQ3_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
O43526	KCNQ2_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
O95259	KCNH1_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
P16389	KCNA2_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
P17658	KCNA6_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
P22001	KCNA3_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
P22459	KCNA4_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
P22460	KCNA5_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
P48547	KCNC1_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
P51787	KCNQ1_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
P56696	KCNQ4_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q03721	KCNC4_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q09470	KCNA1_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q12809	KCNH2_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q14003	KCNC3_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q14721	KCNB1_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q16322	KCA10_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q6PIU1	KCNV1_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q8NCM2	KCNH5_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q8TAE7	KCNG3_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q8TDN1	KCNG4_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q8TDN2	KCNV2_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q92953	KCNB2_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q96KK3	KCNS1_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q96L42	KCNH8_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q96PR1	KCNC2_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q96RP8	KCNA7_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q9BQ31	KCNS3_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q9H252	KCNH6_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q9H3M0	KCNF1_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q9NR82	KCNQ5_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q9NS40	KCNH7_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q9NSA2	KCND1_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q9NZV8	KCND2_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q9UIX4	KCNG1_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q9UJ96	KCNG2_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q9UK17	KCND3_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q9ULD8	KCNH3_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q9ULS6	KCNS2_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
Q9UQ05	KCNH4_HUMAN	amifampridine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22805230	NC1=CC=NC=C1N	CHEMBL354077
P04350	TBB4A_HUMAN	cabazitaxel			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23337758	[H][C@](O)(C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O)[C@@]([H])(NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL1201748
P07437	TBB5_HUMAN	cabazitaxel			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23337758	[H][C@](O)(C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O)[C@@]([H])(NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL1201748
P68371	TBB4B_HUMAN	cabazitaxel			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23337758	[H][C@](O)(C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O)[C@@]([H])(NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL1201748
Q13509	TBB3_HUMAN	cabazitaxel			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23337758	[H][C@](O)(C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O)[C@@]([H])(NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL1201748
Q13885	TBB2A_HUMAN	cabazitaxel			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23337758	[H][C@](O)(C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O)[C@@]([H])(NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL1201748
Q3ZCM7	TBB8_HUMAN	cabazitaxel			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23337758	[H][C@](O)(C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O)[C@@]([H])(NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL1201748
Q9BUF5	TBB6_HUMAN	cabazitaxel			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23337758	[H][C@](O)(C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O)[C@@]([H])(NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL1201748
Q9BVA1	TBB2B_HUMAN	cabazitaxel			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23337758	[H][C@](O)(C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O)[C@@]([H])(NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL1201748
Q9H4B7	TBB1_HUMAN	cabazitaxel			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23337758	[H][C@](O)(C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O)[C@@]([H])(NC(=O)OC(C)(C)C)C1=CC=CC=C1	CHEMBL1201748
Q9H244	P2Y12_HUMAN	cangrelor	8.627087593078613	IC50	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204958lbl.pdf	CSCCNC1=NC(SCCC(F)(F)F)=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O	CHEMBL334966
Q9H244	P2Y12_HUMAN	prasugrel			ANTAGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201772	[H]C(N1CCC2=C(C1)C=C(OC(C)=O)S2)(C(=O)C1CC1)C1=C(F)C=CC=C1	CHEMBL1201772
P19235	EPOR_HUMAN	epoetin theta			AGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001033/WC500043300.pdf		CHEMBL2108290
P35367	HRH1_HUMAN	phenyltoloxamine			ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/28684	CN(C)CCOC1=C(CC2=CC=CC=C2)C=CC=C1	CHEMBL186720
P05106	ITB3_HUMAN	eptifibatide	6.2441253662109375	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020718s037lbl.pdf	NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O	CHEMBL1174
P08514	ITA2B_HUMAN	eptifibatide	6.2441253662109375	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020718s037lbl.pdf	NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O	CHEMBL1174
P05106	ITB3_HUMAN	tirofiban	7.958607196807861	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020912s021,020913s018lbl.pdf	CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O	CHEMBL916
P08514	ITA2B_HUMAN	tirofiban	7.958607196807861	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020912s021,020913s018lbl.pdf	CCCCS(=O)(=O)N[C@@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)C(O)=O	CHEMBL916
Q99835	SMO_HUMAN	sonidegib	8.221848487854004	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22042473	[H][C@]1(C)CN(C[C@@]([H])(C)O1)C1=NC=C(NC(=O)C2=CC=CC(=C2C)C2=CC=C(OC(F)(F)F)C=C2)C=C1	CHEMBL2105737
Q01959	SC6A3_HUMAN	cocaine			INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2286	[H][C@@]12CC[C@@]([H])(N1C)[C@@]([H])(C(=O)OC)[C@]([H])(C2)OC(=O)C1=CC=CC=C1	CHEMBL120901
P08069	IGF1R_HUMAN	mecasermin	8.30980396270752	IC50	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021839s016lbl.pdf	[H]NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC4=CC=CC=C4)NC2=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)CNC1=O)C(C)C)C(C)C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N3)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O	CHEMBL1201716
P13569	CFTR_HUMAN	lumacaftor	6.455932140350342	EC50	PHARMACOLOGICAL CHAPERONE	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf	CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC=CC(=C1)C(O)=O	CHEMBL2103870
P01589	IL2RA_HUMAN	aldesleukin			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf		CHEMBL1201438
P14784	IL2RB_HUMAN	aldesleukin			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf		CHEMBL1201438
P31785	IL2RG_HUMAN	aldesleukin			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf		CHEMBL1201438
O76074	PDE5A_HUMAN	mirodenafil	9.468521118164062	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/18638004	CCCOC1=CC=C(C=C1C1=NC2C(N(CC)C=C2CCC)C(=O)N1)S(=O)(=O)N1CCN(CCO)CC1	CHEMBL4297518
P14416	DRD2_HUMAN	cariprazine	9.3100004196167	Ki	PARTIAL AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf	CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1	CHEMBL2024517
P08908	5HT1A_HUMAN	cariprazine	8.59000015258789	Ki	PARTIAL AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf	CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1	CHEMBL2024517
P28223	5HT2A_HUMAN	cariprazine	7.730000019073486	Ki	ANTAGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf	CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1	CHEMBL2024517
P10912	GHR_HUMAN	somatrem			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/6285914		CHEMBL1201620
P00747	PLMN_HUMAN	reteplase			ACTIVATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8891469		CHEMBL1201593
P40238	TPOR_HUMAN	lusutrombopag	7.0757207139	EC50	AGONIST	SCIENTIFIC LITERATURE	http://dx.doi.org/10.1016/S0168-8278(14)61094-1	CCCCCCO[C@@H](C)C1=CC=CC(C2=CSC(NC(=O)C3=CC(Cl)=C(\C=C(/C)C(O)=O)C(Cl)=C3)=N2)=C1OC	CHEMBL2107831
P05113	IL5_HUMAN	mepolizumab	10.0	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125526Orig1s000Lbl.pdf		CHEMBL2108429
P46098	5HT3A_HUMAN	indisetron	8.739928245544434	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19967488	CN1C[C@@H]2C[C@@H](C[C@H](C1)N2C)NC(=O)C1=NNC2=C1C=CC=C2	CHEMBL2104994
P46098	5HT3A_HUMAN	azasetron	9.267605781555176	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19967488	[H]C1(CN2CCC1CC2)NC(=O)C1=C2OCC(=O)N(C)C2=CC(Cl)=C1	CHEMBL1598608
P46098	5HT3A_HUMAN	dolasetron	7.698318958282471	Ki	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1397053	[H][C@]12C[C@@H](C[C@]3([H])CC(C1)C(=O)CN23)OC(=O)C1=CNC2=C1C=CC=C2	CHEMBL2368924
P00533	EGFR_HUMAN	osimertinib	7.823908805847168	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf	COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C	CHEMBL3353410
P35498	SCN1A_HUMAN	procainamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL605	CCN(CC)CCNC(=O)C1=CC=C(N)C=C1	CHEMBL605
P35499	SCN4A_HUMAN	procainamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL605	CCN(CC)CCNC(=O)C1=CC=C(N)C=C1	CHEMBL605
Q01118	SCN7A_HUMAN	procainamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL605	CCN(CC)CCNC(=O)C1=CC=C(N)C=C1	CHEMBL605
Q14524	SCN5A_HUMAN	procainamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL605	CCN(CC)CCNC(=O)C1=CC=C(N)C=C1	CHEMBL605
Q15858	SCN9A_HUMAN	procainamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL605	CCN(CC)CCNC(=O)C1=CC=C(N)C=C1	CHEMBL605
Q99250	SCN2A_HUMAN	procainamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL605	CCN(CC)CCNC(=O)C1=CC=C(N)C=C1	CHEMBL605
Q9NY46	SCN3A_HUMAN	procainamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL605	CCN(CC)CCNC(=O)C1=CC=C(N)C=C1	CHEMBL605
Q9UI33	SCNBA_HUMAN	procainamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL605	CCN(CC)CCNC(=O)C1=CC=C(N)C=C1	CHEMBL605
Q9UQD0	SCN8A_HUMAN	procainamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL605	CCN(CC)CCNC(=O)C1=CC=C(N)C=C1	CHEMBL605
Q9Y5Y9	SCNAA_HUMAN	procainamide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL605	CCN(CC)CCNC(=O)C1=CC=C(N)C=C1	CHEMBL605
P35498	SCN1A_HUMAN	tocainide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1762	CC(N)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1762
P35499	SCN4A_HUMAN	tocainide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1762	CC(N)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1762
Q01118	SCN7A_HUMAN	tocainide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1762	CC(N)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1762
Q14524	SCN5A_HUMAN	tocainide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1762	CC(N)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1762
Q15858	SCN9A_HUMAN	tocainide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1762	CC(N)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1762
Q99250	SCN2A_HUMAN	tocainide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1762	CC(N)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1762
Q9NY46	SCN3A_HUMAN	tocainide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1762	CC(N)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1762
Q9UI33	SCNBA_HUMAN	tocainide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1762	CC(N)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1762
Q9UQD0	SCN8A_HUMAN	tocainide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1762	CC(N)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1762
Q9Y5Y9	SCNAA_HUMAN	tocainide			BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1762	CC(N)C(=O)NC1=C(C)C=CC=C1C	CHEMBL1762
Q13370	PDE3B_HUMAN	pimobendan	6.389999866485596	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11855658	COC1=CC=C(C=C1)C1=NC2=C(N1)C=CC(=C2)C1=NNC(=O)CC1C	CHEMBL24646
Q14432	PDE3A_HUMAN	pimobendan	6.389999866485596	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/11855658	COC1=CC=C(C=C1)C1=NC2=C(N1)C=CC(=C2)C1=NNC(=O)CC1C	CHEMBL24646
O15399	NMDE4_HUMAN	ketamine	6.380000114440918	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL742	CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1	CHEMBL742
O60391	NMD3B_HUMAN	ketamine	6.380000114440918	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL742	CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1	CHEMBL742
Q05586	NMDZ1_HUMAN	ketamine	6.380000114440918	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL742	CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1	CHEMBL742
Q12879	NMDE1_HUMAN	ketamine	6.380000114440918	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL742	CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1	CHEMBL742
Q13224	NMDE2_HUMAN	ketamine	6.380000114440918	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL742	CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1	CHEMBL742
Q14957	NMDE3_HUMAN	ketamine	6.380000114440918	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL742	CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1	CHEMBL742
Q8TCU5	NMD3A_HUMAN	ketamine	6.380000114440918	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL742	CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1	CHEMBL742
O15399	NMDE4_HUMAN	amantadine	4.980000019073486	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL660	NC12CC3CC(CC(C3)C1)C2	CHEMBL660
O60391	NMD3B_HUMAN	amantadine	4.980000019073486	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL660	NC12CC3CC(CC(C3)C1)C2	CHEMBL660
Q05586	NMDZ1_HUMAN	amantadine	4.980000019073486	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL660	NC12CC3CC(CC(C3)C1)C2	CHEMBL660
Q12879	NMDE1_HUMAN	amantadine	4.980000019073486	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL660	NC12CC3CC(CC(C3)C1)C2	CHEMBL660
Q13224	NMDE2_HUMAN	amantadine	4.980000019073486	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL660	NC12CC3CC(CC(C3)C1)C2	CHEMBL660
Q14957	NMDE3_HUMAN	amantadine	4.980000019073486	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL660	NC12CC3CC(CC(C3)C1)C2	CHEMBL660
Q8TCU5	NMD3A_HUMAN	amantadine	4.980000019073486	Ki	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL660	NC12CC3CC(CC(C3)C1)C2	CHEMBL660
Q09428	ABCC8_HUMAN	diazoxide	4.630000114440918	EC50	OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL181	CC1=NC2=CC=C(Cl)C=C2S(=O)(=O)N1	CHEMBL181
Q14654	KCJ11_HUMAN	diazoxide	4.630000114440918	EC50	OPENER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL181	CC1=NC2=CC=C(Cl)C=C2S(=O)(=O)N1	CHEMBL181
P35498	SCN1A_HUMAN	prilocaine	4.269999980926514	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1194	CCCNC(C)C(=O)NC1=C(C)C=CC=C1	CHEMBL1194
Q99250	SCN2A_HUMAN	prilocaine	4.269999980926514	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1194	CCCNC(C)C(=O)NC1=C(C)C=CC=C1	CHEMBL1194
Q9NY46	SCN3A_HUMAN	prilocaine	4.269999980926514	IC50	BLOCKER	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1194	CCCNC(C)C(=O)NC1=C(C)C=CC=C1	CHEMBL1194
Q96S37	S22AC_HUMAN	lesinurad	5.136677265167236	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf	OC(=O)CSC1=NN=C(Br)N1C1=C2C=CC=CC2=C(C=C1)C1CC1	CHEMBL2105716
Q01668	CAC1D_HUMAN	lacidipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17276408	CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(\C=C\C(=O)OC(C)(C)C)C=CC=C1)C(=O)OCC	CHEMBL460291
Q13936	CAC1C_HUMAN	lacidipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17276408	CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(\C=C\C(=O)OC(C)(C)C)C=CC=C1)C(=O)OCC	CHEMBL460291
Q13936	CAC1C_HUMAN	(S)-nitrendipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17276408	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC	CHEMBL251230
Q01668	CAC1D_HUMAN	benidipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17276408	COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1	CHEMBL2074972
Q13936	CAC1C_HUMAN	benidipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17276408	COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1	CHEMBL2074972
P37231	PPARG_HUMAN	lobeglitazone	7.744727611541748	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22047812	[H]C1(CC2=CC=C(OCCN(C)C3=NC=NC(OC4=CC=C(OC)C=C4)=C3)C=C2)SC(=O)NC1=O	CHEMBL3585580
P10275	ANDR_HUMAN	danazol			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1479	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC3=C(C[C@]12C)C=NO3	CHEMBL1479
P43116	PE2R2_HUMAN	rioprostil			AGONIST	KEGG DRUG	http://www.kegg.jp/entry/D05732	[H][C@@]1(O)CC(=O)[C@]([H])(CCCCCCCO)[C@@]1([H])\C=C\CC(C)(O)CCCC	CHEMBL3301679
P23219	PGH1_HUMAN	acemetacin			INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D01582	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O	CHEMBL189171
P35354	PGH2_HUMAN	acemetacin			INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D01582	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O	CHEMBL189171
P08235	MCR_HUMAN	canrenone	6.522878646850586	IC50	ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21771637	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C	CHEMBL1463345
P13631	RARG_HUMAN	acitretin			AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1131	COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1	CHEMBL1131
P30559	OXYR_HUMAN	carbetocin	8.148741722106934	Ki	AGONIST	DRUG LABEL	https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2015-PI-01665-1	[H][C@]1(CSCCCC(=O)N[C@@H](CC2=CC=C(OC)C=C2)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	CHEMBL3301668
Q01668	CAC1D_HUMAN	lercanidipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8821512	COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL250270
Q13936	CAC1C_HUMAN	lercanidipine			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8821512	COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1	CHEMBL250270
P35354	PGH2_HUMAN	felbinac			INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D01675	OC(=O)CC1=CC=C(C=C1)C1=CC=CC=C1	CHEMBL413965
P10275	ANDR_HUMAN	mestanolone			AGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01533	[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C	CHEMBL261514
P35354	PGH2_HUMAN	floctafenine	5.958607196807861	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23755755	OCC(O)COC(=O)C1=C(NC2=CC=NC3=C(C=CC=C23)C(F)(F)F)C=CC=C1	CHEMBL2105075
P23219	PGH1_HUMAN	floctafenine	6.267606258392334	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23755755	OCC(O)COC(=O)C1=C(NC2=CC=NC3=C(C=CC=C23)C(F)(F)F)C=CC=C1	CHEMBL2105075
P01589	IL2RA_HUMAN	denileukin diftitox			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103767s5119lbl.pdf		CHEMBL1201550
P14784	IL2RB_HUMAN	denileukin diftitox			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103767s5119lbl.pdf		CHEMBL1201550
P31785	IL2RG_HUMAN	denileukin diftitox			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103767s5119lbl.pdf		CHEMBL1201550
P06729	CD2_HUMAN	alefacept			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125036s0144lbl.pdf		CHEMBL1201571
P33681	CD80_HUMAN	abatacept	7.92	Kd	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125118s179lbl.pdf		CHEMBL1201823
P42081	CD86_HUMAN	abatacept	7.92	Kd	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125118s179lbl.pdf		CHEMBL1201823
P33681	CD80_HUMAN	belatacept			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125288s062lbl.pdf		CHEMBL1742990
P42081	CD86_HUMAN	belatacept			INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125288s062lbl.pdf		CHEMBL1742990
P01375	TNFA_HUMAN	infliximab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103772s5370lbl.pdf		CHEMBL1201581
P13612	ITA4_HUMAN	vedolizumab	8.300000190734863	IC50	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf		CHEMBL1743087
P26010	ITB7_HUMAN	vedolizumab	8.300000190734863	IC50	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf		CHEMBL1743087
P04150	GCR_HUMAN	cortivazol			AGONIST	KEGG DRUG	http://www.kegg.jp/entry/D03594	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C=C(C)C2=CC3=C(C[C@]12C)C=NN3C1=CC=CC=C1	CHEMBL2105842
Q16552	IL17_HUMAN	ixekizumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf		CHEMBL1743034
P05113	IL5_HUMAN	reslizumab	10.091514587402344	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf		CHEMBL2107884
P01584	IL1B_HUMAN	rilonacept	12.301030158996582	Kd	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125249lbl.pdf		CHEMBL1201830
P00747	PLMN_HUMAN	urokinase			ACTIVATOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021846s101lbl.pdf		CHEMBL1201420
P25021	HRH2_HUMAN	ebrotidine			ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8736619	NC(=N)NC1=NC(CSCCN\C=N\S(=O)(=O)C2=CC=C(Br)C=C2)=CS1	CHEMBL1742471
P09917	LOX5_HUMAN	benoxaprofen			INHIBITOR	KEGG DRUG	http://www.kegg.jp/entry/D03080	CC(C(O)=O)C1=CC2=C(OC(=N2)C2=CC=C(Cl)C=C2)C=C1	CHEMBL340978
P35367	HRH1_HUMAN	bisulepine			ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D07532	CN(C)CC\C=C1/C2=C(SC=C2)SCC2=C1C=CC=C2	
P35367	HRH1_HUMAN	bamipine			ANTAGONIST	KEGG DRUG	http://www.kegg.jp/entry/D07197	CN1CCC(CC1)N(CC1=CC=CC=C1)C1=CC=CC=C1	CHEMBL520400
P03372	ESR1_HUMAN	estriol	8.67	Ki	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2821	[H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CHEMBL193482
P19235	EPOR_HUMAN	darbepoetin alfa			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103951s5363lbl.pdf		CHEMBL1201566
P17181	INAR1_HUMAN	peginterferon alfa-2a			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103964s5264lbl.pdf		CHEMBL1201560
P48551	INAR2_HUMAN	peginterferon alfa-2a			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103964s5264lbl.pdf		CHEMBL1201560
P19235	EPOR_HUMAN	epoetin beta			AGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000116/WC500024979.pdf		CHEMBL2109092
P17181	INAR1_HUMAN	peginterferon alfa-2b			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103949s5299lbl.pdf		CHEMBL1201561
P48551	INAR2_HUMAN	peginterferon alfa-2b			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103949s5299lbl.pdf		CHEMBL1201561
P19235	EPOR_HUMAN	methoxy polyethylene glycol-epoetin beta			AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125164s071s072s073lbl.pdf		CHEMBL3707314
Q99062	CSF3R_HUMAN	lenograstim			ACTIVATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/10776839		CHEMBL2109128
P11473	VDR_HUMAN	eldecalcitol			AGONIST	KEGG DRUG	http://www.kegg.jp/entry/D07578	[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)[C@@]([H])(OCCCO)[C@H](O)C1=C)[C@H](C)CCCC(C)(C)O	CHEMBL4297608
P19235	EPOR_HUMAN	epoetin zeta			AGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000872/WC500054377.pdf		CHEMBL2108593
P31645	SC6A4_HUMAN	dapoxetine	8.95	IC50	INHIBITOR	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7901	CN(C)[C@@H](CCOC1=CC=CC2=C1C=CC=C2)C1=CC=CC=C1	CHEMBL2106574
P11387	TOP1_HUMAN	belotecan	6.561441898345947	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/9875499	CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C(CCNC(C)C)C4=CC=CC=C4N=C13)C2=O	CHEMBL2107315
P08588	ADRB1_HUMAN	esmolol	6.9	Ki	ANTAGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7178	COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1	CHEMBL768
P04150	GCR_HUMAN	halopredone acetate			AGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01743	[H][C@@]12CC[C@](OC(C)=O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@@H](F)C2=CC(=O)C(Br)=C[C@]12C	CHEMBL2106520
Q96RI1	NR1H4_HUMAN	obeticholic acid	7.004364967346191	EC50	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf	[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@H](O)[C@]([H])(CC)[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C	CHEMBL566315
P41180	CASR_HUMAN	etelcalcetide	4.6	EC50	AGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003995/WC500217100.pdf	C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O	CHEMBL3545183
P17752	TPH1_HUMAN	telotristat ethyl	7.79587984085083	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208794s000lbl.pdf	CCOC(=O)[C@@H](N)CC1=CC=C(C=C1)C1=NC(N)=NC(O[C@H](C2=C(C=C(Cl)C=C2)N2C=CC(C)=N2)C(F)(F)F)=C1	CHEMBL2103855
P04150	GCR_HUMAN	clobetasone butyrate			AGONIST	KEGG DRUG	http://www.kegg.jp/entry/D01273	[H][C@@]12C[C@H](C)[C@](OC(=O)CCC)(C(=O)CCl)[C@@]1(C)CC(=O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	CHEMBL2308885
P34995	PE2R1_HUMAN	limaprost			AGONIST	KEGG DRUG	http://www.kegg.jp/entry/D02722	CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O	CHEMBL2107456
P42261	GRIA1_HUMAN	ketamine			OPENER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/27144355	CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1	CHEMBL742
P42262	GRIA2_HUMAN	ketamine			OPENER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/27144355	CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1	CHEMBL742
P42263	GRIA3_HUMAN	ketamine			OPENER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/27144355	CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1	CHEMBL742
P48058	GRIA4_HUMAN	ketamine			OPENER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/27144355	CNC1(CCCCC1=O)C1=C(Cl)C=CC=C1	CHEMBL742
P11802	CDK4_HUMAN	ribociclib	8.0	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf	CN(C)C(=O)C1=CC2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N1C1CCCC1	CHEMBL3545110
Q00534	CDK6_HUMAN	ribociclib	7.408935546875	IC50	INHIBITOR	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf	CN(C)C(=O)C1=CC2=C(N=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2)N1C1CCCC1	CHEMBL3545110
Q9NZQ7	PD1L1_HUMAN	avelumab			ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf		CHEMBL3833373
P09874	PARP1_HUMAN	niraparib	8.42	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf	[H][C@]1(CCCNC1)C1=CC=C(C=C1)N1C=C2C=CC=C(C(N)=O)C2=N1	CHEMBL1094636
Q9UGN5	PARP2_HUMAN	niraparib	8.68	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf	[H][C@]1(CCCNC1)C1=CC=C(C=C1)N1C=C2C=CC=C(C(N)=O)C2=N1	CHEMBL1094636
P35372	OPRM_HUMAN	naldemedine			ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208854s000lbl.pdf	[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CC(C(=O)NC(C)(C)C1=NC(=NO1)C1=CC=CC=C1)=C2O	CHEMBL2105755
P11836	CD20_HUMAN	ocrelizumab	9.08	Kd	ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf		CHEMBL2108041
P24394	IL4RA_HUMAN	dupilumab	11.06	IC50	ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf		CHEMBL2108675
Q05940	VMAT2_HUMAN	deutetrabenazine			INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf	[H]C12CC(=O)C(CC(C)C)CN1CCC1=C2C=C(OC([2H])([2H])[2H])C(OC([2H])([2H])[2H])=C1	CHEMBL3137326
Q05940	VMAT2_HUMAN	valbenazine	8.522878646850586	Ki	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf	[H][C@]12C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CCC1=C2C=C(OC)C(OC)=C1	CHEMBL2364639
P00491	PNPH_HUMAN	forodesine	10.142667770385742	Ki	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17897085	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C1=CNC2=C1NC=NC2=O	CHEMBL218291
P36888	FLT3_HUMAN	midostaurin	7.96	Kd	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997Orig1Orig2s000lbl.pdf	[H][C@]12C[C@]([H])([C@@H](OC)[C@](C)(O1)N1C3=CC=CC=C3C3=C4CNC(=O)C4=C4C5=CC=CC=C5N2C4=C13)N(C)C(=O)C1=CC=CC=C1	CHEMBL608533
Q03431	PTH1R_HUMAN	abaloparatide	9.699999809265137	IC50	AGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf	[H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(N)=O	CHEMBL3301581
Q9UM73	ALK_HUMAN	brigatinib	9.221848487854004	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdf	COC1=C(NC2=NC=C(Cl)C(NC3=CC=CC=C3P(C)(C)=O)=N2)C=CC(=C1)N1CCC(CC1)N1CCN(C)CC1	CHEMBL3545311
Q9NZQ7	PD1L1_HUMAN	durvalumab			ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf		CHEMBL3301587
P08887	IL6RA_HUMAN	sarilumab	11.100000381469727	Kd	ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761037s000lbl.pdf		CHEMBL2108730
P40189	IL6RB_HUMAN	sarilumab	11.100000381469727	Kd	ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761037s000lbl.pdf		CHEMBL2108730
P14416	DRD2_HUMAN	ropinirole	8.14	Ki	AGONIST	IUPHAR	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7295	CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2	CHEMBL589
P35354	PGH2_HUMAN	polmacoxib	8.080851554870605	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/22278334	CC1(C)OC(=C(C1=O)C1=CC=CC(F)=C1)C1=CC=C(C=C1)S(N)(=O)=O	CHEMBL166863
P27487	DPP4_HUMAN	evogliptin	9.045757293701172	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/21093089	[H][C@]1(COC(C)(C)C)N(CCNC1=O)C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F	CHEMBL1779710
P00742	FA10_HUMAN	betrixaban	8.823908805847168	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf	COC1=CC=C(NC(=O)C2=CC=C(C=C2)C(=N)N(C)C)C(=C1)C(=O)NC1=CC=C(Cl)C=N1	CHEMBL512351
P23945	FSHR_HUMAN	corifollitropin alfa			AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/1446593		CHEMBL2108185
P29460	IL12B_HUMAN	guselkumab			ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf		CHEMBL2364648
Q9NPF7	IL23A_HUMAN	guselkumab			ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf		CHEMBL2364648
P20273	CD22_HUMAN	inotuzumab ozogamicin	9.7	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004119/WC500231261.pdf		CHEMBL2108611
Q07869	PPARA_HUMAN	pemafibrate	9.0	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/17553678	CC[C@@H](OC1=CC=CC(CN(CCCOC2=CC=C(OC)C=C2)C2=NC3=C(O2)C=CC=C3)=C1)C(O)=O	CHEMBL247951
P35354	PGH2_HUMAN	imrecoxib	7.823908805847168	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/15210067	CCCN1CC(=C(C1=O)C1=CC=C(C)C=C1)C1=CC=C(C=C1)S(C)(=O)=O	CHEMBL504535
P48735	IDHP_HUMAN	enasidenib	7.0	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf	CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C1=CC=CC(=N1)C(F)(F)F	CHEMBL3989908
P00533	EGFR_HUMAN	neratinib	7.036211967468262	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf	CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C	CHEMBL180022
P04626	ERBB2_HUMAN	neratinib	7.229147911071777	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf	CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C	CHEMBL180022
Q15303	ERBB4_HUMAN	neratinib	8.619789123535156	Kd	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf	CCOC1=CC2=NC=C(C#N)C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN(C)C	CHEMBL180022
P04629	NTRK1_HUMAN	cenegermin			AGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004209/WC500232105.pdf	[H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC3=CNC4=C3C=CC=C4)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC4=CNC5=C4C=CC=C5)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC1=O)C(C)C)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C(C)C)C(C)C)C(C)C)[C@@H](C)CC)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N3)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC1=CNC3=C1C=CC=C3)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)[C@@H](C)CC	CHEMBL4297852
P08138	TNR16_HUMAN	cenegermin			AGONIST	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004209/WC500232105.pdf	[H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC3=CNC4=C3C=CC=C4)NC(=O)[C@H](CC3=CNC=N3)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC4=CNC5=C4C=CC=C5)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC1=O)C(C)C)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C(C)C)C(C)C)C(C)C)[C@@H](C)CC)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N3)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC1=CNC3=C1C=CC=C3)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)[C@@H](C)CC	CHEMBL4297852
Q06187	BTK_HUMAN	acalabrutinib	8.29243	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf	CC#CC(=O)N1CCC[C@H]1C1=NC(=C2N1C=CN=C2N)C1=CC=C(C=C1)C(=O)NC1=CC=CC=N1	CHEMBL3707348
P17948	VGFR1_HUMAN	tivozanib	9.677781	IC50	INHIBITOR	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004131/WC500239033.pdf	COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1	CHEMBL1289494
P35968	VGFR2_HUMAN	tivozanib	9.79588	IC50	INHIBITOR	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004131/WC500239033.pdf	COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1	CHEMBL1289494
P35916	VGFR3_HUMAN	tivozanib	9.619789	IC50	INHIBITOR	DRUG LABEL	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004131/WC500239033.pdf	COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=NOC(C)=C4)C(Cl)=C3)=CC=NC2=C1	CHEMBL1289494
P30988	CALCR_HUMAN	calcitonin (salmon synthetic)	11.08566	EC50	AGONIST	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017808s036lbl.pdf	[H]N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC1=O)[C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O	CHEMBL1201661
P30988	CALCR_HUMAN	calcitonin human	7.809668	IC50	AGONIST	CHEMBL	https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1201614	[H]N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC1=O)[C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(N)=O	CHEMBL1201614
P31639	SC5A2_HUMAN	ertugliflozin	9.057	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf	CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1	CHEMBL1770248
P30556	AGTR1_HUMAN	angiotensin II	9.3	IC50	AGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209360s000lbl.pdf	[H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O	CHEMBL408403
P10275	ANDR_HUMAN	apalutamide	7.79588	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210951s000lbl.pdf	CNC(=O)C1=CC=C(C=C1F)N1C(=S)N(C(=O)C11CCC1)C1=CC(=C(N=C1)C#N)C(F)(F)F	CHEMBL3183409
P01730	CD4_HUMAN	ibalizumab			ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065s001lbl.pdf		CHEMBL1743029
P43405	KSYK_HUMAN	fostamatinib	7.387216143	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209299lbl.pdf	COC1=CC(NC2=NC(NC3=CC=C4OC(C)(C)C(=O)N(COP(O)(O)=O)C4=N3)=C(F)C=N2)=CC(OC)=C1OC	CHEMBL2103830
Q9GZV9	FGF23_HUMAN	burosumab			ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761068s000lbl.pdf		CHEMBL3707326
P25103	NK1R_HUMAN	fosnetupitant	9.022275924682617	Ki	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210493s000lbl.pdf/drugsatfda_docs/label/2014/125477s007lbl.pdf	CN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=C(C)C=CC=C1)N1CC[N+](C)(COP(O)(O)=O)CC1	CHEMBL3989917
P40238	TPOR_HUMAN	avatrombopag	8.481486	EC50	AGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf	OC(=O)C1CCN(CC1)C1=NC=C(C=C1Cl)C(=O)NC1=NC(C2=CC(Cl)=CS2)=C(S1)N1CCN(CC1)C1CCCCC1	CHEMBL2103883
P15056	BRAF_HUMAN	encorafenib	9.327902	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf	COC(=O)N[C@@H](C)CNC1=NC(=CC=N1)C1=CN(N=C1C1=C(F)C(NS(C)(=O)=O)=CC(Cl)=C1)C(C)C	CHEMBL3301612
P04049	RAF1_HUMAN	encorafenib	9.522879	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf	COC(=O)N[C@@H](C)CNC1=NC(=CC=N1)C1=CN(N=C1C1=C(F)C(NS(C)(=O)=O)=CC(Cl)=C1)C(C)C	CHEMBL3301612
Q02750	MP2K1_HUMAN	binimetinib	7.9	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf	CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO	CHEMBL3187723
P36507	MP2K2_HUMAN	binimetinib	7.9	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf	CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO	CHEMBL3187723
O60894	RAMP1_HUMAN	erenumab	10.69897	Ki	ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf		CHEMBL3833329
Q16602	CALRL_HUMAN	erenumab	10.69897	Ki	ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf		CHEMBL3833329
P29460	IL12B_HUMAN	tildrakizumab	9.5	Kd	ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf		CHEMBL2108681
Q9NPF7	IL23A_HUMAN	tildrakizumab	9.5	Kd	ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf		CHEMBL2108681
O75874	IDHC_HUMAN	ivosidenib	7.1487416513	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf	FC1=CN=CC(=C1)N([C@H](C(=O)NC1CC(F)(F)C1)C1=CC=CC=C1Cl)C(=O)[C@@H]1CCC(=O)N1C1=NC=CC(=C1)C#N	CHEMBL3989958
P30968	GNRHR_HUMAN	elagolix	8.823908741	IC50	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210450s000lbl.pdf	[H][C@@](CN1C(=O)N(CC2=C(F)C=CC=C2C(F)(F)F)C(C)=C(C1=O)C1=C(F)C(OC)=CC=C1)(NCCCC(O)=O)C1=CC=CC=C1	CHEMBL502182
O00329	PK3CD_HUMAN	duvelisib	10.63827216	Kd	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf	C[C@H](NC1=NC=NC2=C1N=CN2)C1=CC2=C(C(Cl)=CC=C2)C(=O)N1C1=CC=CC=C1	CHEMBL3039502
P48736	PK3CG_HUMAN	duvelisib	9.619788758	Kd	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf	C[C@H](NC1=NC=NC2=C1N=CN2)C1=CC2=C(C(Cl)=CC=C2)C(=O)N1C1=CC=CC=C1	CHEMBL3039502
P00533	EGFR_HUMAN	dacomitinib	8.22184875	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf	COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN1CCCCC1	CHEMBL2105719
P04626	ERBB2_HUMAN	dacomitinib	7.3400838	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf	COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN1CCCCC1	CHEMBL2105719
Q15303	ERBB4_HUMAN	dacomitinib	7.132532512	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf	COC1=CC2=NC=NC(NC3=CC=C(F)C(Cl)=C3)=C2C=C1NC(=O)\C=C\CN1CCCCC1	CHEMBL2105719
P09874	PARP1_HUMAN	talazoparib tosylate	8.920818754	Ki	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	CN1N=CN=C1[C@@H]1[C@H](NC2=C3C1=NNC(=O)C3=CC(F)=C2)C1=CC=C(F)C=C1	CHEMBL3137318
Q9UGN5	PARP2_HUMAN	talazoparib tosylate	9.060480747	Ki	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	CN1N=CN=C1[C@@H]1[C@H](NC2=C3C1=NNC(=O)C3=CC(F)=C2)C1=CC=C(F)C=C1	CHEMBL3137318
Q9UM73	ALK_HUMAN	lorlatinib	9.9586073148	Ki	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf	C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12	CHEMBL3286830
P08922	ROS1_HUMAN	lorlatinib	9.3010299957	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf	C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12	CHEMBL3286830
P29376	LTK_HUMAN	lorlatinib	8.568636236	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf	C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12	CHEMBL3286830
P16591	FER_HUMAN	lorlatinib	8.48148606	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf	C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12	CHEMBL3286830
P07332	FES_HUMAN	lorlatinib	8.2218487496	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf	C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12	CHEMBL3286830
P04629	NTRK1_HUMAN	lorlatinib	7.619788758	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf	C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12	CHEMBL3286830
Q16620	NTRK2_HUMAN	lorlatinib	7.638272164	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf	C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12	CHEMBL3286830
Q16288	NTRK3_HUMAN	lorlatinib	7.337242168	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf	C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12	CHEMBL3286830
Q05397	FAK1_HUMAN	lorlatinib	7.769551079	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf	C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12	CHEMBL3286830
Q14289	FAK2_HUMAN	lorlatinib	7.853871964	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf	C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12	CHEMBL3286830
Q07912	ACK1_HUMAN	lorlatinib	7.769551079	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf	C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=CC=C(F)C=C12	CHEMBL3286830
P11229	ACM1_HUMAN	revefenacin	9.38	Ki	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf	CN(CCN1CCC(CC1)OC(=O)NC1=C(C=CC=C1)C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1	CHEMBL3833319
P08172	ACM2_HUMAN	revefenacin	9.52	Ki	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf	CN(CCN1CCC(CC1)OC(=O)NC1=C(C=CC=C1)C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1	CHEMBL3833319
P20309	ACM3_HUMAN	revefenacin	9.75	Ki	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf	CN(CCN1CCC(CC1)OC(=O)NC1=C(C=CC=C1)C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1	CHEMBL3833319
P08173	ACM4_HUMAN	revefenacin	9.26	Ki	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf	CN(CCN1CCC(CC1)OC(=O)NC1=C(C=CC=C1)C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1	CHEMBL3833319
P08912	ACM5_HUMAN	revefenacin	8.2	Ki	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf	CN(CCN1CCC(CC1)OC(=O)NC1=C(C=CC=C1)C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1	CHEMBL3833319
Q99835	SMO_HUMAN	glasdegib	8.301029996	IC50	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf	CN1CC[C@H](C[C@@H]1C1=NC2=C(N1)C=CC=C2)NC(=O)NC1=CC=C(C=C1)C#N	CHEMBL2043437
P04629	NTRK1_HUMAN	larotrectinib	8.187086643	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf	O[C@H]1CCN(C1)C(=O)NC1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=CC(F)=CC=C1F	CHEMBL3889654
Q16620	NTRK2_HUMAN	larotrectinib	8.091514981	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf	O[C@H]1CCN(C1)C(=O)NC1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=CC(F)=CC=C1F	CHEMBL3889654
Q16288	NTRK3_HUMAN	larotrectinib	7.974694135	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf	O[C@H]1CCN(C1)C(=O)NC1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=CC(F)=CC=C1F	CHEMBL3889654
P36888	FLT3_HUMAN	gilteritinib	8.301029996	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf	CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)N=C1NC1CCOCC1	CHEMBL3301603
P41180	CASR_HUMAN	evocalcet	7.031517051	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/29724589	C[C@@H](N[C@H]1CCN(C1)C1=CC=C(CC(O)=O)C=C1)C1=CC=CC2=CC=CC=C12	CHEMBL4297621
P03952	KLKB1_HUMAN	lanadelumab			INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf		CHEMBL3545189
P13945	ADRB3_HUMAN	vibegron	8.958607315	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/30411311	[H][C@@]1(CC2=CC=C(NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)C=C2)CC[C@@]([H])(N1)[C@H](O)C1=CC=CC=C1	CHEMBL2107826
P43116	PE2R2_HUMAN	omidenepag isopropyl	8.080921908	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/30465134	CC(C)OC(=O)CNC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=N1	CHEMBL3707245
P20273	CD22_HUMAN	moxetumomab pasudotox	8.2	Kd	BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761104s000lbl.pdf		CHEMBL1743043
P06881	CALCA_HUMAN	fremanezumab	10.3	Kd	ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761089s000lbl.pdf		CHEMBL4297756
P06881	CALCA_HUMAN	galcanezumab	8.7	Kd	ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761063s000lbl.pdf		CHEMBL3707328
Q15116	PDCD1_HUMAN	cemiplimab	7.102372909	Kd	ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf		CHEMBL4297723
P01579	IFNG_HUMAN	emapalumab	9.1	Kd	ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761107s000lbl.pdf		CHEMBL3989977
P01031	CO5_HUMAN	ravulizumab	9.356547324	Kd	ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761108s000lbl.pdf		CHEMBL3989986
P26951	IL3RA_HUMAN	tagraxofusp			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761116s000lbl.pdf		CHEMBL4297573
P32927	IL3RB_HUMAN	tagraxofusp			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761116s000lbl.pdf		CHEMBL4297573
Q9Y2T6	GPR55_HUMAN	cannabidiol			ANTAGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23108553	CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1	CHEMBL190461
Q8NER1	TRPV1_HUMAN	cannabidiol			INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/23108553	CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1	CHEMBL190461
P21453	S1PR1_HUMAN	siponimod	9.4089	EC50	MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/31144287	CCC1=CC(=CC=C1CN1CC(C1)C(O)=O)C(\C)=N\OCC1=CC=C(C2CCCCC2)C(=C1)C(F)(F)F	CHEMBL2336071
Q9H228	S1PR5_HUMAN	siponimod	9.0088	EC50	MODULATOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/31144287	CCC1=CC(=CC=C1CN1CC(C1)C(O)=O)C(\C)=N\OCC1=CC=C(C2CCCCC2)C(=C1)C(F)(F)F	CHEMBL2336071
P11362	FGFR1_HUMAN	erdafitinib	8.9208	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf	COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC2=NC(=CN=C2C=C1)C1=CN(C)N=C1	CHEMBL3545376
P21802	FGFR2_HUMAN	erdafitinib	8.6021	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf	COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC2=NC(=CN=C2C=C1)C1=CN(C)N=C1	CHEMBL3545376
P22607	FGFR3_HUMAN	erdafitinib	8.5229	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf	COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC2=NC(=CN=C2C=C1)C1=CN(C)N=C1	CHEMBL3545376
P22455	FGFR4_HUMAN	erdafitinib	8.2441	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf	COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC2=NC(=CN=C2C=C1)C1=CN(C)N=C1	CHEMBL3545376
P35968	VGFR2_HUMAN	erdafitinib	7.4342	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf	COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC2=NC(=CN=C2C=C1)C1=CN(C)N=C1	CHEMBL3545376
P42336	PK3CA_HUMAN	alpelisib	8.3372	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf	CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F	CHEMBL2396661
P40259	CD79B_HUMAN	polatuzumab vedotin			ANTIBODY BINDING	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf		CHEMBL3301582
P10275	ANDR_HUMAN	darolutamide	7.187	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)[C@@H](C)O	CHEMBL4297185
Q9NPF7	IL23A_HUMAN	risankizumab	11.0	Kd	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf		CHEMBL3990029
P17181	INAR1_HUMAN	ropeginterferon alfa-2b			BINDING AGENT	DRUG LABEL	https://www.ema.europa.eu/en/documents/product-information/besremi-epar-product-information_en.pdf		CHEMBL4297819
P48551	INAR2_HUMAN	ropeginterferon alfa-2b			BINDING AGENT	DRUG LABEL	https://www.ema.europa.eu/en/documents/product-information/besremi-epar-product-information_en.pdf		CHEMBL4297819
P13866	SC5A1_HUMAN	sotagliflozin	7.4436	IC50	INHIBITOR	DRUG LABEL	https://www.ema.europa.eu/en/documents/product-information/zynquista-epar-product-information_en.pdf	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1	CHEMBL3039507
P31639	SC5A2_HUMAN	sotagliflozin	8.7447	IC50	INHIBITOR	DRUG LABEL	https://www.ema.europa.eu/en/documents/product-information/zynquista-epar-product-information_en.pdf	CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1	CHEMBL3039507
P36888	FLT3_HUMAN	quizartinib	8.796	Kd	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/19654408	CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1	CHEMBL576982
O14980	XPO1_HUMAN	selinexor	7.7	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212306s000lbl.pdf	FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F	CHEMBL3545185
P32245	MC4R_HUMAN	bremelanotide	8.0	Kd	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/12851303	CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O	CHEMBL2070241
P60880	SNP25_HUMAN	prabotulinumtoxinA			BLOCKER	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761085s000lbl.pdf		CHEMBL4297229
P07333	CSF1R_HUMAN	pexidartinib	7.88	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/26222558	FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1	CHEMBL3813873
P10721	KIT_HUMAN	pexidartinib	7.56	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/26222558	FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1	CHEMBL3813873
P23458	JAK1_HUMAN	upadacitinib	7.33	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf	CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F	CHEMBL3622821
O60674	JAK2_HUMAN	upadacitinib	6.92	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf	CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F	CHEMBL3622821
P52333	JAK3_HUMAN	upadacitinib	5.63	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf	CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F	CHEMBL3622821
P36888	FLT3_HUMAN	pexidartinib	6.79	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/26222558	FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1	CHEMBL3813873
O60674	JAK2_HUMAN	fedratinib	8.52	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf	CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C	CHEMBL1287853
P36888	FLT3_HUMAN	fedratinib	7.82	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf	CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C	CHEMBL1287853
P30874	SSR2_HUMAN	gallium (68Ga) edotreotide	8.6	Ki	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210828s000lbl.pdf	[68Ga+3].C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1	
P48764	SL9A3_HUMAN	tenapanor	9.06	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf	CN1C[C@@H](C2=CC=CC(=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C(Cl)C=C(Cl)C=C23)C2=CC(Cl)=CC(Cl)=C2C1	CHEMBL3301627
P13631	RARG_HUMAN	trifarotene	8.11	EC50	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/29706423	CC(C)(C)C1=CC(=CC=C1N1CCCC1)C1=C(OCCO)C=CC(=C1)C1=CC=C(C=C1)C(O)=O	CHEMBL3707313
P30939	5HT1F_HUMAN	lasmiditan	8.65	Ki	AGONIST	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/20855361	CN1CCC(CC1)C(=O)C1=NC(NC(=O)C2=C(F)C=C(F)C=C2F)=CC=C1	CHEMBL3039520
Q06187	BTK_HUMAN	zanubrutinib	9.52	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf	NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1	CHEMBL3936761
P69905	HBA_HUMAN	voxelotor	5.09	EC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf	CC(C)N1N=CC=C1C1=C(COC2=C(C=O)C(O)=CC=C2)C=CC=N1	CHEMBL4101807
P16109	LYAM3_HUMAN	crizanlizumab	5.59	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf		CHEMBL4297734
P11387	TOP1_HUMAN	trastuzumab deruxtecan	7.51	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf		CHEMBL4297844
P11532	DMD_HUMAN	golodirsen			ANTISENSE INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211970s000lbl.pdf		CHEMBL4297762
P28223	5HT2A_HUMAN	lumateperone	9.26	Ki	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf	[H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=C3N2CCN(C)C3=CC=C1	CHEMBL3233142
P14416	DRD2_HUMAN	lumateperone	7.49	Ki	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf	[H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=C3N2CCN(C)C3=CC=C1	CHEMBL3233142
O43613	OX1R_HUMAN	lemborexant	8.22	Ki	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	CC1=NC=C(OC[C@]2(C[C@H]2C(=O)NC2=CC=C(F)C=N2)C2=CC=CC(F)=C2)C(C)=N1	CHEMBL3545367
O43614	OX2R_HUMAN	lemborexant	8.52	Ki	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	CC1=NC=C(OC[C@]2(C[C@H]2C(=O)NC2=CC=C(F)C=N2)C2=CC=CC(F)=C2)C(C)=N1	CHEMBL3545367
Q9BQB4	SOST_HUMAN	romosozumab	11.7	Kd	BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf		CHEMBL2107874
P15692	VEGFA_HUMAN	brolucizumab	8.8	Kd	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf		CHEMBL3707357
O95390	GDF11_HUMAN	luspatercept	10.13	Kd	BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761136lbl.pdf		CHEMBL3039545
O14793	GDF8_HUMAN	luspatercept	9.69	Kd	BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761136lbl.pdf		CHEMBL3039545
Q96NY8	NECT4_HUMAN	enfortumab vedotin	10.24	Ki	BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf		CHEMBL3301579
P04626	ERBB2_HUMAN	trastuzumab deruxtecan	8.13	Kd	BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf		CHEMBL4297844
Q9NZQ7	PD1L1_HUMAN	atezolizumab	9.39	Kd	ANTIBODY BINDING	DRUG LABEL	http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761034s000lbl.pdf		CHEMBL3707227
P13569	CFTR_HUMAN	elexacaftor				DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf	C[C@@H]1CN(C2=C(C=CC(=N2)N2C=CC(OCC(C)(C)C(F)(F)F)=N2)C(=O)NS(=O)(=O)C2=CN(C)N=C2C)C(C)(C)C1	CHEMBL4298128
Q16602	CALRL_HUMAN	ubrogepant	10.2	Ki	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf	C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC2=NC=CC=C42)C(=O)N1CC(F)(F)F)C1=CC=CC=C1	CHEMBL2364638
Q96KS0	EGLN2_HUMAN	roxadustat	5.24	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/30805897	CC1=C2C=C(OC3=CC=CC=C3)C=CC2=C(O)C(=N1)C(=O)NCC(O)=O	CHEMBL2338329
Q9GZT9	EGLN1_HUMAN	roxadustat	4.54	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/30805897	CC1=C2C=C(OC3=CC=CC=C3)C=CC2=C(O)C(=N1)C(=O)NCC(O)=O	CHEMBL2338329
Q9H6Z9	EGLN3_HUMAN	roxadustat	5.18	IC50	INHIBITOR	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/30805897	CC1=C2C=C(OC3=CC=CC=C3)C=CC2=C(O)C(=N1)C(=O)NCC(O)=O	CHEMBL2338329
P11532	DMD_HUMAN	eteplirsen			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206488lbl.pdf		CHEMBL2108278
P02766	TTHY_HUMAN	patisiran			ANTISENSE INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf		CHEMBL3989987
P02766	TTHY_HUMAN	inotersen 			ANTISENSE INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211172lbl.pdf		CHEMBL4297537
P13196	HEM1_HUMAN	givosiran			ANTISENSE INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0212194s000lbl.pdf		CHEMBL4297760
P02656	APOC3_HUMAN	volanesorsen			ANTISENSE INHIBITOR	DRUG LABEL	https://www.ema.europa.eu/en/documents/assessment-report/waylivra-epar-public-assessment-report_en.pdf		CHEMBL3544989
P60880	SNP25_HUMAN	botulinum toxin type A			BLOCKER	SCIENTIFIC LITERATURE	http://www.ncbi.nlm.nih.gov/pubmed/8103915		CHEMBL4297862
P04350	TBB4A_HUMAN	polatuzumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf		CHEMBL3301582
P07437	TBB5_HUMAN	polatuzumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf		CHEMBL3301582
P68371	TBB4B_HUMAN	polatuzumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf		CHEMBL3301582
Q13509	TBB3_HUMAN	polatuzumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf		CHEMBL3301582
Q13885	TBB2A_HUMAN	polatuzumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf		CHEMBL3301582
Q3ZCM7	TBB8_HUMAN	polatuzumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf		CHEMBL3301582
Q9BUF5	TBB6_HUMAN	polatuzumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf		CHEMBL3301582
Q9BVA1	TBB2B_HUMAN	polatuzumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf		CHEMBL3301582
Q9H4B7	TBB1_HUMAN	polatuzumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf		CHEMBL3301582
P04350	TBB4A_HUMAN	enfortumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf		CHEMBL3301579
P07437	TBB5_HUMAN	enfortumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf		CHEMBL3301579
P68371	TBB4B_HUMAN	enfortumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf		CHEMBL3301579
Q13509	TBB3_HUMAN	enfortumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf		CHEMBL3301579
Q13885	TBB2A_HUMAN	enfortumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf		CHEMBL3301579
Q3ZCM7	TBB8_HUMAN	enfortumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf		CHEMBL3301579
Q9BUF5	TBB6_HUMAN	enfortumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf		CHEMBL3301579
Q9BVA1	TBB2B_HUMAN	enfortumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf		CHEMBL3301579
Q9H4B7	TBB1_HUMAN	enfortumab vedotin			BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf		CHEMBL3301579
Q16602	CALRL_HUMAN	rimegepant	10.56	Ki	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf	[H][C@]1(CC[C@@H](C2=C(F)C(F)=CC=C2)[C@]([H])(N)C2=CC=CN=C12)OC(=O)N1CCC(CC1)N1C(=O)NC2=NC=CC=C12	CHEMBL2178422
P53396	ACLY_HUMAN	bempedoic acid	5.69	Ki	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf	CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O	CHEMBL3545313
P21453	S1PR1_HUMAN	ozanimod	9.39	EC50	AGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf	CC(C)OC1=CC=C(C=C1C#N)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1	CHEMBL3707246
Q9H228	S1PR5_HUMAN	ozanimod	7.96	EC50	AGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf	CC(C)OC1=CC=C(C=C1C#N)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1	CHEMBL3707246
P15538	C11B1_HUMAN	osilodrostat	8.6	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf	FC1=C(C=CC(=C1)C#N)[C@H]1CCC2=CN=CN12	CHEMBL3099695
P28907	CD38_HUMAN	isatuximab	9.7	Kd	BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761113s000lbl.pdf		CHEMBL3545131
P06881	CALCA_HUMAN	eptinezumab	10.82	Kd	BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf		CHEMBL2109621
P10092	CALCB_HUMAN	eptinezumab	10.24	Kd	BINDING AGENT	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf		CHEMBL2109621
P08069	IGF1R_HUMAN	teprotumumab	9.0	IC50	ANTAGONIST	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761143s000lbl.pdf		CHEMBL1743079
Q02750	MP2K1_HUMAN	selumetinib	7.85	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C=C12)C(=O)NOCCO	CHEMBL1614701
P36507	MP2K2_HUMAN	selumetinib	7.85	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C=C12)C(=O)NOCCO	CHEMBL1614701
P04626	ERBB2_HUMAN	tucatinib	8.16	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf	CC1=CC(NC2=NC=NC3=C2C=C(NC2=NC(C)(C)CO2)C=C3)=CC=C1OC1=CC2=NC=NN2C=C1	CHEMBL3989868
P21860	ERBB3_HUMAN	tucatinib	8.16	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf	CC1=CC(NC2=NC=NC3=C2C=C(NC2=NC(C)(C)CO2)C=C3)=CC=C1OC1=CC2=NC=NN2C=C1	CHEMBL3989868
P11362	FGFR1_HUMAN	pemigatinib	9.4	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf	CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F	CHEMBL4297522
P21802	FGFR2_HUMAN	pemigatinib	9.3	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf	CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F	CHEMBL4297522
P22607	FGFR3_HUMAN	pemigatinib	9.0	IC50	INHIBITOR	DRUG LABEL	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf	CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F	CHEMBL4297522
